<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Topical treatments for scalp psoriasis - Schlager, JG - 2016 | Cochrane Library</title> <meta content="Topical treatments for scalp psoriasis - Schlager, JG - 2016 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009687.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Topical treatments for scalp psoriasis - Schlager, JG - 2016 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009687.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD009687.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Topical treatments for scalp psoriasis" name="citation_title"/> <meta content="Justin Gabriel Schlager" name="citation_author"/> <meta content="Charité ‐ Universitätsmedizin Berlin" name="citation_author_institution"/> <meta content="Stefanie Rosumeck" name="citation_author"/> <meta content="Charité ‐ Universitätsmedizin Berlin" name="citation_author_institution"/> <meta content="Ricardo Niklas Werner" name="citation_author"/> <meta content="Charité ‐ Universitätsmedizin Berlin" name="citation_author_institution"/> <meta content="Anja Jacobs" name="citation_author"/> <meta content="Federal Joint Committee (G‐BA, Gemeinsamer Bundesausschuss)" name="citation_author_institution"/> <meta content="Jochen Schmitt" name="citation_author"/> <meta content="Faculty of Medicine Carl Gustav Carus, Technischen Universität (TU) Dresden" name="citation_author_institution"/> <meta content="Christoph Schlager" name="citation_author"/> <meta content="The University of Nottingham" name="citation_author_institution"/> <meta content="Alexander Nast" name="citation_author"/> <meta content="Charité ‐ Universitätsmedizin Berlin" name="citation_author_institution"/> <meta content="alexander.nast@charite.de" name="citation_author_email"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="2" name="citation_issue"/> <meta content="10.1002/14651858.CD009687.pub2" name="citation_doi"/> <meta content="2016" name="citation_date"/> <meta content="2016/02/26" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009687.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009687.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009687.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Administration, Topical; Chronic Disease; Dermatologic Agents [adverse effects, *therapeutic use]; Psoriasis [*drug therapy]; Randomized Controlled Trials as Topic; Scalp Dermatoses [*drug therapy]; Steroids [adverse effects, *therapeutic use]; Vitamin D [adverse effects, *therapeutic use]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009687.pub2&amp;doi=10.1002/14651858.CD009687.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009687.pub2&amp;doi=10.1002/14651858.CD009687.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009687.pub2&amp;doi=10.1002/14651858.CD009687.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009687.pub2&amp;doi=10.1002/14651858.CD009687.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009687.pub2&amp;doi=10.1002/14651858.CD009687.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009687.pub2&amp;doi=10.1002/14651858.CD009687.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009687.pub2&amp;doi=10.1002/14651858.CD009687.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009687.pub2&amp;doi=10.1002/14651858.CD009687.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009687.pub2&amp;doi=10.1002/14651858.CD009687.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009687.pub2&amp;doi=10.1002/14651858.CD009687.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009687.pub2&amp;doi=10.1002/14651858.CD009687.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009687.pub2&amp;doi=10.1002/14651858.CD009687.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009687.pub2&amp;doi=10.1002/14651858.CD009687.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009687.pub2&amp;doi=10.1002/14651858.CD009687.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009687.pub2&amp;doi=10.1002/14651858.CD009687.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009687.pub2&amp;doi=10.1002/14651858.CD009687.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009687.pub2&amp;doi=10.1002/14651858.CD009687.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009687.pub2&amp;doi=10.1002/14651858.CD009687.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009687.pub2&amp;doi=10.1002/14651858.CD009687.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009687.pub2&amp;doi=10.1002/14651858.CD009687.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009687.pub2&amp;doi=10.1002/14651858.CD009687.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009687.pub2&amp;doi=10.1002/14651858.CD009687.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009687.pub2&amp;doi=10.1002/14651858.CD009687.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773519000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773548000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000"}};Liferay.authToken="EBp84H4P";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD009687\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD009687\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009687\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009687\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513680837000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","de","ru","hr","fr","fa"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD009687.pub2",title:"Topical treatments for scalp psoriasis",firstPublishedDate:"Feb 26, 2016 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Skin Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734739000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=EBp84H4P&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD009687.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD009687.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD009687.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD009687.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD009687.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD009687.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;de&quot;,&quot;title&quot;:&quot;Laienverständliche Zusammenfassung&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Conclusiones de los autores&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Antecedentes&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Objetivos&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Métodos&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Discusión&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD009687.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD009687.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD009687.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD009687.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>9390 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD009687.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009687.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009687.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009687.pub2/full#CD009687-abs-0004"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009687.pub2/full#CD009687-sec-0249"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009687.pub2/full#CD009687-sec-0022"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009687.pub2/full#CD009687-sec-0023"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009687.pub2/full#CD009687-sec-0038"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009687.pub2/full#CD009687-sec-0039"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009687.pub2/full#CD009687-sec-0068"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009687.pub2/full#CD009687-sec-0230"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009687.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009687.pub2/appendices#CD009687-sec-0254"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009687.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009687.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/table_n/CD009687StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/table_n/CD009687StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009687.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009687.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009687.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD009687.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD009687.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD009687.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2016 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Topical treatments for scalp psoriasis</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD009687.pub2/information#CD009687-cr-0002">Justin Gabriel Schlager</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD009687.pub2/information#CD009687-cr-0003">Stefanie Rosumeck</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD009687.pub2/information#CD009687-cr-0004">Ricardo Niklas Werner</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD009687.pub2/information#CD009687-cr-0005">Anja Jacobs</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD009687.pub2/information#CD009687-cr-0006">Jochen Schmitt</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD009687.pub2/information#CD009687-cr-0007">Christoph Schlager</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD009687.pub2/information#CD009687-cr-0008"><i class="icon corresponding-author fa fa-envelope"></i>Alexander Nast</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/information/en#CD009687-sec-0260">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 26 February 2016 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD009687.pub2">https://doi.org/10.1002/14651858.CD009687.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD009687-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD009687-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD009687-abs-0003">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD009687-abs-0010">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD009687-abs-0002">Français</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD009687-abs-0001" lang="en"> <section id="CD009687-sec-0001"> <h3 class="title" id="CD009687-sec-0001">Background</h3> <p>People with chronic plaque psoriasis often have lesions on the scalp. Hair makes the scalp difficult to treat and the adjacent facial skin is particularly sensitive to topical treatments. </p> </section> <section id="CD009687-sec-0002"> <h3 class="title" id="CD009687-sec-0002">Objectives</h3> <p>To assess the efficacy and safety of topical treatments for scalp psoriasis.</p> </section> <section id="CD009687-sec-0003"> <h3 class="title" id="CD009687-sec-0003">Search methods</h3> <p>We searched the following databases up to August 2015: the Cochrane Skin Group Specialised Register, CENTRAL (2015, Issue 7), MEDLINE (from 1946), EMBASE (from 1974) and LILACS (from 1982). We also searched five trials registers, screened abstracts of six psoriasis‐specific conferences and checked the reference lists of included studies for further references to relevant randomised controlled trials. </p> </section> <section id="CD009687-sec-0004"> <h3 class="title" id="CD009687-sec-0004">Selection criteria</h3> <p>Randomised controlled trials (RCTs) with a parallel‐group, cross‐over or within‐patient design of topical treatments for people of all ages with scalp psoriasis. </p> </section> <section id="CD009687-sec-0005"> <h3 class="title" id="CD009687-sec-0005">Data collection and analysis</h3> <p>Two authors independently carried out study selection, data extraction and 'Risk of bias' assessment. Disagreements were settled by reference to a third author. </p> <p>To assess the quality of evidence, we focused on the following outcomes: 'clearance' or 'response' as assessed by the investigator global assessment (IGA), improvement in quality of life, adverse events requiring withdrawal of treatment and 'response' as assessed by the patient global assessment (PGA). </p> <p>We expressed the results of the single studies as risk ratios (RR) with 95% confidence intervals (CI) for dichotomous outcomes, and mean differences (MD) with 95% CI for continuous outcomes. If studies were sufficiently homogeneous, we meta‐analysed the data by using the random‐effects model. Where it was not possible to calculate a point estimate for a single study, we described the data qualitatively. We also presented the number needed to treat to benefit (NNTB). </p> <p>We categorised topical corticosteroids according to the German classification of corticosteroid potency as mild, moderate, high and very high. </p> </section> <section id="CD009687-sec-0006"> <h3 class="title" id="CD009687-sec-0006">Main results</h3> <p>We included 59 RCTs with a total of 11,561 participants. Thirty studies were either conducted or sponsored by the manufacturer of the study medication. The risk of bias varied considerably among the included studies. For instance, most authors did not state the randomisation method and few addressed allocation concealment. Most findings were limited to short‐term treatments, since most studies were conducted for less than six months. Only one trial investigated long‐term therapy (12 months). Although we found a wide variety of different interventions, we limited the grading of the quality of evidence to three major comparisons: steroid versus vitamin D, two‐compound combination of steroid and vitamin D versus steroid monotherapy and versus vitamin D. </p> <p>In terms of clearance, as assessed by the IGA, steroids were better than vitamin D (RR 1.82; 95% CI 1.52 to 2.18; four studies, 2180 participants, NNTB = 8; 95% CI 7 to 11; moderate quality evidence). Statistically, the two‐compound combination was superior to steroid monotherapy, however the additional benefit was small (RR 1.22; 95% CI 1.08 to 1.36; four studies, 2474 participants, NNTB = 17; 95% CI 11 to 41; moderate quality evidence). The two‐compound combination was more effective than vitamin D alone (RR 2.28; 95% CI 1.87 to 2.78; four studies, 2008 participants, NNTB = 6; 95% CI 5 to 7; high quality evidence). </p> <p>In terms of treatment response, as assessed by the IGA, corticosteroids were more effective than vitamin D (RR 2.09; 95% CI 1.80 to 2.41; three studies, 1827 participants; NNTB = 4; 95% CI 4 to 5; high quality evidence). The two‐compound combination was better than steroid monotherapy, but the additional benefit was small (RR 1.15; 95% CI 1.06 to 1.25; three studies, 2444 participants, NNTB = 13; 95% CI 9 to 24; moderate quality evidence). It was also more effective than vitamin D alone (RR 2.31; 95% CI 1.75 to 3.04; four studies, 2222 participants, NNTB = 3; 95% CI 3 to 4; moderate quality evidence). </p> <p>Reporting of quality of life data was poor and data were insufficient to be included for meta‐analysis. </p> <p>Steroids caused fewer withdrawals due to adverse events than vitamin D (RR 0.22; 95% CI 0.11 to 0.42; four studies, 2291 participants; moderate quality evidence). The two‐compound combination and steroid monotherapy did not differ in the number of adverse events leading withdrawal (RR 0.88; 95% CI 0.42 to 1.88; three studies, 2433 participants; moderate quality evidence). The two‐compound combination led to fewer withdrawals due to adverse events than vitamin D (RR 0.19; 95% CI 0.11 to 0.36; three studies, 1970 participants; high quality evidence). No study reported the type of adverse event requiring withdrawal. </p> <p>In terms of treatment response, as assessed by the PGA, steroids were more effective than vitamin D (RR 1.48; 95% CI 1.28 to 1.72; three studies, 1827 participants; NNTB = 5; 95% CI 5 to 7; moderate quality evidence). Statistically, the two‐compound combination was better than steroid monotherapy, however the benefit was not clinically important (RR 1.13; 95% CI 1.06 to 1.20; two studies, 2226 participants; NNTB = 13; 95% CI 9 to 26; high quality evidence). The two‐compound combination was more effective than vitamin D (RR 1.76; 95% CI 1.46 to 2.12; four studies, 2222 participants; NNTB = 4; 95% CI 3 to 6; moderate quality evidence). </p> <p>Common adverse events with these three interventions were local irritation, skin pain and folliculitis. Systemic adverse events were rare and probably not drug‐related. </p> <p>In addition to the results of the major three comparisons we found that the two‐compound combination, steroids and vitamin D monotherapy were more effective than the vehicle. Steroids of moderate, high and very high potency tended to be similarly effective and well tolerated. There are inherent limitations in this review concerning the evaluation of salicylic acid, tar, dithranol or other topical treatments. </p> </section> <section id="CD009687-sec-0007"> <h3 class="title" id="CD009687-sec-0007">Authors' conclusions</h3> <p>The two‐compound combination as well as corticosteroid monotherapy were more effective and safer than vitamin D monotherapy. Given the similar safety profile and only slim benefit of the two‐compound combination over the steroid alone, monotherapy with generic topical steroids may be fully acceptable for short‐term therapy. </p> <p>Future RCTs should investigate how specific therapies improve the participants' quality of life. Long‐term assessments are needed (i.e. 6 to 12 months). </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD009687-abs-0004" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD009687-abs-0004">English</a> </li> <li class="section-language"> <a class="" href="full/de#CD009687-abs-0005">Deutsch</a> </li> <li class="section-language"> <a class="" href="full/es#CD009687-abs-0009">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD009687-abs-0011">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD009687-abs-0008">Français</a> </li> <li class="section-language"> <a class="" href="full/hr#CD009687-abs-0007">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/ru#CD009687-abs-0006">Русский</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD009687-abs-0004" lang="en"> <h3>Topical treatments for psoriasis of the scalp</h3> <p><b>Background</b> </p> <p>People with chronic plaque psoriasis often have lesions on the scalp. As well as itching, the reddish, scaly lesions are visible and are often embarrassing. 'Topical' treatments (drugs applied to the skin, e.g. as creams) are usually tried first, but applying them to the scalp is difficult because of the hair. There are a number of topical drugs in use, such as corticosteroids (also known as steroids), vitamin D, tar‐based preparations, tacrolimus, dithranol or salicylic acid. Some topical corticosteroids have more potency than others so are categorised into four levels of strength: mild, moderate, high and very high. As psoriasis remains a long‐term condition, it is of great importance to know which of the drugs work best, what kind of side effects they may have and how likely they are to occur. </p> <p><b>Review question</b> </p> <p>What are the most effective and safest treatments for psoriasis on the scalp?</p> <p><b>Study characteristics</b> </p> <p>We looked at 59 randomised controlled trials with 11,561 participants. Thirty studies were either conducted or sponsored by the manufacturer of the study medication. </p> <p><b>Quality of the evidence</b> </p> <p>On average, the overall quality of the evidence was moderate for the three most important comparisons that included corticosteroids (e.g. betamethasone dipropionate), vitamin D (e.g. calcipotriol) and their combination product. We looked for a reduction in the severity of the psoriasis, improvement in quality of life and harmful side effects of the treatments. Most findings were based on short‐term therapies with a duration of less than six months. </p> <p><b>Key results</b> </p> <p>Prior investigators found that the combination product was more effective than the steroid alone, but clinically the benefit was questionable. Both treatments reduced scalp psoriasis better than vitamin D. </p> <p>Due to poor information, we could not assess which treatment improved quality of life best. Most studies simply did not measure the improvement in quality of life. </p> <p>Participants who applied vitamin D stopped treatment more often because of harmful side effects than those who applied a topical steroid or the combination product. Steroids were as likely as the combination product to cause discontinuation of the treatment because of side effects. However, only a few participants who used one of the three medications experienced harmful side effects. No study reported the type of side effect that made participants stop the treatment. </p> <p>Participants assessed the efficacy of the treatments similarly to the investigator: those who applied a steroid or the combination product responded better to treatment than participants who used vitamin D alone. Statistically, the combination product was more effective than the steroid alone, but clinically the benefit was questionable. </p> <p>The most common harmful side effects of these treatments were irritation, itching and skin pain at the site of application. Side effects on other sites of the body were very rare and most likely not caused by the drug. </p> <p>Other findings were the following: steroids, vitamin D and their combination product were more effective than the vehicle preparation (cream, shampoo etc) that did not contain the active drug. Compared to one another, steroids tended to be similarly effective and have similar side effects, even though some were of a higher strength. </p> <p>We could not sufficiently assess the efficacy and safety of other topical treatments, such as salicylic acid, tar or dithranol. </p> <p><b>Conclusion</b> </p> <p>Steroids and the two‐compound combination of a steroid and vitamin D were most effective with the least risk of causing harmful side effects. Given the similar safety profile and only slim benefit of the two‐compound combination over the steroid alone, topical steroids on their own may be fully acceptable for short‐term therapy. </p> <p>The following questions remain unanswered and should be investigated by future trials: Is there truly no difference in terms of effectiveness or safety between topical corticosteroids of different strength? Does the vehicle preparation (e.g. cream or shampoo) have any influence on how the active agent works? Which topical treatment leads to disease control over a long time span without risking patient's safety? Finally, there is a strong need for more studies that assess which topical treatments improve quality of life best. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD009687-sec-0249" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD009687-sec-0249">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD009687-sec-0313">Español</a> </li> </nav> </div> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD009687-sec-0249"></div> <h3 class="title" id="CD009687-sec-0250">Implications for practice</h3> <section id="CD009687-sec-0250"> <p>Corticosteroids of high or very high potency are more effective than vitamin D. The combination product of a corticosteroid and vitamin D is of small benefit over corticosteroid monotherapy. The combination product is superior to vitamin D alone. Corticosteroids, vitamin D and their combination product are more effective than the vehicle. Corticosteroids of moderate, high and very high potency are similarly effective. There is not enough evidence to allow a final conclusion as to whether salicylic acid is of additional benefit in combination with corticosteroids. Few and mostly unreliable data suggest that the efficacy of tar or dithranol preparations is limited. There might not be a difference whether corticosteroids are used once or twice daily. </p> <p>Adverse events were mostly limited to the site of application and included burning sensations, pruritus, skin irritation or folliculitis, among others. For short‐term treatment, the combination of corticosteroids with vitamin D and the corticosteroid monotherapy do not differ in their risk of causing adverse events and both were better tolerated than vitamin D alone. For long‐term therapy, the two‐compound combination caused fewer adverse events and withdrawals due to adverse events than vitamin D monotherapy. Limited evidence indicates no difference in the risk of adverse effects between corticosteroids of moderate, high or very high potency. Tar and dithranol preparations appear to be well tolerated, but the evidence is poor. The tolerability of salicylic acid cannot be analysed due to the lack of relevant data. </p> <p>Besides some trials on corticosteroids, there are no suitable and reliable data to determine the additional benefit of specific vehicles on the efficacy and safety of active ingredients. </p> <p>Given the similar safety profile and only slim benefit of the two‐compound combination over the steroid alone, monotherapy with generic topical corticosteroids may be fully acceptable for short‐term therapy. </p> <p>The 14 studies in '<a href="./references#CD009687-sec-0268" title="">Characteristics of studies awaiting classification</a>' may alter the conclusions of the review once assessed. </p> </section> <h3 class="title" id="CD009687-sec-0251">Implications for research</h3> <section id="CD009687-sec-0251"> <p>The evaluation of the efficacy and safety of almost all included treatments is restricted to their short‐term use (less than six months). As for any chronic condition, disease control over a long time span without compromising the participant's safety is crucial. Moreover, it is not known whether the relapse of psoriatic lesions is linked to a worsening of the condition. These aspects should be addressed in future randomised controlled trials (RCTs). </p> <p>The evaluation of tar preparations and other products, such as ciclopirox olamine, tacrolimus, dithranol and urea combination or steroids in combination with salicylic acid, was limited due to insufficient evidence. Some treatments are no longer part of current practice. However, other preparations, such as topical tacrolimus, may remain or become an alternative treatment option for mild disease severity or as part of a treatment regimen for the maintenance of remission. Moreover, there is a need for further evidence to assess the assumption that corticosteroids of moderate, high and very high potency are similarly effective and safe. </p> <p>For most treatments there is a lack of evidence on the improvement of quality of life. More evidence would help participants and their physicians to decide which treatment may be best. The scalp is a visible part of the body and difficult to treat due to the hair. Therefore, future trials should evaluate patients' tolerance of the topical preparation, which may involve the assessment of smelliness, stickiness or oiliness, among others. This is an important issue with great influence on the quality of life and patient compliance. </p> <p>The wide spectrum of different efficacy, safety and quality of life tools makes the comparison of different treatments a great challenge. Poor transparency and inconsistent definition of existing tools made it additionally difficult to summarise the evidence. It would be of great benefit to achieve an agreement on an internationally recognised outcome set. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD009687-sec-0022" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD009687-sec-0022"></div> <div class="table" id="CD009687-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Steroid compared to vitamin D for scalp psoriasis</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Steroid compared to vitamin D for scalp psoriasis</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> scalp psoriasis<br/> <b>Intervention:</b> steroid <br/> <b>Comparison:</b> vitamin D </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with vitamin D</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with steroid</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Number of participants achieving 'clearance' by IGA</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.82<br/> (1.52 to 2.18) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2180<br/> (4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>159 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>289 per 1000<br/> (241 to 346) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Number of participants achieving 'response' by IGA</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 2.09<br/> (1.80 to 2.41) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1827<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/> HIGH </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>251 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>525 per 1000<br/> (452 to 605) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Quality of life</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>(0 studies)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>No study addressed this outcome.</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000<br/> (0 to 0) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Number of participants withdrawing due to adverse events (AE)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.22<br/> (0.11 to 0.42) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2291<br/> (4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>No study reported the sort of AE that caused withdrawal. In 2 small studies with high risk of bias (<a href="./references#CD009687-bbs2-0034" title="KöseO . Calcipotriol ointment vs clobetasol solution in scalp psoriasis. Journal of Dermatological Treatment1997;8(4):287. [EMBASE: 1998022654] ">Köse 1997</a>, N = 43 participants; <a href="./references#CD009687-bbs2-0059" title="YilmazH , AydinF , SenturkN , CanturkT , TuranliAY . A comparison between the effects of calcipotriol lotion, momethasone furoate lotion and their combinations for the treatment of scalp psoriasis [Kalsipotriol Losyon, Mometazon Furoat Losyonve Kombinasyonlarinin Saçli Deri Psoriazisi Tedavisindeki Etkinliginin Karsilastirilmasi]. Turkderm Deri Hastaliklari ve Frengi Arsivi2005;39(2):109‐14. [EMBASE: 2006204571] ">Yilmaz 2005</a>, N = 30 participants) no withdrawals occurred. </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>53 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>12 per 1000<br/> (6 to 22) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Number of participants achieving 'response' by PGA</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.48<br/> (1.28 to 1.72) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1827<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>403 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>596 per 1000<br/> (516 to 693) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>AE:</b> adverse event; <b>CI:</b> confidence interval; <b>IGA:</b> investigator's global assessment; <b>OR:</b> odds ratio; <b>PGA:</b> patient global assessment; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Downgraded by one level for risk of bias: three out of four studies with unclear blinding of outcome assessment (<a href="./references#CD009687-bbs2-0032" title="KlaberMR , HutchinsonPE , Pedvis‐LeftickA , KragballeK , ReunalaTL , van deKerkhofPC , et al. Comparative effects of calcipotriol solution (50 micrograms/ml) and betamethasone 17‐valerate solution (1 mg/ml) in the treatment of scalp psoriasis. British Journal of Dermatology1994;131(5):678‐83. [MEDLINE: 7999600] ">Klaber 1994</a>; <a href="./references#CD009687-bbs2-0053" title="van deKerkhofP , AnsteyA , BarnesL , BolducC . A new scalp formulation of calcipotriene plus betamethasone in the treatment of scalp psoriasis compared to its active ingredients in the same vehicle. Journal of the American Academy of Dermatology2007;56(2):AB182. van deKerkhofPC , HoffmannV , AnsteyA , BarnesL , BolducC , ReichK , et al. A new scalp formulation of calcipotriol plus betamethasone dipropionate compared with each of its active ingredients in the same vehicle for the treatment of scalp psoriasis: a randomized, double‐blind, controlled trial. British Journal of Dermatology2009;160(1):170‐6. [MEDLINE: 19067709] ">van de Kerkhof 2009</a>; <a href="./references#CD009687-bbs2-0059" title="YilmazH , AydinF , SenturkN , CanturkT , TuranliAY . A comparison between the effects of calcipotriol lotion, momethasone furoate lotion and their combinations for the treatment of scalp psoriasis [Kalsipotriol Losyon, Mometazon Furoat Losyonve Kombinasyonlarinin Saçli Deri Psoriazisi Tedavisindeki Etkinliginin Karsilastirilmasi]. Turkderm Deri Hastaliklari ve Frengi Arsivi2005;39(2):109‐14. [EMBASE: 2006204571] ">Yilmaz 2005</a>); all studies with unclear allocation concealment. </p> <p><sup>2</sup> Downgraded by one level for risk of bias: two out of four studies with unclear blinding of outcome assessment (<a href="./references#CD009687-bbs2-0032" title="KlaberMR , HutchinsonPE , Pedvis‐LeftickA , KragballeK , ReunalaTL , van deKerkhofPC , et al. Comparative effects of calcipotriol solution (50 micrograms/ml) and betamethasone 17‐valerate solution (1 mg/ml) in the treatment of scalp psoriasis. British Journal of Dermatology1994;131(5):678‐83. [MEDLINE: 7999600] ">Klaber 1994</a>; <a href="./references#CD009687-bbs2-0053" title="van deKerkhofP , AnsteyA , BarnesL , BolducC . A new scalp formulation of calcipotriene plus betamethasone in the treatment of scalp psoriasis compared to its active ingredients in the same vehicle. Journal of the American Academy of Dermatology2007;56(2):AB182. van deKerkhofPC , HoffmannV , AnsteyA , BarnesL , BolducC , ReichK , et al. A new scalp formulation of calcipotriol plus betamethasone dipropionate compared with each of its active ingredients in the same vehicle for the treatment of scalp psoriasis: a randomized, double‐blind, controlled trial. British Journal of Dermatology2009;160(1):170‐6. [MEDLINE: 19067709] ">van de Kerkhof 2009</a>); all studies with unclear allocation concealment. </p> <p><sup>3</sup> Downgraded by one level for risk of bias: all three studies with unclear allocation concealment; one study with unclear risk of bias in selective reporting (<a href="./references#CD009687-bbs2-0046" title="ReygagneP , MrowietzU , DecroixJ , deWaard‐van der SpekFB , AcebesLO , FigueiredoA , et al. Clobetasol propionate shampoo 0.05% and calcipotriol solution 0.005%: a randomized comparison of efficacy and safety in subjects with scalp psoriasis. Journal of Dermatological Treatment2005;16(1):31‐6. [MEDLINE: 15897165] ReygagneP , MrowietzU , DecroixJ , van derSpekW , Olmos AcebesL , et al. Four‐week efficacy and safety comparison of a new clobetasol shampoo and calcipotriol solution 0.005% in subjects with scalp psoriasis. Journal of the European Academy of Dermatology &amp; Venereology2002;16(Suppl 1):285. ">Reygagne 2005</a>); one study with unclear blinding of outcome assessment (<a href="./references#CD009687-bbs2-0053" title="van deKerkhofP , AnsteyA , BarnesL , BolducC . A new scalp formulation of calcipotriene plus betamethasone in the treatment of scalp psoriasis compared to its active ingredients in the same vehicle. Journal of the American Academy of Dermatology2007;56(2):AB182. van deKerkhofPC , HoffmannV , AnsteyA , BarnesL , BolducC , ReichK , et al. A new scalp formulation of calcipotriol plus betamethasone dipropionate compared with each of its active ingredients in the same vehicle for the treatment of scalp psoriasis: a randomized, double‐blind, controlled trial. British Journal of Dermatology2009;160(1):170‐6. [MEDLINE: 19067709] ">van de Kerkhof 2009</a>). </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD009687-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Steroid plus vitamin D compared to steroid for scalp psoriasis</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Steroid plus vitamin D compared to steroid for scalp psoriasis</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> scalp psoriasis <br/> <b>Intervention:</b> steroid plus vitamin D<br/> <b>Comparison:</b> steroid </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with steroid</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with steroid plus vitamin D</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Number of participants achieving 'clearance' by IGA</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.22<br/> (1.08 to 1.36) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2474<br/> (4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>287 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>350 per 1000<br/> (310 to 391) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Number of participants achieving 'response' by IGA</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.15<br/> (1.06 to 1.25) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2444<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>546 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>628 per 1000<br/> (579 to 683) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Quality of life</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>(0 studies)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>No study addressed this outcome</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000<br/> (0 to 0) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Number of participants withdrawing due to adverse events (AE)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.88<br/> (0.42 to 1.88) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2433<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>No study reported the sort of AE that caused withdrawal. In one small study with high risk of bias (<a href="./references#CD009687-bbs2-0059" title="YilmazH , AydinF , SenturkN , CanturkT , TuranliAY . A comparison between the effects of calcipotriol lotion, momethasone furoate lotion and their combinations for the treatment of scalp psoriasis [Kalsipotriol Losyon, Mometazon Furoat Losyonve Kombinasyonlarinin Saçli Deri Psoriazisi Tedavisindeki Etkinliginin Karsilastirilmasi]. Turkderm Deri Hastaliklari ve Frengi Arsivi2005;39(2):109‐14. [EMBASE: 2006204571] ">Yilmaz 2005</a>, N = 30 participants) no withdrawals occurred. </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>12 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>11 per 1000<br/> (5 to 23) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Number of participants achieving 'response' by PGA</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.13<br/> (1.06 to 1.20) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2226<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/> HIGH </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>613 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>692 per 1000<br/> (649 to 735) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>AE:</b> adverse event; <b>CI:</b> confidence interval; <b>IGA:</b> investigator's global assessment; <b>OR:</b> odds ratio; <b>PGA:</b> patient global assessment; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Downgraded by one level for imprecision because CI crosses line of minimal important difference (MID) threshold: statistically significant difference of uncertain clinical importance. </p> <p><sup>2</sup> Downgraded by one level for inconsistency due to moderate heterogeneity (I² = 35%). </p> <p><sup>3</sup> Downgraded by one level for imprecision because CI crosses line of MID threshold: uncertain whether there is any difference. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD009687-tbl-0003"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Steroid plus vitamin D compared to vitamin D for scalp psoriasis</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Steroid plus vitamin D compared to vitamin D for scalp psoriasis</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> scalp psoriasis <br/> <b>Intervention:</b> steroid plus vitamin D<br/> <b>Comparison:</b> vitamin D </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with vitamin D</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with steroid plus vitamin D</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Number of participants achieving 'clearance' by IGA</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 2.28<br/> (1.87 to 2.78) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2008<br/> (4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/> HIGH </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>145 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>330 per 1000<br/> (270 to 402) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Number of participants achieving 'response' by IGA</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 2.31<br/> (1.75 to 3.04) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2222<br/> (4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>280 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>646 per 1000<br/> (489 to 850) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Quality of life</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>(0 studies)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Only one study (<a href="./references#CD009687-bbs2-0156" title="OrtonneJ , ChimentiS , LugerT , PuigL , ReidF , TruebRM . Scalp psoriasis: European consensus on grading and treatment algorithm. Journal of the European Academy of Dermatology &amp; Venereology2009;23(12):1435‐44. [MEDLINE: 19614856] ">Ortonne 2009</a>) addressed this outcome, but did not provide sufficient information to allow assessment of the quality of evidence. </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000<br/> (0 to 0) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Number of participants withdrawing due to adverse events</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.19<br/> (0.11 to 0.36) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1970<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/> HIGH </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>No study reported the sort of AE that caused withdrawal. In one small study with high risk of bias (<a href="./references#CD009687-bbs2-0059" title="YilmazH , AydinF , SenturkN , CanturkT , TuranliAY . A comparison between the effects of calcipotriol lotion, momethasone furoate lotion and their combinations for the treatment of scalp psoriasis [Kalsipotriol Losyon, Mometazon Furoat Losyonve Kombinasyonlarinin Saçli Deri Psoriazisi Tedavisindeki Etkinliginin Karsilastirilmasi]. Turkderm Deri Hastaliklari ve Frengi Arsivi2005;39(2):109‐14. [EMBASE: 2006204571] ">Yilmaz 2005</a>, N = 30 participants) no withdrawals occurred. </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>56 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>11 per 1000<br/> (6 to 20) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Number of participants achieving 'response' by PGA</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.76<br/> (1.46 to 2.12) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2222<br/> (4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>427 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>751 per 1000<br/> (623 to 905) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>AE:</b> adverse event; <b>CI:</b> confidence interval; <b>IGA:</b> investigator's global assessment; <b>OR:</b> odds ratio; <b>PGA:</b> patient global assessment; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Downgraded by one level for inconsistency due to substantial heterogeneity (I² = 81%), may be due to different application frequency in studies (once versus twice daily). </p> <p><sup>2</sup> Downgraded by one level for inconsistency due to substantial heterogeneity (I² = 77%), may be due to different application frequency in studies (once versus twice daily). </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD009687-sec-0023" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD009687-sec-0023">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD009687-sec-0270">Español</a> </li> </nav> </div> </div> <section class="background" lang="en"> <div class="section-header" id="CD009687-sec-0023"></div> <p>An explanation of technical and medical terms is provided in <a href="#CD009687-tbl-0004">Table 1</a>. </p> <div class="table" id="CD009687-tbl-0004"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Glossary of technical and medical terms</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Medical terms</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Explanation</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Apoptosis</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The process of programmed cell death, which is the natural developmental and maintenance process of the normal removal of cells </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Immuno‐suppressive</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Specific property of certain medications (e.g. corticosteroids) that diminish the response or activation of the immune system </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hyperproliferation</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>An abnormality associated with a high rate of growth of cells by rapid division</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Differentiation</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The process by which a less specialised cell becomes a more specialised cell type</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Erythematous</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>An abnormal redness of the skin caused by various agents, such as sunlight or drugs etc, which irritate and congest the blood capillaries </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Plaque psoriasis</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Patches with the well‐defined characteristic of red, raised skin. They can appear on any skin surface, although the knees, elbows, scalp, trunk and nails are the most common locations. </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Keratolytic agents</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A chemical or physical agent that causes peeling by the softening and shedding of the horny outer layer of the skin </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hypervascularisation</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A local increase in the formation of blood vessels leading to a higher blood supply of the tissue mainly as a response to the action of the vascular endothelial growth factor (VEGF) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pro‐inflammatory</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Provoking inflammation</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Anti‐inflammatory</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Inhibiting or reducing inflammation</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Keratinocytes</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Skin cells forming the superficial layer of the skin (epidermis)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Epigenetics</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The interactions of specific proteins with the genome that influence the expression of certain genes without changing the genetic sequence </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PUVA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A photochemotherapy of certain dermatological conditions with psoralen and ultra violet A light (UVA). Usually, psoralen is applied topically on the affected area to increase the sensibility to the UVA light. </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rosacea</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A chronic skin disease affecting mainly the cheeks, nose, forehead, scalp and ears. On the involved ruddy skin thin superficial blood vessels (teleangiectasia), papules and pustules may appear. In a certain type of rosacea, some facial areas (e.g. nose) enlarge and become bulbous (e.g. rhinophyma). </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cytoplasm</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The watery fluid (cytosol) inside the cell in which the organelles and the skeleton of the cell are embedded </p> </td> </tr> </tbody> </table> </div> <section id="CD009687-sec-0024"> <h3 class="title" id="CD009687-sec-0024">Description of the condition</h3> <section id="CD009687-sec-0025"> <h4 class="title">Psoriasis in general</h4> <p>Psoriasis affects approximately 2% of the population in Western Europe and the US (<a href="./references#CD009687-bbs2-0111" title="BarkerJN . The pathophysiology of psoriasis. Lancet1991;338(8761):227‐30. [MEDLINE: 1676787] ">Barker 1991</a>; <a href="./references#CD009687-bbs2-0147" title="KruegerGG , BergstresserPR , LoweNJ , VoorheesJJ , WeinsteinGD . Psoriasis. Journal of the American Academy of Dermatology1984;11(5 Pt 2):937‐47. [MEDLINE: 6389615] ">Krueger 1984</a>; <a href="./references#CD009687-bbs2-0183" title="van deKerkhofPC , FranssenME . Psoriasis of the scalp. Diagnosis and management. American Journal of Clinical Dermatology2001;2(3):159‐65. [MEDLINE: 11705093] ">van de Kerkhof 2001</a>), and 0.2% to 0.6% in Far‐Eastern populations such as China, Taiwan or Japan (<a href="./references#CD009687-bbs2-0116" title="ChangYT , ChenTJ , LiuPC , ChenYC , ChenYJ , HuangYL , et al. Epidemiological study of psoriasis in the national health insurance database in Taiwan. Acta Dermato‐Venereologica2009;89(3):262‐6. [MEDLINE: 19479122] ">Chang 2009</a>; <a href="./references#CD009687-bbs2-0188" title="YipSY . The prevalence of psoriasis in the Mongoloid race. Journal of the American Academy of Dermatology1984;10(6):965‐8. [MEDLINE: 6736341] ">Yip 1984</a>). Psoriasis shows two peaks of disease‐onset: the first is at around 20 years, and the second at approximately 50 years (<a href="./references#CD009687-bbs2-0189" title="Zeljko‐PenavicJ , SitumM , SimicD , Vurnek‐ZivkovicM . Quality of life in psoriatic patients and the relationship between type I and type II psoriasis. Collegium Antropologicum2010;34(Suppl 1):195‐8. [MEDLINE: 20402318] ">Zeljko‐Penavic 2010</a>). There are different types including pustular, guttate, inverse, erythrodermic or chronic plaque psoriasis (psoriasis vulgaris), with the latter accounting for 90% of the cases (<a href="./references#CD009687-bbs2-0135" title="GriffithsCE , BarkerJN . Pathogenesis and clinical features of psoriasis. Lancet2007;370(9583):263‐71. [MEDLINE: 17658397] ">Griffiths 2007</a>). Clinical signs are characterised by well‐demarcated reddish (erythematous) plaques of thickened skin and silvery white scaling. Disease severity can range from a few small plaques to severe cases with up to 90% of the body surface affected (<a href="./references#CD009687-bbs2-0173" title="SternRS . Psoriasis. Lancet1997;350(9074):349‐53. [MEDLINE: 9251649] ">Stern 1997</a>). Typically the plaques are distributed symmetrically on knees and elbows, the trunk or the sacral region. The impairment of quality of life was found to be similar to that of people with other major medical conditions such as cardiovascular diseases, diabetes or even cancer (<a href="./references#CD009687-bbs2-0163" title="RappSR , FeldmanSR , ExumML , FleischerABJr , ReboussinDM . Psoriasis causes as much disability as other major medical diseases. Journal of the American Academy of Dermatology1999;41(3 Pt 1):401‐7. [MEDLINE: 10459113] ">Rapp 1999</a>). Furthermore, people with psoriasis have a higher risk of experiencing cardiovascular co‐morbidities and psychiatric disorders such as depression and anxiety (<a href="./references#CD009687-bbs2-0123" title="Devrimci‐OzguvenH , KundakciTN , KumbasarH , BoyvatA . The depression, anxiety, life satisfaction and affective expression levels in psoriasis patients. Journal of the European Academy of Dermatology &amp; Venereology2000;14(4):267‐71. [MEDLINE: 11204514] ">Devrimci‐Ozguven 2000</a>; <a href="./references#CD009687-bbs2-0126" title="DowlatshahiEA , WakkeeM , ArendsLR , NijstenT . The prevalence and odds of depressive symptoms and clinical depression in psoriasis patients: a systematic review and meta‐analysis. Journal of Investigative Dermatology2014;134(6):1542‐51. [MEDLINE: 24284419] ">Dowlatshahi 2014</a>). Around 20% of them also experience inflammation of smaller and major joints or tendons (<a href="./references#CD009687-bbs2-0164" title="ReichK , KrügerK , MössnerR , AugustinM . Epidemiology and clinical pattern of psoriatic arthritis in Germany: a prospective interdisciplinary epidemiological study of 1511 patients with plaque‐type psoriasis. British Journal of Dermatology2009;160(5):1040‐7. [MEDLINE: 19210498] ">Reich 2009</a>). Thus, rheumatologists routinely search for psoriatic lesions (e.g. on the scalp) in order to evaluate psoriatic arthritis as a differential diagnosis. </p> </section> <section id="CD009687-sec-0026"> <h4 class="title">Scalp psoriasis</h4> <p>Regardless of the type of psoriasis, up to 79% of people with the condition present with scalp involvement, which has frequently been the first site to show symptoms of the disease (<a href="./references#CD009687-bbs2-0181" title="van deKerkhofPC , Steegers‐TheunissenRP , KuipersMV . Evaluation of topical drug treatment in psoriasis. Dermatology1998;197(1):31‐6. [MEDLINE: 9693182] ">van de Kerkhof 1998</a>). Psoriatic scalp lesions are characterised by thickened, well‐demarcated erythematous plaques, with scaling and frequent itching. The lesions are typically located behind the ear (retro‐auricular) and neck, but may appear anywhere on the scalp. The extent varies from fine scaling to thick erythematous crusted plaques on the entire scalp, typically crossing the hair line and affecting a small area of the adjacent facial skin. In severe cases, hair loss due to psoriatic plaques has been reported (<a href="./references#CD009687-bbs2-0171" title="ShusterS . Psoriatic alopecia. British Journal of Dermatology1972;87(1):73‐7. [MEDLINE: 5043203] ">Shuster 1972</a>; <a href="./references#CD009687-bbs2-0180" title="van deKerkhofPC , ChangA . Scarring alopecia and psoriasis. British Journal of Dermatology1992;126(5):524‐5. [MEDLINE: 1610698] ">van de Kerkhof 1992</a>). Compared to sites of the body that can easily be covered by clothes, people with psoriasis on the scalp or face are often troubled, because lesions are difficult to hide. Together with pruritus, this has been shown to be one of the most distressing symptoms (<a href="./references#CD009687-bbs2-0182" title="van deKerkhofPC , deHoopD , deKorteJ , KuipersMV . Scalp psoriasis, clinical presentations and therapeutic management. Dermatology1998;197(4):326‐34. [MEDLINE: 9873169] ">van de Kerkhof 1998a</a>). Embarrassment may lead to social stigmatisation and rejection resulting in reduction of a person's self esteem, social withdrawal and avoidance behaviour (<a href="./references#CD009687-bbs2-0133" title="GinsburgIH , LinkBG . Psychosocial consequences of rejection and stigma feelings in psoriasis patients. International Journal of Dermatology1993;32(8):587‐91. [MEDLINE: 8407075] ">Ginsburg 1993</a>). </p> </section> <section id="CD009687-sec-0027"> <h4 class="title">Pathophysiology</h4> <p>Psoriasis is a chronic immune‐mediated disease. A histological examination of psoriatic plaques reveals hyperproliferation of abnormal keratinocytes, hypervascularisation and infiltration of immune cells, mainly CD4‐ and CD8‐positive T‐lymphocytes as well as dendritic cells (<a href="./references#CD009687-bbs2-0113" title="Bata‐CsorgoZ , HammerbergC , VoorheesJJ , CooperKD . Intralesional T‐lymphocyte activation as a mediator of psoriatic epidermal hyperplasia. Journal of Investigative Dermatology1995;105(1 Suppl):89S‐94S. [MEDLINE: 7616005] ">Bata‐Csorgo 1995</a>; <a href="./references#CD009687-bbs2-0179" title="ValdimarssonH , BakerBS , JonsdottirI , PowlesA , FryL . Psoriasis: a T‐cell‐mediated autoimmune disease induced by streptococcal superantigens?. Immunology Today1995;16(3):145‐9. [MEDLINE: 7718088] ">Valdimarsson 1995</a>). Pro‐inflammatory cytokines, such as tumour necrosis factor‐α (TNF‐α), interferon‐α (IFN‐α), several interleukins (IL‐2, IL‐6, IL‐8, IL‐12, IL‐17) and vascular endothelial growth factor (VEGF), play a key role in the pathologic interaction between immune cells and keratinocytes (<a href="./references#CD009687-bbs2-0110" title="AustinLM , OzawaM , KikuchiT , WaltersIB , KruegerJG . The majority of epidermal T cells in Psoriasis vulgaris lesions can produce type 1 cytokines, interferon‐gamma, interleukin‐2, and tumor necrosis factor‐alpha, defining TC1 (cytotoxic T lymphocyte) and TH1 effector populations: a type 1 differentiation bias is also measured in circulating blood T cells in psoriatic patients. Journal of Investigative Dermatology1999;113(5):752‐9. [MEDLINE: 10571730] ">Austin 1999</a>; <a href="./references#CD009687-bbs2-0161" title="PrinzJC , GrossB , VollmerS , TrommlerP , StrobelI , MeurerM , et al. T cell clones from psoriasis skin lesions can promote keratinocyte proliferation in vitro via secreted products. European Journal of Immunology1994;24(3):593‐8. [MEDLINE: 8125129] ">Prinz 1994</a>). Furthermore, psoriasis shows a close association with autoimmune‐associated HLA and DR antigens (<a href="./references#CD009687-bbs2-0111" title="BarkerJN . The pathophysiology of psoriasis. Lancet1991;338(8761):227‐30. [MEDLINE: 1676787] ">Barker 1991</a>; <a href="./references#CD009687-bbs2-0174" title="TagamiH . Triggering factors. Clinics in Dermatology1997;15(5):677‐85. [MEDLINE: 9313966] ">Tagami 1997</a>). </p> <p>The inheritable component of psoriasis is reflected by a higher incidence of cases in families of affected individuals. Recent studies identified numerous different gene loci and epigenetic alterations that are linked to the predisposition and progression of the disease (<a href="./references#CD009687-bbs2-0177" title="TrowbridgeRM , PittelkowMR . Epigenetics in the pathogenesis and pathophysiology of psoriasis vulgaris. Journal of Drugs in Dermatology2014;13(2):111‐8. [MEDLINE: 24509958] ">Trowbridge 2014</a>; <a href="./references#CD009687-bbs2-0178" title="TsoiLC , SpainSL , KnightJ , EllinghausE , StuartPE , CaponF , et al. Identification of 15 new psoriasis susceptibility loci highlights the role of innate immunity. Nature Genetics2012;44(12):1341‐8. [PUBMED: 23143594 ] ">Tsoi 2012</a>). </p> <p>However, there is evidence indicating that the interaction between genes and certain environmental factors is an important cause of the disease (<a href="./references#CD009687-bbs2-0124" title="DikaE , BardazziF , BalestriR , MaibachHI . Environmental factors and psoriasis. Current Problems in Dermatology2007;35:118‐35. [PUBMED: 17641494] ">Dika 2007</a>; <a href="./references#CD009687-bbs2-0136" title="GudjonssonJE . Genetic variation and psoriasis. Giornale Italiano di Dermatologia e Venereologia2008;143(5):299‐305. [MEDLINE: 18833071] ">Gudjonsson 2008</a>). A wide range of different stimuli, including physical, psychological and chemical, are recognised as being connected to the emergence of psoriasis, irrespective of the actual type. This list includes medication (e.g. beta‐blockers, antimalarials, lithium), infections (streptococcus, HIV), smoking, alcohol consumption and stress (<a href="./references#CD009687-bbs2-0107" title="AbelEA , DiCiccoLM , OrenbergEK , FrakiJE , FarberEM . Drugs in exacerbation of psoriasis. Journal of the American Academy of Dermatology1986;15(5 Pt 1):1007‐22. [MEDLINE: 2878015] ">Abel 1986</a>; <a href="./references#CD009687-bbs2-0108" title="Al'AbadieMS , KentGG , GawkrodgerDJ . The relationship between stress and the onset and exacerbation of psoriasis and other skin conditions. British Journal of Dermatology1994;130(2):199‐203. [MEDLINE: 8123572] ">Al'Abadie 1994</a>; <a href="./references#CD009687-bbs2-0117" title="ChaputJC , PoynardT , NaveauS , PensoD , DurrmeyerO , SuplissonD . Psoriasis, alcohol, and liver disease. British Medical Journal Clinical Research Ed1985;291(6487):25. [MEDLINE: 3926048] ">Chaput 1985</a>; <a href="./references#CD009687-bbs2-0148" title="LiW , HanJ , ChoiHK , QureshiAA . Smoking and risk of incident psoriasis among women and men in the United States: a combined analysis. American Journal of Epidemiology2012;175(5):402‐13. [MEDLINE: 22247049] ">Li 2012</a>; <a href="./references#CD009687-bbs2-0169" title="SettyAR , CurhanG , ChoiHK . Smoking and the risk of psoriasis in women: Nurses' Health Study II. American Journal of Medicine2007;120(11):953‐9. [MEDLINE: 17976422] ">Setty 2007</a>; <a href="./references#CD009687-bbs2-0175" title="TelferNR , ChalmersRJ , WhaleK , ColmanG . The role of streptococcal infection in the initiation of guttate psoriasis. Archives of Dermatology1992;128(1):39‐42. [MEDLINE: 1739285] ">Telfer 1992</a>; <a href="./references#CD009687-bbs2-0176" title="TobinAM , HigginsEM , NorrisS , KirbyB . Prevalence of psoriasis in patients with alcoholic liver disease. Clinical &amp; Experimental Dermatology2009;34(6):698‐701. [MEDLINE: 19438541] ">Tobin 2009</a>). Despite all recent scientific efforts, a complete understanding of all causes of the disease remains a challenge (<a href="./references#CD009687-bbs2-0177" title="TrowbridgeRM , PittelkowMR . Epigenetics in the pathogenesis and pathophysiology of psoriasis vulgaris. Journal of Drugs in Dermatology2014;13(2):111‐8. [MEDLINE: 24509958] ">Trowbridge 2014</a>). </p> <p>Scalp psoriasis can occasionally be confused with seborrhoeic dermatitis affecting the scalp. Seborrhoeic dermatitis is another inflammatory condition, which commonly affects the entire scalp, resulting in mild inflammation and dandruff. It can also affect the sides of the nose, eyebrows and ears, as well as the chest, armpits and groin. Psoriasis, on the other hand, is usually well demarcated and has a coarser scale, but early diffuse psoriasis of the scalp can sometimes look very similar to seborrhoeic dermatitis. A scalp biopsy may help to distinguish between the two conditions (<a href="./references#CD009687-bbs2-0121" title="DelRossoJQ . Adult seborrheic dermatitis: a status report on practical topical management. Journal of Clinical &amp; Aesthetic Dermatology2011;4(5):32‐8. [PUBMED: 21607192] ">Del Rosso 2011</a>; <a href="./references#CD009687-bbs2-0144" title="KimGW , JungHJ , KoHC , KimMB , LeeWJ , LeeSJ , et al. Dermoscopy can be useful in differentiating scalp psoriasis from seborrhoeic dermatitis. British Journal of Dermatology2011;164(3):652‐6. [MEDLINE: 21155753] ">Kim 2011</a>; <a href="./references#CD009687-bbs2-0151" title="MashalyHM , MasoodNA , MohamedAS . Classification of papulo‐squamous skin diseases using image analysis. Skin Research &amp; Technology2012;18(1):36‐44. [MEDLINE: 21338407] ">Mashaly 2011</a>). Sometimes, however, both skin conditions coexist, which is commonly called 'seborrhiasis'. A healthy scalp exhibits a physiological colonisation of <i>Pityrosporum ovale</i> , a yeast of the <i>Malassezia</i> species. However, both conditions can be associated with overgrowth in particular with <i>Malassezia globosa</i> and <i>Malassezia furfur</i>. This may trigger the disease and lead to exacerbation of inflammation and hyperproliferation of keratinocytes (<a href="./references#CD009687-bbs2-0112" title="BaroniA , PaolettiI , RuoccoE , AgozzinoM , TufanoMA , DonnarummaG . Possible role of Malassezia furfur in psoriasis: modulation of TGF‐beta1, integrin, and HSP70 expression in human keratinocytes and in the skin of psoriasis‐affected patients. Journal of Cutaneous Pathology2004;31(1):35‐42. [MEDLINE: 14675283] ">Baroni 2004</a>; <a href="./references#CD009687-bbs2-0134" title="Gomez‐MoyanoE , Crespo‐ErchigaV , Martinez‐PilarL , Godoy DiazD , Martinez‐GarciaS , Lova NavarroM , et al. Do Malassezia species play a role in exacerbation of scalp psoriasis? [Les levures Malassezia jouent‐elles un rôle dans les poussées du psoriasis du cuir chevelu?]. Journal de Mycologie Médicale2014;24(2):87‐92. [MEDLINE: 24411177] ">Gomez‐Moyano 2014</a>; <a href="./references#CD009687-bbs2-0166" title="RosenbergEW , BelewPW . Improvement of psoriasis of the scalp with ketoconazole. Archives of Dermatology1982;118(6):370‐1. [MEDLINE: 6284060] ">Rosenberg 1982</a>). </p> </section> </section> <section id="CD009687-sec-0028"> <h3 class="title" id="CD009687-sec-0028">Description of the intervention</h3> <p>Hair makes the scalp less accessible to topical agents. In addition, the proximity of the sensitive skin of the face increases the risk of local adverse effects of treatment, such as atrophy, iatrogenic rosacea or acne and irritation (<a href="./references#CD009687-bbs2-0141" title="HornEJ , DommS , KatzHI , LebwohlM , MrowietzU , KragballeK , et al. Topical corticosteroids in psoriasis: strategies for improving safety. Journal of the European Academy of Dermatology &amp; Venereology2010;24(2):119‐24. [MEDLINE: 20175860] ">Horn 2010</a>). The use of topical agents may be further limited by cosmetically unpleasant effects leading to dissatisfaction and decreased compliance. </p> <p>People with widespread psoriasis including the scalp may be treated with psoralen combined with ultraviolet A (PUVA) or systemic therapies that may consist of methotrexate, ciclosporin or biologic agents, among others. However, topical treatments remain the first‐line therapy for moderate body and scalp psoriasis. There is a wide range of treatment options for scalp psoriasis, including steroids, vitamin D3 analogues, tar preparations, dithranol, salicylic acid and tacrolimus, among others (<a href="./references#CD009687-bbs2-0156" title="OrtonneJ , ChimentiS , LugerT , PuigL , ReidF , TruebRM . Scalp psoriasis: European consensus on grading and treatment algorithm. Journal of the European Academy of Dermatology &amp; Venereology2009;23(12):1435‐44. [MEDLINE: 19614856] ">Ortonne 2009</a>; <a href="./references#CD009687-bbs2-0159" title="PappK , Berth‐JonesJ , KragballeK , WozelG , de laBrassinneM . Scalp psoriasis: a review of current topical treatment options. Journal of the European Academy of Dermatology &amp; Venereology2007;21(9):1151‐60. [MEDLINE: 17894698] ">Papp 2007</a>). These may provide a gamut of therapies for the physician and patient, but it also highlights the lack of an effective, sustainable treatment. All available therapies may partially control signs of psoriasis, but none has been shown to achieve a cure or long‐term remission. </p> <section id="CD009687-sec-0029"> <h4 class="title">Corticosteroids</h4> <p>Topical corticosteroids are one of the mainstay therapies for psoriasis (<a href="./references#CD009687-bbs2-0156" title="OrtonneJ , ChimentiS , LugerT , PuigL , ReidF , TruebRM . Scalp psoriasis: European consensus on grading and treatment algorithm. Journal of the European Academy of Dermatology &amp; Venereology2009;23(12):1435‐44. [MEDLINE: 19614856] ">Ortonne 2009</a>). The molecule binds to specific intracellular (cytosolic) receptors and modulates the inhibition and induction of regulatory proteins. The latter have influence on the transcription of genes coding for pro‐inflammatory proteins (such as cytokines, TNF‐α). Besides this genomic effect, they further interact with the cellular membrane (<a href="./references#CD009687-bbs2-0114" title="BosJD , SpulsPI . Topical treatments in psoriasis: today and tomorrow. Clinics in Dermatology2008;26(5):432‐7. [MEDLINE: 18755361] ">Bos 2008</a>). Prolonged use of topical corticosteroids may induce local adverse effects, such as cutaneous atrophy (skin thinning) and telangiectasia (small, dilated blood vessels in the skin), or systemic side effects, such as diabetes, hypertension and hypothalamic‐pituitary‐adrenal (HPA) axis suppression (<a href="./references#CD009687-bbs2-0132" title="GardinalI , AmmouryA , PaulC . Moderate to severe psoriasis: from topical to biological treatment. Journal of the European Academy of Dermatology &amp; Venereology2009;23(11):1324‐6. [PUBMED: 19470061] ">Gardinal 2009</a>; <a href="./references#CD009687-bbs2-0141" title="HornEJ , DommS , KatzHI , LebwohlM , MrowietzU , KragballeK , et al. Topical corticosteroids in psoriasis: strategies for improving safety. Journal of the European Academy of Dermatology &amp; Venereology2010;24(2):119‐24. [MEDLINE: 20175860] ">Horn 2010</a>). Topical corticosteroids are available in a variety of forms including emollient creams, ointments, gels, sprays, lotions, solutions, nail lacquers, tape and foam (<a href="./references#CD009687-bbs2-0141" title="HornEJ , DommS , KatzHI , LebwohlM , MrowietzU , KragballeK , et al. Topical corticosteroids in psoriasis: strategies for improving safety. Journal of the European Academy of Dermatology &amp; Venereology2010;24(2):119‐24. [MEDLINE: 20175860] ">Horn 2010</a>). They are classified according to their potency, but the classification systems are not consistent (seven classes in the USA, four in Germany or the UK). In this review, we categorised topical corticosteroids into four groups (1 to 4) according to the German steroid classification system (<a href="./references#CD009687-bbs2-0154" title="NiednerR . Glucocorticosteroids in dermatology [Glukokortikosteroide in der Dermatologie]. Dt Ärzteblatt1996;93(44):A2868‐72. [www.aerzteblatt.de/pdf/93/44/a2868_2.pdf] ">Niedner 1996</a>): mild (1), moderate (2), high (3) and very high potency (4). We listed the following agents as corticosteroids of moderate potency: fluocinolone acetonide 0.01%, hydrocortisone 17‐butyrate 0.1%, desoximetasone 0.05%, triamcinolone acetonide as 0.1% and 0.2% solution. Corticosteroids of high potency are amcinonide 0.1%, betamethasone dipropionate, betamethasone valerate as 0.1%, 0.12% and 1% solution, halcinonide 0.1%, fluocinonide, desoximetasone 0.25% and mometasone furoate. The only corticosteroid of very high potency within this review is clobetasol propionate 0.05%. None of the included studies analysed corticosteroids of mild potency. </p> </section> <section id="CD009687-sec-0030"> <h4 class="title">Vitamin D analogues</h4> <p>Topical vitamin D (calcitriol) and its analogues (calcipotriol, tacalcitol) are an important alternative to corticosteroids for the long‐term treatment of psoriasis (<a href="./references#CD009687-bbs2-0159" title="PappK , Berth‐JonesJ , KragballeK , WozelG , de laBrassinneM . Scalp psoriasis: a review of current topical treatment options. Journal of the European Academy of Dermatology &amp; Venereology2007;21(9):1151‐60. [MEDLINE: 17894698] ">Papp 2007</a>). After binding to their cytoplasmic receptor (VDR) and translocation into the nucleus, they initiate the transcription of vitamin D responsive genes through interaction with other regulatory proteins. This process regulates cell differentiation and causes inhibition of cell proliferation and inflammation (<a href="./references#CD009687-bbs2-0114" title="BosJD , SpulsPI . Topical treatments in psoriasis: today and tomorrow. Clinics in Dermatology2008;26(5):432‐7. [MEDLINE: 18755361] ">Bos 2008</a>; <a href="./references#CD009687-bbs2-0145" title="KragballeK , WildfangIL . Calcipotriol (MC 903), a novel vitamin D3 analogue stimulates terminal differentiation and inhibits proliferation of cultured human keratinocytes. Archives of Dermatological Research1990;282(3):164‐7. [MEDLINE: 2164359] ">Kragballe 1990</a>). Although topical vitamin D analogues are a safe alternative, initially they commonly cause peri‐lesional irritation, but the main concern may be the possible but rare increase of serum and urine calcium levels. Therefore, the total concentration should not exceed 100 g/week (<a href="./references#CD009687-bbs2-0146" title="KragballeK , IversenL . Calcipotriol. A new topical antipsoriatic. Dermatologic Clinics1993;11(1):137‐41. [MEDLINE: 8435908] ">Kragballe 1993</a>). However, calcipotriol, the most established vitamin D derivative, has not been shown to affect calcium homeostasis (<a href="./references#CD009687-bbs2-0146" title="KragballeK , IversenL . Calcipotriol. A new topical antipsoriatic. Dermatologic Clinics1993;11(1):137‐41. [MEDLINE: 8435908] ">Kragballe 1993</a>; <a href="./references#CD009687-bbs2-0183" title="van deKerkhofPC , FranssenME . Psoriasis of the scalp. Diagnosis and management. American Journal of Clinical Dermatology2001;2(3):159‐65. [MEDLINE: 11705093] ">van de Kerkhof 2001</a>). It can be dispensed as a cream, lotion, solution or shampoo, each at a concentration of 50 µg/gm. </p> </section> <section id="CD009687-sec-0031"> <h4 class="title">Tar‐based preparations</h4> <p>There are a number of different tar preparations including pine tar and coal tar. The latter is the most effective and frequently used (<a href="./references#CD009687-bbs2-0159" title="PappK , Berth‐JonesJ , KragballeK , WozelG , de laBrassinneM . Scalp psoriasis: a review of current topical treatment options. Journal of the European Academy of Dermatology &amp; Venereology2007;21(9):1151‐60. [MEDLINE: 17894698] ">Papp 2007</a>). It is a semisolid by‐product obtained through the distillation of bituminous coal, and it was employed in ancient times, both as monotherapy for psoriasis and in combination with other topical agents, systemic medicines and phototherapy (<a href="./references#CD009687-bbs2-0109" title="ArnoldWP . Tar. Clinics in Dermatology1997;15(5):739‐44. [MEDLINE: 9313972] ">Arnold 1997</a>; <a href="./references#CD009687-bbs2-0119" title="Cosmetic Ingredient Review ExpertPanel . Final safety assessment of coal tar as used in cosmetics. International Journal of Toxicology2008;27(Suppl 2):1‐24. [PUBMED: 18830861] ">Cosmetic Ingredient Review Expert Panel 2008</a>; <a href="./references#CD009687-bbs2-0130" title="FrankelAJ , ZeichnerJA , DelRossoJQ . Coal tar 2% foam in combination with a superpotent corticosteroid foam for plaque psoriasis: case report and clinical implications. Journal of Clinical &amp; Aesthetic Dermatology2010;3(10):42‐5. [MEDLINE: 20967195] ">Frankel 2010</a>; <a href="./references#CD009687-bbs2-0157" title="PaghdalKV , SchwartzRA . Topical tar: back to the future. Journal of the American Academy of Dermatology2009;61(2):294‐302. [MEDLINE: 19185953] ">Paghdal 2009</a>). The polycyclic aromatic hydrocarbons in coal tar make the skin more sensitive to UV light (<a href="./references#CD009687-bbs2-0153" title="MenterA . Goeckerman therapy versus biologics in the treatment of psoriasis. Journal of the American Academy of Dermatology2010;62(3):516‐7. [MEDLINE: 20159322] ">Menter 2010</a>). However, the main mode of action remains unclear (<a href="./references#CD009687-bbs2-0183" title="van deKerkhofPC , FranssenME . Psoriasis of the scalp. Diagnosis and management. American Journal of Clinical Dermatology2001;2(3):159‐65. [MEDLINE: 11705093] ">van de Kerkhof 2001</a>; <a href="./references#CD009687-bbs2-0159" title="PappK , Berth‐JonesJ , KragballeK , WozelG , de laBrassinneM . Scalp psoriasis: a review of current topical treatment options. Journal of the European Academy of Dermatology &amp; Venereology2007;21(9):1151‐60. [MEDLINE: 17894698] ">Papp 2007</a>). Tar has anti‐inflammatory, anti‐proliferative and strong pruritus‐reducing properties, but due to the unpleasant smell, cosmetic disadvantage and mutagenic potential, it became less popular in the treatment of scalp psoriasis (<a href="./references#CD009687-bbs2-0183" title="van deKerkhofPC , FranssenME . Psoriasis of the scalp. Diagnosis and management. American Journal of Clinical Dermatology2001;2(3):159‐65. [MEDLINE: 11705093] ">van de Kerkhof 2001</a>). Therefore, many efforts have been made to increase its acceptability and tar is now available in non‐staining and washable formulations including lotions and shampoo or in combination with other active agents (<a href="./references#CD009687-bbs2-0125" title="DograS , KaurI . Childhood psoriasis. Indian Journal of Dermatology, Venereology &amp; Leprology2010;76(4):357‐65. [MEDLINE: 20657115] ">Dogra 2010</a>; <a href="./references#CD009687-bbs2-0183" title="van deKerkhofPC , FranssenME . Psoriasis of the scalp. Diagnosis and management. American Journal of Clinical Dermatology2001;2(3):159‐65. [MEDLINE: 11705093] ">van de Kerkhof 2001</a>). </p> </section> <section id="CD009687-sec-0032"> <h4 class="title">Calcineurin inhibitors</h4> <p>Calcineurin is an intracellular enzyme that regulates the transcription of certain genes. In leucocytes, such as T‐helper cells and Langerhans cells, it activates the transcription of pro‐inflammatory cytokines such as interleukins (IL‐2, IL‐4, IL‐10) and interferon‐gamma. Tacrolimus and pimecrolimus are nonsteroidal immunosuppressing macrolactams that block calcineurin and subsequently the proliferation and activation of these immune cells (<a href="./references#CD009687-bbs2-0149" title="LugerT , PaulC . Potential new indications of topical calcineurin inhibitors. Dermatology: International Journal for Clinical and Investigative Dermatology2007;215(Suppl 1):45‐54. [MEDLINE: 18174692] ">Luger 2007</a>; <a href="./references#CD009687-bbs2-0158" title="Panhans‐GrossA , NovakN , KraftS , BieberT . Human epidermal Langerhans' cells are targets for the immunosuppressive macrolide tacrolimus (FK506). Journal of Allergy &amp; Clinical Immunology2001;107(2):345‐52. [MEDLINE: 11174203] ">Panhans‐Gross 2001</a>). Some studies, including randomised controlled trials, have shown the potential efficacy and safety of using calcineurin inhibitors for many dermatologic conditions (<a href="./references#CD009687-bbs2-0120" title="DayI , LinAN . Use of pimecrolimus cream in disorders other than atopic dermatitis. Journal of Cutaneous Medicine &amp; Surgery2008;12(1):17‐26. [MEDLINE: 18258153] ">Day 2008</a>; <a href="./references#CD009687-bbs2-0153" title="MenterA . Goeckerman therapy versus biologics in the treatment of psoriasis. Journal of the American Academy of Dermatology2010;62(3):516‐7. [MEDLINE: 20159322] ">Menter 2010</a>). In psoriasis, calcineurin inhibitors may be used as an alternative, especially for those body regions, such as the face, which are prone to adverse events during long‐term treatment with topical corticosteroids (<a href="./references#CD009687-bbs2-0125" title="DograS , KaurI . Childhood psoriasis. Indian Journal of Dermatology, Venereology &amp; Leprology2010;76(4):357‐65. [MEDLINE: 20657115] ">Dogra 2010</a>). Based on reports of conditions other than psoriasis, a carcinogenic risk has been the subject of ongoing discussion (<a href="./references#CD009687-bbs2-0155" title="NiwaY , TerashimaT , SumiH . Topical application of the immunosuppressant tacrolimus accelerates carcinogenesis in mouse skin. British Journal of Dermatology2003;149(5):960‐7. [MEDLINE: 14632799] ">Niwa 2003</a>; <a href="./references#CD009687-bbs2-0186" title="WeischerM , RockenM , BerneburgM . Calcineurin inhibitors and rapamycin: cancer protection or promotion?. Experimental Dermatology2007;16(5):385‐93. [MEDLINE: 17437481] ">Weischer 2007</a>). Calcineurin inhibitors have not yet been approved as topical treatment for psoriasis. </p> </section> <section id="CD009687-sec-0033"> <h4 class="title">Anthralin (dithranol)</h4> <p>Anthralin (dithranol) is a synthetic version of chrysarobin, derived from the Araroba tree of South America. It has been shown to induce a release of reactive oxygen species with an inhibiting effect on the proliferation of keratinocytes and the transformation of leucocytes (<a href="./references#CD009687-bbs2-0137" title="HegemannL , FruchtmannR , vanRooijenLA , Muller‐PeddinghausR , MahrleG . The antipsoriatic drug, anthralin, inhibits protein kinase C‐‐implications for its mechanism of action. Archives of Dermatological Research1992;284(3):179‐83. [MEDLINE: 1503504] ">Hegemann 1992</a>; <a href="./references#CD009687-bbs2-0150" title="MahrleG , BonnekohB , WeversA , HegemannL . Anthralin: how does it act and are there more favourable derivatives?. Acta Dermato‐Venereologica. Supplementum.1994;186:83‐4. [MEDLINE: 8073848] ">Mahrle 1994</a>). It is used in increasing concentrations (0.1% to 3%) for application to the scalp. It has been shown that anthralin is more easily applied during hospitalisation, although out‐patient short‐contact therapies are also in practice. Common adverse events are discolouration of the hair and irritation of the skin (<a href="./references#CD009687-bbs2-0125" title="DograS , KaurI . Childhood psoriasis. Indian Journal of Dermatology, Venereology &amp; Leprology2010;76(4):357‐65. [MEDLINE: 20657115] ">Dogra 2010</a>; <a href="./references#CD009687-bbs2-0183" title="van deKerkhofPC , FranssenME . Psoriasis of the scalp. Diagnosis and management. American Journal of Clinical Dermatology2001;2(3):159‐65. [MEDLINE: 11705093] ">van de Kerkhof 2001</a>). A few studies support the use of anthralin combined with other topical treatments or UVB phototherapy to improve the response in psoriasis of the body (<a href="./references#CD009687-bbs2-0125" title="DograS , KaurI . Childhood psoriasis. Indian Journal of Dermatology, Venereology &amp; Leprology2010;76(4):357‐65. [MEDLINE: 20657115] ">Dogra 2010</a>; <a href="./references#CD009687-bbs2-0187" title="YamamotoT , MatsuuchiM , IrimajiriJ , OtoyamaK , NishiokaK . Topical anthralin for psoriasis vulgaris: evaluation of 70 Japanese patients. Journal of Dermatology2000;27(7):482‐5. [MEDLINE: 10935350] ">Yamamoto 2000</a>). </p> </section> <section id="CD009687-sec-0034"> <h4 class="title">Salicylic acid</h4> <p>Due to its potent keratolytic effect, salicylic acid is often the initial treatment option where excessive scaling is present. It is most frequently used in a 5% to 10% preparation, but other formulations, such as in a solution, gel or petroleum jelly, are available. Salicylic acid appears to increase the penetration of other topical agents, such as corticosteroids, making a combination therapy meaningful (<a href="./references#CD009687-bbs2-0115" title="ChanCS , VanVoorheesAS , LebwohlMG , KormanNJ , YoungM , BeboBFJr , et al. Treatment of severe scalp psoriasis: from the Medical Board of the National Psoriasis Foundation. Journal of the American Academy of Dermatology2009;60(6):962‐71. [MEDLINE: 19375191] ">Chan 2009</a>; <a href="./references#CD009687-bbs2-0184" title="van deKerkhofPC , KragballeK . Recommendations for the topical treatment of psoriasis. Journal of the European Academy of Dermatology &amp; Venereology2005;19(4):495‐9. [MEDLINE: 15987303] ">van de Kerkhof 2005</a>). </p> </section> <section id="CD009687-sec-0035"> <h4 class="title">Antifungals</h4> <p>As previously mentioned, an overgrowth of <i>Pityrosporum</i> (<i>Malassezia</i> yeast) may be associated with inflammatory skin disorders such as scalp psoriasis or seborrhoeic dermatitis. Therefore, broad‐spectrum antifungals such as azole derivatives (e.g. ketoconazole) or ciclopirox olamine are a therapeutic approach for the treatment of scalp psoriasis (<a href="./references#CD009687-bbs2-0162" title="PuigL , RiberaM , HernanzJM , BelinchonI , Santos‐JuanesJ , LinaresM , et al. Treatment of scalp psoriasis: review of the evidence and Delphi consensus of the Psoriasis Group of the Spanish Academy of Dermatology and Venereology [Tratamiento de la psoriasis del cuero cabelludo. Revisión de la evidencia y Consenso Delphi del Grupo de Psoriasis de la Academia Española de Dermatología y Venereología]. Actas Dermo‐Sifiliográficas2010;101(10):827‐46. [MEDLINE: 21159259] ">Puig 2010</a>). Ketoconazole blocks the synthesis of the cholesterin‐like ergosterol, an essential component of the fungal cell membrane, leading to disruption and fungal cell death (<a href="./references#CD009687-bbs2-0128" title="FaergemannJ , BorgersM , DegreefH . A new ketoconazole topical gel formulation in seborrhoeic dermatitis: an updated review of the mechanism. Expert Opinion on Pharmacotherapy2007;8(9):1365‐71. [MEDLINE: 17563270] ">Faergemann 2007</a>). Ciclopirox, on the other hand, has a very complex fungistatic and fungicidal mode of action: it affects cell metabolism, leading to decreased uptake of essential substrates and increases the intracellular concentration of toxic peroxides. In addition, ciclopirox shows antimicrobial properties (<a href="./references#CD009687-bbs2-0165" title="RoquesC , BrousseS , PanizzuttiC . In vitro antifungal efficacy of ciclopirox olamine alone and associated with zinc pyrithione compared to ketoconazole against Malassezia globosa and Malassezia restricta reference strains. Mycopathologia2006;162(6):395‐400. [MEDLINE: 17146583] ">Roques 2006</a>). </p> </section> </section> <section id="CD009687-sec-0036"> <h3 class="title" id="CD009687-sec-0036">How the intervention might work</h3> <p>Topical preparations consist of an active agent within a vehicle of emollients or moisturisers. A diverse array of products is used to ensure the penetration of the active ingredient (<a href="./references#CD009687-bbs2-0156" title="OrtonneJ , ChimentiS , LugerT , PuigL , ReidF , TruebRM . Scalp psoriasis: European consensus on grading and treatment algorithm. Journal of the European Academy of Dermatology &amp; Venereology2009;23(12):1435‐44. [MEDLINE: 19614856] ">Ortonne 2009</a>; <a href="./references#CD009687-bbs2-0172" title="StaubachP , LunterDJ . Basic or maintenance therapy in dermatology. Appropriate vehicles, possibilities and limitations [Basistherapie in der Dermatologie. Geeignete Grundlagen, Möglichkeiten und Grenzen]. Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und Verwandte Gebiete2014;65(1):63‐72; quiz 73‐4. [MEDLINE: 24445946] ">Staubach 2014</a>; <a href="./references#CD009687-bbs2-0183" title="van deKerkhofPC , FranssenME . Psoriasis of the scalp. Diagnosis and management. American Journal of Clinical Dermatology2001;2(3):159‐65. [MEDLINE: 11705093] ">van de Kerkhof 2001</a>; <a href="./references#CD009687-bbs2-0185" title="vonStebutE . Significance of topical therapy in clinical situations. Location‐dependent principles [Stellenwert der topischen Therapie in klinischen Behandlungssituationen]. Hautarzt2014;65(3):186‐91. [MEDLINE: 24419475] ">von Stebut 2014</a>). They can be categorised as shampoos, hydrophilic vehicles (alcohol‐based lotions, foam, hydro‐gel, solution) and lipophilic preparations (cream, ointment, lipo‐gel, oil). They help to maintain the integrity of the cells of the scalp when damage occurs due to abnormal cell growth. Additionally, they have anti‐inflammatory properties and reduce itching (<a href="./references#CD009687-bbs2-0129" title="FluhrJ , CavallottiC , BerardescaE . Emollients, moisturizers, and keratolytic agents in psoriasis. Clinics in Dermatology2008;26(4):380‐6. [MEDLINE: 18691519] ">Fluhr 2008</a>; <a href="./references#CD009687-bbs2-0172" title="StaubachP , LunterDJ . Basic or maintenance therapy in dermatology. Appropriate vehicles, possibilities and limitations [Basistherapie in der Dermatologie. Geeignete Grundlagen, Möglichkeiten und Grenzen]. Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und Verwandte Gebiete2014;65(1):63‐72; quiz 73‐4. [MEDLINE: 24445946] ">Staubach 2014</a>). Depending on disease severity and the person's preference, different application methods may be used: short‐contacts (shampoo), leave‐ons (e.g. lotion, gel, cream) or even occlusive dressings. Particularly in scalp psoriasis, a convenient preparation is crucial for acceptability and hinges on the person's personal preference. The choice of the vehicle is therefore as critical as the active agent itself in order to encourage patient compliance and, thus, treatment efficacy (<a href="./references#CD009687-bbs2-0115" title="ChanCS , VanVoorheesAS , LebwohlMG , KormanNJ , YoungM , BeboBFJr , et al. Treatment of severe scalp psoriasis: from the Medical Board of the National Psoriasis Foundation. Journal of the American Academy of Dermatology2009;60(6):962‐71. [MEDLINE: 19375191] ">Chan 2009</a>). </p> <p>Corticosteroids, vitamin D analogues, calcineurin inhibitors and coal tar preparations use their anti‐proliferative, immuno‐suppressive and anti‐inflammatory properties to act upon the underlying histopathological process of psoriatic lesions. The choice of the most appropriate treatment depends on the severity of the disease and whether acute or maintenance therapy is needed. </p> </section> <section id="CD009687-sec-0037"> <h3 class="title" id="CD009687-sec-0037">Why it is important to do this review</h3> <p>Many different regimens have been studied for the treatment of scalp psoriasis: antifungals, dithranol, retinoids, vitamin D analogues, corticosteroids, phototherapy, pulsed magnetic fields, Grenz rays, keratolytics, emollients, steroids, salicylic acid, calcipotriol, coal tar, dithranol and tacrolimus, among others (<a href="./references#CD009687-bbs2-0143" title="KhanSA , WilliamsonDM , GatecliffM , ToshJ . The treatment of chronic psoriasis a two‐centre comparative study. Practitioner1981;225(1356):932‐4. [MEDLINE: 7029508] ">Khan 1981</a>; <a href="./references#CD009687-bbs2-0160" title="PatelV , HornEJ , LoboscoSJ , FoxKM , StevensSR , LebwohlM . Psoriasis treatment patterns: results of a cross‐sectional survey of dermatologists. Journal of the American Academy of Dermatology2008;58(6):964‐9. [MEDLINE: 18378352] ">Patel 2008</a>). However, there is still no evidence‐based consensus in the literature to support decision‐making during clinical practice. Therefore we have systematically assessed the evidence for the efficacy of topical treatments for scalp psoriasis in order to be able to offer guidance to healthcare practitioners in their clinical practice. </p> <p>The plans for this review were published as a protocol 'Topical treatments for scalp psoriasis' (<a href="./references#CD009687-bbs2-0142" title="JalesRD , NastA , SaconatoH , AtallahÁN , HirataSH . Topical treatments for scalp psoriasis. Cochrane Database of Systematic Reviews2012, Issue 4. [DOI: 10.1002/14651858.CD009687] ">Jales 2012</a>). </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD009687-sec-0038" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD009687-sec-0038">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD009687-sec-0285">Español</a> </li> </nav> </div> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD009687-sec-0038"></div> <p>To assess the efficacy and safety of topical treatments for scalp psoriasis.</p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD009687-sec-0039" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD009687-sec-0039">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD009687-sec-0286">Español</a> </li> </nav> </div> </div> <section class="methods" lang="en"> <div class="section-header" id="CD009687-sec-0039"></div> <section id="CD009687-sec-0040"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD009687-sec-0041"> <h4 class="title">Types of studies</h4> <p>We only included randomised controlled trials (RCTs) of parallel‐group, cross‐over or within‐patient design. </p> </section> <section id="CD009687-sec-0042"> <h4 class="title">Types of participants</h4> <p>We included participants of all ages who were diagnosed with scalp psoriasis according to clinical or biopsy findings used by authors of primary studies, for example, the classical history, signs and symptoms, and typical histopathologic features (<a href="./references#CD009687-bbs2-0167" title="RzanyB , NaldiL , SchaferT , SternR , WilliamsH . The diagnosis of psoriasis: diagnostic criteria. British Journal of Dermatology1998;138(5):917. [MEDLINE: 9666855] ">Rzany 1998</a>). </p> </section> <section id="CD009687-sec-0043"> <h4 class="title">Types of interventions</h4> <p>We made no restrictions regarding the topical active agent, the agent vehicle or the type of comparison. The following topical medications were included: </p> <p> <ul id="CD009687-list-0001"> <li> <p>corticosteroids (e.g. betamethasone dipropionate, clobetasol propionate);</p> </li> <li> <p>vitamin D (calcipotriol);</p> </li> <li> <p>corticosteroid plus vitamin D combination products (e.g. betamethasone dipropionate plus calcipotriol); </p> </li> <li> <p>corticosteroid plus salicylic acid combination products;</p> </li> <li> <p>tar‐based preparations (e.g. coal tar, pine tar);</p> </li> <li> <p>other combination products, containing dithranol, coconut oil, urea or salicylic acid;</p> </li> <li> <p>ciclopirox olamine (antifungal);</p> </li> <li> <p>tacrolimus; and</p> </li> <li> <p>cocois.</p> </li> </ul> </p> </section> <section id="CD009687-sec-0044"> <h4 class="title">Types of outcome measures</h4> <section id="CD009687-sec-0045"> <h5 class="title">Primary outcomes</h5> <p> <ol id="CD009687-list-0002"> <li> <p>Reduction in clinician‐assessed severity.</p> </li> <li> <p>Improvement in quality of life.</p> </li> <li> <p>Adverse events requiring withdrawal of treatment, such as serious allergic reactions.</p> </li> </ol> </p> </section> <section id="CD009687-sec-0046"> <h5 class="title">Secondary outcomes</h5> <p> <ol id="CD009687-list-0003"> <li> <p>Subjective reduction in severity of psoriasis.</p> </li> <li> <p>Minor adverse events not requiring withdrawal of treatment such as rash or itching.</p> </li> <li> <p>Time free of disease or duration of response as measured by the proportion of participants relapsing to baseline scores during continued treatment or following discontinuation of treatment. </p> </li> </ol> </p> <p>We analysed outcomes according to short‐term (≤ six months) and long‐term (&gt; six months) evaluations. </p> </section> </section> </section> <section id="CD009687-sec-0047"> <h3 class="title">Search methods for identification of studies</h3> <p>We aimed to identify all RCTs regardless of language or publication status (published, unpublished, in press or in progress). </p> <section id="CD009687-sec-0048"> <h4 class="title">Electronic searches</h4> <p>We searched the following databases up to 17 August 2015:</p> <p> <ul id="CD009687-list-0004"> <li> <p>the Cochrane Skin Group Specialised Register using the search terms 'scalp and psoria*';</p> </li> <li> <p>the Cochrane Central Register of Controlled Trials (CENTRAL 2015, Issue 7) using the search strategy in <a href="./appendices#CD009687-sec-0255">Appendix 1</a>; </p> </li> <li> <p>MEDLINE via Ovid (from 1946) using the strategy in <a href="./appendices#CD009687-sec-0256">Appendix 2</a>; </p> </li> <li> <p>EMBASE via Ovid (from 1974) using the strategy in <a href="./appendices#CD009687-sec-0257">Appendix 3</a>; and </p> </li> <li> <p>LILACS (Latin American and Caribbean Health Science Information database, from 1982, using the search terms (cuero cabelludo and psoria$) or (scalp and psoria$) and the controlled clinical trials topic‐specific query filter. </p> </li> </ul> </p> <section id="CD009687-sec-0049"> <h5 class="title">Trials registers</h5> <p>We searched the following trials registers on 15 September 2015 using the search term "scalp psoriasis" unless otherwise stated: </p> <p> <ul id="CD009687-list-0005"> <li> <p>the ISRCTN registry (<a href="http://www.controlled-trials.com/" target="_blank">www.controlled‐trials.com</a>); </p> </li> <li> <p>the US National Institutes of Health Ongoing Trials Register (<a href="http://www.clinicaltrials.gov/" target="_blank">www.clinicaltrials.gov</a>); </p> </li> <li> <p>the Australian New Zealand Clinical Trials Registry (<a href="http://www.anzctr.org.au/" target="_blank">www.anzctr.org.au</a>), using the terms "scalp AND psoriasis"; </p> </li> <li> <p>the World Health Organization International Clinical Trials Registry Platform (<a href="http://www.who.int/trialsearch/" target="_blank">www.who.int/trialsearch/</a>); </p> </li> <li> <p>the EU Clinical Trials Register (<a href="https://www.clinicaltrialsregister.eu/" target="_blank">https://www.clinicaltrialsregister.eu/</a>). </p> </li> </ul> </p> </section> </section> <section id="CD009687-sec-0050"> <h4 class="title">Searching other resources</h4> <section id="CD009687-sec-0051"> <h5 class="title">Reference lists</h5> <p>We scanned the bibliographies of retrieved studies for further references to relevant RCTs. </p> </section> <section id="CD009687-sec-0052"> <h5 class="title">Handsearching</h5> <p>We handsearched the following six psoriasis‐specific conferences of the past 12 years up to September 2015 for relevant RCTs presented as abstracts: </p> <p> <ul id="CD009687-list-0006"> <li> <p>American Academy of Dermatology (AAD);</p> </li> <li> <p>European Academy of Dermatology and Venerology (EADV);</p> </li> <li> <p>Deutsche Dermatologische Gesellschaft (DDG);</p> </li> <li> <p>Psoriasis ‐ From Gene to Clinic;</p> </li> <li> <p>Psoriasis International Network ‐ Paris; and</p> </li> <li> <p>International Federation of Psoriasis Associations (IFPA) ‐ Stockholm.</p> </li> </ul> </p> </section> <section id="CD009687-sec-0053"> <h5 class="title">Adverse effects</h5> <p>We did not perform a separate search for adverse effects of the target intervention. However, we did examine data on adverse effects from the included studies we identified. </p> </section> <section id="CD009687-sec-0054"> <h5 class="title">Correspondence</h5> <p>We attempted to obtain unpublished data via correspondence with trial authors and sponsors if contact details were available. </p> </section> </section> </section> <section id="CD009687-sec-0055"> <h3 class="title" id="CD009687-sec-0055">Data collection and analysis</h3> <p>Some parts of the methods section of this review use text that was originally published in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD009687-bbs2-0140" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>). </p> <section id="CD009687-sec-0056"> <h4 class="title">Selection of studies</h4> <p>Two authors (JGS and SR) independently screened abstracts of all publications obtained from the searches. For those that we considered as possibly relevant, we sought to obtain the full article. We read all available full texts to assess their relevance based on the inclusion criteria. </p> <p>The same authors screened all conference abstracts of the associations listed above for eligibility. </p> </section> <section id="CD009687-sec-0057"> <h4 class="title">Data extraction and management</h4> <p>Two authors (JGS and SR) independently extracted data from the included studies. Whenever disputes arose, we achieved resolution by consultation with a third author (AJ). For data extraction, we utilised Microsoft Office Excel 2003. </p> </section> <section id="CD009687-sec-0058"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>We assessed the methodological quality of the trials included in the review using the criteria described in the<i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD009687-bbs2-0140" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>): </p> <p> <ul id="CD009687-list-0007"> <li> <p>Was the random allocation sequence adequately generated?</p> </li> <li> <p>Was allocation adequately concealed?</p> </li> <li> <p>Was knowledge of the allocated interventions after assignment prevented (performance bias or detection bias)? </p> </li> <li> <p>Were incomplete outcome data adequately addressed?</p> </li> <li> <p>Are reports of the study free of suggestion of selective reporting?</p> </li> <li> <p>Was the study apparently free of other bias?</p> </li> </ul> </p> <p>We classified each of the items as low, high or unclear risk of bias (see <a href="./references#CD009687-sec-0266" title="">Characteristics of included studies</a>). </p> </section> <section id="CD009687-sec-0059"> <h4 class="title">Measures of treatment effect</h4> <p>We expressed the results of the single studies as risk ratios (RR) with 95% confidence intervals (CI) for dichotomous outcomes, and mean differences (MD) and 95% CI for continuous outcomes. Where it was not possible to calculate a point estimate due to missing measures of variance for continuous outcomes, we described the data qualitatively. If included studies were sufficiently homogeneous, we pooled the effect estimates of the single studies in a meta‐analysis. Specifically for dichotomous data with statistically significant effect estimates, we expressed the results as number needed to treat to benefit (NNTB) with 95% confidence intervals and the baseline risk to which it applies (<a href="./references#CD009687-bbs2-0118" title="ChristensenPM , KristiansenIS . Number‐needed‐to‐treat (NNT)‐‐needs treatment with care. Basic &amp; Clinical Pharmacology &amp; Toxicology2006;99(1):12‐6. [MEDLINE: 16867164] ">Christensen 2006</a>). We planned to calculate the standardised mean difference when the trials assessed the same outcome, but used different instruments or scales. However, the included trials did not use different instruments or scales to make this procedure necessary. </p> </section> <section id="CD009687-sec-0060"> <h4 class="title">Unit of analysis issues</h4> <p>The unit of analysis was based on the individual participant (unit to be randomised for interventions to be compared). We analysed cross‐over study designs by using the first phase of the trials (before crossing over the treatments), as it was difficult to determine whether there was any carry‐over effect. In cases where the study design was based on within‐participant studies (instead of a cross‐over design), or even if insufficient information was available to perform these analyses, we reported the estimate effects separately in additional tables in the same manner as they appeared in the original publications (<a href="./references#CD009687-bbs2-0140" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>). </p> <p>There were numerous multi‐arm studies. However, there was no risk of unit of analysis error, since we did not include any intervention or control group twice in the same meta‐analysis. </p> </section> <section id="CD009687-sec-0061"> <h4 class="title">Dealing with missing data</h4> <p>We analysed data using intention‐to‐treat (ITT) wherever possible. If outcome data or statistics were missing, we attempted to contact the authors or sponsors of the study to request these data. Where missing data or statistics were not available from authors or sponsors, we conducted available case analysis. Where studies had not already conducted ITT analysis for dichotomous efficacy outcomes, we imputed missing data as treatment failure. We then recalculated the data by following the ITT principle. However, some studies that had missing data only reported the total amount of drop‐outs, but not the number of drop‐outs per treatment group. In these cases, we conducted available case analysis as well, since treatment failure imputation was not possible. </p> <p>We planned to impute missing standard deviations for continuous outcomes where appropriate, however the majority of the included studies with continuous outcome data (e.g. TSS) had missing standard deviations, so we were unable to do this. </p> </section> <section id="CD009687-sec-0062"> <h4 class="title">Assessment of heterogeneity</h4> <p>We quantified inconsistency among the pooled estimates using the I² statistic (where I² statistic = [(Q ‐ df)/Q] x 100% [Q is the Chi² statistic and df its degree of freedom]). This illustrates the percentage of the variability in effect estimates resulting from heterogeneity, rather than sampling error (<a href="./references#CD009687-bbs2-0138" title="HigginsJP , ThompsonSG . Quantifying heterogeneity in a meta‐analysis. Statistics in Medicine2002;21(11):1539‐58. [MEDLINE: 12111919] ">Higgins 2002</a>; <a href="./references#CD009687-bbs2-0139" title="HigginsJP , ThompsonSG , DeeksJJ , AltmanDG . Measuring inconsistency in meta‐analyses. BMJ2003;327(7414):557‐60. [MEDLINE: 12958120] ">Higgins 2003</a>). We presented data using a random‐effects model (<a href="./references#CD009687-bbs2-0122" title="DerSimonianR , LairdN . Meta‐analysis in clinical trials. Controlled Clinical Trials1986;7(3):177‐88. [MEDLINE: 3802833] ">DerSimonian 1986</a>). Wherever heterogeneity among the included studies was substantial, we did not pool study results, but presented them individually. We then attempted to explain the heterogeneity using prespecified subgroups and sensitivity analyses. </p> <p>Thresholds for the interpretation of the I² statistic can be misleading, since the importance of inconsistency depends on several factors. A rough guide for the interpretation is as follows (<a href="./references#CD009687-bbs2-0140" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>): </p> <p> <ul id="CD009687-list-0008"> <li> <p>0% to 40% = might not be important;</p> </li> <li> <p>30% to 60% = may represent moderate heterogeneity*;</p> </li> <li> <p>50% to 90% = may represent substantial heterogeneity*; and</p> </li> <li> <p>75% to 100% = considerable heterogeneity*.</p> </li> </ul> </p> <p>*The importance of the observed value of the I² statistic depends on the magnitude and direction of effects and the strength of the evidence for heterogeneity (e.g. P value from the Chi² statistic, or a confidence interval for the I² statistic). </p> </section> <section id="CD009687-sec-0063"> <h4 class="title">Assessment of reporting biases</h4> <p>We planned to assess publication bias by preparing a funnel plot. However, as none of the comparisons included more than 10 studies, funnel plots would not give any meaningful information. </p> </section> <section id="CD009687-sec-0064"> <h4 class="title">Data synthesis</h4> <p>We synthesised and presented qualitative information relative to methods, risk of bias, description of participants and outcome measures in a <a href="./references#CD009687-sec-0266" title="">Characteristics of included studies</a> table within the review. For quantitative data, we meta‐analysed the data using the random‐effects model, since substantial clinical and methodological heterogeneity were expected between the studies, which by themselves can generate substantial statistical heterogeneity. When data from primary studies were not parametric (e.g. effects reported as medians, quartiles, etc), or they were without sufficient statistical information (e.g. standard deviations, standard error, etc), we presented them qualitatively. </p> </section> <section id="CD009687-sec-0065"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We planned to perform subgroup analysis according to age range, severity of scalp psoriasis and type of available treatments. Wherever meta‐analysis for a class of agents was performed, we additionally analysed subgroups with respect to the individual active agent and its vehicle (e.g. rinse‐off or leave‐ons). Particularly in the case of steroids, we undertook meta‐analysis pooling all agents, regardless of potency, but we analysed effect estimates of subgroups with respect to each individual steroid. </p> <p>In our investigation for clinical heterogeneity among trials we compared the following characteristics of study populations: age range, the proportion who were female, dosage and disease severity at baseline. We further assessed methodological heterogeneity by comparing study duration, and evaluated whether allocation concealment or blinding of participants and investigator were performed. Possible statistical heterogeneity observed among subgroups was not assumed as a true causal relationship between dependent (estimate effects) and independent variables (the subgroups), but only as hypotheses that could be tested in future trials. </p> </section> <section id="CD009687-sec-0066"> <h4 class="title">Sensitivity analysis</h4> <p>We carried out sensitivity analyses according to the following methodological aspects: intention‐to‐treat, available data analysis and concealment of allocation. We further planned to evaluate the estimate effects according to the inclusion and exclusion of studies reported only as abstracts. </p> <section id="CD009687-sec-0067"> <h5 class="title">'Summary of findings' tables</h5> <p>In 'Summary of findings' tables we present the quality of evidence and the corresponding illustrative risk of important dichotomous outcomes. We focused on three comparisons that we thought to be of major clinical interest: </p> <p> <ul id="CD009687-list-0009"> <li> <p>Steroids versus vitamin D (<a href="./full#CD009687-tbl-0001">summary of findings Table for the main comparison</a>). </p> </li> <li> <p>Steroid plus vitamin D compared to steroid (<a href="./full#CD009687-tbl-0002">summary of findings Table 2</a>). </p> </li> <li> <p>Steroid plus vitamin D compared to vitamin D (<a href="./full#CD009687-tbl-0003">summary of findings Table 3</a>). </p> </li> </ul> </p> <p>We graded the level of evidence for dichotomous outcomes using the GRADE approach as described in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD009687-bbs2-0140" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>): we assessed the boundaries of the CI. If the confidence limit crossed the minimal clinically important difference (MID) thresholds we downgraded. The MID represents the smallest difference between treatment groups for an outcome score that clinicians or participants identify as meaningful. GRADE suggests these thresholds to be greater than 25% benefit (1.25) and 25% harm (0.75). If one or both thresholds were crossed we downgraded. </p> </section> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD009687-sec-0068" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD009687-sec-0068"></div> <section id="CD009687-sec-0069"> <h3 class="title">Description of studies</h3> <section id="CD009687-sec-0070"> <h4 class="title">Results of the search</h4> <p>The electronic searches of the six main databases (see <a href="#CD009687-sec-0048">Electronic searches</a>) retrieved 290 records. During our handsearch of conference abstracts we detected two additional studies that appeared to meet the inclusion criteria. Our search in the trials registers identified seven further studies. Our screening of the reference lists of the included publications did not reveal any additional RCTs. We therefore had a total of 299 records. </p> <p>We excluded 176 records based on titles and abstracts. We tried to obtain the full texts or abstracts of the remaining 123 records. We excluded 27 studies (28 references) (see <a href="./references#CD009687-sec-0267" title="">Characteristics of excluded studies</a>). We added 14 records to <a href="./references#CD009687-sec-0268" title="">Characteristics of studies awaiting classification</a>. We classified six studies as <a href="./references#CD009687-bbs1-0004" title="">Ongoing studies</a>. </p> <p>We included 59 studies that were reported by the remaining 75 references. For further description of our screening process, see the study flow diagram (<a href="#CD009687-fig-0001">Figure 1</a>). </p> <div class="figure" id="CD009687-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD009687-fig-0001" src="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/image_n/nCD009687-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> </section> <section id="CD009687-sec-0071"> <h4 class="title">Included studies</h4> <p>This review included 59 studies with a total of 11,561 participants.</p> <section id="CD009687-sec-0072"> <h5 class="title">Design</h5> <p>Of the RCTs, 40 were head‐to‐head comparisons, 15 vehicle‐controlled and four compared active treatments with each other as well as versus the vehicle. The latter four trials, thus, assessed more than one comparison. Two publications were within‐patient (split‐face) trials, of which one was active‐controlled (<a href="./references#CD009687-bbs2-0025" title="JarrattM , DavisJG , GiltnerMP , JonesML , PeetsEA . Comparative studies of augmented betamethasone dipropionate lotion 0.05% and clobetasol propionate solution 0.05%: Correlation of the vasoconstriction assay and clinical activity in scalp psoriasis. Advances in Therapy1991;8(2):103‐11. [EMBASE: 1991176103] ">Jarratt 1991</a>), and the other vehicle‐controlled (<a href="./references#CD009687-bbs2-0037" title="LepawMI . Double‐blind comparison of halcinonide solution and placebo control in treatment of psoriasis of the scalp. Cutis1978;21(4):571‐3. [MEDLINE: 346315] ">Lepaw 1978</a>). </p> <p>Data on treatment duration were available for all 59 trials. The median duration was four weeks, ranging from five days (<a href="./references#CD009687-bbs2-0034" title="KöseO . Calcipotriol ointment vs clobetasol solution in scalp psoriasis. Journal of Dermatological Treatment1997;8(4):287. [EMBASE: 1998022654] ">Köse 1997</a>), to 52 weeks (<a href="./references#CD009687-bbs2-0038" title="CambazardF . Xamiol, a new treatment in scalp psoriasis: short‐ and long‐term results [Un nouveau traitement dans le psoriasis du cuir chevelu : Xamiol®: Résultats à court terme et à long terme]. Annales de Dermatologie et de Vénéréologie2009;136(Suppl 3):546‐50. [EMBASE: 2009406816] LugerTA , CambazardF , LarsenFG , BourcierM , GuptaG , ClonierF , et al. A study of the safety and efficacy of calcipotriol and betamethasone dipropionate scalp formulation in the long‐term management of scalp psoriasis. Dermatology2008;217(4):321‐8. [MEDLINE: 18787325] ">Luger 2008</a>). Nine trials (9/59 = 15%) reported data on follow‐up visits, with a mean follow‐up duration of 2.4 weeks (range: one to eight weeks). We defined follow‐up as post‐treatment assessments. </p> <p>The oldest included study was published in 1972 (<a href="./references#CD009687-bbs2-0019" title="HarrisJJ . A national double‐blind clinical trial of a new corticosteroid lotion: a 12‐investigator cooperative analysis. Current Therapeutic Research, Clinical &amp; Experimental1972;14(9):638‐46. [MEDLINE: 4263888] ">Harris 1972</a>), the most recent one in 2015 (<a href="./references#CD009687-bbs2-0041" title="NCT01195831 . Efficacy and safety of Xamiol® gel compared to calcipotriol scalp solution in patients with scalp psoriasis. clinicaltrials.gov/show/NCT01195831 (accessed 5 November 2014). ">NCT01195831</a>). Most of the trials (35/59 = 59%) were multicentre studies. </p> </section> <section id="CD009687-sec-0073"> <h5 class="title">Sample size</h5> <p>Except for one (<a href="./references#CD009687-bbs2-0002" title="BarrettC , LowsonD , BladesKJ . Limited benefit of combined use of tar‐based shampoo with 50 mug/ml calcipotriol solution in scalp psoriasis. Journal of Dermatological Treatment2005;16(3):175. [EMBASE: 2005434030] ">Barrett 2005</a>), all included trials provided data on the number of randomised participants. The sample size varied from 26 (<a href="./references#CD009687-bbs2-0001" title="AndresP , PoncetM , FarzanehS , SotoP . Short‐term safety assessment of clobetasol propionate 0.05% shampoo: hypothalamic‐pituitary‐adrenal axis suppression, atrophogenicity, and ocular safety in subjects with scalp psoriasis. Journal of Drugs in Dermatology2006;5(4):328‐32. [MEDLINE: 16673799] ">Andres 2006</a>), to 1505 (<a href="./references#CD009687-bbs2-0027" title="JemecGB , GanslandtC , OrtonneJP , PoulinY , BurdenAD , deUnamunoP , et al. A new scalp formulation of calcipotriene plus betamethasone compared with its active ingredients and the vehicle in the treatment of scalp psoriasis: a randomized, double‐blind, controlled trial. Journal of the American Academy of Dermatology2008;59(3):455‐63. [MEDLINE: 18694678] JemecGBE , BurdenD , PoulinY , OrtonneJP . A new scalp formulation of calcipotriene plus betamethasone in the treatment of scalp psoriasis compared to its active ingredients and the vehicle (Abstract P2733). Journal of the American Academy of Dermatology2007;56(2):AB182. ">Jemec 2008</a>) participants. </p> </section> <section id="CD009687-sec-0074"> <h5 class="title">Participants</h5> <p>The 59 included trials evaluated a total of 11,561 participants. In 38 studies (38/59 = 64%), data on the age of participants (N = 9051) were available. The mean age of the these participants was 45.2 years. However, this mean score does not include four studies that only provided data on the age range of all included participants. Forty trials (40/59 = 68%) provided information with regard to the gender of the included participants (N = 9061). With a mean of 49% (range: 22% to 68%) the percentage of female was nearly equal to that of the male participants. </p> <p>In 46 studies (46/59 = 78%; N = 9875 participants) a baseline severity of the study population was reported. In three trials, mean baseline severity data were available only for the whole study population but not for each intervention group. The other 43 studies provided distinct information on baseline severity for each study group. There was a wide spectrum of different severity scores. Most studies (31/46 = 67%) assessed baseline severity by the Total Sign Score (TSS). Others provided different data on baseline severity, e.g. the degree of scaling (<a href="./references#CD009687-bbs2-0006" title="CurleyRK , VickersCF , NorrisT , GloverDR . A comparative study of betamethasone dipropionate with salicylic acid and betamethasone valerate for the treatment of steroid‐responsive dermatoses of the scalp. Journal of Dermatological Treatment1990;1(4):203‐6. [EMBASE: 1990343409] ">Curley 1990</a>), Psoriasis Area and Severity Index (PASI) (<a href="./references#CD009687-bbs2-0003" title="BergstromKG , ArambulaK , KimballAB . Medication formulation affects quality of life: a randomized single‐blind study of clobetasol propionate foam 0.05% compared with a combined program of clobetasol cream 0.05% and solution 0.05% for the treatment of psoriasis. Cutis2003;72(5):407‐11. [MEDLINE: 14655784] ">Bergstrom 2003</a>; <a href="./references#CD009687-bbs2-0052" title="Van deKerkhofPC , GreenC , HambergKJ , HutchinsonPE , JensenJK , KidsonP , et al. Safety and efficacy of combined high‐dose treatment with calcipotriol ointment and solution in patients with psoriasis. Dermatology2002;204(3):214‐21. [MEDLINE: 12037450] ">van de Kerkhof 2002</a>), or the percentage of scalp area affected (<a href="./references#CD009687-bbs2-0012" title="FeldmanSR , MillsM , BrundageT , EastmanWJ . A multicenter, randomized, double‐blind study of the efficacy and safety of calcipotriene foam, 0.005%, vs vehicle foam in the treatment of plaque‐type psoriasis of the scalp. Journal of Drugs in Dermatology2013;12(3):300‐6. [MEDLINE: 23545912] ">Feldman 2013</a>). However, we sought to extract any available baseline data for disease severity in order to assess the comparability of the intervention groups. </p> <p>The definition and the scale of the TSS was not consistent throughout the studies. Some definitions included only the scores of erythema, scaling and thickness, others added the score of pruritus. The scale, therefore, had a range of either 0 to 9, 0 to 12, or 0 to 16, classifying the baseline severity as none, mild, moderate, severe and sometimes very severe. In order to classify the disease severity, we primarily used the definition given by each individual study. In seven studies we calculated the baseline TSS with data reported. In these and other studies, which did not provide a clear definition of the TSS, we adjusted for scale size (0 to 9) and graded the severity as mild (0 to 4.5), moderate (4.6 to 7.5) or severe (7.6 to 9). For 35 trials, a classification of the mean baseline severity was possible: the population of 30 of these trials had a moderate baseline severity. Of the other five trials, two study populations were of mild baseline severity, one of mild to moderate, one of moderate to severe, and one of severe baseline severity. </p> </section> <section id="CD009687-sec-0075"> <h5 class="title">Interventions</h5> <p>The included studies assessed the following medications:</p> <p> <ul id="CD009687-list-0010"> <li> <p>corticosteroids (e.g. betamethasone dipropionate, clobetasol propionate);</p> </li> <li> <p>vitamin D (calcipotriol);</p> </li> <li> <p>corticosteroid plus vitamin D combination products (e.g. betamethasone dipropionate plus calcipotriol); </p> </li> <li> <p>corticosteroid plus salicylic acid combination products;</p> </li> <li> <p>tar‐based preparations (e.g. coal tar, pine tar);</p> </li> <li> <p>other combination products, containing dithranol, coconut oil, urea or salicylic acid;</p> </li> <li> <p>ciclopirox olamine (antifungal);</p> </li> <li> <p>tacrolimus; and</p> </li> <li> <p>cocois.</p> </li> </ul> </p> <p>The interventions in the included studies were grouped into 15 main comparisons.</p> <p>We analysed vehicle‐controlled studies and head‐to‐head trials. The latter also involved comparisons of steroids, which were of varying or similar potency. Furthermore, we included studies that assessed a specific steroid in different application forms or its once‐ versus twice‐daily use. </p> <p>Applying the active agent in an appropriate vehicle is crucial (<a href="./references#CD009687-bbs2-0115" title="ChanCS , VanVoorheesAS , LebwohlMG , KormanNJ , YoungM , BeboBFJr , et al. Treatment of severe scalp psoriasis: from the Medical Board of the National Psoriasis Foundation. Journal of the American Academy of Dermatology2009;60(6):962‐71. [MEDLINE: 19375191] ">Chan 2009</a>). We therefore classified vehicles into two main groups: rinse‐offs (including shampoos) and leave‐ons. The latter was further divided in two subgroups: hydrophilic (including alcoholic solutions, foams, lotion, hydrogels, oil in water emulsions) and lipophilic leave‐ons (ointments, oleo gels, oils, creams, water in oil formulation). In addition, we distinguished occlusive and non‐occlusive dressings. We analysed identical active agents that were not of the same vehicle group as two different topical treatments. </p> <p>We classified topical corticosteroids into four groups (1 to 4) according to the German steroid classification system (<a href="./references#CD009687-bbs2-0154" title="NiednerR . Glucocorticosteroids in dermatology [Glukokortikosteroide in der Dermatologie]. Dt Ärzteblatt1996;93(44):A2868‐72. [www.aerzteblatt.de/pdf/93/44/a2868_2.pdf] ">Niedner 1996</a>): </p> <p> <ol id="CD009687-list-0011"> <li> <p>Mild potency: none of the included trials assessed topical corticosteroids of mild potency. </p> </li> <li> <p>Moderate potency: fluocinolone acetonide 0.01%, hydrocortisone 17‐butyrate 0.1%, desoximetasone 0.05%, triamcinolone acetonide as 0.1% and 0.2% solution </p> </li> <li> <p>High potency: amcinonide 0.1%, betamethasone dipropionate, betamethasone valerate as 0.1%, 0.12% and 1% solution, halcinonide 0.1%, fluocinonide, fluocinolone acetonide 0.025%, desoximetasone 0.25% and mometasone furoate. </p> </li> <li> <p>Very high potency: clobetasol propionate.</p> </li> </ol> </p> </section> <section id="CD009687-sec-0076"> <h5 class="title">Outcomes</h5> <p>We further classified our pre‐specified outcomes below and recorded the number of studies, which provided data on these outcomes: </p> <section id="CD009687-sec-0077"> <h6 class="title">Primary outcomes</h6> <p>1) Reduction in clinician‐assessed severity:</p> <p> <ul id="CD009687-list-0012"> <li> <p>number of participants achieving 'clearance' according to the Investigators' Global Assessment of Disease Severity (IGA): 22 studies = 37%; </p> </li> <li> <p>number of participants achieving 'response' according to the IGA: 24 studies = 41%;</p> </li> <li> <p>mean score of the IGA: six studies = 10%; and</p> </li> <li> <p>mean of the Total Severity Score (TSS): 34 studies = 58%.</p> </li> </ul> </p> <p>2) Improvement in quality of life:</p> <p> <ul id="CD009687-list-0013"> <li> <p>any tool evaluating the improvement in quality of life: four studies = 7%.</p> </li> </ul> </p> <p>3) Adverse events requiring withdrawal of treatment, such as serious allergic reactions. This outcome was reported as 'Number of participants withdrawing due to adverse events': 30 studies = 51%. </p> </section> <section id="CD009687-sec-0078"> <h6 class="title">Secondary outcomes</h6> <p>1) Subjective reduction in severity of psoriasis:</p> <p> <ul id="CD009687-list-0014"> <li> <p>number of participants achieving 'clearance' according to the Patients' Global Assessment of Disease Severity (PGA): four studies = 7%; </p> </li> <li> <p>number of participants achieving 'response' according to the PGA: 12 studies = 20%; and </p> </li> <li> <p>mean score of the PGA: seven studies = 12%.</p> </li> </ul> </p> <p>2) Minor adverse events not requiring withdrawal of treatment such as rash or itching. This outcome was reported as 'Number of participants with at least one adverse event': 39 studies = 66%. </p> <p>3) Time span free of disease or duration of response as measured by the proportion of participants relapsing to baseline scores during continued treatment or following discontinuation of treatment: no studies. </p> <p>Most efficacy and safety analyses could only be made for short‐term treatments, since 58 studies were carried out for less than six months. The only trial that provided results concerning efficacy and safety for long‐term treatment had a study duration of 52 weeks (<a href="./references#CD009687-bbs2-0038" title="CambazardF . Xamiol, a new treatment in scalp psoriasis: short‐ and long‐term results [Un nouveau traitement dans le psoriasis du cuir chevelu : Xamiol®: Résultats à court terme et à long terme]. Annales de Dermatologie et de Vénéréologie2009;136(Suppl 3):546‐50. [EMBASE: 2009406816] LugerTA , CambazardF , LarsenFG , BourcierM , GuptaG , ClonierF , et al. A study of the safety and efficacy of calcipotriol and betamethasone dipropionate scalp formulation in the long‐term management of scalp psoriasis. Dermatology2008;217(4):321‐8. [MEDLINE: 18787325] ">Luger 2008</a>). However, this study reported the number of participants with satisfactorily controlled disease, which included all those with mild to absent disease status. This outcome did not meet our pre‐specified definition of treatment success (number of participants achieving 'response' by IGA) and was therefore not suitable for efficacy analysis. However, we extracted and analysed the long‐term safety data. </p> <p>For eight studies that stated IGA or PGA as continuous outcomes three provided sufficient statistical information in order to determine an effect estimate (<a href="./references#CD009687-bbs2-0009" title="EllisCN , HorwitzSN , MenterA . Amcinonide lotion 0.1% in the treatment of patients with psoriasis of the scalp. Current Therapeutic Research ‐ Clinical and Experimental1988;44(2):315‐24. [EMBASE: 1989002095] ">Ellis 1988</a>; <a href="./references#CD009687-bbs2-0011" title="FeldmanSR , RavisSM , FleischerAB , McMichaelA , JonesE , KaplanR , et al. Betamethasone valerate in foam vehicle is effective with both daily and twice a day dosing: a single‐blind, open‐label study in the treatment of scalp psoriasis. Journal of Cutaneous Medicine &amp; Surgery2001;5(5):386‐9. [MEDLINE: 11907847] ">Feldman 2001</a>; <a href="./references#CD009687-bbs2-0048" title="ShuttleworthD , GallowayDB , BoormanGC , DonaldAE . A double‐blind, placebo‐controlled study of the clinical efficacy of ciclopirox olamine (1.5%) shampoo for the control of scalp psoriasis. Journal of Dermatological Treatment1998;9(3):163‐7. [EMBASE: 1998346163] ">Shuttleworth 1998</a>). The remaining five trials did not report any measure of variance, thus, we described results qualitatively (<a href="./references#CD009687-bbs2-0010" title="EllisCN , MenterMA . A randomized, blinded comparison of amcinonide lotion and fluocinonide solution in patients with psoriasis of the scalp. Current Therapeutic Research ‐ Clinical and Experimental1989;46(3):471‐7. [EMBASE: 1989232557] ">Ellis 1989</a>; <a href="./references#CD009687-bbs2-0018" title="GriffithsC , BarkerJ , FinlayA , MizziF , ArsonnaudS . A new formulation of clobetasol proprionate is more effective and safer than 1% tar shampoo in scalp. Annales de Dermatologie et de Vénéréologie2002;129:1S740. GriffithsC , BarkerJ , FinlayA , MizziF , ArsonnaudS . A new formulation of clobetasol proprionate is safe and more effective than 1% tar shampoo in scalp psoriasis. Journal of the European Academy of Dermatology &amp; Venereology2002;16(Suppl 1):277. GriffithsCE , FinlayAY , FlemingCJ , BarkerJN , MizziF , ArsonnaudS . A randomized, investigator‐masked clinical evaluation of the efficacy and safety of clobetasol propionate 0.05% shampoo and tar blend 1% shampoo in the treatment of moderate to severe scalp psoriasis. Journal of Dermatological Treatment2006;17(2):90‐5. [MEDLINE: 16766333] ">Griffiths 2006</a>; <a href="./references#CD009687-bbs2-0040" title="MonkBE , MasonRBS , MunroCS , DarleyCR . An open and single‐blind comparative assessment of unguentum cocois compound in the treatment of psoriasis of the scalp. Journal of Dermatological Treatment1995;6(3):159‐61. [EMBASE: 1995319726] ">Monk 1995</a>; <a href="./references#CD009687-bbs2-0044" title="ReganaMS , MiradaA , TrullásC , DilméE . Increased efficacy and acceptability of a nonecoal tar shampoo for scalp psoriasis: Better efficacy and acceptability. 67th Annual Meeting of the American Academy of Dermatology, AAD San Francisco, CA United States. Conference Start: 20090306 Conference End: 20090310. Journal of the American Academy of Dermatology2009;60(3 Suppl 1):AB179. [EMBASE: 70142428] ">Regaña 2009</a>; <a href="./references#CD009687-bbs2-0057" title="WillisI , CornellRC , PenneysNS , ZaiasN . Multicenter study comparing 0.05% gel formulations of desoximetasone and fluocinonide in patients with scalp psoriasis. Clinical Therapeutics1986;8(3):275‐82. [MEDLINE: 3521856] ">Willis 1986</a>). The studies defined the IGA or PGA score differently. However, for most trials, a higher score meant a better outcome. In one study the IGA was provided as both a dichotomous and continuous outcome (<a href="./references#CD009687-bbs2-0057" title="WillisI , CornellRC , PenneysNS , ZaiasN . Multicenter study comparing 0.05% gel formulations of desoximetasone and fluocinonide in patients with scalp psoriasis. Clinical Therapeutics1986;8(3):275‐82. [MEDLINE: 3521856] ">Willis 1986</a>). However, since the authors did not provide any measure of variance, we only extracted the dichotomous data. </p> <p>Of the 34 trials that reported TSS as an efficacy outcome but no corresponding standard deviation (SD), we either calculated the mean TSS change from baseline or used the mean change provided in the text. Only one study that reported TSS as an efficacy outcome provided the SD (<a href="./references#CD009687-bbs2-0005" title="BuckleyC , HoffmannV . Calcipotriol plus betamethasone dipropionate gel is effective and safe in the treatment of scalp psoriasis (a phase II study). (Abstract P06.57). Journal of the European Academy of Dermatology &amp; Venereology2005;19(Suppl 2):175. BuckleyC , HoffmannV , ShapiroJ , SaariS , CambazardF , MilsgaardM . Calcipotriol plus betamethasone dipropionate scalp formulation is effective and well tolerated in the treatment of scalp psoriasis: a phase II study. Dermatology2008;217(2):107‐13. [MEDLINE: 18463448] ">Buckley 2008</a>). </p> <p>Nine studies reported data on follow‐up visits. Neither provided a definition of 'relapse' that was consistent with our protocol, nor did any study measure the time span until relapse occurred. </p> </section> </section> </section> <section id="CD009687-sec-0079"> <h4 class="title">Excluded studies</h4> <p>Studies that assessed systemic, ultraviolet (UV) or Grenz ray therapy were not eligible for this review. Therefore we excluded studies which allowed any systemic anti‐psoriatic treatment or concomitant UV/Grenz ray therapy of the scalp. </p> <p>Of the 123 identified publications that appeared to meet the inclusion criteria, we excluded 28 (see <a href="./references#CD009687-sec-0267" title="">Characteristics of excluded studies</a>). Seventeen studies did not have a randomised controlled design or did not clearly report any randomisation. Five trials assessed body psoriasis or other scalp dermatoses without providing results for scalp psoriasis separately. In four trials, the treatment did not meet this review's eligibility criteria. One study was of unclear design. </p> <section id="CD009687-sec-0080"> <h5 class="title">Studies awaiting classification</h5> <p>Fourteen studies are awaiting classification pending further information (<a href="./references#CD009687-sec-0268" title="">Characteristics of studies awaiting classification</a>). We attempted to contact nine authors in order to obtain additional data or information. Only three authors answered our requests. One referred us to the sponsor of his study, who did not respond to our enquiries. One other could not provide any additional data, since the study results were not yet processed. A third author refused to supply any unpublished data. One trial was already completed, but the results are not yet available (<a href="./references#CD009687-bbs2-0088" title="NCT01914627 . Parallel group trial to evaluate the efficacy and safety of Loion® compared to 10% salicylic acid in patients with chronic psoriasis capitis. www.clinicaltrials.gov/show/NCT01914627 (accessed 29 April 2015). ">Augustin 2014</a>). </p> </section> <section id="CD009687-sec-0081"> <h5 class="title">Ongoing studies</h5> <p>After searching the trials registers, we retrieved six records that appeared to meet the inclusion criteria. They are listed in <a href="./references#CD009687-bbs1-0004" title="">Ongoing studies</a>. </p> </section> </section> </section> <section id="CD009687-sec-0082"> <h3 class="title">Risk of bias in included studies</h3> <p>An overview of the risk of bias for the included studies, which was considerably heterogenous, is provided in <a href="#CD009687-fig-0002">Figure 2</a>. For detailed information concerning the reasons on which our risk evaluation of the individual study is based, please refer to the <a href="./references#CD009687-sec-0266" title="">Characteristics of included studies</a>. </p> <div class="figure" id="CD009687-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study.Legend: &quot;?&quot; = unclear risk of bias; &quot;+&quot; = low risk of bias; &quot;‐&quot; = high risk of bias" data-id="CD009687-fig-0002" src="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/image_n/nCD009687-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study. </p> <p>Legend: "?" = unclear risk of bias; "+" = low risk of bias; "‐" = high risk of bias</p> </div> </div> </div> <section id="CD009687-sec-0083"> <h4 class="title">Adequate sequence generation</h4> <p>Only 11 trials (19%) reported appropriate randomisation methods and we judged them at low risk of bias. Of this group, nine created a computer‐generated randomisation list, one used a table with random digits (<a href="./references#CD009687-bbs2-0023" title="HillstromL . Comparison of topical treatment with desoxymethasone solution 0.25% with salicylic acid 1% and betamethasone valerate solution 0.1% in patients with psoriasis of the scalp. Journal of International Medical Research1984;12(3):170‐3. [MEDLINE: 6734919] ">Hillstrom 1984</a>), and one reported a randomised block design (<a href="./references#CD009687-bbs2-0048" title="ShuttleworthD , GallowayDB , BoormanGC , DonaldAE . A double‐blind, placebo‐controlled study of the clinical efficacy of ciclopirox olamine (1.5%) shampoo for the control of scalp psoriasis. Journal of Dermatological Treatment1998;9(3):163‐7. [EMBASE: 1998346163] ">Shuttleworth 1998</a>). The other 48 studies did not provide sufficient information to permit judgement as to whether the sequence generation was adequately performed. </p> </section> <section id="CD009687-sec-0084"> <h4 class="title">Allocation</h4> <p>Only four (7%) of the 59 trials supplied sufficient information to assess whether allocation concealment was ensured throughout the study and we therefore judged them at low risk of bias. The remaining 55 studies did not address this or did not report sufficient information to permit judgement as to whether the allocation concealment was performed appropriately or not. </p> </section> <section id="CD009687-sec-0085"> <h4 class="title">Blinding</h4> <p>Of the 59 included studies, 33 had a double‐blind design, 14 were single‐blind studies, two had 'third‐party' blinding, six had an open‐label design and four did not report any blinding. </p> <p>Of the 33 studies (56%) with a double‐blind design, only seven clearly addressed their method to ensure blinding of participants and outcome assessors (<a href="./references#CD009687-bbs2-0012" title="FeldmanSR , MillsM , BrundageT , EastmanWJ . A multicenter, randomized, double‐blind study of the efficacy and safety of calcipotriene foam, 0.005%, vs vehicle foam in the treatment of plaque‐type psoriasis of the scalp. Journal of Drugs in Dermatology2013;12(3):300‐6. [MEDLINE: 23545912] ">Feldman 2013</a>; <a href="./references#CD009687-bbs2-0015" title="FredrikssonT . A clinical comparison of 3 corticosteroid alcoholic solutions in the treatment of psoriasis of the scalp. Pharmatherapeutica1976;1(4):252‐6. [EMBASE: 0977155168] ">Fredriksson 1976</a>; <a href="./references#CD009687-bbs2-0017" title="GreenC , GanpuleM , HarrisD , KavanaghG , KennedyC , MallettR , et al. Comparative effects of calcipotriol (MC903) solution and placebo (vehicle of MC903) in the treatment of psoriasis of the scalp. British Journal of Dermatology1994;130(4):483‐7. [MEDLINE: 8186114] ">Green 1994</a>; <a href="./references#CD009687-bbs2-0019" title="HarrisJJ . A national double‐blind clinical trial of a new corticosteroid lotion: a 12‐investigator cooperative analysis. Current Therapeutic Research, Clinical &amp; Experimental1972;14(9):638‐46. [MEDLINE: 4263888] ">Harris 1972</a>; <a href="./references#CD009687-bbs2-0021" title="HillstromL , PetterssonL . Studies with betamethasone dipropionate lotion with salicylic acid (Diprosalic) in psoriasis and seborrhoic eczema of the scalp. Current Therapeutic Research ‐ Clinical and Experimental1978;24(1):46‐50. [EMBASE: 0979244015] ">Hillstrom 1978</a>; <a href="./references#CD009687-bbs2-0027" title="JemecGB , GanslandtC , OrtonneJP , PoulinY , BurdenAD , deUnamunoP , et al. A new scalp formulation of calcipotriene plus betamethasone compared with its active ingredients and the vehicle in the treatment of scalp psoriasis: a randomized, double‐blind, controlled trial. Journal of the American Academy of Dermatology2008;59(3):455‐63. [MEDLINE: 18694678] JemecGBE , BurdenD , PoulinY , OrtonneJP . A new scalp formulation of calcipotriene plus betamethasone in the treatment of scalp psoriasis compared to its active ingredients and the vehicle (Abstract P2733). Journal of the American Academy of Dermatology2007;56(2):AB182. ">Jemec 2008</a>; <a href="./references#CD009687-bbs2-0037" title="LepawMI . Double‐blind comparison of halcinonide solution and placebo control in treatment of psoriasis of the scalp. Cutis1978;21(4):571‐3. [MEDLINE: 346315] ">Lepaw 1978</a>). We judged them to be of low risk of bias for both domains. Eleven double‐blind trials did not provide sufficient information on how blinding of participants/personnel and outcome assessment was ensured throughout the study. For this reason, we evaluated the risk of bias as unclear concerning performance and detection bias in these studies (<a href="./references#CD009687-bbs2-0004" title="BrenemanDL , DavisMB , BergerV , ChaneyR . A double‐blind trial comparing the efficacy and safety of augmented betamethasone dipropionate lotion with fluocinonide solution in the treatment of severe scalp psoriasis. Journal of Dermatological Treatment1992;3(1):19‐21. [EMBASE: 1992153744] ">Breneman 1992</a>; <a href="./references#CD009687-bbs2-0006" title="CurleyRK , VickersCF , NorrisT , GloverDR . A comparative study of betamethasone dipropionate with salicylic acid and betamethasone valerate for the treatment of steroid‐responsive dermatoses of the scalp. Journal of Dermatological Treatment1990;1(4):203‐6. [EMBASE: 1990343409] ">Curley 1990</a>; <a href="./references#CD009687-bbs2-0010" title="EllisCN , MenterMA . A randomized, blinded comparison of amcinonide lotion and fluocinonide solution in patients with psoriasis of the scalp. Current Therapeutic Research ‐ Clinical and Experimental1989;46(3):471‐7. [EMBASE: 1989232557] ">Ellis 1989</a>; <a href="./references#CD009687-bbs2-0013" title="FranzTJ , ParsellDA , HalualaniRM , HanniganJF , KalbachJP , HarkonenWS . Betamethasone valerate foam 0.12%: a novel vehicle with enhanced delivery and efficacy. International Journal of Dermatology1999;38(8):628‐32. [MEDLINE: 10487457] ">Franz 1999</a>; <a href="./references#CD009687-bbs2-0014" title="FranzTJ , ParsellDA , MyersJA , HanniganJF . Clobetasol propionate foam 0.05%: a novel vehicle with enhanced delivery. International Journal of Dermatology2000;39(7):535‐8. [MEDLINE: 10940121] ">Franz 2000</a>; <a href="./references#CD009687-bbs2-0016" title="GipL . Hydrocortisone 17‐butyrate 0.1% cream and fluocinolone acetonide 0.025% cream: a double‐blind comparison in patients suffering from psoriasis of the scalp. Current Therapeutic Research ‐ Clinical and Experimental1981;29(1 II):198‐201. [EMBASE: 1981110060] ">Gip 1981</a>; <a href="./references#CD009687-bbs2-0022" title="HillstromL , PetterssonL , SvenssonL . Comparison of betamethasone dipropionate lotion with salicylic acid (Diprosalic(TM)) and clobetasol propionate lotion (Dermovate(TM)) in the treatment of psoriasis of the scalp. Journal of International Medical Research1982;10(6):419‐22. [MEDLINE: 7152080] ">Hillstrom 1982</a>; <a href="./references#CD009687-bbs2-0023" title="HillstromL . Comparison of topical treatment with desoxymethasone solution 0.25% with salicylic acid 1% and betamethasone valerate solution 0.1% in patients with psoriasis of the scalp. Journal of International Medical Research1984;12(3):170‐3. [MEDLINE: 6734919] ">Hillstrom 1984</a>; <a href="./references#CD009687-bbs2-0025" title="JarrattM , DavisJG , GiltnerMP , JonesML , PeetsEA . Comparative studies of augmented betamethasone dipropionate lotion 0.05% and clobetasol propionate solution 0.05%: Correlation of the vasoconstriction assay and clinical activity in scalp psoriasis. Advances in Therapy1991;8(2):103‐11. [EMBASE: 1991176103] ">Jarratt 1991</a>; <a href="./references#CD009687-bbs2-0032" title="KlaberMR , HutchinsonPE , Pedvis‐LeftickA , KragballeK , ReunalaTL , van deKerkhofPC , et al. Comparative effects of calcipotriol solution (50 micrograms/ml) and betamethasone 17‐valerate solution (1 mg/ml) in the treatment of scalp psoriasis. British Journal of Dermatology1994;131(5):678‐83. [MEDLINE: 7999600] ">Klaber 1994</a>; <a href="./references#CD009687-bbs2-0036" title="LassusA . Local treatment of psoriasis of the scalp with clobetasol propionate and betamethasone‐17,21‐dipropionate: a double‐blind comparison. Current Medical Research &amp; Opinion1976;4(5):365‐7. [MEDLINE: 795609] ">Lassus 1976</a>). We evaluated the other 15 of the 33 studies with a double‐blind design to be at low risk of performance bias and unclear risk of detection bias (<a href="./references#CD009687-bbs2-0005" title="BuckleyC , HoffmannV . Calcipotriol plus betamethasone dipropionate gel is effective and safe in the treatment of scalp psoriasis (a phase II study). (Abstract P06.57). Journal of the European Academy of Dermatology &amp; Venereology2005;19(Suppl 2):175. BuckleyC , HoffmannV , ShapiroJ , SaariS , CambazardF , MilsgaardM . Calcipotriol plus betamethasone dipropionate scalp formulation is effective and well tolerated in the treatment of scalp psoriasis: a phase II study. Dermatology2008;217(2):107‐13. [MEDLINE: 18463448] ">Buckley 2008</a>; <a href="./references#CD009687-bbs2-0009" title="EllisCN , HorwitzSN , MenterA . Amcinonide lotion 0.1% in the treatment of patients with psoriasis of the scalp. Current Therapeutic Research ‐ Clinical and Experimental1988;44(2):315‐24. [EMBASE: 1989002095] ">Ellis 1988</a>; <a href="./references#CD009687-bbs2-0026" title="ClaudelJ‐P , FredonL , MaccariF , SavaryJ . Nantes, March 26, 2009: A new response to psoriasis of the scalp: Clobex®, first corticosteroid shampoo [Nantes, le 26 mars 2009: Une nouvelle réponse au psoriasis du cuir chevelu: Clobex®, premier shampooing corticoïde]. Nouvelles Dermatologiques2009;28(6 Pt 1):341‐4. [EMBASE: 2009457722] JarratM , BenemanD , GottliebA , PoulinY , FoleyV . Efficacy and safety comparison of clobetasol proprionate shampoo 0.05% and vehicle in scalp psoriasis. Journal of the European Academy of Dermatology &amp; Venereology2002;16(Suppl 1):282‐3. JarrattM , BrenemanD , GottliebAB , PoulinY , LiuY , FoleyV . Clobetasol propionate shampoo 0.05%: a new option to treat patients with moderate to severe scalp psoriasis. Journal of Drugs in Dermatology2004;3(4):367‐73. [MEDLINE: 15303780] ">Jarratt 2004</a>; <a href="./references#CD009687-bbs2-0030" title="KissI , McCrearyHL , SiskinSB , EpinetteWW . A randomized, double ‐ blind, parallel group dose ranging comparison of the efficacy and safety of calcipotriene solution in the treatment of scalp psoriasis. American Academy of Dermatology. 54th annual meeting February 10‐15. Journal of the American Academy of Dermatology1996:P301. ">Kiss 1996</a>; <a href="./references#CD009687-bbs2-0031" title="KissI , McCrearyHL , SiskinSB , EpinetteWW . A randomized, double ‐ blind, parallel group dose ranging comparison of the efficacy and safety of calcipotriene solution in the treatment of scalp psoriasis. American Academy of Dermatology. 54th annual meeting February 10‐15. Journal of the American Academy of Dermatology1996:P301. ">Kiss 1996a</a>; <a href="./references#CD009687-bbs2-0038" title="CambazardF . Xamiol, a new treatment in scalp psoriasis: short‐ and long‐term results [Un nouveau traitement dans le psoriasis du cuir chevelu : Xamiol®: Résultats à court terme et à long terme]. Annales de Dermatologie et de Vénéréologie2009;136(Suppl 3):546‐50. [EMBASE: 2009406816] LugerTA , CambazardF , LarsenFG , BourcierM , GuptaG , ClonierF , et al. A study of the safety and efficacy of calcipotriol and betamethasone dipropionate scalp formulation in the long‐term management of scalp psoriasis. Dermatology2008;217(4):321‐8. [MEDLINE: 18787325] ">Luger 2008</a>; <a href="./references#CD009687-bbs2-0039" title="MedanskyRS , HandlerRM . Treating psoriasis of the scalp with a new corticosteroid lotion. Illinois Medical Journal1974;145(6):503‐4. [MEDLINE: 4152499] ">Medansky 1974</a>; <a href="./references#CD009687-bbs2-0042" title="OlsenEA , CramDL , EllisCN , HickmanJG , JacobsonC , JenkinsEE , et al. A double‐blind, vehicle‐controlled study of clobetasol propionate 0.05% (Temovate) scalp application in the treatment of moderate to severe scalp psoriasis. Journal of the American Academy of Dermatology1991;24(3):443‐7. [MEDLINE: 2061442] ">Olsen 1991</a>; <a href="./references#CD009687-bbs2-0043" title="PauporteM , MaibachH , LoweN , PuglieseM , FriedmanDJ , MendelsohnH , et al. Fluocinolone acetonide topical oil for scalp psoriasis. Journal of Dermatological Treatment2004;15(6):360‐4. [MEDLINE: 15764047] ">Pauporte 2004</a>; <a href="./references#CD009687-bbs2-0047" title="RuzickaT , TrompkeC . Treatment of scalp psoriasis. An effective and safe tacalcitol emulsion [Behandlung der Kopfhaut‐Psoriasis: Gute Wirksamkeit und Sicherheit durch Tacalcitol‐Emulsion]. Hautarzt2004;55(2):165‐70. [MEDLINE: 14968327] ">Ruzicka 2004</a>; <a href="./references#CD009687-bbs2-0048" title="ShuttleworthD , GallowayDB , BoormanGC , DonaldAE . A double‐blind, placebo‐controlled study of the clinical efficacy of ciclopirox olamine (1.5%) shampoo for the control of scalp psoriasis. Journal of Dermatological Treatment1998;9(3):163‐7. [EMBASE: 1998346163] ">Shuttleworth 1998</a>; <a href="./references#CD009687-bbs2-0049" title="Cook‐BoldenFE , GoffeBS , HudsonCP , SofenHL . Efficacy and safety results from a randomized, double‐blind, vehicle‐controlled study of clobetasol propionate spray for the treatment of moderate to severe plaque psoriasis of the scalp (Poster P3368) 68th Annual Meeting of the American Academy of Dermatology, AAD Miami, FL United States. Journal of the American Academy of Dermatology2010;62(3 Suppl 1):AB140. [EMBASE: 70142994] Cook‐BoldenFE , GoffeBS , HudsonCP , SofenHL . Patient satisfaction with clobetasol propionate spray, 0.05% for the management of moderate to severe plaque psoriasis of the scalp. 70th Annual Meeting of the American Academy of Dermatology San Diego, CA United States. Conference Start: 20120316 Conference End: 20120320. Journal of the American Academy of Dermatology2012;66(4 Suppl 1):AB197. [EMBASE: 70704639] Cook‐BoldenFE , GoffeBS , SofenHL , ColonLE , GottschalkRW . Successful treatment of moderate to severe plaque psoriasis of the scalp with clobetasol propionate spray, 0.05% (Abstract P3347). 69th Annual Meeting of the American Academy of Dermatology New Orleans, LA United States. Conference Start: 20110204 Conference End: 20110208. Journal of the American Academy of Dermatology2011;64(2 Suppl 1):AB157. [EMBASE: 70331905] Cook‐BoldenFE , GoffeBS , SofenHL , HudsonCP , ColonLE , GottschalkRW , et al. Patient satisfaction with clobetasol proprionate spray, 0.05% for the treatment of moderate to severe plaque psoriasis of the scalp. 36th Annual Hawaii Dermatology Seminar of the Skin Disease Education Foundation Waikoloa, HI United States. Conference Start: 20120219 Conference End: 20120224. Seminars in Cutaneous Medicine &amp; Surgery2012;31(1):A9‐A10. [EMBASE: 70706927] SofenH , HudsonCP , Cook‐BoldenFE , PrestonN , ColonLE , CaveneySW , et al. Clobetasol propionate 0.05% spray for the management of moderate‐to‐severe plaque psoriasis of the scalp: results from a randomized controlled trial. Journal of Drugs in Dermatology2011;10(8):885‐92. [MEDLINE: 21818510] ">Sofen 2011</a>; <a href="./references#CD009687-bbs2-0051" title="TyringS , MendozaN , AppellM , BibbyA , FosterR , HamiltonT , et al. A calcipotriene/betamethasone dipropionate two‐compound scalp formulation in the treatment of scalp psoriasis in Hispanic/Latino and Black/African American patients: results of the randomized, 8‐week, double‐blind phase of a clinical trial. International Journal of Dermatology2010;49(11):1328‐33. [MEDLINE: 20964660] ">Tyring 2010</a>; <a href="./references#CD009687-bbs2-0053" title="van deKerkhofP , AnsteyA , BarnesL , BolducC . A new scalp formulation of calcipotriene plus betamethasone in the treatment of scalp psoriasis compared to its active ingredients in the same vehicle. Journal of the American Academy of Dermatology2007;56(2):AB182. van deKerkhofPC , HoffmannV , AnsteyA , BarnesL , BolducC , ReichK , et al. A new scalp formulation of calcipotriol plus betamethasone dipropionate compared with each of its active ingredients in the same vehicle for the treatment of scalp psoriasis: a randomized, double‐blind, controlled trial. British Journal of Dermatology2009;160(1):170‐6. [MEDLINE: 19067709] ">van de Kerkhof 2009</a>; <a href="./references#CD009687-bbs2-0057" title="WillisI , CornellRC , PenneysNS , ZaiasN . Multicenter study comparing 0.05% gel formulations of desoximetasone and fluocinonide in patients with scalp psoriasis. Clinical Therapeutics1986;8(3):275‐82. [MEDLINE: 3521856] ">Willis 1986</a>). </p> <p>Of the 14 single‐blind studies (24%), 12 followed an investigator‐only masked design (<a href="./references#CD009687-bbs2-0001" title="AndresP , PoncetM , FarzanehS , SotoP . Short‐term safety assessment of clobetasol propionate 0.05% shampoo: hypothalamic‐pituitary‐adrenal axis suppression, atrophogenicity, and ocular safety in subjects with scalp psoriasis. Journal of Drugs in Dermatology2006;5(4):328‐32. [MEDLINE: 16673799] ">Andres 2006</a>; <a href="./references#CD009687-bbs2-0011" title="FeldmanSR , RavisSM , FleischerAB , McMichaelA , JonesE , KaplanR , et al. Betamethasone valerate in foam vehicle is effective with both daily and twice a day dosing: a single‐blind, open‐label study in the treatment of scalp psoriasis. Journal of Cutaneous Medicine &amp; Surgery2001;5(5):386‐9. [MEDLINE: 11907847] ">Feldman 2001</a>; <a href="./references#CD009687-bbs2-0018" title="GriffithsC , BarkerJ , FinlayA , MizziF , ArsonnaudS . A new formulation of clobetasol proprionate is more effective and safer than 1% tar shampoo in scalp. Annales de Dermatologie et de Vénéréologie2002;129:1S740. GriffithsC , BarkerJ , FinlayA , MizziF , ArsonnaudS . A new formulation of clobetasol proprionate is safe and more effective than 1% tar shampoo in scalp psoriasis. Journal of the European Academy of Dermatology &amp; Venereology2002;16(Suppl 1):277. GriffithsCE , FinlayAY , FlemingCJ , BarkerJN , MizziF , ArsonnaudS . A randomized, investigator‐masked clinical evaluation of the efficacy and safety of clobetasol propionate 0.05% shampoo and tar blend 1% shampoo in the treatment of moderate to severe scalp psoriasis. Journal of Dermatological Treatment2006;17(2):90‐5. [MEDLINE: 16766333] ">Griffiths 2006</a>; <a href="./references#CD009687-bbs2-0024" title="HousmanTS , McMichaelAJ , MellenBG , DerrowAE , McCartyMA , FeldmanSR . Use of 0.12% betamethasone valerate foam vs 0.01% fluocinolone acetonide topical oil to treat scalp psoriasis: quantitative assessment of patient preference and treatment efficacy. Cosmetic Dermatology2002;15(11):27‐30. [EMBASE: 2006007462] HousmanTS , McMichaelAJ , MellenBG , DerrowE , McCartyMA , FeldmanSR . Betamethasone valerate foam vs. fluocinolone acetonide topical oil in the treatment of scalp psoriasis: quantitative assessment of patients' preference and efficacy (Abstract 203). Journal of Investigative Dermatology2002;119(1):241. ">Housman 2002</a>; <a href="./references#CD009687-bbs2-0029" title="KatzHI , LindholmJS , WeissJS , ShavinJS , MormanM , BressinckR , et al. Efficacy and safety of twice‐daily augmented betamethasone dipropionate lotion versus clobetasol propionate solution in patients with moderate‐to‐severe scalp psoriasis. Clinical Therapeutics1995;17(3):390‐401. [MEDLINE: 7585843] ">Katz 1995</a>; <a href="./references#CD009687-bbs2-0035" title="KragballeK , GanslandtC , OrtonneJP . A calcipotriol plus betamethasone dipropionate scalp formulation significantly reduces itching in scalp psoriasis. Abstract P3343. American Academy of Dermatology 67th Annual Meeting March 6‐10, 2009. Journal of the American Academy of Dermatology2009;60(3 Suppl 1):AB172. KragballeK , HoffmannV , OrtonneJP , TanJ , NordinP , SegaertS . Efficacy and safety of calcipotriol plus betamethasone dipropionate scalp formulation compared with calcipotriol scalp solution in the treatment of scalp psoriasis: a randomized controlled trial. British Journal of Dermatology2009;161(1):159‐66. [MEDLINE: 19416259] NCT00243464 . A calcipotriol plus betamethasone diproprionate scalp formulation significantly reduces itching in scalp. www.clinicaltrials.gov/show/NCT00243464?term=NCT00243464 (accessed 5 November 2014). OrtonneJP , GanslandtC , TanJ , NordinP , KragballeK , SegaertS . Quality of life in patients with scalp psoriasis treated with calcipotriol/betamethasone dipropionate scalp formulation: a randomized controlled trial. Journal of the European Academy of Dermatology &amp; Venereology2009;23(8):919‐26. [MEDLINE: 19453810] ">Kragballe 2009</a>; <a href="./references#CD009687-bbs2-0040" title="MonkBE , MasonRBS , MunroCS , DarleyCR . An open and single‐blind comparative assessment of unguentum cocois compound in the treatment of psoriasis of the scalp. Journal of Dermatological Treatment1995;6(3):159‐61. [EMBASE: 1995319726] ">Monk 1995</a>; <a href="./references#CD009687-bbs2-0041" title="NCT01195831 . Efficacy and safety of Xamiol® gel compared to calcipotriol scalp solution in patients with scalp psoriasis. clinicaltrials.gov/show/NCT01195831 (accessed 5 November 2014). ">NCT01195831</a>; <a href="./references#CD009687-bbs2-0045" title="ReygagneP , DiaconuJ , PrèsH , ErnstTM , MeyerKG . Efficacy and safety comparison of clobetasol proprionate shampoo, gel and vehicle in scalp psoriasis. Journal of the European Academy of Dermatology &amp; Venereology2002;16(Suppl 1):283. ">Reygagne 2002</a>; <a href="./references#CD009687-bbs2-0046" title="ReygagneP , MrowietzU , DecroixJ , deWaard‐van der SpekFB , AcebesLO , FigueiredoA , et al. Clobetasol propionate shampoo 0.05% and calcipotriol solution 0.005%: a randomized comparison of efficacy and safety in subjects with scalp psoriasis. Journal of Dermatological Treatment2005;16(1):31‐6. [MEDLINE: 15897165] ReygagneP , MrowietzU , DecroixJ , van derSpekW , Olmos AcebesL , et al. Four‐week efficacy and safety comparison of a new clobetasol shampoo and calcipotriol solution 0.005% in subjects with scalp psoriasis. Journal of the European Academy of Dermatology &amp; Venereology2002;16(Suppl 1):285. ">Reygagne 2005</a>; <a href="./references#CD009687-bbs2-0056" title="WilhemKP , OckerG , TebbsV , GuilabertA . A new mometasone formulation (LAS 41002 emulsion with 36% water content) is effective, well tolerated and cosmetically acceptable in the treatment of scalp psoriasis. Abstract ‐ 22nd Congress of the European Academy of Dermatology and Venereology, 2‐6 October 2013, Istanbul. Journal of the European Academy of Dermatology &amp; Venereology. 2013. ">Wilhelm 2013</a>; <a href="./references#CD009687-bbs2-0058" title="WrightS , MannRJ . Comparison of a cream containing 0.1% dithranol in a 17% urea base (Psoradrate(TM)) with coal tar pomade in the treatment of scalp psoriasis. Clinical &amp; Experimental Dermatology1985;10(4):375‐8. [MEDLINE: 3899424] ">Wright 1985</a>), and we rated them to be at high risk of performance bias. Of these 12 studies, eight did not provide sufficient information on how blinding of outcome assessment was ensured; therefore we rated the risk of detection bias as unclear (<a href="./references#CD009687-bbs2-0001" title="AndresP , PoncetM , FarzanehS , SotoP . Short‐term safety assessment of clobetasol propionate 0.05% shampoo: hypothalamic‐pituitary‐adrenal axis suppression, atrophogenicity, and ocular safety in subjects with scalp psoriasis. Journal of Drugs in Dermatology2006;5(4):328‐32. [MEDLINE: 16673799] ">Andres 2006</a>; <a href="./references#CD009687-bbs2-0011" title="FeldmanSR , RavisSM , FleischerAB , McMichaelA , JonesE , KaplanR , et al. Betamethasone valerate in foam vehicle is effective with both daily and twice a day dosing: a single‐blind, open‐label study in the treatment of scalp psoriasis. Journal of Cutaneous Medicine &amp; Surgery2001;5(5):386‐9. [MEDLINE: 11907847] ">Feldman 2001</a>; <a href="./references#CD009687-bbs2-0018" title="GriffithsC , BarkerJ , FinlayA , MizziF , ArsonnaudS . A new formulation of clobetasol proprionate is more effective and safer than 1% tar shampoo in scalp. Annales de Dermatologie et de Vénéréologie2002;129:1S740. GriffithsC , BarkerJ , FinlayA , MizziF , ArsonnaudS . A new formulation of clobetasol proprionate is safe and more effective than 1% tar shampoo in scalp psoriasis. Journal of the European Academy of Dermatology &amp; Venereology2002;16(Suppl 1):277. GriffithsCE , FinlayAY , FlemingCJ , BarkerJN , MizziF , ArsonnaudS . A randomized, investigator‐masked clinical evaluation of the efficacy and safety of clobetasol propionate 0.05% shampoo and tar blend 1% shampoo in the treatment of moderate to severe scalp psoriasis. Journal of Dermatological Treatment2006;17(2):90‐5. [MEDLINE: 16766333] ">Griffiths 2006</a>; <a href="./references#CD009687-bbs2-0024" title="HousmanTS , McMichaelAJ , MellenBG , DerrowAE , McCartyMA , FeldmanSR . Use of 0.12% betamethasone valerate foam vs 0.01% fluocinolone acetonide topical oil to treat scalp psoriasis: quantitative assessment of patient preference and treatment efficacy. Cosmetic Dermatology2002;15(11):27‐30. [EMBASE: 2006007462] HousmanTS , McMichaelAJ , MellenBG , DerrowE , McCartyMA , FeldmanSR . Betamethasone valerate foam vs. fluocinolone acetonide topical oil in the treatment of scalp psoriasis: quantitative assessment of patients' preference and efficacy (Abstract 203). Journal of Investigative Dermatology2002;119(1):241. ">Housman 2002</a>; <a href="./references#CD009687-bbs2-0041" title="NCT01195831 . Efficacy and safety of Xamiol® gel compared to calcipotriol scalp solution in patients with scalp psoriasis. clinicaltrials.gov/show/NCT01195831 (accessed 5 November 2014). ">NCT01195831</a>; <a href="./references#CD009687-bbs2-0045" title="ReygagneP , DiaconuJ , PrèsH , ErnstTM , MeyerKG . Efficacy and safety comparison of clobetasol proprionate shampoo, gel and vehicle in scalp psoriasis. Journal of the European Academy of Dermatology &amp; Venereology2002;16(Suppl 1):283. ">Reygagne 2002</a>; <a href="./references#CD009687-bbs2-0056" title="WilhemKP , OckerG , TebbsV , GuilabertA . A new mometasone formulation (LAS 41002 emulsion with 36% water content) is effective, well tolerated and cosmetically acceptable in the treatment of scalp psoriasis. Abstract ‐ 22nd Congress of the European Academy of Dermatology and Venereology, 2‐6 October 2013, Istanbul. Journal of the European Academy of Dermatology &amp; Venereology. 2013. ">Wilhelm 2013</a>; <a href="./references#CD009687-bbs2-0058" title="WrightS , MannRJ . Comparison of a cream containing 0.1% dithranol in a 17% urea base (Psoradrate(TM)) with coal tar pomade in the treatment of scalp psoriasis. Clinical &amp; Experimental Dermatology1985;10(4):375‐8. [MEDLINE: 3899424] ">Wright 1985</a>). We evaluated the other four studies to be at low risk of detection bias (<a href="./references#CD009687-bbs2-0029" title="KatzHI , LindholmJS , WeissJS , ShavinJS , MormanM , BressinckR , et al. Efficacy and safety of twice‐daily augmented betamethasone dipropionate lotion versus clobetasol propionate solution in patients with moderate‐to‐severe scalp psoriasis. Clinical Therapeutics1995;17(3):390‐401. [MEDLINE: 7585843] ">Katz 1995</a>; <a href="./references#CD009687-bbs2-0035" title="KragballeK , GanslandtC , OrtonneJP . A calcipotriol plus betamethasone dipropionate scalp formulation significantly reduces itching in scalp psoriasis. Abstract P3343. American Academy of Dermatology 67th Annual Meeting March 6‐10, 2009. Journal of the American Academy of Dermatology2009;60(3 Suppl 1):AB172. KragballeK , HoffmannV , OrtonneJP , TanJ , NordinP , SegaertS . Efficacy and safety of calcipotriol plus betamethasone dipropionate scalp formulation compared with calcipotriol scalp solution in the treatment of scalp psoriasis: a randomized controlled trial. British Journal of Dermatology2009;161(1):159‐66. [MEDLINE: 19416259] NCT00243464 . A calcipotriol plus betamethasone diproprionate scalp formulation significantly reduces itching in scalp. www.clinicaltrials.gov/show/NCT00243464?term=NCT00243464 (accessed 5 November 2014). OrtonneJP , GanslandtC , TanJ , NordinP , KragballeK , SegaertS . Quality of life in patients with scalp psoriasis treated with calcipotriol/betamethasone dipropionate scalp formulation: a randomized controlled trial. Journal of the European Academy of Dermatology &amp; Venereology2009;23(8):919‐26. [MEDLINE: 19453810] ">Kragballe 2009</a>; <a href="./references#CD009687-bbs2-0040" title="MonkBE , MasonRBS , MunroCS , DarleyCR . An open and single‐blind comparative assessment of unguentum cocois compound in the treatment of psoriasis of the scalp. Journal of Dermatological Treatment1995;6(3):159‐61. [EMBASE: 1995319726] ">Monk 1995</a>; <a href="./references#CD009687-bbs2-0046" title="ReygagneP , MrowietzU , DecroixJ , deWaard‐van der SpekFB , AcebesLO , FigueiredoA , et al. Clobetasol propionate shampoo 0.05% and calcipotriol solution 0.005%: a randomized comparison of efficacy and safety in subjects with scalp psoriasis. Journal of Dermatological Treatment2005;16(1):31‐6. [MEDLINE: 15897165] ReygagneP , MrowietzU , DecroixJ , van derSpekW , Olmos AcebesL , et al. Four‐week efficacy and safety comparison of a new clobetasol shampoo and calcipotriol solution 0.005% in subjects with scalp psoriasis. Journal of the European Academy of Dermatology &amp; Venereology2002;16(Suppl 1):285. ">Reygagne 2005</a>). </p> <p>Two of the 14 studies that were stated to be single‐blinded did not clearly state whether investigators or participants were blinded, or whether the outcome assessor was blinded, so we assessed both studies to be at unclear risk concerning performance and detection bias (<a href="./references#CD009687-bbs2-0003" title="BergstromKG , ArambulaK , KimballAB . Medication formulation affects quality of life: a randomized single‐blind study of clobetasol propionate foam 0.05% compared with a combined program of clobetasol cream 0.05% and solution 0.05% for the treatment of psoriasis. Cutis2003;72(5):407‐11. [MEDLINE: 14655784] ">Bergstrom 2003</a>; <a href="./references#CD009687-bbs2-0007" title="DeCuyperC , DeGreefH , De LaBrassinneM , DelesculeJ , DerumeuaxL , HeenenM , et al. A randomized single‐blind study to compare hydrocortisone 17‐butyrate 0.1% emulsion versus betamethasone 17,21‐dipropionate 0.05% lotion in the treatment of patients suffering from psoriasis of the scalp. Journal of the European Academy of Dermatology &amp; Venereology1995;5(Suppl 1):S104‐5. ">De Cuyper 1995</a>). </p> <p>Two trials (3%) addressed a 'third‐party' blinding, but it remained unclear how this was performed (<a href="./references#CD009687-bbs2-0050" title="SwinehartJM , BarkoffJR , DvorkinD , FisherG , PeetsE . Mometasone furoate lotion once daily versus triamcinolone acetonide lotion twice daily in psoriasis. International Journal of Dermatology1989;28(10):680‐1. [MEDLINE: 2687182] ">Swinehart 1989</a>; <a href="./references#CD009687-bbs2-0054" title="Van derPloegDE , CornellRC , BinderR , WeintraubJS , JarrattM , JonesML , et al. Clinical trial in scalp psoriasis mometasone furoate lotion 0.1% applied once daily vs betamethasone valerate lotion 0.1% applied twice daily. Acta Therapeutica1989;15(2):145‐52. ">Van der Ploeg 1989</a>). We assessed both studies as being at high risk of performance bias and at unclear risk of detection bias. </p> <p>We considered six studies (10%) that had an open‐label design to be at high risk of performance and detection bias (<a href="./references#CD009687-bbs2-0002" title="BarrettC , LowsonD , BladesKJ . Limited benefit of combined use of tar‐based shampoo with 50 mug/ml calcipotriol solution in scalp psoriasis. Journal of Dermatological Treatment2005;16(3):175. [EMBASE: 2005434030] ">Barrett 2005</a>; <a href="./references#CD009687-bbs2-0028" title="JosseM , MengeaudV , KhemisA . Efficacy of a new keratolytic shampoo containing glycolic acid and ictyol for the treatment of scalp psoriasis: results of a comparative study (Abstract P1604). Journal of the American Academy of Dermatology2006;54(3 Suppl):AB128. JosseM , MengeaudV , KhemisA , OrtonneJP . Efficacy of a new keratolytic shampoo containing glycolic acid and ictyol for the treatment of scalp psoriasis ‐ results of a comparative study (Abstract P16.34). Journal of the European Academy of Dermatology &amp; Venereology2005;19(Suppl 2):391. ">Josse 2005</a>; <a href="./references#CD009687-bbs2-0033" title="KlaberMR , McKinnonC . Calcipotriol (Dovonex©) scalp solution in the treatment of scalp psoriasis: comparative efficacy with 1% coal tar/1% coconut oil/0.5% salicylic acid (Capasal©) shampoo, and long‐term experience. Journal of Dermatological Treatment2000;11(1):21‐8. [EMBASE: 2000114933] ">Klaber 2000</a>; <a href="./references#CD009687-bbs2-0044" title="ReganaMS , MiradaA , TrullásC , DilméE . Increased efficacy and acceptability of a nonecoal tar shampoo for scalp psoriasis: Better efficacy and acceptability. 67th Annual Meeting of the American Academy of Dermatology, AAD San Francisco, CA United States. Conference Start: 20090306 Conference End: 20090310. Journal of the American Academy of Dermatology2009;60(3 Suppl 1):AB179. [EMBASE: 70142428] ">Regaña 2009</a>; <a href="./references#CD009687-bbs2-0052" title="Van deKerkhofPC , GreenC , HambergKJ , HutchinsonPE , JensenJK , KidsonP , et al. Safety and efficacy of combined high‐dose treatment with calcipotriol ointment and solution in patients with psoriasis. Dermatology2002;204(3):214‐21. [MEDLINE: 12037450] ">van de Kerkhof 2002</a>; <a href="./references#CD009687-bbs2-0055" title="WallARJ , BibbyAJ . Combined use of calcipotriol solution (50 ug/ml) and Polytar Liquid in scalp psoriasis (Abstract P‐689). Journal of the European Academy of Dermatology &amp; Venereology1999;12(Suppl 2):S337. ">Wall 1999</a>). </p> <p>Another four studies (7%) did not report any blinding. We considered two of them to be at unclear risk of performance and detection bias (<a href="./references#CD009687-bbs2-0008" title="DuwebGA , AbuzaribaO , RahimM , al‐TaweelM , AbdullaSA . Scalp psoriasis: topical calcipotriol 50 micrograms/g/ml solution vs. betamethasone valerate 1% lotion. International Journal of Clinical Pharmacology Research2000;20(3‐4):65‐8. [MEDLINE: 11314240] ">Duweb 2000</a>; <a href="./references#CD009687-bbs2-0020" title="HeYL , GuoZP . Clinical efficacy of 0.1% tacrolimus ointment on plaque psoriasis of scalp and face. Journal of Clinical Dermatology2008;37(4):254‐5. [EMBASE: 2008250949] ">He 2008</a>). <a href="./references#CD009687-bbs2-0034" title="KöseO . Calcipotriol ointment vs clobetasol solution in scalp psoriasis. Journal of Dermatological Treatment1997;8(4):287. [EMBASE: 1998022654] ">Köse 1997</a> reported no blinding and due to differences in treatment application and duration between the two intervention groups, it is unlikely that blinding of participants/personnel and outcome assessment was performed, so we rated them to be at high risk of performance and detection bias. For the fourth study, the blinding of participants and personnel was considered not to be possible due to the different application mode in the groups (high risk of performance bias); we rated the risk of detection bias as being unclear (<a href="./references#CD009687-bbs2-0059" title="YilmazH , AydinF , SenturkN , CanturkT , TuranliAY . A comparison between the effects of calcipotriol lotion, momethasone furoate lotion and their combinations for the treatment of scalp psoriasis [Kalsipotriol Losyon, Mometazon Furoat Losyonve Kombinasyonlarinin Saçli Deri Psoriazisi Tedavisindeki Etkinliginin Karsilastirilmasi]. Turkderm Deri Hastaliklari ve Frengi Arsivi2005;39(2):109‐14. [EMBASE: 2006204571] ">Yilmaz 2005</a>). </p> </section> <section id="CD009687-sec-0086"> <h4 class="title">Incomplete outcome data</h4> <p>Forty studies (68%) ensured the completeness of the outcome data and we judged them as low risk of bias. Of this group, 14 trials provided data on the intention‐to‐treat (ITT) population, in 10 studies no drop‐outs occurred and in 16 trials the drop‐out rate was considered as too small (&lt; 10% per group) to introduce bias. </p> <p>Of the nine studies (15%) that did not provide complete outcome data and we judged as high risk of bias, two used 'as‐treated' analyses, three had questionable reasons to exclude randomised participants from analysis, three did not use appropriate imputation methods while having drop‐out rates of more than 10% per group and one did not state the reasons of attrition. </p> <p>In 10 trials (17%) it remained unclear if the outcome data were sufficiently addressed.</p> </section> <section id="CD009687-sec-0087"> <h4 class="title">Selective reporting</h4> <p>Thirty studies (51%) reported results for all outcomes that were pre‐specified in the methods section. We considered 21 studies (36%) to be at high risk of selective reporting bias, since they either did not provide results of pre‐specified outcomes or additionally reported outcomes that were not mentioned in the methods section. </p> <p>In eight studies (14%), we rated the risk of bias as unclear for the following reasons: three studies were only available as an abstract, another two studies did not report results for pre‐specified outcomes which, however, were not relevant for this review. Three studies did not provide results in sufficient detail. </p> </section> <section id="CD009687-sec-0088"> <h4 class="title">Other potential sources of bias</h4> <p>We judged eight studies (14%) to be at high risk of an other potential bias:</p> <p>Due to low baseline disease severity, <a href="./references#CD009687-bbs2-0004" title="BrenemanDL , DavisMB , BergerV , ChaneyR . A double‐blind trial comparing the efficacy and safety of augmented betamethasone dipropionate lotion with fluocinonide solution in the treatment of severe scalp psoriasis. Journal of Dermatological Treatment1992;3(1):19‐21. [EMBASE: 1992153744] ">Breneman 1992</a> excluded 12 participants from efficacy analysis but included them for safety analysis. This may have led to an overestimation of treatment safety. </p> <p>Baseline severity was imbalanced between treatment groups in two studies (<a href="./references#CD009687-bbs2-0001" title="AndresP , PoncetM , FarzanehS , SotoP . Short‐term safety assessment of clobetasol propionate 0.05% shampoo: hypothalamic‐pituitary‐adrenal axis suppression, atrophogenicity, and ocular safety in subjects with scalp psoriasis. Journal of Drugs in Dermatology2006;5(4):328‐32. [MEDLINE: 16673799] ">Andres 2006</a>; <a href="./references#CD009687-bbs2-0014" title="FranzTJ , ParsellDA , MyersJA , HanniganJF . Clobetasol propionate foam 0.05%: a novel vehicle with enhanced delivery. International Journal of Dermatology2000;39(7):535‐8. [MEDLINE: 10940121] ">Franz 2000</a>). <a href="./references#CD009687-bbs2-0011" title="FeldmanSR , RavisSM , FleischerAB , McMichaelA , JonesE , KaplanR , et al. Betamethasone valerate in foam vehicle is effective with both daily and twice a day dosing: a single‐blind, open‐label study in the treatment of scalp psoriasis. Journal of Cutaneous Medicine &amp; Surgery2001;5(5):386‐9. [MEDLINE: 11907847] ">Feldman 2001</a> did not state IGA or PGA data at baseline. The degree of improvement according to these scores was therefore not evaluable. </p> <p>During the within‐patient study of <a href="./references#CD009687-bbs2-0037" title="LepawMI . Double‐blind comparison of halcinonide solution and placebo control in treatment of psoriasis of the scalp. Cutis1978;21(4):571‐3. [MEDLINE: 346315] ">Lepaw 1978</a>, participants had to apply both drugs three times per day for two weeks. Since no evaluation of compliance was reported, the results might have been biased. </p> <p>In one study data that were stated in the figures were not consistent with those reported in the text (<a href="./references#CD009687-bbs2-0006" title="CurleyRK , VickersCF , NorrisT , GloverDR . A comparative study of betamethasone dipropionate with salicylic acid and betamethasone valerate for the treatment of steroid‐responsive dermatoses of the scalp. Journal of Dermatological Treatment1990;1(4):203‐6. [EMBASE: 1990343409] ">Curley 1990</a>). </p> <p>In another trial the application frequency varied among participants, which might have introduced bias (<a href="./references#CD009687-bbs2-0019" title="HarrisJJ . A national double‐blind clinical trial of a new corticosteroid lotion: a 12‐investigator cooperative analysis. Current Therapeutic Research, Clinical &amp; Experimental1972;14(9):638‐46. [MEDLINE: 4263888] ">Harris 1972</a>). </p> <p>One study stopped earlier than scheduled, because too many participants were lost to follow‐up (<a href="./references#CD009687-bbs2-0058" title="WrightS , MannRJ . Comparison of a cream containing 0.1% dithranol in a 17% urea base (Psoradrate(TM)) with coal tar pomade in the treatment of scalp psoriasis. Clinical &amp; Experimental Dermatology1985;10(4):375‐8. [MEDLINE: 3899424] ">Wright 1985</a>). Thus, it was likely that the effect of the intervention was overestimated. </p> <p>In five studies (8%) it was unclear whether they had been affected by other potential sources of bias. <a href="./references#CD009687-bbs2-0022" title="HillstromL , PetterssonL , SvenssonL . Comparison of betamethasone dipropionate lotion with salicylic acid (Diprosalic(TM)) and clobetasol propionate lotion (Dermovate(TM)) in the treatment of psoriasis of the scalp. Journal of International Medical Research1982;10(6):419‐22. [MEDLINE: 7152080] ">Hillstrom 1982</a> assessed blood cortisol levels of some participants, but the criteria for selecting these participants for this specific analysis was unclear. The same accounts for <a href="./references#CD009687-bbs2-0047" title="RuzickaT , TrompkeC . Treatment of scalp psoriasis. An effective and safe tacalcitol emulsion [Behandlung der Kopfhaut‐Psoriasis: Gute Wirksamkeit und Sicherheit durch Tacalcitol‐Emulsion]. Hautarzt2004;55(2):165‐70. [MEDLINE: 14968327] ">Ruzicka 2004</a>: in some participants, who received calcipotriol, vitamin D metabolites were additionally assessed. The authors did not state why only selected participants underwent this analysis. However, vitamin D metabolites and blood cortisol levels were not relevant for this review. The assessment of <a href="./references#CD009687-bbs2-0041" title="NCT01195831 . Efficacy and safety of Xamiol® gel compared to calcipotriol scalp solution in patients with scalp psoriasis. clinicaltrials.gov/show/NCT01195831 (accessed 5 November 2014). ">NCT01195831</a> was limited to information that has been published in a trial register. Due to the lack of available data, we could not assess whether disease severity of both treatment groups was similar at baseline. <a href="./references#CD009687-bbs2-0048" title="ShuttleworthD , GallowayDB , BoormanGC , DonaldAE . A double‐blind, placebo‐controlled study of the clinical efficacy of ciclopirox olamine (1.5%) shampoo for the control of scalp psoriasis. Journal of Dermatological Treatment1998;9(3):163‐7. [EMBASE: 1998346163] ">Shuttleworth 1998</a> reported results of a clinical assessment of overall scalp psoriasis, but this score was not clearly defined. Therefore, the degree of improvement from baseline was not clear. The baseline disease severity of <a href="./references#CD009687-bbs2-0051" title="TyringS , MendozaN , AppellM , BibbyA , FosterR , HamiltonT , et al. A calcipotriene/betamethasone dipropionate two‐compound scalp formulation in the treatment of scalp psoriasis in Hispanic/Latino and Black/African American patients: results of the randomized, 8‐week, double‐blind phase of a clinical trial. International Journal of Dermatology2010;49(11):1328‐33. [MEDLINE: 20964660] ">Tyring 2010</a> was not balanced among the treatment groups. It was unclear if the degree of imbalance could have induced bias. </p> <p>We could not identify any other potential bias in the remaining 46 studies.</p> </section> </section> <section id="CD009687-sec-0089"> <h3 class="title" id="CD009687-sec-0089">Effects of interventions</h3> <p>See: <a href="./full#CD009687-tbl-0001"><b>Summary of findings for the main comparison</b> Steroid compared to vitamin D for scalp psoriasis</a>; <a href="./full#CD009687-tbl-0002"><b>Summary of findings 2</b> Steroid plus vitamin D compared to steroid for scalp psoriasis</a>; <a href="./full#CD009687-tbl-0003"><b>Summary of findings 3</b> Steroid plus vitamin D compared to vitamin D for scalp psoriasis</a> </p> <p>In this review, all interventions are grouped into 15 main comparisons, which we have listed below to aid navigation of this section. </p> <p> <ol id="CD009687-list-0015"> <li> <p>Steroid: once versus twice daily</p> </li> <li> <p>Steroid versus the vehicle</p> </li> <li> <p>Vitamin D versus the vehicle</p> </li> <li> <p>Steroid plus vitamin D versus the vehicle</p> </li> <li> <p>Steroid versus steroid: very high versus high potency</p> </li> <li> <p>Steroid versus steroid: high versus moderate potency</p> </li> <li> <p>Steroid versus steroid: both of high potency</p> </li> <li> <p>Steroid versus vitamin D</p> </li> <li> <p>Steroid plus salicylic acid versus steroid</p> </li> <li> <p>Steroid plus vitamin D versus steroid</p> </li> <li> <p>Steroid plus vitamin D versus vitamin D</p> </li> <li> <p>Tar and dithranol</p> </li> <li> <p>Steroid: vehicle comparisons</p> </li> <li> <p>Other steroid and salicylic acid containing comparisons</p> </li> <li> <p>Antifungals versus vehicle</p> </li> </ol> </p> <p>We reported where comparisons addressed our pre‐specified outcomes. Where outcomes are absent from the text, it is because the included studies did not report the outcome for that particular comparison. </p> <p><b>Efficacy outcomes</b> </p> <p>We extracted data on efficacy outcomes (IGA, PGA, TSS) that were reported for the fourth week after initiation of the trial. Where study duration was shorter or no data were provided for this time point, we reported the next closest evaluation to week four. </p> <p>Physicians' Global Assessment of disease severity is sometimes used synonymously with IGA (Investigators' Global Assessment of disease severity). However, it should not be confused with Patients' Global Assessment of disease severity (PGA). In this review, we therefore used the term IGA if the assessor evaluated treatment response, and PGA if the participants rated their treatment response. </p> <p>In accordance with the European Medicines Agency (<a href="./references#CD009687-bbs2-0127" title="European Medicines Agency, Committee for Medicinal Products for Human Use (CHMP). Guideline on clinical investigation of medical products indicated for the treatment of psoriasis, 18 November 2004. www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003329.pdf (accessed 20 November 2014). ">EMA 2004</a>), we believe the IGA or PGA to be the most practicable outcome for clinicians or participants in order to assess the improvement in scalp psoriasis. We therefore primarily extracted IGA and PGA as dichotomous outcomes ('clearance', 'response') for meta‐analysis. If a study only stated mean scores (continuous outcomes), we extracted and analysed these data with the corresponding measure of variance. If there was insufficient statistical information (e.g. standard deviation, SD, standard error, SE), we described the findings qualitatively. </p> <p>There were a vast variety of IGA or PGA scales grading the psoriatic lesions on the scalp as clear, almost clear or very mild or minimal, mild, moderate, severe or worse. In some cases, the latter indicated the highest, in others the lowest number of the scale. We therefore defined two steps of treatment efficacy: 'clearance' and 'response'. We matched all outcomes that stated clearance, whether assessed by the investigator or participant, with IGA and PGA 'clearance', respectively. IGA and PGA 'response' were defined as participants showing 75% to 100% improvement of disease severity. This also included a treatment response that ranged from almost clear through minimal or very mild or marked improvement to clear based on a five‐point scale. All objective and subjective outcomes that corresponded to this definition were matched with IGA and PGA, respectively. </p> <p>We additionally extracted and calculated the mean difference of the Total Severity Score (TSS) if sufficient statistical information (e.g. standard deviation (SD) or standard error (SE)) was provided. In the absence of the measure of variance, we described TSS data qualitatively as the mean percentage change from baseline. </p> <p>As the majority of the included studies with continuous outcome data (e.g. TSS) had missing standard deviations, we decided not to use any statistical techniques in order to impute the missing SD. In our opinion, the imputation of SDs would have led to results in our analyses that remain linked to a high uncertainty. </p> <p><b>Safety outcomes</b> </p> <p>To assess tolerability of topical treatments, we evaluated withdrawal rates due to adverse events and the number of participants with at least one adverse event. For these outcomes, we retrieved the total endpoint number reported, whether the outcome assessor rated them as drug‐related or not. We found this to be justifiable, since any adverse events that were not drug‐related should have been distributed equally among all groups if randomisation was successful. For two reasons, we did not assess the particular risk for certain adverse events. On the one hand, we could not foresee all interventions that our review would include. On the other hand, it was likely that randomised controlled trials (RCTs) used different methods in monitoring or detecting adverse events. Some studies may have searched more accurately for specific adverse events, such as atrophy and, thus, detected a higher incidence than others. However, we aimed to report the sort of adverse event that caused discontinuation of the treatment. We also aimed to report the five most frequent adverse events of each therapy. Yet, for some therapies no or only few adverse events occurred or were reported by the authors. </p> <p><b>Sensitivity analysis</b> (<a href="#CD009687-tbl-0005">Table 2</a>) </p> <div class="table" id="CD009687-tbl-0005"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Sensitivity analyses: summary table</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Comparison</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Outcome</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Sensitivity analysis: ITT population¹</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Sensitivity analysis: allocation concealment²</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Meta‐analysis³</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Steroid versus the vehicle</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IGA: clearance</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 11.67; 95% CI 4.88 to 27.90</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 20.49; 95% CI 2.89 to 145.19</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 14.58; 95% CI 7.28 to 29.17</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IGA: response</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 7.67; 95% CI 4.24 to 13.89</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 6.11; 95% CI 2.98 to 12.52</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 5.24; 95% CI 3.83 to 7.17</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Withdrawal due to AE</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.22; 95% CI 0.08 to 0.61</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.33; 95% CI 0.01 to 7.76</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.27; 95% CI 0.11 to 0.67</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of participants with at least 1 AE</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.87; 95% CI 0.70 to 1.09</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.56; 95% CI 0.56 to 4.37</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.87; 95% CI 0.70 to 1.08</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Steroid versus vitamin D</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IGA: clearance</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.81; 95% CI 1.47 to 2.24</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not applicable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.82; 95% CI 1.52 to 2.18</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Withdrawal due to AE</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.22; 95% CI 0.08 to 0.57</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not applicable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.22; 95% CI 0.11 to 0.42</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PGA: clearance</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 4.00; 95% CI 1.01 to 15.81</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not applicable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 2.22; 95% CI 1.47 to 3.35</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Steroid plus vitamin D versus vitamin D</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IGA: clearance</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not applicable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 3.55; 95% CI 1.84 to 6.85</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 2.28; 95% CI 1.87 to 2.78</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IGA: response</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not applicable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 3.04; 95% CI 1.99 to 4.66</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 2.31; 95% CI 1.75 to 3.04</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Withdrawal due to AE (short‐term)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not applicable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.11; 95% CI 0.02 to 0.51</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.19; 95% CI 0.11 to 0.36</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of participants with at least 1 AE (short‐term)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not applicable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.61; 95% CI 0.47 to 0.78</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.70; 95% CI 0.58 to 0.85</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>Bold text indicates a meaningful difference between effect estimates.</p> <p><sup>1</sup>Total effect estimate of all studies that provided sufficient information to ensure that ITT analysis was performed. </p> <p><sup>2</sup>Total effect estimate of all studies that provided sufficient information to ensure that allocation concealment was adequately performed. </p> <p><sup>3</sup>Total effect estimate of meta‐analysis that included all relevant studies, regardless if ITT analysis or allocation concealment was performed or not. </p> <p>AE: adverse event<br/> CI: confidence interval<br/> IGA: investigator's global assessment<br/> ITT: intention‐to‐treat<br/> PGA: patient global assessment<br/> RR: risk ratio </p> </div> </div> <p>To assess the robustness of the effect estimates of meta‐analysis, we undertook sensitivity analysis with respect to studies that reported data on an intention‐to‐treat (ITT) population. In addition, we evaluated effect estimates of trials that performed adequate concealment of allocation. Wherever sensitivity analysis was possible, we stated the findings under the corresponding outcome heading of the comparison. </p> <p>None of the included abstracts was eligible for meta‐analysis. It was therefore not necessary to evaluate estimate effects of meta‐analysis according to inclusion and exclusion of abstracts. </p> <section id="CD009687-sec-0090"> <h4 class="title">1. Steroid: once versus twice daily</h4> <p>One study (N = 79 participants) compared the once versus twice‐daily use of betamethasone valerate 0.12% (<a href="./references#CD009687-bbs2-0011" title="FeldmanSR , RavisSM , FleischerAB , McMichaelA , JonesE , KaplanR , et al. Betamethasone valerate in foam vehicle is effective with both daily and twice a day dosing: a single‐blind, open‐label study in the treatment of scalp psoriasis. Journal of Cutaneous Medicine &amp; Surgery2001;5(5):386‐9. [MEDLINE: 11907847] ">Feldman 2001</a>). </p> <section id="CD009687-sec-0091"> <h5 class="title">Primary outcomes</h5> <section id="CD009687-sec-0092"> <h6 class="title">1) Reduction in clinician‐assessed severity</h6> <p> <ul id="CD009687-list-0016"> <li> <p>Mean score of the IGA (Investigators' Global Assessment of Disease Severity) (<a href="./references#CD009687-fig-0007" title="">Analysis 1.1</a>) </p> </li> </ul> </p> <p>There was a small difference for this outcome in favour of the twice‐daily use, which was statistically significant (mean difference (MD) 0.60; 95% confidence interval (CI) 0.05 to 1.15). </p> <p><b>2) Number of participants withdrawing due to adverse events</b> </p> <p>One participant withdrew because of a burning sensation. The authors did not state if this participant applied the study medication once or twice daily. </p> </section> </section> <section id="CD009687-sec-0093"> <h5 class="title">Secondary outcomes</h5> <section id="CD009687-sec-0094"> <h6 class="title">1) Subjective reduction in severity of psoriasis</h6> <p> <ul id="CD009687-list-0017"> <li> <p>Mean score of the PGA (Patients' Global Assessment of Disease Severity) (<a href="./references#CD009687-fig-0008" title="">Analysis 1.2</a>). </p> </li> </ul> </p> <p>There was no significant difference between the treatment groups for this outcome (MD 0.40; 95% CI ‐0.20 to 1.00). </p> </section> </section> </section> <section id="CD009687-sec-0095"> <h4 class="title">2. Steroid versus the vehicle</h4> <section id="CD009687-sec-0096"> <h5 class="title">Primary outcomes</h5> <section id="CD009687-sec-0097"> <h6 class="title">1) Reduction in clinician‐assessed severity</h6> <p> <ul id="CD009687-list-0018"> <li> <p>Number of participants achieving 'clearance' according to the IGA (<a href="./references#CD009687-fig-0009" title="">Analysis 2.1</a>) </p> </li> </ul> </p> <p>Four studies that compared a steroid with its vehicle reported this outcome. Two assessed a steroid of high potency (<a href="./references#CD009687-bbs2-0009" title="EllisCN , HorwitzSN , MenterA . Amcinonide lotion 0.1% in the treatment of patients with psoriasis of the scalp. Current Therapeutic Research ‐ Clinical and Experimental1988;44(2):315‐24. [EMBASE: 1989002095] ">Ellis 1988</a>; <a href="./references#CD009687-bbs2-0027" title="JemecGB , GanslandtC , OrtonneJP , PoulinY , BurdenAD , deUnamunoP , et al. A new scalp formulation of calcipotriene plus betamethasone compared with its active ingredients and the vehicle in the treatment of scalp psoriasis: a randomized, double‐blind, controlled trial. Journal of the American Academy of Dermatology2008;59(3):455‐63. [MEDLINE: 18694678] JemecGBE , BurdenD , PoulinY , OrtonneJP . A new scalp formulation of calcipotriene plus betamethasone in the treatment of scalp psoriasis compared to its active ingredients and the vehicle (Abstract P2733). Journal of the American Academy of Dermatology2007;56(2):AB182. ">Jemec 2008</a>), and two a very high potency steroid (<a href="./references#CD009687-bbs2-0042" title="OlsenEA , CramDL , EllisCN , HickmanJG , JacobsonC , JenkinsEE , et al. A double‐blind, vehicle‐controlled study of clobetasol propionate 0.05% (Temovate) scalp application in the treatment of moderate to severe scalp psoriasis. Journal of the American Academy of Dermatology1991;24(3):443‐7. [MEDLINE: 2061442] ">Olsen 1991</a>; <a href="./references#CD009687-bbs2-0049" title="Cook‐BoldenFE , GoffeBS , HudsonCP , SofenHL . Efficacy and safety results from a randomized, double‐blind, vehicle‐controlled study of clobetasol propionate spray for the treatment of moderate to severe plaque psoriasis of the scalp (Poster P3368) 68th Annual Meeting of the American Academy of Dermatology, AAD Miami, FL United States. Journal of the American Academy of Dermatology2010;62(3 Suppl 1):AB140. [EMBASE: 70142994] Cook‐BoldenFE , GoffeBS , HudsonCP , SofenHL . Patient satisfaction with clobetasol propionate spray, 0.05% for the management of moderate to severe plaque psoriasis of the scalp. 70th Annual Meeting of the American Academy of Dermatology San Diego, CA United States. Conference Start: 20120316 Conference End: 20120320. Journal of the American Academy of Dermatology2012;66(4 Suppl 1):AB197. [EMBASE: 70704639] Cook‐BoldenFE , GoffeBS , SofenHL , ColonLE , GottschalkRW . Successful treatment of moderate to severe plaque psoriasis of the scalp with clobetasol propionate spray, 0.05% (Abstract P3347). 69th Annual Meeting of the American Academy of Dermatology New Orleans, LA United States. Conference Start: 20110204 Conference End: 20110208. Journal of the American Academy of Dermatology2011;64(2 Suppl 1):AB157. [EMBASE: 70331905] Cook‐BoldenFE , GoffeBS , SofenHL , HudsonCP , ColonLE , GottschalkRW , et al. Patient satisfaction with clobetasol proprionate spray, 0.05% for the treatment of moderate to severe plaque psoriasis of the scalp. 36th Annual Hawaii Dermatology Seminar of the Skin Disease Education Foundation Waikoloa, HI United States. Conference Start: 20120219 Conference End: 20120224. Seminars in Cutaneous Medicine &amp; Surgery2012;31(1):A9‐A10. [EMBASE: 70706927] SofenH , HudsonCP , Cook‐BoldenFE , PrestonN , ColonLE , CaveneySW , et al. Clobetasol propionate 0.05% spray for the management of moderate‐to‐severe plaque psoriasis of the scalp: results from a randomized controlled trial. Journal of Drugs in Dermatology2011;10(8):885‐92. [MEDLINE: 21818510] ">Sofen 2011</a>). Meta‐analysis of all four trials, which included 1315 participants, indicated that steroids were significantly more effective than the vehicle (risk ratio (RR) 14.58; 95% CI 7.28 to 29.17; number needed to treat to benefit (NNTB) = 4; 95% CI 4 to 5). Heterogeneity was not important (I² = 0%). </p> <p>Effect estimates were significant for each subgroup: amcinonide 0.1% (RR 16.80; 95% CI 2.29 to 123.30; NNTB = 5; 95% CI 4 to 10), betamethasone dipropionate (RR 10.15; 95% CI 3.83 to 26.88; NNTB = 4; 95% CI 4 to 5), clobetasol propionate as hydrophilic leave‐on (RR 22.83; 95% CI 7.31 to 71.30; I² = 0%; NNTB = 4; 95% CI 3 to 5). </p> <section id="CD009687-sec-0098"> <p><b>Sensitivity analysis</b></p> <p>Sensitivity analysis with regard to ITT population included two studies (<a href="./references#CD009687-bbs2-0027" title="JemecGB , GanslandtC , OrtonneJP , PoulinY , BurdenAD , deUnamunoP , et al. A new scalp formulation of calcipotriene plus betamethasone compared with its active ingredients and the vehicle in the treatment of scalp psoriasis: a randomized, double‐blind, controlled trial. Journal of the American Academy of Dermatology2008;59(3):455‐63. [MEDLINE: 18694678] JemecGBE , BurdenD , PoulinY , OrtonneJP . A new scalp formulation of calcipotriene plus betamethasone in the treatment of scalp psoriasis compared to its active ingredients and the vehicle (Abstract P2733). Journal of the American Academy of Dermatology2007;56(2):AB182. ">Jemec 2008</a>; <a href="./references#CD009687-bbs2-0049" title="Cook‐BoldenFE , GoffeBS , HudsonCP , SofenHL . Efficacy and safety results from a randomized, double‐blind, vehicle‐controlled study of clobetasol propionate spray for the treatment of moderate to severe plaque psoriasis of the scalp (Poster P3368) 68th Annual Meeting of the American Academy of Dermatology, AAD Miami, FL United States. Journal of the American Academy of Dermatology2010;62(3 Suppl 1):AB140. [EMBASE: 70142994] Cook‐BoldenFE , GoffeBS , HudsonCP , SofenHL . Patient satisfaction with clobetasol propionate spray, 0.05% for the management of moderate to severe plaque psoriasis of the scalp. 70th Annual Meeting of the American Academy of Dermatology San Diego, CA United States. Conference Start: 20120316 Conference End: 20120320. Journal of the American Academy of Dermatology2012;66(4 Suppl 1):AB197. [EMBASE: 70704639] Cook‐BoldenFE , GoffeBS , SofenHL , ColonLE , GottschalkRW . Successful treatment of moderate to severe plaque psoriasis of the scalp with clobetasol propionate spray, 0.05% (Abstract P3347). 69th Annual Meeting of the American Academy of Dermatology New Orleans, LA United States. Conference Start: 20110204 Conference End: 20110208. Journal of the American Academy of Dermatology2011;64(2 Suppl 1):AB157. [EMBASE: 70331905] Cook‐BoldenFE , GoffeBS , SofenHL , HudsonCP , ColonLE , GottschalkRW , et al. Patient satisfaction with clobetasol proprionate spray, 0.05% for the treatment of moderate to severe plaque psoriasis of the scalp. 36th Annual Hawaii Dermatology Seminar of the Skin Disease Education Foundation Waikoloa, HI United States. Conference Start: 20120219 Conference End: 20120224. Seminars in Cutaneous Medicine &amp; Surgery2012;31(1):A9‐A10. [EMBASE: 70706927] SofenH , HudsonCP , Cook‐BoldenFE , PrestonN , ColonLE , CaveneySW , et al. Clobetasol propionate 0.05% spray for the management of moderate‐to‐severe plaque psoriasis of the scalp: results from a randomized controlled trial. Journal of Drugs in Dermatology2011;10(8):885‐92. [MEDLINE: 21818510] ">Sofen 2011</a>), whereas sensitivity analysis with regard to adequate concealment of allocation only included <a href="./references#CD009687-bbs2-0049" title="Cook‐BoldenFE , GoffeBS , HudsonCP , SofenHL . Efficacy and safety results from a randomized, double‐blind, vehicle‐controlled study of clobetasol propionate spray for the treatment of moderate to severe plaque psoriasis of the scalp (Poster P3368) 68th Annual Meeting of the American Academy of Dermatology, AAD Miami, FL United States. Journal of the American Academy of Dermatology2010;62(3 Suppl 1):AB140. [EMBASE: 70142994] Cook‐BoldenFE , GoffeBS , HudsonCP , SofenHL . Patient satisfaction with clobetasol propionate spray, 0.05% for the management of moderate to severe plaque psoriasis of the scalp. 70th Annual Meeting of the American Academy of Dermatology San Diego, CA United States. Conference Start: 20120316 Conference End: 20120320. Journal of the American Academy of Dermatology2012;66(4 Suppl 1):AB197. [EMBASE: 70704639] Cook‐BoldenFE , GoffeBS , SofenHL , ColonLE , GottschalkRW . Successful treatment of moderate to severe plaque psoriasis of the scalp with clobetasol propionate spray, 0.05% (Abstract P3347). 69th Annual Meeting of the American Academy of Dermatology New Orleans, LA United States. Conference Start: 20110204 Conference End: 20110208. Journal of the American Academy of Dermatology2011;64(2 Suppl 1):AB157. [EMBASE: 70331905] Cook‐BoldenFE , GoffeBS , SofenHL , HudsonCP , ColonLE , GottschalkRW , et al. Patient satisfaction with clobetasol proprionate spray, 0.05% for the treatment of moderate to severe plaque psoriasis of the scalp. 36th Annual Hawaii Dermatology Seminar of the Skin Disease Education Foundation Waikoloa, HI United States. Conference Start: 20120219 Conference End: 20120224. Seminars in Cutaneous Medicine &amp; Surgery2012;31(1):A9‐A10. [EMBASE: 70706927] SofenH , HudsonCP , Cook‐BoldenFE , PrestonN , ColonLE , CaveneySW , et al. Clobetasol propionate 0.05% spray for the management of moderate‐to‐severe plaque psoriasis of the scalp: results from a randomized controlled trial. Journal of Drugs in Dermatology2011;10(8):885‐92. [MEDLINE: 21818510] ">Sofen 2011</a>. Both supported the effect estimate of the meta‐analysis of the four studies (<a href="#CD009687-tbl-0005">Table 2</a>). </p> <p> <ul id="CD009687-list-0019"> <li> <p>Number of participants achieving 'response' according to the IGA</p> </li> </ul> </p> <p>Ten studies that compared a steroid with the vehicle addressed this outcome. Nine had a parallel‐group and one a within‐patient design. Two studies assessed a steroid of moderate potency (<a href="./references#CD009687-bbs2-0013" title="FranzTJ , ParsellDA , HalualaniRM , HanniganJF , KalbachJP , HarkonenWS . Betamethasone valerate foam 0.12%: a novel vehicle with enhanced delivery and efficacy. International Journal of Dermatology1999;38(8):628‐32. [MEDLINE: 10487457] ">Franz 1999</a>; <a href="./references#CD009687-bbs2-0019" title="HarrisJJ . A national double‐blind clinical trial of a new corticosteroid lotion: a 12‐investigator cooperative analysis. Current Therapeutic Research, Clinical &amp; Experimental1972;14(9):638‐46. [MEDLINE: 4263888] ">Harris 1972</a>), four investigated steroids of high potency (<a href="./references#CD009687-bbs2-0027" title="JemecGB , GanslandtC , OrtonneJP , PoulinY , BurdenAD , deUnamunoP , et al. A new scalp formulation of calcipotriene plus betamethasone compared with its active ingredients and the vehicle in the treatment of scalp psoriasis: a randomized, double‐blind, controlled trial. Journal of the American Academy of Dermatology2008;59(3):455‐63. [MEDLINE: 18694678] JemecGBE , BurdenD , PoulinY , OrtonneJP . A new scalp formulation of calcipotriene plus betamethasone in the treatment of scalp psoriasis compared to its active ingredients and the vehicle (Abstract P2733). Journal of the American Academy of Dermatology2007;56(2):AB182. ">Jemec 2008</a>; <a href="./references#CD009687-bbs2-0009" title="EllisCN , HorwitzSN , MenterA . Amcinonide lotion 0.1% in the treatment of patients with psoriasis of the scalp. Current Therapeutic Research ‐ Clinical and Experimental1988;44(2):315‐24. [EMBASE: 1989002095] ">Ellis 1988</a>; <a href="./references#CD009687-bbs2-0037" title="LepawMI . Double‐blind comparison of halcinonide solution and placebo control in treatment of psoriasis of the scalp. Cutis1978;21(4):571‐3. [MEDLINE: 346315] ">Lepaw 1978</a>; <a href="./references#CD009687-bbs2-0039" title="MedanskyRS , HandlerRM . Treating psoriasis of the scalp with a new corticosteroid lotion. Illinois Medical Journal1974;145(6):503‐4. [MEDLINE: 4152499] ">Medansky 1974</a>), and four a very high potency steroid (<a href="./references#CD009687-bbs2-0014" title="FranzTJ , ParsellDA , MyersJA , HanniganJF . Clobetasol propionate foam 0.05%: a novel vehicle with enhanced delivery. International Journal of Dermatology2000;39(7):535‐8. [MEDLINE: 10940121] ">Franz 2000</a>; <a href="./references#CD009687-bbs2-0026" title="ClaudelJ‐P , FredonL , MaccariF , SavaryJ . Nantes, March 26, 2009: A new response to psoriasis of the scalp: Clobex®, first corticosteroid shampoo [Nantes, le 26 mars 2009: Une nouvelle réponse au psoriasis du cuir chevelu: Clobex®, premier shampooing corticoïde]. Nouvelles Dermatologiques2009;28(6 Pt 1):341‐4. [EMBASE: 2009457722] JarratM , BenemanD , GottliebA , PoulinY , FoleyV . Efficacy and safety comparison of clobetasol proprionate shampoo 0.05% and vehicle in scalp psoriasis. Journal of the European Academy of Dermatology &amp; Venereology2002;16(Suppl 1):282‐3. JarrattM , BrenemanD , GottliebAB , PoulinY , LiuY , FoleyV . Clobetasol propionate shampoo 0.05%: a new option to treat patients with moderate to severe scalp psoriasis. Journal of Drugs in Dermatology2004;3(4):367‐73. [MEDLINE: 15303780] ">Jarratt 2004</a>; <a href="./references#CD009687-bbs2-0042" title="OlsenEA , CramDL , EllisCN , HickmanJG , JacobsonC , JenkinsEE , et al. A double‐blind, vehicle‐controlled study of clobetasol propionate 0.05% (Temovate) scalp application in the treatment of moderate to severe scalp psoriasis. Journal of the American Academy of Dermatology1991;24(3):443‐7. [MEDLINE: 2061442] ">Olsen 1991</a>; <a href="./references#CD009687-bbs2-0049" title="Cook‐BoldenFE , GoffeBS , HudsonCP , SofenHL . Efficacy and safety results from a randomized, double‐blind, vehicle‐controlled study of clobetasol propionate spray for the treatment of moderate to severe plaque psoriasis of the scalp (Poster P3368) 68th Annual Meeting of the American Academy of Dermatology, AAD Miami, FL United States. Journal of the American Academy of Dermatology2010;62(3 Suppl 1):AB140. [EMBASE: 70142994] Cook‐BoldenFE , GoffeBS , HudsonCP , SofenHL . Patient satisfaction with clobetasol propionate spray, 0.05% for the management of moderate to severe plaque psoriasis of the scalp. 70th Annual Meeting of the American Academy of Dermatology San Diego, CA United States. Conference Start: 20120316 Conference End: 20120320. Journal of the American Academy of Dermatology2012;66(4 Suppl 1):AB197. [EMBASE: 70704639] Cook‐BoldenFE , GoffeBS , SofenHL , ColonLE , GottschalkRW . Successful treatment of moderate to severe plaque psoriasis of the scalp with clobetasol propionate spray, 0.05% (Abstract P3347). 69th Annual Meeting of the American Academy of Dermatology New Orleans, LA United States. Conference Start: 20110204 Conference End: 20110208. Journal of the American Academy of Dermatology2011;64(2 Suppl 1):AB157. [EMBASE: 70331905] Cook‐BoldenFE , GoffeBS , SofenHL , HudsonCP , ColonLE , GottschalkRW , et al. Patient satisfaction with clobetasol proprionate spray, 0.05% for the treatment of moderate to severe plaque psoriasis of the scalp. 36th Annual Hawaii Dermatology Seminar of the Skin Disease Education Foundation Waikoloa, HI United States. Conference Start: 20120219 Conference End: 20120224. Seminars in Cutaneous Medicine &amp; Surgery2012;31(1):A9‐A10. [EMBASE: 70706927] SofenH , HudsonCP , Cook‐BoldenFE , PrestonN , ColonLE , CaveneySW , et al. Clobetasol propionate 0.05% spray for the management of moderate‐to‐severe plaque psoriasis of the scalp: results from a randomized controlled trial. Journal of Drugs in Dermatology2011;10(8):885‐92. [MEDLINE: 21818510] ">Sofen 2011</a>). Meta‐analysis of all nine trials with control groups, including 2114 participants, indicated that steroids were significantly more effective than the vehicle (RR 5.24; 95% CI 3.83 to 7.17; NNTB = 3; 95% CI 3 to 3; <a href="./references#CD009687-fig-0010" title="">Analysis 2.2</a>). Heterogeneity was moderate (I² = 44%). </p> <p>Effect estimates were superior to the vehicle for each subgroup: betamethasone dipropionate (RR 4.06; 95% CI 2.85 to 5.79; NNTB = 3; 95% CI 3 to 3), amcinonide 0.1% (RR 5.19; 95% CI 2.60 to 10.36; NNTB = 3; 95% CI 2 to 4), betamethasone valerate 0.1% (RR 2.96; 95% CI 1.81 to 4.85; NNTB = 3; 95% CI 3 to 5), clobetasol propionate as hydrophilic leave‐on (RR 7.93; 95% CI 5.46 to 11.51; NNTB = 2; 95% CI 2 to 2), clobetasol propionate as rinse‐off (RR 15.83; 95% CI 2.23 to 112.33; NNTB = 4; 95% CI 3 to 5). </p> <p>In a split‐face comparison, which compared halcinonide 0.1% as a hydrophilic leave‐on with the vehicle, 16 out of 27 participants responded on the side treated with the steroid (<a href="./references#CD009687-bbs2-0037" title="LepawMI . Double‐blind comparison of halcinonide solution and placebo control in treatment of psoriasis of the scalp. Cutis1978;21(4):571‐3. [MEDLINE: 346315] ">Lepaw 1978</a>). Only one participant responded on the vehicle side. </p> </section> <section id="CD009687-sec-0099"> <p><b>Sensitivity analysis</b></p> <p>Sensitivity analysis with regard to ITT population included five studies (<a href="./references#CD009687-bbs2-0014" title="FranzTJ , ParsellDA , MyersJA , HanniganJF . Clobetasol propionate foam 0.05%: a novel vehicle with enhanced delivery. International Journal of Dermatology2000;39(7):535‐8. [MEDLINE: 10940121] ">Franz 2000</a>; <a href="./references#CD009687-bbs2-0026" title="ClaudelJ‐P , FredonL , MaccariF , SavaryJ . Nantes, March 26, 2009: A new response to psoriasis of the scalp: Clobex®, first corticosteroid shampoo [Nantes, le 26 mars 2009: Une nouvelle réponse au psoriasis du cuir chevelu: Clobex®, premier shampooing corticoïde]. Nouvelles Dermatologiques2009;28(6 Pt 1):341‐4. [EMBASE: 2009457722] JarratM , BenemanD , GottliebA , PoulinY , FoleyV . Efficacy and safety comparison of clobetasol proprionate shampoo 0.05% and vehicle in scalp psoriasis. Journal of the European Academy of Dermatology &amp; Venereology2002;16(Suppl 1):282‐3. JarrattM , BrenemanD , GottliebAB , PoulinY , LiuY , FoleyV . Clobetasol propionate shampoo 0.05%: a new option to treat patients with moderate to severe scalp psoriasis. Journal of Drugs in Dermatology2004;3(4):367‐73. [MEDLINE: 15303780] ">Jarratt 2004</a>; <a href="./references#CD009687-bbs2-0027" title="JemecGB , GanslandtC , OrtonneJP , PoulinY , BurdenAD , deUnamunoP , et al. A new scalp formulation of calcipotriene plus betamethasone compared with its active ingredients and the vehicle in the treatment of scalp psoriasis: a randomized, double‐blind, controlled trial. Journal of the American Academy of Dermatology2008;59(3):455‐63. [MEDLINE: 18694678] JemecGBE , BurdenD , PoulinY , OrtonneJP . A new scalp formulation of calcipotriene plus betamethasone in the treatment of scalp psoriasis compared to its active ingredients and the vehicle (Abstract P2733). Journal of the American Academy of Dermatology2007;56(2):AB182. ">Jemec 2008</a>; <a href="./references#CD009687-bbs2-0039" title="MedanskyRS , HandlerRM . Treating psoriasis of the scalp with a new corticosteroid lotion. Illinois Medical Journal1974;145(6):503‐4. [MEDLINE: 4152499] ">Medansky 1974</a>; <a href="./references#CD009687-bbs2-0049" title="Cook‐BoldenFE , GoffeBS , HudsonCP , SofenHL . Efficacy and safety results from a randomized, double‐blind, vehicle‐controlled study of clobetasol propionate spray for the treatment of moderate to severe plaque psoriasis of the scalp (Poster P3368) 68th Annual Meeting of the American Academy of Dermatology, AAD Miami, FL United States. Journal of the American Academy of Dermatology2010;62(3 Suppl 1):AB140. [EMBASE: 70142994] Cook‐BoldenFE , GoffeBS , HudsonCP , SofenHL . Patient satisfaction with clobetasol propionate spray, 0.05% for the management of moderate to severe plaque psoriasis of the scalp. 70th Annual Meeting of the American Academy of Dermatology San Diego, CA United States. Conference Start: 20120316 Conference End: 20120320. Journal of the American Academy of Dermatology2012;66(4 Suppl 1):AB197. [EMBASE: 70704639] Cook‐BoldenFE , GoffeBS , SofenHL , ColonLE , GottschalkRW . Successful treatment of moderate to severe plaque psoriasis of the scalp with clobetasol propionate spray, 0.05% (Abstract P3347). 69th Annual Meeting of the American Academy of Dermatology New Orleans, LA United States. Conference Start: 20110204 Conference End: 20110208. Journal of the American Academy of Dermatology2011;64(2 Suppl 1):AB157. [EMBASE: 70331905] Cook‐BoldenFE , GoffeBS , SofenHL , HudsonCP , ColonLE , GottschalkRW , et al. Patient satisfaction with clobetasol proprionate spray, 0.05% for the treatment of moderate to severe plaque psoriasis of the scalp. 36th Annual Hawaii Dermatology Seminar of the Skin Disease Education Foundation Waikoloa, HI United States. Conference Start: 20120219 Conference End: 20120224. Seminars in Cutaneous Medicine &amp; Surgery2012;31(1):A9‐A10. [EMBASE: 70706927] SofenH , HudsonCP , Cook‐BoldenFE , PrestonN , ColonLE , CaveneySW , et al. Clobetasol propionate 0.05% spray for the management of moderate‐to‐severe plaque psoriasis of the scalp: results from a randomized controlled trial. Journal of Drugs in Dermatology2011;10(8):885‐92. [MEDLINE: 21818510] ">Sofen 2011</a>), and with regard to adequate allocation concealment only included one study (<a href="./references#CD009687-bbs2-0049" title="Cook‐BoldenFE , GoffeBS , HudsonCP , SofenHL . Efficacy and safety results from a randomized, double‐blind, vehicle‐controlled study of clobetasol propionate spray for the treatment of moderate to severe plaque psoriasis of the scalp (Poster P3368) 68th Annual Meeting of the American Academy of Dermatology, AAD Miami, FL United States. Journal of the American Academy of Dermatology2010;62(3 Suppl 1):AB140. [EMBASE: 70142994] Cook‐BoldenFE , GoffeBS , HudsonCP , SofenHL . Patient satisfaction with clobetasol propionate spray, 0.05% for the management of moderate to severe plaque psoriasis of the scalp. 70th Annual Meeting of the American Academy of Dermatology San Diego, CA United States. Conference Start: 20120316 Conference End: 20120320. Journal of the American Academy of Dermatology2012;66(4 Suppl 1):AB197. [EMBASE: 70704639] Cook‐BoldenFE , GoffeBS , SofenHL , ColonLE , GottschalkRW . Successful treatment of moderate to severe plaque psoriasis of the scalp with clobetasol propionate spray, 0.05% (Abstract P3347). 69th Annual Meeting of the American Academy of Dermatology New Orleans, LA United States. Conference Start: 20110204 Conference End: 20110208. Journal of the American Academy of Dermatology2011;64(2 Suppl 1):AB157. [EMBASE: 70331905] Cook‐BoldenFE , GoffeBS , SofenHL , HudsonCP , ColonLE , GottschalkRW , et al. Patient satisfaction with clobetasol proprionate spray, 0.05% for the treatment of moderate to severe plaque psoriasis of the scalp. 36th Annual Hawaii Dermatology Seminar of the Skin Disease Education Foundation Waikoloa, HI United States. Conference Start: 20120219 Conference End: 20120224. Seminars in Cutaneous Medicine &amp; Surgery2012;31(1):A9‐A10. [EMBASE: 70706927] SofenH , HudsonCP , Cook‐BoldenFE , PrestonN , ColonLE , CaveneySW , et al. Clobetasol propionate 0.05% spray for the management of moderate‐to‐severe plaque psoriasis of the scalp: results from a randomized controlled trial. Journal of Drugs in Dermatology2011;10(8):885‐92. [MEDLINE: 21818510] ">Sofen 2011</a>). Both supported the effect estimate of the meta‐analysis of the nine studies (<a href="#CD009687-tbl-0005">Table 2</a>). </p> <p> <ul id="CD009687-list-0020"> <li> <p>Mean of the total severity score (TSS) (<a href="./references#CD009687-fig-0011" title="">Analysis 2.3</a>) </p> </li> </ul> </p> <p>Seven studies that compared a steroid with the vehicle reported the reduction of disease severity by measuring the mean change of TSS from baseline (<a href="./references#CD009687-bbs2-0013" title="FranzTJ , ParsellDA , HalualaniRM , HanniganJF , KalbachJP , HarkonenWS . Betamethasone valerate foam 0.12%: a novel vehicle with enhanced delivery and efficacy. International Journal of Dermatology1999;38(8):628‐32. [MEDLINE: 10487457] ">Franz 1999</a>; <a href="./references#CD009687-bbs2-0014" title="FranzTJ , ParsellDA , MyersJA , HanniganJF . Clobetasol propionate foam 0.05%: a novel vehicle with enhanced delivery. International Journal of Dermatology2000;39(7):535‐8. [MEDLINE: 10940121] ">Franz 2000</a>; <a href="./references#CD009687-bbs2-0026" title="ClaudelJ‐P , FredonL , MaccariF , SavaryJ . Nantes, March 26, 2009: A new response to psoriasis of the scalp: Clobex®, first corticosteroid shampoo [Nantes, le 26 mars 2009: Une nouvelle réponse au psoriasis du cuir chevelu: Clobex®, premier shampooing corticoïde]. Nouvelles Dermatologiques2009;28(6 Pt 1):341‐4. [EMBASE: 2009457722] JarratM , BenemanD , GottliebA , PoulinY , FoleyV . Efficacy and safety comparison of clobetasol proprionate shampoo 0.05% and vehicle in scalp psoriasis. Journal of the European Academy of Dermatology &amp; Venereology2002;16(Suppl 1):282‐3. JarrattM , BrenemanD , GottliebAB , PoulinY , LiuY , FoleyV . Clobetasol propionate shampoo 0.05%: a new option to treat patients with moderate to severe scalp psoriasis. Journal of Drugs in Dermatology2004;3(4):367‐73. [MEDLINE: 15303780] ">Jarratt 2004</a>; <a href="./references#CD009687-bbs2-0027" title="JemecGB , GanslandtC , OrtonneJP , PoulinY , BurdenAD , deUnamunoP , et al. A new scalp formulation of calcipotriene plus betamethasone compared with its active ingredients and the vehicle in the treatment of scalp psoriasis: a randomized, double‐blind, controlled trial. Journal of the American Academy of Dermatology2008;59(3):455‐63. [MEDLINE: 18694678] JemecGBE , BurdenD , PoulinY , OrtonneJP . A new scalp formulation of calcipotriene plus betamethasone in the treatment of scalp psoriasis compared to its active ingredients and the vehicle (Abstract P2733). Journal of the American Academy of Dermatology2007;56(2):AB182. ">Jemec 2008</a>; <a href="./references#CD009687-bbs2-0042" title="OlsenEA , CramDL , EllisCN , HickmanJG , JacobsonC , JenkinsEE , et al. A double‐blind, vehicle‐controlled study of clobetasol propionate 0.05% (Temovate) scalp application in the treatment of moderate to severe scalp psoriasis. Journal of the American Academy of Dermatology1991;24(3):443‐7. [MEDLINE: 2061442] ">Olsen 1991</a>; <a href="./references#CD009687-bbs2-0043" title="PauporteM , MaibachH , LoweN , PuglieseM , FriedmanDJ , MendelsohnH , et al. Fluocinolone acetonide topical oil for scalp psoriasis. Journal of Dermatological Treatment2004;15(6):360‐4. [MEDLINE: 15764047] ">Pauporte 2004</a>; <a href="./references#CD009687-bbs2-0049" title="Cook‐BoldenFE , GoffeBS , HudsonCP , SofenHL . Efficacy and safety results from a randomized, double‐blind, vehicle‐controlled study of clobetasol propionate spray for the treatment of moderate to severe plaque psoriasis of the scalp (Poster P3368) 68th Annual Meeting of the American Academy of Dermatology, AAD Miami, FL United States. Journal of the American Academy of Dermatology2010;62(3 Suppl 1):AB140. [EMBASE: 70142994] Cook‐BoldenFE , GoffeBS , HudsonCP , SofenHL . Patient satisfaction with clobetasol propionate spray, 0.05% for the management of moderate to severe plaque psoriasis of the scalp. 70th Annual Meeting of the American Academy of Dermatology San Diego, CA United States. Conference Start: 20120316 Conference End: 20120320. Journal of the American Academy of Dermatology2012;66(4 Suppl 1):AB197. [EMBASE: 70704639] Cook‐BoldenFE , GoffeBS , SofenHL , ColonLE , GottschalkRW . Successful treatment of moderate to severe plaque psoriasis of the scalp with clobetasol propionate spray, 0.05% (Abstract P3347). 69th Annual Meeting of the American Academy of Dermatology New Orleans, LA United States. Conference Start: 20110204 Conference End: 20110208. Journal of the American Academy of Dermatology2011;64(2 Suppl 1):AB157. [EMBASE: 70331905] Cook‐BoldenFE , GoffeBS , SofenHL , HudsonCP , ColonLE , GottschalkRW , et al. Patient satisfaction with clobetasol proprionate spray, 0.05% for the treatment of moderate to severe plaque psoriasis of the scalp. 36th Annual Hawaii Dermatology Seminar of the Skin Disease Education Foundation Waikoloa, HI United States. Conference Start: 20120219 Conference End: 20120224. Seminars in Cutaneous Medicine &amp; Surgery2012;31(1):A9‐A10. [EMBASE: 70706927] SofenH , HudsonCP , Cook‐BoldenFE , PrestonN , ColonLE , CaveneySW , et al. Clobetasol propionate 0.05% spray for the management of moderate‐to‐severe plaque psoriasis of the scalp: results from a randomized controlled trial. Journal of Drugs in Dermatology2011;10(8):885‐92. [MEDLINE: 21818510] ">Sofen 2011</a>). Throughout all studies, all steroids led to a higher percentage reduction of TSS, regardless of steroid potency. The mean difference of percentage change from baseline compared to the vehicle ranged from 27% for fluocinolone acetonide 0.01% (<a href="./references#CD009687-bbs2-0043" title="PauporteM , MaibachH , LoweN , PuglieseM , FriedmanDJ , MendelsohnH , et al. Fluocinolone acetonide topical oil for scalp psoriasis. Journal of Dermatological Treatment2004;15(6):360‐4. [MEDLINE: 15764047] ">Pauporte 2004</a>), to 54% for clobetasol propionate as a hydrophilic leave‐on (<a href="./references#CD009687-bbs2-0049" title="Cook‐BoldenFE , GoffeBS , HudsonCP , SofenHL . Efficacy and safety results from a randomized, double‐blind, vehicle‐controlled study of clobetasol propionate spray for the treatment of moderate to severe plaque psoriasis of the scalp (Poster P3368) 68th Annual Meeting of the American Academy of Dermatology, AAD Miami, FL United States. Journal of the American Academy of Dermatology2010;62(3 Suppl 1):AB140. [EMBASE: 70142994] Cook‐BoldenFE , GoffeBS , HudsonCP , SofenHL . Patient satisfaction with clobetasol propionate spray, 0.05% for the management of moderate to severe plaque psoriasis of the scalp. 70th Annual Meeting of the American Academy of Dermatology San Diego, CA United States. Conference Start: 20120316 Conference End: 20120320. Journal of the American Academy of Dermatology2012;66(4 Suppl 1):AB197. [EMBASE: 70704639] Cook‐BoldenFE , GoffeBS , SofenHL , ColonLE , GottschalkRW . Successful treatment of moderate to severe plaque psoriasis of the scalp with clobetasol propionate spray, 0.05% (Abstract P3347). 69th Annual Meeting of the American Academy of Dermatology New Orleans, LA United States. Conference Start: 20110204 Conference End: 20110208. Journal of the American Academy of Dermatology2011;64(2 Suppl 1):AB157. [EMBASE: 70331905] Cook‐BoldenFE , GoffeBS , SofenHL , HudsonCP , ColonLE , GottschalkRW , et al. Patient satisfaction with clobetasol proprionate spray, 0.05% for the treatment of moderate to severe plaque psoriasis of the scalp. 36th Annual Hawaii Dermatology Seminar of the Skin Disease Education Foundation Waikoloa, HI United States. Conference Start: 20120219 Conference End: 20120224. Seminars in Cutaneous Medicine &amp; Surgery2012;31(1):A9‐A10. [EMBASE: 70706927] SofenH , HudsonCP , Cook‐BoldenFE , PrestonN , ColonLE , CaveneySW , et al. Clobetasol propionate 0.05% spray for the management of moderate‐to‐severe plaque psoriasis of the scalp: results from a randomized controlled trial. Journal of Drugs in Dermatology2011;10(8):885‐92. [MEDLINE: 21818510] ">Sofen 2011</a>). None of the studies reported the measure of variance. </p> </section> </section> <section id="CD009687-sec-0100"> <h6 class="title">2) Improvement in quality of life</h6> <p>One study (N = 81 participants), which compared clobetasol propionate with its vehicle, assessed quality of life (<a href="./references#CD009687-bbs2-0049" title="Cook‐BoldenFE , GoffeBS , HudsonCP , SofenHL . Efficacy and safety results from a randomized, double‐blind, vehicle‐controlled study of clobetasol propionate spray for the treatment of moderate to severe plaque psoriasis of the scalp (Poster P3368) 68th Annual Meeting of the American Academy of Dermatology, AAD Miami, FL United States. Journal of the American Academy of Dermatology2010;62(3 Suppl 1):AB140. [EMBASE: 70142994] Cook‐BoldenFE , GoffeBS , HudsonCP , SofenHL . Patient satisfaction with clobetasol propionate spray, 0.05% for the management of moderate to severe plaque psoriasis of the scalp. 70th Annual Meeting of the American Academy of Dermatology San Diego, CA United States. Conference Start: 20120316 Conference End: 20120320. Journal of the American Academy of Dermatology2012;66(4 Suppl 1):AB197. [EMBASE: 70704639] Cook‐BoldenFE , GoffeBS , SofenHL , ColonLE , GottschalkRW . Successful treatment of moderate to severe plaque psoriasis of the scalp with clobetasol propionate spray, 0.05% (Abstract P3347). 69th Annual Meeting of the American Academy of Dermatology New Orleans, LA United States. Conference Start: 20110204 Conference End: 20110208. Journal of the American Academy of Dermatology2011;64(2 Suppl 1):AB157. [EMBASE: 70331905] Cook‐BoldenFE , GoffeBS , SofenHL , HudsonCP , ColonLE , GottschalkRW , et al. Patient satisfaction with clobetasol proprionate spray, 0.05% for the treatment of moderate to severe plaque psoriasis of the scalp. 36th Annual Hawaii Dermatology Seminar of the Skin Disease Education Foundation Waikoloa, HI United States. Conference Start: 20120219 Conference End: 20120224. Seminars in Cutaneous Medicine &amp; Surgery2012;31(1):A9‐A10. [EMBASE: 70706927] SofenH , HudsonCP , Cook‐BoldenFE , PrestonN , ColonLE , CaveneySW , et al. Clobetasol propionate 0.05% spray for the management of moderate‐to‐severe plaque psoriasis of the scalp: results from a randomized controlled trial. Journal of Drugs in Dermatology2011;10(8):885‐92. [MEDLINE: 21818510] ">Sofen 2011</a>). The scalpdex score at the end of treatment indicated that very highly potent clobetasol propionate led to a significantly higher improvement in quality of life than the vehicle (MD ‐20.70; 95% CI ‐30.46 to ‐10.94; <a href="./references#CD009687-fig-0012" title="">Analysis 2.4</a>). </p> </section> <section id="CD009687-sec-0101"> <h6 class="title">3) Number of participants withdrawing due to adverse events</h6> <p>Six studies that compared a steroid with its vehicle addressed this outcome. Three trials evaluated steroids of high potency (<a href="./references#CD009687-bbs2-0009" title="EllisCN , HorwitzSN , MenterA . Amcinonide lotion 0.1% in the treatment of patients with psoriasis of the scalp. Current Therapeutic Research ‐ Clinical and Experimental1988;44(2):315‐24. [EMBASE: 1989002095] ">Ellis 1988</a>; <a href="./references#CD009687-bbs2-0013" title="FranzTJ , ParsellDA , HalualaniRM , HanniganJF , KalbachJP , HarkonenWS . Betamethasone valerate foam 0.12%: a novel vehicle with enhanced delivery and efficacy. International Journal of Dermatology1999;38(8):628‐32. [MEDLINE: 10487457] ">Franz 1999</a>; <a href="./references#CD009687-bbs2-0027" title="JemecGB , GanslandtC , OrtonneJP , PoulinY , BurdenAD , deUnamunoP , et al. A new scalp formulation of calcipotriene plus betamethasone compared with its active ingredients and the vehicle in the treatment of scalp psoriasis: a randomized, double‐blind, controlled trial. Journal of the American Academy of Dermatology2008;59(3):455‐63. [MEDLINE: 18694678] JemecGBE , BurdenD , PoulinY , OrtonneJP . A new scalp formulation of calcipotriene plus betamethasone in the treatment of scalp psoriasis compared to its active ingredients and the vehicle (Abstract P2733). Journal of the American Academy of Dermatology2007;56(2):AB182. ">Jemec 2008</a>), and three studies investigated very highly potent steroids (<a href="./references#CD009687-bbs2-0026" title="ClaudelJ‐P , FredonL , MaccariF , SavaryJ . Nantes, March 26, 2009: A new response to psoriasis of the scalp: Clobex®, first corticosteroid shampoo [Nantes, le 26 mars 2009: Une nouvelle réponse au psoriasis du cuir chevelu: Clobex®, premier shampooing corticoïde]. Nouvelles Dermatologiques2009;28(6 Pt 1):341‐4. [EMBASE: 2009457722] JarratM , BenemanD , GottliebA , PoulinY , FoleyV . Efficacy and safety comparison of clobetasol proprionate shampoo 0.05% and vehicle in scalp psoriasis. Journal of the European Academy of Dermatology &amp; Venereology2002;16(Suppl 1):282‐3. JarrattM , BrenemanD , GottliebAB , PoulinY , LiuY , FoleyV . Clobetasol propionate shampoo 0.05%: a new option to treat patients with moderate to severe scalp psoriasis. Journal of Drugs in Dermatology2004;3(4):367‐73. [MEDLINE: 15303780] ">Jarratt 2004</a>; <a href="./references#CD009687-bbs2-0042" title="OlsenEA , CramDL , EllisCN , HickmanJG , JacobsonC , JenkinsEE , et al. A double‐blind, vehicle‐controlled study of clobetasol propionate 0.05% (Temovate) scalp application in the treatment of moderate to severe scalp psoriasis. Journal of the American Academy of Dermatology1991;24(3):443‐7. [MEDLINE: 2061442] ">Olsen 1991</a>; <a href="./references#CD009687-bbs2-0049" title="Cook‐BoldenFE , GoffeBS , HudsonCP , SofenHL . Efficacy and safety results from a randomized, double‐blind, vehicle‐controlled study of clobetasol propionate spray for the treatment of moderate to severe plaque psoriasis of the scalp (Poster P3368) 68th Annual Meeting of the American Academy of Dermatology, AAD Miami, FL United States. Journal of the American Academy of Dermatology2010;62(3 Suppl 1):AB140. [EMBASE: 70142994] Cook‐BoldenFE , GoffeBS , HudsonCP , SofenHL . Patient satisfaction with clobetasol propionate spray, 0.05% for the management of moderate to severe plaque psoriasis of the scalp. 70th Annual Meeting of the American Academy of Dermatology San Diego, CA United States. Conference Start: 20120316 Conference End: 20120320. Journal of the American Academy of Dermatology2012;66(4 Suppl 1):AB197. [EMBASE: 70704639] Cook‐BoldenFE , GoffeBS , SofenHL , ColonLE , GottschalkRW . Successful treatment of moderate to severe plaque psoriasis of the scalp with clobetasol propionate spray, 0.05% (Abstract P3347). 69th Annual Meeting of the American Academy of Dermatology New Orleans, LA United States. Conference Start: 20110204 Conference End: 20110208. Journal of the American Academy of Dermatology2011;64(2 Suppl 1):AB157. [EMBASE: 70331905] Cook‐BoldenFE , GoffeBS , SofenHL , HudsonCP , ColonLE , GottschalkRW , et al. Patient satisfaction with clobetasol proprionate spray, 0.05% for the treatment of moderate to severe plaque psoriasis of the scalp. 36th Annual Hawaii Dermatology Seminar of the Skin Disease Education Foundation Waikoloa, HI United States. Conference Start: 20120219 Conference End: 20120224. Seminars in Cutaneous Medicine &amp; Surgery2012;31(1):A9‐A10. [EMBASE: 70706927] SofenH , HudsonCP , Cook‐BoldenFE , PrestonN , ColonLE , CaveneySW , et al. Clobetasol propionate 0.05% spray for the management of moderate‐to‐severe plaque psoriasis of the scalp: results from a randomized controlled trial. Journal of Drugs in Dermatology2011;10(8):885‐92. [MEDLINE: 21818510] ">Sofen 2011</a>). Meta‐analysis of four studies, including 1315 participants, indicated a significantly lower risk of withdrawal in the steroid group (RR 0.27; 95% CI 0.11 to 0.67; <a href="./references#CD009687-fig-0013" title="">Analysis 2.5</a>). The main reasons for withdrawal were burning sensation or irritation at the site of application and other unacceptable adverse events that were not further specified by the authors. The heterogeneity among studies was not important (I² = 0%). </p> <p>The lower risk of withdrawal due to adverse events was only significant for betamethasone dipropionate (N = 692 participants; RR 0.21; 95% CI 0.07 to 0.61). It was not significant for amcinonide 0.1% (N = 165 participants; RR 0.99; 95% CI 0.06 to 15.53) nor for clobetasol propionate in a hydrophilic leave‐on (N = 458 participants; RR 0.33; 95% CI 0.03 to 3.13). For betamethasone valerate 0.1% (N = 172 participants) and clobetasol propionate as a rinse‐off (N = 142 participants), none of the participants in either group withdrew due to adverse events. </p> <section id="CD009687-sec-0102"> <p><b>Sensitivity analysis</b></p> <p>One study was included in the sensitivity analysis with regard to adequate allocation concealment (<a href="./references#CD009687-bbs2-0049" title="Cook‐BoldenFE , GoffeBS , HudsonCP , SofenHL . Efficacy and safety results from a randomized, double‐blind, vehicle‐controlled study of clobetasol propionate spray for the treatment of moderate to severe plaque psoriasis of the scalp (Poster P3368) 68th Annual Meeting of the American Academy of Dermatology, AAD Miami, FL United States. Journal of the American Academy of Dermatology2010;62(3 Suppl 1):AB140. [EMBASE: 70142994] Cook‐BoldenFE , GoffeBS , HudsonCP , SofenHL . Patient satisfaction with clobetasol propionate spray, 0.05% for the management of moderate to severe plaque psoriasis of the scalp. 70th Annual Meeting of the American Academy of Dermatology San Diego, CA United States. Conference Start: 20120316 Conference End: 20120320. Journal of the American Academy of Dermatology2012;66(4 Suppl 1):AB197. [EMBASE: 70704639] Cook‐BoldenFE , GoffeBS , SofenHL , ColonLE , GottschalkRW . Successful treatment of moderate to severe plaque psoriasis of the scalp with clobetasol propionate spray, 0.05% (Abstract P3347). 69th Annual Meeting of the American Academy of Dermatology New Orleans, LA United States. Conference Start: 20110204 Conference End: 20110208. Journal of the American Academy of Dermatology2011;64(2 Suppl 1):AB157. [EMBASE: 70331905] Cook‐BoldenFE , GoffeBS , SofenHL , HudsonCP , ColonLE , GottschalkRW , et al. Patient satisfaction with clobetasol proprionate spray, 0.05% for the treatment of moderate to severe plaque psoriasis of the scalp. 36th Annual Hawaii Dermatology Seminar of the Skin Disease Education Foundation Waikoloa, HI United States. Conference Start: 20120219 Conference End: 20120224. Seminars in Cutaneous Medicine &amp; Surgery2012;31(1):A9‐A10. [EMBASE: 70706927] SofenH , HudsonCP , Cook‐BoldenFE , PrestonN , ColonLE , CaveneySW , et al. Clobetasol propionate 0.05% spray for the management of moderate‐to‐severe plaque psoriasis of the scalp: results from a randomized controlled trial. Journal of Drugs in Dermatology2011;10(8):885‐92. [MEDLINE: 21818510] ">Sofen 2011</a>). It did not show any significant difference in the risk of withdrawal due to adverse events between the steroid and the vehicle group. However, sensitivity analysis with regard to the ITT population, which included two studies (<a href="./references#CD009687-bbs2-0027" title="JemecGB , GanslandtC , OrtonneJP , PoulinY , BurdenAD , deUnamunoP , et al. A new scalp formulation of calcipotriene plus betamethasone compared with its active ingredients and the vehicle in the treatment of scalp psoriasis: a randomized, double‐blind, controlled trial. Journal of the American Academy of Dermatology2008;59(3):455‐63. [MEDLINE: 18694678] JemecGBE , BurdenD , PoulinY , OrtonneJP . A new scalp formulation of calcipotriene plus betamethasone in the treatment of scalp psoriasis compared to its active ingredients and the vehicle (Abstract P2733). Journal of the American Academy of Dermatology2007;56(2):AB182. ">Jemec 2008</a>; <a href="./references#CD009687-bbs2-0049" title="Cook‐BoldenFE , GoffeBS , HudsonCP , SofenHL . Efficacy and safety results from a randomized, double‐blind, vehicle‐controlled study of clobetasol propionate spray for the treatment of moderate to severe plaque psoriasis of the scalp (Poster P3368) 68th Annual Meeting of the American Academy of Dermatology, AAD Miami, FL United States. Journal of the American Academy of Dermatology2010;62(3 Suppl 1):AB140. [EMBASE: 70142994] Cook‐BoldenFE , GoffeBS , HudsonCP , SofenHL . Patient satisfaction with clobetasol propionate spray, 0.05% for the management of moderate to severe plaque psoriasis of the scalp. 70th Annual Meeting of the American Academy of Dermatology San Diego, CA United States. Conference Start: 20120316 Conference End: 20120320. Journal of the American Academy of Dermatology2012;66(4 Suppl 1):AB197. [EMBASE: 70704639] Cook‐BoldenFE , GoffeBS , SofenHL , ColonLE , GottschalkRW . Successful treatment of moderate to severe plaque psoriasis of the scalp with clobetasol propionate spray, 0.05% (Abstract P3347). 69th Annual Meeting of the American Academy of Dermatology New Orleans, LA United States. Conference Start: 20110204 Conference End: 20110208. Journal of the American Academy of Dermatology2011;64(2 Suppl 1):AB157. [EMBASE: 70331905] Cook‐BoldenFE , GoffeBS , SofenHL , HudsonCP , ColonLE , GottschalkRW , et al. Patient satisfaction with clobetasol proprionate spray, 0.05% for the treatment of moderate to severe plaque psoriasis of the scalp. 36th Annual Hawaii Dermatology Seminar of the Skin Disease Education Foundation Waikoloa, HI United States. Conference Start: 20120219 Conference End: 20120224. Seminars in Cutaneous Medicine &amp; Surgery2012;31(1):A9‐A10. [EMBASE: 70706927] SofenH , HudsonCP , Cook‐BoldenFE , PrestonN , ColonLE , CaveneySW , et al. Clobetasol propionate 0.05% spray for the management of moderate‐to‐severe plaque psoriasis of the scalp: results from a randomized controlled trial. Journal of Drugs in Dermatology2011;10(8):885‐92. [MEDLINE: 21818510] ">Sofen 2011</a>), supported the findings of the meta‐analysis of the four studies, which was that participants of the steroid group had a significantly lower risk of withdrawal due to adverse events (<a href="#CD009687-tbl-0005">Table 2</a>). </p> </section> </section> </section> <section id="CD009687-sec-0103"> <h5 class="title">Secondary outcomes</h5> <section id="CD009687-sec-0104"> <h6 class="title">1) Subjective reduction in severity of psoriasis</h6> <p> <ul id="CD009687-list-0021"> <li> <p>Number of participants achieving 'response' according to the PGA (<a href="./references#CD009687-fig-0014" title="">Analysis 2.6</a>) </p> </li> </ul> </p> <p>Five studies that compared a steroid with its vehicle reported this outcome. Two studies assessed a steroid of high potency (<a href="./references#CD009687-bbs2-0013" title="FranzTJ , ParsellDA , HalualaniRM , HanniganJF , KalbachJP , HarkonenWS . Betamethasone valerate foam 0.12%: a novel vehicle with enhanced delivery and efficacy. International Journal of Dermatology1999;38(8):628‐32. [MEDLINE: 10487457] ">Franz 1999</a>; <a href="./references#CD009687-bbs2-0027" title="JemecGB , GanslandtC , OrtonneJP , PoulinY , BurdenAD , deUnamunoP , et al. A new scalp formulation of calcipotriene plus betamethasone compared with its active ingredients and the vehicle in the treatment of scalp psoriasis: a randomized, double‐blind, controlled trial. Journal of the American Academy of Dermatology2008;59(3):455‐63. [MEDLINE: 18694678] JemecGBE , BurdenD , PoulinY , OrtonneJP . A new scalp formulation of calcipotriene plus betamethasone in the treatment of scalp psoriasis compared to its active ingredients and the vehicle (Abstract P2733). Journal of the American Academy of Dermatology2007;56(2):AB182. ">Jemec 2008</a>), and three assessed a very highly potent steroid (<a href="./references#CD009687-bbs2-0014" title="FranzTJ , ParsellDA , MyersJA , HanniganJF . Clobetasol propionate foam 0.05%: a novel vehicle with enhanced delivery. International Journal of Dermatology2000;39(7):535‐8. [MEDLINE: 10940121] ">Franz 2000</a>; <a href="./references#CD009687-bbs2-0026" title="ClaudelJ‐P , FredonL , MaccariF , SavaryJ . Nantes, March 26, 2009: A new response to psoriasis of the scalp: Clobex®, first corticosteroid shampoo [Nantes, le 26 mars 2009: Une nouvelle réponse au psoriasis du cuir chevelu: Clobex®, premier shampooing corticoïde]. Nouvelles Dermatologiques2009;28(6 Pt 1):341‐4. [EMBASE: 2009457722] JarratM , BenemanD , GottliebA , PoulinY , FoleyV . Efficacy and safety comparison of clobetasol proprionate shampoo 0.05% and vehicle in scalp psoriasis. Journal of the European Academy of Dermatology &amp; Venereology2002;16(Suppl 1):282‐3. JarrattM , BrenemanD , GottliebAB , PoulinY , LiuY , FoleyV . Clobetasol propionate shampoo 0.05%: a new option to treat patients with moderate to severe scalp psoriasis. Journal of Drugs in Dermatology2004;3(4):367‐73. [MEDLINE: 15303780] ">Jarratt 2004</a>; <a href="./references#CD009687-bbs2-0042" title="OlsenEA , CramDL , EllisCN , HickmanJG , JacobsonC , JenkinsEE , et al. A double‐blind, vehicle‐controlled study of clobetasol propionate 0.05% (Temovate) scalp application in the treatment of moderate to severe scalp psoriasis. Journal of the American Academy of Dermatology1991;24(3):443‐7. [MEDLINE: 2061442] ">Olsen 1991</a>). Data from all five studies with dichotomous data, which included 1571 participants, indicated that steroids were significantly more effective than the vehicle, according to the participants' assessment. The heterogeneity among the studies was substantial (I² = 70.4%). This considerable heterogeneity may be explained by the variety of steroids that were assessed. Subgroup analysis indicated that the effect estimates for all steroid subgroups were superior to the vehicle: betamethasone dipropionate (RR 3.04; 95% 2.17 to 4.26; NNTB = 3; 95% CI 2 to 3), betamethasone valerate 0.1% (RR 3.52; 95% CI 1.97 to 6.29; NNTB = 3; 95% CI 2 to 4), clobetasol propionate in a hydrophilic leave‐on (RR 6.92; 95% CI 4.42 to 10.83; I² = 0%; NNTB = 3; 95% CI 2 to 3), clobetasol propionate as a rinse‐off vehicle (RR 14.35; 95% CI 2.02 to 102.12; NNTB = 4; 95% CI 3 to 6). </p> <section id="CD009687-sec-0105"> <p><b>Sensitivity analysis</b></p> <p>Due to clinical heterogeneity of the studies we did not perform meta‐analysis and sensitivity analysis was not feasible. </p> <p> <ul id="CD009687-list-0022"> <li> <p>Mean score of the PGA (<a href="./references#CD009687-fig-0015" title="">Analysis 2.7</a>) </p> </li> </ul> </p> <p>In one study that analysed 131 participants the mean PGA score of the amcinonide 0.1% group was significantly lower compared to the vehicle group (MD ‐0.87; 95% CI ‐1.17 to ‐0.57) (<a href="./references#CD009687-bbs2-0009" title="EllisCN , HorwitzSN , MenterA . Amcinonide lotion 0.1% in the treatment of patients with psoriasis of the scalp. Current Therapeutic Research ‐ Clinical and Experimental1988;44(2):315‐24. [EMBASE: 1989002095] ">Ellis 1988</a>). This indicated that the steroid led to a greater improvement. </p> </section> </section> <section id="CD009687-sec-0106"> <h6 class="title">2) Number of participants with at least one adverse event</h6> <p>Seven parallel‐group trials and one within‐patient study that compared a steroid with its vehicle addressed this outcome. Meta‐analysis of the seven studies of parallel‐group design, which included 1307 participants, indicated that steroids and the vehicle do not differ significantly in the risk of adverse events (RR 0.87; 95% CI 0.70 to 1.08; <a href="./references#CD009687-fig-0016" title="">Analysis 2.8</a>). Common local adverse events in both treatment groups were a burning or stinging sensation, pruritus and other local irritation. Folliculitis or acne appeared most notably in participants that were treated with steroids. Heterogeneity was not important (I² = 0%). </p> <p>Effect estimates for each steroid subgroup were as follows: betamethasone valerate 0.1% (RR 0.25; 95% CI 0.01 to 5.86; <a href="./references#CD009687-bbs2-0019" title="HarrisJJ . A national double‐blind clinical trial of a new corticosteroid lotion: a 12‐investigator cooperative analysis. Current Therapeutic Research, Clinical &amp; Experimental1972;14(9):638‐46. [MEDLINE: 4263888] ">Harris 1972</a>), amcinonide 0.1% (RR 1.39; 95% CI 0.32 to 5.99; <a href="./references#CD009687-bbs2-0009" title="EllisCN , HorwitzSN , MenterA . Amcinonide lotion 0.1% in the treatment of patients with psoriasis of the scalp. Current Therapeutic Research ‐ Clinical and Experimental1988;44(2):315‐24. [EMBASE: 1989002095] ">Ellis 1988</a>), betamethasone dipropionate (RR 0.87; 95% CI 0.69 to 1.10; <a href="./references#CD009687-bbs2-0027" title="JemecGB , GanslandtC , OrtonneJP , PoulinY , BurdenAD , deUnamunoP , et al. A new scalp formulation of calcipotriene plus betamethasone compared with its active ingredients and the vehicle in the treatment of scalp psoriasis: a randomized, double‐blind, controlled trial. Journal of the American Academy of Dermatology2008;59(3):455‐63. [MEDLINE: 18694678] JemecGBE , BurdenD , PoulinY , OrtonneJP . A new scalp formulation of calcipotriene plus betamethasone in the treatment of scalp psoriasis compared to its active ingredients and the vehicle (Abstract P2733). Journal of the American Academy of Dermatology2007;56(2):AB182. ">Jemec 2008</a>), fluocinolone acetonide 0.01% (RR 3.00; 95% CI 0.13 to 71.61; <a href="./references#CD009687-bbs2-0043" title="PauporteM , MaibachH , LoweN , PuglieseM , FriedmanDJ , MendelsohnH , et al. Fluocinolone acetonide topical oil for scalp psoriasis. Journal of Dermatological Treatment2004;15(6):360‐4. [MEDLINE: 15764047] ">Pauporte 2004</a>), clobetasol propionate in a hydrophilic leave‐on (RR 1.56; 95% CI 0.56 to 4.37; <a href="./references#CD009687-bbs2-0049" title="Cook‐BoldenFE , GoffeBS , HudsonCP , SofenHL . Efficacy and safety results from a randomized, double‐blind, vehicle‐controlled study of clobetasol propionate spray for the treatment of moderate to severe plaque psoriasis of the scalp (Poster P3368) 68th Annual Meeting of the American Academy of Dermatology, AAD Miami, FL United States. Journal of the American Academy of Dermatology2010;62(3 Suppl 1):AB140. [EMBASE: 70142994] Cook‐BoldenFE , GoffeBS , HudsonCP , SofenHL . Patient satisfaction with clobetasol propionate spray, 0.05% for the management of moderate to severe plaque psoriasis of the scalp. 70th Annual Meeting of the American Academy of Dermatology San Diego, CA United States. Conference Start: 20120316 Conference End: 20120320. Journal of the American Academy of Dermatology2012;66(4 Suppl 1):AB197. [EMBASE: 70704639] Cook‐BoldenFE , GoffeBS , SofenHL , ColonLE , GottschalkRW . Successful treatment of moderate to severe plaque psoriasis of the scalp with clobetasol propionate spray, 0.05% (Abstract P3347). 69th Annual Meeting of the American Academy of Dermatology New Orleans, LA United States. Conference Start: 20110204 Conference End: 20110208. Journal of the American Academy of Dermatology2011;64(2 Suppl 1):AB157. [EMBASE: 70331905] Cook‐BoldenFE , GoffeBS , SofenHL , HudsonCP , ColonLE , GottschalkRW , et al. Patient satisfaction with clobetasol proprionate spray, 0.05% for the treatment of moderate to severe plaque psoriasis of the scalp. 36th Annual Hawaii Dermatology Seminar of the Skin Disease Education Foundation Waikoloa, HI United States. Conference Start: 20120219 Conference End: 20120224. Seminars in Cutaneous Medicine &amp; Surgery2012;31(1):A9‐A10. [EMBASE: 70706927] SofenH , HudsonCP , Cook‐BoldenFE , PrestonN , ColonLE , CaveneySW , et al. Clobetasol propionate 0.05% spray for the management of moderate‐to‐severe plaque psoriasis of the scalp: results from a randomized controlled trial. Journal of Drugs in Dermatology2011;10(8):885‐92. [MEDLINE: 21818510] ">Sofen 2011</a>), clobetasol propionate as a rinse‐off (RR 0.59; 95% CI 0.29 to 1.18; <a href="./references#CD009687-bbs2-0026" title="ClaudelJ‐P , FredonL , MaccariF , SavaryJ . Nantes, March 26, 2009: A new response to psoriasis of the scalp: Clobex®, first corticosteroid shampoo [Nantes, le 26 mars 2009: Une nouvelle réponse au psoriasis du cuir chevelu: Clobex®, premier shampooing corticoïde]. Nouvelles Dermatologiques2009;28(6 Pt 1):341‐4. [EMBASE: 2009457722] JarratM , BenemanD , GottliebA , PoulinY , FoleyV . Efficacy and safety comparison of clobetasol proprionate shampoo 0.05% and vehicle in scalp psoriasis. Journal of the European Academy of Dermatology &amp; Venereology2002;16(Suppl 1):282‐3. JarrattM , BrenemanD , GottliebAB , PoulinY , LiuY , FoleyV . Clobetasol propionate shampoo 0.05%: a new option to treat patients with moderate to severe scalp psoriasis. Journal of Drugs in Dermatology2004;3(4):367‐73. [MEDLINE: 15303780] ">Jarratt 2004</a>; <a href="./references#CD009687-bbs2-0045" title="ReygagneP , DiaconuJ , PrèsH , ErnstTM , MeyerKG . Efficacy and safety comparison of clobetasol proprionate shampoo, gel and vehicle in scalp psoriasis. Journal of the European Academy of Dermatology &amp; Venereology2002;16(Suppl 1):283. ">Reygagne 2002</a>). </p> <p>In the split‐face study, one out of 27 participants experienced an adverse event on the side treated with the vehicle (<a href="./references#CD009687-bbs2-0037" title="LepawMI . Double‐blind comparison of halcinonide solution and placebo control in treatment of psoriasis of the scalp. Cutis1978;21(4):571‐3. [MEDLINE: 346315] ">Lepaw 1978</a>). </p> <section id="CD009687-sec-0107"> <p><b>Sensitivity analysis</b></p> <p>Sensitivity analysis with regard to ITT population included three studies (<a href="./references#CD009687-bbs2-0026" title="ClaudelJ‐P , FredonL , MaccariF , SavaryJ . Nantes, March 26, 2009: A new response to psoriasis of the scalp: Clobex®, first corticosteroid shampoo [Nantes, le 26 mars 2009: Une nouvelle réponse au psoriasis du cuir chevelu: Clobex®, premier shampooing corticoïde]. Nouvelles Dermatologiques2009;28(6 Pt 1):341‐4. [EMBASE: 2009457722] JarratM , BenemanD , GottliebA , PoulinY , FoleyV . Efficacy and safety comparison of clobetasol proprionate shampoo 0.05% and vehicle in scalp psoriasis. Journal of the European Academy of Dermatology &amp; Venereology2002;16(Suppl 1):282‐3. JarrattM , BrenemanD , GottliebAB , PoulinY , LiuY , FoleyV . Clobetasol propionate shampoo 0.05%: a new option to treat patients with moderate to severe scalp psoriasis. Journal of Drugs in Dermatology2004;3(4):367‐73. [MEDLINE: 15303780] ">Jarratt 2004</a>; <a href="./references#CD009687-bbs2-0027" title="JemecGB , GanslandtC , OrtonneJP , PoulinY , BurdenAD , deUnamunoP , et al. A new scalp formulation of calcipotriene plus betamethasone compared with its active ingredients and the vehicle in the treatment of scalp psoriasis: a randomized, double‐blind, controlled trial. Journal of the American Academy of Dermatology2008;59(3):455‐63. [MEDLINE: 18694678] JemecGBE , BurdenD , PoulinY , OrtonneJP . A new scalp formulation of calcipotriene plus betamethasone in the treatment of scalp psoriasis compared to its active ingredients and the vehicle (Abstract P2733). Journal of the American Academy of Dermatology2007;56(2):AB182. ">Jemec 2008</a>; <a href="./references#CD009687-bbs2-0049" title="Cook‐BoldenFE , GoffeBS , HudsonCP , SofenHL . Efficacy and safety results from a randomized, double‐blind, vehicle‐controlled study of clobetasol propionate spray for the treatment of moderate to severe plaque psoriasis of the scalp (Poster P3368) 68th Annual Meeting of the American Academy of Dermatology, AAD Miami, FL United States. Journal of the American Academy of Dermatology2010;62(3 Suppl 1):AB140. [EMBASE: 70142994] Cook‐BoldenFE , GoffeBS , HudsonCP , SofenHL . Patient satisfaction with clobetasol propionate spray, 0.05% for the management of moderate to severe plaque psoriasis of the scalp. 70th Annual Meeting of the American Academy of Dermatology San Diego, CA United States. Conference Start: 20120316 Conference End: 20120320. Journal of the American Academy of Dermatology2012;66(4 Suppl 1):AB197. [EMBASE: 70704639] Cook‐BoldenFE , GoffeBS , SofenHL , ColonLE , GottschalkRW . Successful treatment of moderate to severe plaque psoriasis of the scalp with clobetasol propionate spray, 0.05% (Abstract P3347). 69th Annual Meeting of the American Academy of Dermatology New Orleans, LA United States. Conference Start: 20110204 Conference End: 20110208. Journal of the American Academy of Dermatology2011;64(2 Suppl 1):AB157. [EMBASE: 70331905] Cook‐BoldenFE , GoffeBS , SofenHL , HudsonCP , ColonLE , GottschalkRW , et al. Patient satisfaction with clobetasol proprionate spray, 0.05% for the treatment of moderate to severe plaque psoriasis of the scalp. 36th Annual Hawaii Dermatology Seminar of the Skin Disease Education Foundation Waikoloa, HI United States. Conference Start: 20120219 Conference End: 20120224. Seminars in Cutaneous Medicine &amp; Surgery2012;31(1):A9‐A10. [EMBASE: 70706927] SofenH , HudsonCP , Cook‐BoldenFE , PrestonN , ColonLE , CaveneySW , et al. Clobetasol propionate 0.05% spray for the management of moderate‐to‐severe plaque psoriasis of the scalp: results from a randomized controlled trial. Journal of Drugs in Dermatology2011;10(8):885‐92. [MEDLINE: 21818510] ">Sofen 2011</a>), whereas sensitivity analysis with regard to adequate allocation concealment included only <a href="./references#CD009687-bbs2-0049" title="Cook‐BoldenFE , GoffeBS , HudsonCP , SofenHL . Efficacy and safety results from a randomized, double‐blind, vehicle‐controlled study of clobetasol propionate spray for the treatment of moderate to severe plaque psoriasis of the scalp (Poster P3368) 68th Annual Meeting of the American Academy of Dermatology, AAD Miami, FL United States. Journal of the American Academy of Dermatology2010;62(3 Suppl 1):AB140. [EMBASE: 70142994] Cook‐BoldenFE , GoffeBS , HudsonCP , SofenHL . Patient satisfaction with clobetasol propionate spray, 0.05% for the management of moderate to severe plaque psoriasis of the scalp. 70th Annual Meeting of the American Academy of Dermatology San Diego, CA United States. Conference Start: 20120316 Conference End: 20120320. Journal of the American Academy of Dermatology2012;66(4 Suppl 1):AB197. [EMBASE: 70704639] Cook‐BoldenFE , GoffeBS , SofenHL , ColonLE , GottschalkRW . Successful treatment of moderate to severe plaque psoriasis of the scalp with clobetasol propionate spray, 0.05% (Abstract P3347). 69th Annual Meeting of the American Academy of Dermatology New Orleans, LA United States. Conference Start: 20110204 Conference End: 20110208. Journal of the American Academy of Dermatology2011;64(2 Suppl 1):AB157. [EMBASE: 70331905] Cook‐BoldenFE , GoffeBS , SofenHL , HudsonCP , ColonLE , GottschalkRW , et al. Patient satisfaction with clobetasol proprionate spray, 0.05% for the treatment of moderate to severe plaque psoriasis of the scalp. 36th Annual Hawaii Dermatology Seminar of the Skin Disease Education Foundation Waikoloa, HI United States. Conference Start: 20120219 Conference End: 20120224. Seminars in Cutaneous Medicine &amp; Surgery2012;31(1):A9‐A10. [EMBASE: 70706927] SofenH , HudsonCP , Cook‐BoldenFE , PrestonN , ColonLE , CaveneySW , et al. Clobetasol propionate 0.05% spray for the management of moderate‐to‐severe plaque psoriasis of the scalp: results from a randomized controlled trial. Journal of Drugs in Dermatology2011;10(8):885‐92. [MEDLINE: 21818510] ">Sofen 2011</a>. Both supported the findings of the meta‐analysis of seven studies (<a href="#CD009687-tbl-0005">Table 2</a>). </p> </section> </section> </section> </section> <section id="CD009687-sec-0108"> <h4 class="title">3. Vitamin D versus the vehicle</h4> <section id="CD009687-sec-0109"> <h5 class="title">Primary outcomes</h5> <section id="CD009687-sec-0110"> <h6 class="title">1) Reduction in clinician‐assessed severity</h6> <p> <ul id="CD009687-list-0023"> <li> <p>Number of participants achieving 'clearance' according to the IGA (<a href="./references#CD009687-fig-0017" title="">Analysis 3.1</a>) </p> </li> </ul> </p> <p>Two studies that compared vitamin D with its vehicle reported this outcome (<a href="./references#CD009687-bbs2-0017" title="GreenC , GanpuleM , HarrisD , KavanaghG , KennedyC , MallettR , et al. Comparative effects of calcipotriol (MC903) solution and placebo (vehicle of MC903) in the treatment of psoriasis of the scalp. British Journal of Dermatology1994;130(4):483‐7. [MEDLINE: 8186114] ">Green 1994</a>; <a href="./references#CD009687-bbs2-0027" title="JemecGB , GanslandtC , OrtonneJP , PoulinY , BurdenAD , deUnamunoP , et al. A new scalp formulation of calcipotriene plus betamethasone compared with its active ingredients and the vehicle in the treatment of scalp psoriasis: a randomized, double‐blind, controlled trial. Journal of the American Academy of Dermatology2008;59(3):455‐63. [MEDLINE: 18694678] JemecGBE , BurdenD , PoulinY , OrtonneJP . A new scalp formulation of calcipotriene plus betamethasone in the treatment of scalp psoriasis compared to its active ingredients and the vehicle (Abstract P2733). Journal of the American Academy of Dermatology2007;56(2):AB182. ">Jemec 2008</a>). Meta‐analysis, including 457 participants, indicated that vitamin D was significantly more effective than the vehicle (RR 3.88; 95% CI 1.49 to 10.11; NNTB = 9; 95% CI 6 to 15). Heterogeneity among both studies was not important (I² = 16%). </p> <p> <ul id="CD009687-list-0024"> <li> <p>Number of participants achieving 'response' according to the IGA (<a href="./references#CD009687-fig-0018" title="">Analysis 3.2</a>) </p> </li> </ul> </p> <p>Two studies (<a href="./references#CD009687-bbs2-0012" title="FeldmanSR , MillsM , BrundageT , EastmanWJ . A multicenter, randomized, double‐blind study of the efficacy and safety of calcipotriene foam, 0.005%, vs vehicle foam in the treatment of plaque‐type psoriasis of the scalp. Journal of Drugs in Dermatology2013;12(3):300‐6. [MEDLINE: 23545912] ">Feldman 2013</a>, N = 363 participants; <a href="./references#CD009687-bbs2-0027" title="JemecGB , GanslandtC , OrtonneJP , PoulinY , BurdenAD , deUnamunoP , et al. A new scalp formulation of calcipotriene plus betamethasone compared with its active ingredients and the vehicle in the treatment of scalp psoriasis: a randomized, double‐blind, controlled trial. Journal of the American Academy of Dermatology2008;59(3):455‐63. [MEDLINE: 18694678] JemecGBE , BurdenD , PoulinY , OrtonneJP . A new scalp formulation of calcipotriene plus betamethasone in the treatment of scalp psoriasis compared to its active ingredients and the vehicle (Abstract P2733). Journal of the American Academy of Dermatology2007;56(2):AB182. ">Jemec 2008</a>, N = 408 participants), which compared calcipotriene with its vehicle, reported IGA response rates. The studies were substantially heterogenous (I² = 63%). Effect estimates for each individual study indicated that calcipotriene was significantly superior to the vehicle: <a href="./references#CD009687-bbs2-0027" title="JemecGB , GanslandtC , OrtonneJP , PoulinY , BurdenAD , deUnamunoP , et al. A new scalp formulation of calcipotriene plus betamethasone compared with its active ingredients and the vehicle in the treatment of scalp psoriasis: a randomized, double‐blind, controlled trial. Journal of the American Academy of Dermatology2008;59(3):455‐63. [MEDLINE: 18694678] JemecGBE , BurdenD , PoulinY , OrtonneJP . A new scalp formulation of calcipotriene plus betamethasone in the treatment of scalp psoriasis compared to its active ingredients and the vehicle (Abstract P2733). Journal of the American Academy of Dermatology2007;56(2):AB182. ">Jemec 2008</a> (RR 1.60; 95% CI 1.01 to 2.53; NNTB = 12; 95% CI 7 to 98); <a href="./references#CD009687-bbs2-0012" title="FeldmanSR , MillsM , BrundageT , EastmanWJ . A multicenter, randomized, double‐blind study of the efficacy and safety of calcipotriene foam, 0.005%, vs vehicle foam in the treatment of plaque‐type psoriasis of the scalp. Journal of Drugs in Dermatology2013;12(3):300‐6. [MEDLINE: 23545912] ">Feldman 2013</a> (RR 2.84; 95% CI 1.70 to 4.74; NNTB = 6; 95% 5 to 11). Both studies addressed data for an ITT population and blinded investigators and participants adequately. Differences in both study populations may explain the clinical heterogeneity. The study population of <a href="./references#CD009687-bbs2-0027" title="JemecGB , GanslandtC , OrtonneJP , PoulinY , BurdenAD , deUnamunoP , et al. A new scalp formulation of calcipotriene plus betamethasone compared with its active ingredients and the vehicle in the treatment of scalp psoriasis: a randomized, double‐blind, controlled trial. Journal of the American Academy of Dermatology2008;59(3):455‐63. [MEDLINE: 18694678] JemecGBE , BurdenD , PoulinY , OrtonneJP . A new scalp formulation of calcipotriene plus betamethasone in the treatment of scalp psoriasis compared to its active ingredients and the vehicle (Abstract P2733). Journal of the American Academy of Dermatology2007;56(2):AB182. ">Jemec 2008</a> consisted of 55% women. In contrast, the study population of <a href="./references#CD009687-bbs2-0012" title="FeldmanSR , MillsM , BrundageT , EastmanWJ . A multicenter, randomized, double‐blind study of the efficacy and safety of calcipotriene foam, 0.005%, vs vehicle foam in the treatment of plaque‐type psoriasis of the scalp. Journal of Drugs in Dermatology2013;12(3):300‐6. [MEDLINE: 23545912] ">Feldman 2013</a> consisted of 40% women. The duration of the studies (eight weeks) and dosage (5 µg/ml) were identical. <a href="./references#CD009687-bbs2-0027" title="JemecGB , GanslandtC , OrtonneJP , PoulinY , BurdenAD , deUnamunoP , et al. A new scalp formulation of calcipotriene plus betamethasone compared with its active ingredients and the vehicle in the treatment of scalp psoriasis: a randomized, double‐blind, controlled trial. Journal of the American Academy of Dermatology2008;59(3):455‐63. [MEDLINE: 18694678] JemecGBE , BurdenD , PoulinY , OrtonneJP . A new scalp formulation of calcipotriene plus betamethasone in the treatment of scalp psoriasis compared to its active ingredients and the vehicle (Abstract P2733). Journal of the American Academy of Dermatology2007;56(2):AB182. ">Jemec 2008</a> used a hydrophilic gel whereas <a href="./references#CD009687-bbs2-0012" title="FeldmanSR , MillsM , BrundageT , EastmanWJ . A multicenter, randomized, double‐blind study of the efficacy and safety of calcipotriene foam, 0.005%, vs vehicle foam in the treatment of plaque‐type psoriasis of the scalp. Journal of Drugs in Dermatology2013;12(3):300‐6. [MEDLINE: 23545912] ">Feldman 2013</a> used a foam vehicle. </p> <p> <ul id="CD009687-list-0025"> <li> <p>Mean of the TSS (<a href="./references#CD009687-fig-0019" title="">Analysis 3.3</a>) </p> </li> </ul> </p> <p>Three studies that compared vitamin D with its vehicle addressed the reduction of disease severity by measuring the mean change of TSS from baseline (<a href="./references#CD009687-bbs2-0017" title="GreenC , GanpuleM , HarrisD , KavanaghG , KennedyC , MallettR , et al. Comparative effects of calcipotriol (MC903) solution and placebo (vehicle of MC903) in the treatment of psoriasis of the scalp. British Journal of Dermatology1994;130(4):483‐7. [MEDLINE: 8186114] ">Green 1994</a>; <a href="./references#CD009687-bbs2-0027" title="JemecGB , GanslandtC , OrtonneJP , PoulinY , BurdenAD , deUnamunoP , et al. A new scalp formulation of calcipotriene plus betamethasone compared with its active ingredients and the vehicle in the treatment of scalp psoriasis: a randomized, double‐blind, controlled trial. Journal of the American Academy of Dermatology2008;59(3):455‐63. [MEDLINE: 18694678] JemecGBE , BurdenD , PoulinY , OrtonneJP . A new scalp formulation of calcipotriene plus betamethasone in the treatment of scalp psoriasis compared to its active ingredients and the vehicle (Abstract P2733). Journal of the American Academy of Dermatology2007;56(2):AB182. ">Jemec 2008</a>; <a href="./references#CD009687-bbs2-0047" title="RuzickaT , TrompkeC . Treatment of scalp psoriasis. An effective and safe tacalcitol emulsion [Behandlung der Kopfhaut‐Psoriasis: Gute Wirksamkeit und Sicherheit durch Tacalcitol‐Emulsion]. Hautarzt2004;55(2):165‐70. [MEDLINE: 14968327] ">Ruzicka 2004</a>). Vitamin D showed a higher reduction in disease severity than the vehicle. No study reported the measure of variance. </p> </section> <section id="CD009687-sec-0111"> <h6 class="title">2) Number of participants withdrawing due to adverse events</h6> <p>Three studies that compared vitamin D with its vehicle addressed the number of withdrawals due to adverse events for each group (<a href="./references#CD009687-bbs2-0017" title="GreenC , GanpuleM , HarrisD , KavanaghG , KennedyC , MallettR , et al. Comparative effects of calcipotriol (MC903) solution and placebo (vehicle of MC903) in the treatment of psoriasis of the scalp. British Journal of Dermatology1994;130(4):483‐7. [MEDLINE: 8186114] ">Green 1994</a>; <a href="./references#CD009687-bbs2-0012" title="FeldmanSR , MillsM , BrundageT , EastmanWJ . A multicenter, randomized, double‐blind study of the efficacy and safety of calcipotriene foam, 0.005%, vs vehicle foam in the treatment of plaque‐type psoriasis of the scalp. Journal of Drugs in Dermatology2013;12(3):300‐6. [MEDLINE: 23545912] ">Feldman 2013</a>; <a href="./references#CD009687-bbs2-0027" title="JemecGB , GanslandtC , OrtonneJP , PoulinY , BurdenAD , deUnamunoP , et al. A new scalp formulation of calcipotriene plus betamethasone compared with its active ingredients and the vehicle in the treatment of scalp psoriasis: a randomized, double‐blind, controlled trial. Journal of the American Academy of Dermatology2008;59(3):455‐63. [MEDLINE: 18694678] JemecGBE , BurdenD , PoulinY , OrtonneJP . A new scalp formulation of calcipotriene plus betamethasone in the treatment of scalp psoriasis compared to its active ingredients and the vehicle (Abstract P2733). Journal of the American Academy of Dermatology2007;56(2):AB182. ">Jemec 2008</a>). Meta‐analysis, including 820 participants, indicated no significant difference in the number of withdrawals due to adverse events between the vitamin D and the vehicle group (RR 1.43; 95% CI 0.72 to 2.83; <a href="./references#CD009687-fig-0020" title="">Analysis 3.4</a>). Reasons for withdrawal were pruritus, candidiasis, dermatitis and erythema at site of application or other unacceptable adverse events, which were not further specified by the study authors. Heterogeneity was not important (I² = 0%). </p> </section> </section> <section id="CD009687-sec-0112"> <h5 class="title">Secondary outcomes</h5> <section id="CD009687-sec-0113"> <h6 class="title">1) Subjective reduction in severity of psoriasis</h6> <p> <ul id="CD009687-list-0026"> <li> <p>Number of participants achieving 'clearance' according to the PGA (<a href="./references#CD009687-fig-0021" title="">Analysis 3.5</a>) </p> </li> </ul> </p> <p>One study (N = 49 participants), which compared calcipotriol with its vehicle, reported this outcome (<a href="./references#CD009687-bbs2-0017" title="GreenC , GanpuleM , HarrisD , KavanaghG , KennedyC , MallettR , et al. Comparative effects of calcipotriol (MC903) solution and placebo (vehicle of MC903) in the treatment of psoriasis of the scalp. British Journal of Dermatology1994;130(4):483‐7. [MEDLINE: 8186114] ">Green 1994</a>). According to the participants' assessment, there was no difference between the treatment groups (RR 1.92; 95% CI 0.19 to 19.82). However, this finding was based on only three outcome events. </p> <p> <ul id="CD009687-list-0027"> <li> <p>Number of participants achieving 'response' according to the PGA (<a href="./references#CD009687-fig-0022" title="">Analysis 3.6</a>) </p> </li> </ul> </p> <p>One study (N = 408 participants), which compared calcipotriene with its vehicle, addressed this outcome (<a href="./references#CD009687-bbs2-0027" title="JemecGB , GanslandtC , OrtonneJP , PoulinY , BurdenAD , deUnamunoP , et al. A new scalp formulation of calcipotriene plus betamethasone compared with its active ingredients and the vehicle in the treatment of scalp psoriasis: a randomized, double‐blind, controlled trial. Journal of the American Academy of Dermatology2008;59(3):455‐63. [MEDLINE: 18694678] JemecGBE , BurdenD , PoulinY , OrtonneJP . A new scalp formulation of calcipotriene plus betamethasone in the treatment of scalp psoriasis compared to its active ingredients and the vehicle (Abstract P2733). Journal of the American Academy of Dermatology2007;56(2):AB182. ">Jemec 2008</a>). The results indicated that calcipotriene was superior to the vehicle (RR 1.86; 95% CI 1.29 to 2.67; NNTB = 6; 95% CI 4 to 12). </p> </section> <section id="CD009687-sec-0114"> <h6 class="title">2) Number of participants with at least one adverse event</h6> <p>Three studies, which compared vitamin D with the vehicle, measured the number of participants with at least one adverse event (<a href="./references#CD009687-bbs2-0017" title="GreenC , GanpuleM , HarrisD , KavanaghG , KennedyC , MallettR , et al. Comparative effects of calcipotriol (MC903) solution and placebo (vehicle of MC903) in the treatment of psoriasis of the scalp. British Journal of Dermatology1994;130(4):483‐7. [MEDLINE: 8186114] ">Green 1994</a>; <a href="./references#CD009687-bbs2-0012" title="FeldmanSR , MillsM , BrundageT , EastmanWJ . A multicenter, randomized, double‐blind study of the efficacy and safety of calcipotriene foam, 0.005%, vs vehicle foam in the treatment of plaque‐type psoriasis of the scalp. Journal of Drugs in Dermatology2013;12(3):300‐6. [MEDLINE: 23545912] ">Feldman 2013</a>; <a href="./references#CD009687-bbs2-0027" title="JemecGB , GanslandtC , OrtonneJP , PoulinY , BurdenAD , deUnamunoP , et al. A new scalp formulation of calcipotriene plus betamethasone compared with its active ingredients and the vehicle in the treatment of scalp psoriasis: a randomized, double‐blind, controlled trial. Journal of the American Academy of Dermatology2008;59(3):455‐63. [MEDLINE: 18694678] JemecGBE , BurdenD , PoulinY , OrtonneJP . A new scalp formulation of calcipotriene plus betamethasone in the treatment of scalp psoriasis compared to its active ingredients and the vehicle (Abstract P2733). Journal of the American Academy of Dermatology2007;56(2):AB182. ">Jemec 2008</a>). Meta‐analysis, which included 813 participants, showed no difference between participants treated with vitamin D or the vehicle (RR 1.12; 95% CI 0.92 to 1.36; <a href="./references#CD009687-fig-0023" title="">Analysis 3.7</a>). Heterogeneity was not important (I² = 0%). The most common local adverse events in both groups were irritation, burning sensation, pruritus or pain. </p> </section> <section id="CD009687-sec-0115"> <h6 class="title">Additional studies</h6> <p>The study <a href="./references#CD009687-bbs2-0047" title="RuzickaT , TrompkeC . Treatment of scalp psoriasis. An effective and safe tacalcitol emulsion [Behandlung der Kopfhaut‐Psoriasis: Gute Wirksamkeit und Sicherheit durch Tacalcitol‐Emulsion]. Hautarzt2004;55(2):165‐70. [MEDLINE: 14968327] ">Ruzicka 2004</a>, which included 273 participants, compared the efficacy and safety of a tacalcitol emulsion with its vehicle. The findings could not be sufficiently analysed since the sample size of each treatment group was not stated. According to the investigators' and participants' assessments, 21.1% and 25.0% of the tacalcitol group, respectively, achieved complete clearance. In contrast, 4.5% of the participants in the vehicle group achieved complete clearance, according to the evaluation of investigators and participants. There were no withdrawals due to adverse events. In both groups, 12 participants experienced adverse events, most frequently local irritation. </p> <p>The conference poster abstract of <a href="./references#CD009687-bbs2-0030" title="KissI , McCrearyHL , SiskinSB , EpinetteWW . A randomized, double ‐ blind, parallel group dose ranging comparison of the efficacy and safety of calcipotriene solution in the treatment of scalp psoriasis. American Academy of Dermatology. 54th annual meeting February 10‐15. Journal of the American Academy of Dermatology1996:P301. ">Kiss 1996</a> reported two studies that investigated calcipotriene in different concentrations with the vehicle. One trial (N = 235 participants) assessed calcipotriene 0.005% solution, the other (N = 239 participants) assessed calcipotriene 0.0025% solution. For both studies the sample size of each treatment group was not stated and outcome data were not sufficiently addressed. The findings of both studies could therefore not be analysed. However, the authors reported that both calcipotriene solutions were superior to the vehicle and that safety profiles were similar. Common adverse events were burning, stinging and tingling. </p> </section> </section> </section> <section id="CD009687-sec-0116"> <h4 class="title">4. Steroid plus vitamin D versus the vehicle</h4> <p>Two studies compared the two‐compound combination of betamethasone dipropionate plus calcipotriene with the vehicle (<a href="./references#CD009687-bbs2-0027" title="JemecGB , GanslandtC , OrtonneJP , PoulinY , BurdenAD , deUnamunoP , et al. A new scalp formulation of calcipotriene plus betamethasone compared with its active ingredients and the vehicle in the treatment of scalp psoriasis: a randomized, double‐blind, controlled trial. Journal of the American Academy of Dermatology2008;59(3):455‐63. [MEDLINE: 18694678] JemecGBE , BurdenD , PoulinY , OrtonneJP . A new scalp formulation of calcipotriene plus betamethasone in the treatment of scalp psoriasis compared to its active ingredients and the vehicle (Abstract P2733). Journal of the American Academy of Dermatology2007;56(2):AB182. ">Jemec 2008</a>; <a href="./references#CD009687-bbs2-0051" title="TyringS , MendozaN , AppellM , BibbyA , FosterR , HamiltonT , et al. A calcipotriene/betamethasone dipropionate two‐compound scalp formulation in the treatment of scalp psoriasis in Hispanic/Latino and Black/African American patients: results of the randomized, 8‐week, double‐blind phase of a clinical trial. International Journal of Dermatology2010;49(11):1328‐33. [MEDLINE: 20964660] ">Tyring 2010</a>). Both study populations were ethnically different: Jemec mainly assessed Caucasians, while <a href="./references#CD009687-bbs2-0051" title="TyringS , MendozaN , AppellM , BibbyA , FosterR , HamiltonT , et al. A calcipotriene/betamethasone dipropionate two‐compound scalp formulation in the treatment of scalp psoriasis in Hispanic/Latino and Black/African American patients: results of the randomized, 8‐week, double‐blind phase of a clinical trial. International Journal of Dermatology2010;49(11):1328‐33. [MEDLINE: 20964660] ">Tyring 2010</a> focused on participants of Hispanic and Afro‐American origin. </p> <section id="CD009687-sec-0117"> <h5 class="title">Primary outcomes</h5> <section id="CD009687-sec-0118"> <h6 class="title">1) Reduction in clinician‐assessed severity</h6> <p> <ul id="CD009687-list-0028"> <li> <p>Number of participants achieving 'clearance' according to the IGA (<a href="./references#CD009687-fig-0024" title="">Analysis 4.1</a>) </p> </li> </ul> </p> <p>The results of <a href="./references#CD009687-bbs2-0027" title="JemecGB , GanslandtC , OrtonneJP , PoulinY , BurdenAD , deUnamunoP , et al. A new scalp formulation of calcipotriene plus betamethasone compared with its active ingredients and the vehicle in the treatment of scalp psoriasis: a randomized, double‐blind, controlled trial. Journal of the American Academy of Dermatology2008;59(3):455‐63. [MEDLINE: 18694678] JemecGBE , BurdenD , PoulinY , OrtonneJP . A new scalp formulation of calcipotriene plus betamethasone in the treatment of scalp psoriasis compared to its active ingredients and the vehicle (Abstract P2733). Journal of the American Academy of Dermatology2007;56(2):AB182. ">Jemec 2008</a> showed that the two‐compound combination was significantly superior to the vehicle for this outcome (N = 677 participants; RR 11.31; 95% CI 4.28 to 29.93; NNTB = 4; 95% CI 3 to 4). </p> <p> <ul id="CD009687-list-0029"> <li> <p>Number of participants achieving 'response' according to the IGA (<a href="./references#CD009687-fig-0025" title="">Analysis 4.2</a>) </p> </li> </ul> </p> <p>Both studies reported this outcome and showed that the two‐compound combination was superior to the vehicle. Heterogeneity between the trials was considerable (I² = 92%). This may be explained by the ethnically heterogenous study populations. In addition, the proportion of women in the study population was 35% (<a href="./references#CD009687-bbs2-0051" title="TyringS , MendozaN , AppellM , BibbyA , FosterR , HamiltonT , et al. A calcipotriene/betamethasone dipropionate two‐compound scalp formulation in the treatment of scalp psoriasis in Hispanic/Latino and Black/African American patients: results of the randomized, 8‐week, double‐blind phase of a clinical trial. International Journal of Dermatology2010;49(11):1328‐33. [MEDLINE: 20964660] ">Tyring 2010</a>) versus 55% (<a href="./references#CD009687-bbs2-0027" title="JemecGB , GanslandtC , OrtonneJP , PoulinY , BurdenAD , deUnamunoP , et al. A new scalp formulation of calcipotriene plus betamethasone compared with its active ingredients and the vehicle in the treatment of scalp psoriasis: a randomized, double‐blind, controlled trial. Journal of the American Academy of Dermatology2008;59(3):455‐63. [MEDLINE: 18694678] JemecGBE , BurdenD , PoulinY , OrtonneJP . A new scalp formulation of calcipotriene plus betamethasone in the treatment of scalp psoriasis compared to its active ingredients and the vehicle (Abstract P2733). Journal of the American Academy of Dermatology2007;56(2):AB182. ">Jemec 2008</a>). However, the results of each individual study confirmed the superiority of the two‐compound combination: <a href="./references#CD009687-bbs2-0027" title="JemecGB , GanslandtC , OrtonneJP , PoulinY , BurdenAD , deUnamunoP , et al. A new scalp formulation of calcipotriene plus betamethasone compared with its active ingredients and the vehicle in the treatment of scalp psoriasis: a randomized, double‐blind, controlled trial. Journal of the American Academy of Dermatology2008;59(3):455‐63. [MEDLINE: 18694678] JemecGBE , BurdenD , PoulinY , OrtonneJP . A new scalp formulation of calcipotriene plus betamethasone in the treatment of scalp psoriasis compared to its active ingredients and the vehicle (Abstract P2733). Journal of the American Academy of Dermatology2007;56(2):AB182. ">Jemec 2008</a> (N = 677 participants; RR 4.55; 95% CI 3.02 to 6.85; NNTB = 2; 95% CI 2 to 3), <a href="./references#CD009687-bbs2-0051" title="TyringS , MendozaN , AppellM , BibbyA , FosterR , HamiltonT , et al. A calcipotriene/betamethasone dipropionate two‐compound scalp formulation in the treatment of scalp psoriasis in Hispanic/Latino and Black/African American patients: results of the randomized, 8‐week, double‐blind phase of a clinical trial. International Journal of Dermatology2010;49(11):1328‐33. [MEDLINE: 20964660] ">Tyring 2010</a> (N = 177 participants; RR 1.78; 95% CI 1.21 to 2.60; NNTB = 4; 95% CI 3 to 7). </p> <p> <ul id="CD009687-list-0030"> <li> <p>Mean of the TSS (<a href="./references#CD009687-fig-0026" title="">Analysis 4.3</a>) </p> </li> </ul> </p> <p><a href="./references#CD009687-bbs2-0027" title="JemecGB , GanslandtC , OrtonneJP , PoulinY , BurdenAD , deUnamunoP , et al. A new scalp formulation of calcipotriene plus betamethasone compared with its active ingredients and the vehicle in the treatment of scalp psoriasis: a randomized, double‐blind, controlled trial. Journal of the American Academy of Dermatology2008;59(3):455‐63. [MEDLINE: 18694678] JemecGBE , BurdenD , PoulinY , OrtonneJP . A new scalp formulation of calcipotriene plus betamethasone in the treatment of scalp psoriasis compared to its active ingredients and the vehicle (Abstract P2733). Journal of the American Academy of Dermatology2007;56(2):AB182. ">Jemec 2008</a> (N = 677 participants) addressed the reduction of disease severity by measuring the mean change of TSS from baseline. The two‐compound combination showed a higher reduction in disease severity compared to the vehicle (70% versus 36%). This study did not report the measure of variance. </p> </section> <section id="CD009687-sec-0119"> <h6 class="title">2) Number of participants withdrawing due to adverse events</h6> <p>Both studies addressed this outcome. Meta‐analysis indicated that there was no difference between the groups (N = 843 participants; RR 0.48; 95% CI 0.08 to 2.83). Heterogeneity between the trials was moderate (I² = 40%). <a href="./references#CD009687-bbs2-0027" title="JemecGB , GanslandtC , OrtonneJP , PoulinY , BurdenAD , deUnamunoP , et al. A new scalp formulation of calcipotriene plus betamethasone compared with its active ingredients and the vehicle in the treatment of scalp psoriasis: a randomized, double‐blind, controlled trial. Journal of the American Academy of Dermatology2008;59(3):455‐63. [MEDLINE: 18694678] JemecGBE , BurdenD , PoulinY , OrtonneJP . A new scalp formulation of calcipotriene plus betamethasone in the treatment of scalp psoriasis compared to its active ingredients and the vehicle (Abstract P2733). Journal of the American Academy of Dermatology2007;56(2):AB182. ">Jemec 2008</a> did not report the type of adverse events that led to withdrawal. According to <a href="./references#CD009687-bbs2-0051" title="TyringS , MendozaN , AppellM , BibbyA , FosterR , HamiltonT , et al. A calcipotriene/betamethasone dipropionate two‐compound scalp formulation in the treatment of scalp psoriasis in Hispanic/Latino and Black/African American patients: results of the randomized, 8‐week, double‐blind phase of a clinical trial. International Journal of Dermatology2010;49(11):1328‐33. [MEDLINE: 20964660] ">Tyring 2010</a>, three participants of the two‐compound group withdrew due to adverse events. The reasons were cerebrovascular accident, nausea, depression and tremor. The authors did not believe that the adverse events were drug‐related. </p> </section> </section> <section id="CD009687-sec-0120"> <h5 class="title">Secondary outcomes</h5> <section id="CD009687-sec-0121"> <h6 class="title">1) Subjective reduction in severity of psoriasis</h6> <p> <ul id="CD009687-list-0031"> <li> <p>Number of participants achieving 'response' according to the PGA (<a href="./references#CD009687-fig-0028" title="">Analysis 4.5</a>) </p> </li> </ul> </p> <p>Both studies reported this outcome and showed that the two‐compound combination was superior to the vehicle. The percentage of variability in effect estimates represented considerable heterogeneity (I² = 83%). This may be explained by the ethnically heterogenous study populations and the different percentage of female participants. Furthermore, more participants in the vehicle group of <a href="./references#CD009687-bbs2-0051" title="TyringS , MendozaN , AppellM , BibbyA , FosterR , HamiltonT , et al. A calcipotriene/betamethasone dipropionate two‐compound scalp formulation in the treatment of scalp psoriasis in Hispanic/Latino and Black/African American patients: results of the randomized, 8‐week, double‐blind phase of a clinical trial. International Journal of Dermatology2010;49(11):1328‐33. [MEDLINE: 20964660] ">Tyring 2010</a> responded to treatment compared to the vehicle group of <a href="./references#CD009687-bbs2-0027" title="JemecGB , GanslandtC , OrtonneJP , PoulinY , BurdenAD , deUnamunoP , et al. A new scalp formulation of calcipotriene plus betamethasone compared with its active ingredients and the vehicle in the treatment of scalp psoriasis: a randomized, double‐blind, controlled trial. Journal of the American Academy of Dermatology2008;59(3):455‐63. [MEDLINE: 18694678] JemecGBE , BurdenD , PoulinY , OrtonneJP . A new scalp formulation of calcipotriene plus betamethasone in the treatment of scalp psoriasis compared to its active ingredients and the vehicle (Abstract P2733). Journal of the American Academy of Dermatology2007;56(2):AB182. ">Jemec 2008</a> (0.36 versus 0.21). Subgroup analysis confirmed the superiority of the two‐compound combination: <a href="./references#CD009687-bbs2-0027" title="JemecGB , GanslandtC , OrtonneJP , PoulinY , BurdenAD , deUnamunoP , et al. A new scalp formulation of calcipotriene plus betamethasone compared with its active ingredients and the vehicle in the treatment of scalp psoriasis: a randomized, double‐blind, controlled trial. Journal of the American Academy of Dermatology2008;59(3):455‐63. [MEDLINE: 18694678] JemecGBE , BurdenD , PoulinY , OrtonneJP . A new scalp formulation of calcipotriene plus betamethasone in the treatment of scalp psoriasis compared to its active ingredients and the vehicle (Abstract P2733). Journal of the American Academy of Dermatology2007;56(2):AB182. ">Jemec 2008</a> (N = 677 participants; RR 3.33; 95% CI 2.38 to 4.66; NNTB = 3; 95% CI 2 to 3), <a href="./references#CD009687-bbs2-0051" title="TyringS , MendozaN , AppellM , BibbyA , FosterR , HamiltonT , et al. A calcipotriene/betamethasone dipropionate two‐compound scalp formulation in the treatment of scalp psoriasis in Hispanic/Latino and Black/African American patients: results of the randomized, 8‐week, double‐blind phase of a clinical trial. International Journal of Dermatology2010;49(11):1328‐33. [MEDLINE: 20964660] ">Tyring 2010</a> (N = 177 participants; RR 1.74; 95% CI 1.14 to 2.67; NNTB = 4; 95% CI 3 to 11). </p> </section> <section id="CD009687-sec-0122"> <h6 class="title">2) Number of participants with at least one adverse event</h6> <p>Two studies that compared the two‐compound combination product of calcipotriene and betamethasone dipropionate with the vehicle reported the number of participants with at least one adverse event (<a href="./references#CD009687-bbs2-0027" title="JemecGB , GanslandtC , OrtonneJP , PoulinY , BurdenAD , deUnamunoP , et al. A new scalp formulation of calcipotriene plus betamethasone compared with its active ingredients and the vehicle in the treatment of scalp psoriasis: a randomized, double‐blind, controlled trial. Journal of the American Academy of Dermatology2008;59(3):455‐63. [MEDLINE: 18694678] JemecGBE , BurdenD , PoulinY , OrtonneJP . A new scalp formulation of calcipotriene plus betamethasone in the treatment of scalp psoriasis compared to its active ingredients and the vehicle (Abstract P2733). Journal of the American Academy of Dermatology2007;56(2):AB182. ">Jemec 2008</a>; <a href="./references#CD009687-bbs2-0051" title="TyringS , MendozaN , AppellM , BibbyA , FosterR , HamiltonT , et al. A calcipotriene/betamethasone dipropionate two‐compound scalp formulation in the treatment of scalp psoriasis in Hispanic/Latino and Black/African American patients: results of the randomized, 8‐week, double‐blind phase of a clinical trial. International Journal of Dermatology2010;49(11):1328‐33. [MEDLINE: 20964660] ">Tyring 2010</a>). Meta‐analysis indicated no significant difference (RR 0.86; 95% CI 0.68 to 1.09; <a href="./references#CD009687-fig-0029" title="">Analysis 4.6</a>). Heterogeneity was not important (I² = 0%). The most common adverse events in both groups were skin irritation and pruritus. Others, such as a burning sensation, folliculitis and paraesthesia, mainly occurred in participants that applied the two‐compound combination. </p> </section> </section> </section> <section id="CD009687-sec-0123"> <h4 class="title">5. Steroid versus steroid: very high versus high potency</h4> <p>All studies within this comparison compared clobetasol propionate as a steroid of very high potency with betamethasone dipropionate as a steroid of high potency. </p> <section id="CD009687-sec-0124"> <h5 class="title">Primary outcomes</h5> <section id="CD009687-sec-0125"> <h6 class="title">1) Reduction in clinician‐assessed severity</h6> <p> <ul id="CD009687-list-0032"> <li> <p>Number of participants achieving 'clearance' according to the IGA (<a href="./references#CD009687-fig-0030" title="">Analysis 5.1</a>) </p> </li> </ul> </p> <p>Two studies reported this outcome. One had a within‐patient design (<a href="./references#CD009687-bbs2-0025" title="JarrattM , DavisJG , GiltnerMP , JonesML , PeetsEA . Comparative studies of augmented betamethasone dipropionate lotion 0.05% and clobetasol propionate solution 0.05%: Correlation of the vasoconstriction assay and clinical activity in scalp psoriasis. Advances in Therapy1991;8(2):103‐11. [EMBASE: 1991176103] ">Jarratt 1991</a>), and the other was a parallel‐group trial (<a href="./references#CD009687-bbs2-0029" title="KatzHI , LindholmJS , WeissJS , ShavinJS , MormanM , BressinckR , et al. Efficacy and safety of twice‐daily augmented betamethasone dipropionate lotion versus clobetasol propionate solution in patients with moderate‐to‐severe scalp psoriasis. Clinical Therapeutics1995;17(3):390‐401. [MEDLINE: 7585843] ">Katz 1995</a>). The latter, which assessed 197 participants, found no difference between clobetasol propionate and betamethasone dipropionate (RR 0.68; 95% CI 0.44 to 1.05). The study with a within‐patient design confirmed this finding: in a study population of 55 participants, 27 cleared on the side treated with clobetasol propionate, while 28 cleared on the side treated with betamethasone dipropionate. </p> <p> <ul id="CD009687-list-0033"> <li> <p>Number of participants achieving 'response' according to the IGA (<a href="./references#CD009687-fig-0031" title="">Analysis 5.2</a>) </p> </li> </ul> </p> <p>The results of the parallel‐group trial showed no difference between clobetasol propionate and betamethasone dipropionate for this outcome (N = 197 participants; RR 0.95; 95% CI 0.79 to 1.14) (<a href="./references#CD009687-bbs2-0029" title="KatzHI , LindholmJS , WeissJS , ShavinJS , MormanM , BressinckR , et al. Efficacy and safety of twice‐daily augmented betamethasone dipropionate lotion versus clobetasol propionate solution in patients with moderate‐to‐severe scalp psoriasis. Clinical Therapeutics1995;17(3):390‐401. [MEDLINE: 7585843] ">Katz 1995</a>). The within‐patient study confirmed this finding: in a study population of 55 participants, 51 responded on the side treated with clobetasol propionate, while 52 responded on the side treated with betamethasone dipropionate (<a href="./references#CD009687-bbs2-0025" title="JarrattM , DavisJG , GiltnerMP , JonesML , PeetsEA . Comparative studies of augmented betamethasone dipropionate lotion 0.05% and clobetasol propionate solution 0.05%: Correlation of the vasoconstriction assay and clinical activity in scalp psoriasis. Advances in Therapy1991;8(2):103‐11. [EMBASE: 1991176103] ">Jarratt 1991</a>). </p> <p> <ul id="CD009687-list-0034"> <li> <p>Mean of the TSS (<a href="./references#CD009687-fig-0032" title="">Analysis 5.3</a>) </p> </li> </ul> </p> <p>Two studies reported the reduction of disease severity by measuring the mean change of TSS from the baseline. While <a href="./references#CD009687-bbs2-0029" title="KatzHI , LindholmJS , WeissJS , ShavinJS , MormanM , BressinckR , et al. Efficacy and safety of twice‐daily augmented betamethasone dipropionate lotion versus clobetasol propionate solution in patients with moderate‐to‐severe scalp psoriasis. Clinical Therapeutics1995;17(3):390‐401. [MEDLINE: 7585843] ">Katz 1995</a> reported a higher reduction in TSS by betamethasone dipropionate, <a href="./references#CD009687-bbs2-0036" title="LassusA . Local treatment of psoriasis of the scalp with clobetasol propionate and betamethasone‐17,21‐dipropionate: a double‐blind comparison. Current Medical Research &amp; Opinion1976;4(5):365‐7. [MEDLINE: 795609] ">Lassus 1976</a> found clobetasol propionate to be superior. Measure of variance was not reported in either study. These contradictory results may be explained by clinical and methodological heterogeneity among the studies. It was unclear if <a href="./references#CD009687-bbs2-0036" title="LassusA . Local treatment of psoriasis of the scalp with clobetasol propionate and betamethasone‐17,21‐dipropionate: a double‐blind comparison. Current Medical Research &amp; Opinion1976;4(5):365‐7. [MEDLINE: 795609] ">Lassus 1976</a> randomised properly, since the authors simply stated that they performed a non‐selective sequence generation. In addition, the sample size of <a href="./references#CD009687-bbs2-0029" title="KatzHI , LindholmJS , WeissJS , ShavinJS , MormanM , BressinckR , et al. Efficacy and safety of twice‐daily augmented betamethasone dipropionate lotion versus clobetasol propionate solution in patients with moderate‐to‐severe scalp psoriasis. Clinical Therapeutics1995;17(3):390‐401. [MEDLINE: 7585843] ">Katz 1995</a> (N = 197 participants) was higher than that of <a href="./references#CD009687-bbs2-0036" title="LassusA . Local treatment of psoriasis of the scalp with clobetasol propionate and betamethasone‐17,21‐dipropionate: a double‐blind comparison. Current Medical Research &amp; Opinion1976;4(5):365‐7. [MEDLINE: 795609] ">Lassus 1976</a> (N = 40 participants). </p> </section> <section id="CD009687-sec-0126"> <h6 class="title">2) Number of participants withdrawing due to adverse events</h6> <p>During both studies (N = 236 participants) that reported this outcome, none of the participants withdrew due to adverse events (<a href="./references#CD009687-bbs2-0029" title="KatzHI , LindholmJS , WeissJS , ShavinJS , MormanM , BressinckR , et al. Efficacy and safety of twice‐daily augmented betamethasone dipropionate lotion versus clobetasol propionate solution in patients with moderate‐to‐severe scalp psoriasis. Clinical Therapeutics1995;17(3):390‐401. [MEDLINE: 7585843] ">Katz 1995</a>; <a href="./references#CD009687-bbs2-0036" title="LassusA . Local treatment of psoriasis of the scalp with clobetasol propionate and betamethasone‐17,21‐dipropionate: a double‐blind comparison. Current Medical Research &amp; Opinion1976;4(5):365‐7. [MEDLINE: 795609] ">Lassus 1976</a>). </p> </section> </section> <section id="CD009687-sec-0127"> <h5 class="title">Secondary outcomes</h5> <section id="CD009687-sec-0128"> <h6 class="title">1) Number of participants with at least one adverse event</h6> <p>Two studies that compared clobetasol propionate with betamethasone dipropionate reported the number of participants with at least one adverse event for each group (<a href="./references#CD009687-bbs2-0029" title="KatzHI , LindholmJS , WeissJS , ShavinJS , MormanM , BressinckR , et al. Efficacy and safety of twice‐daily augmented betamethasone dipropionate lotion versus clobetasol propionate solution in patients with moderate‐to‐severe scalp psoriasis. Clinical Therapeutics1995;17(3):390‐401. [MEDLINE: 7585843] ">Katz 1995</a>; <a href="./references#CD009687-bbs2-0036" title="LassusA . Local treatment of psoriasis of the scalp with clobetasol propionate and betamethasone‐17,21‐dipropionate: a double‐blind comparison. Current Medical Research &amp; Opinion1976;4(5):365‐7. [MEDLINE: 795609] ">Lassus 1976</a>). Meta‐analysis that included 236 participants did not indicate any significant difference in the risk of adverse events between the treatment groups (RR 0.90; 95% CI 0.32 to 2.48; <a href="./references#CD009687-fig-0033" title="">Analysis 5.4</a>). Heterogeneity was not important (I² = 18%). However, <a href="./references#CD009687-bbs2-0029" title="KatzHI , LindholmJS , WeissJS , ShavinJS , MormanM , BressinckR , et al. Efficacy and safety of twice‐daily augmented betamethasone dipropionate lotion versus clobetasol propionate solution in patients with moderate‐to‐severe scalp psoriasis. Clinical Therapeutics1995;17(3):390‐401. [MEDLINE: 7585843] ">Katz 1995</a> had a significantly higher incidence of adverse events, with a total number of 69 out of 196. The study reported different types of adverse effects, such as headache, tingling, stinging, numbness, cooling and dry feeling of the skin. <a href="./references#CD009687-bbs2-0036" title="LassusA . Local treatment of psoriasis of the scalp with clobetasol propionate and betamethasone‐17,21‐dipropionate: a double‐blind comparison. Current Medical Research &amp; Opinion1976;4(5):365‐7. [MEDLINE: 795609] ">Lassus 1976</a> only detected pruritus and folliculitis in two participants that applied betamethasone dipropionate. </p> </section> </section> </section> <section id="CD009687-sec-0129"> <h4 class="title">6. Steroid versus steroid: high versus moderate potency</h4> <section id="CD009687-sec-0130"> <h5 class="title">Primary outcomes</h5> <section id="CD009687-sec-0131"> <h6 class="title">1) Reduction in clinician‐assessed severity</h6> <p> <ul id="CD009687-list-0035"> <li> <p>Number of participants achieving 'clearance' according to the IGA (<a href="./references#CD009687-fig-0034" title="">Analysis 6.1</a>) </p> </li> </ul> </p> <p>Two studies, which included 190 participants, compared a steroid of high potency with the moderately potent hydrocortisone 17‐butyrate 0.1% (<a href="./references#CD009687-bbs2-0007" title="DeCuyperC , DeGreefH , De LaBrassinneM , DelesculeJ , DerumeuaxL , HeenenM , et al. A randomized single‐blind study to compare hydrocortisone 17‐butyrate 0.1% emulsion versus betamethasone 17,21‐dipropionate 0.05% lotion in the treatment of patients suffering from psoriasis of the scalp. Journal of the European Academy of Dermatology &amp; Venereology1995;5(Suppl 1):S104‐5. ">De Cuyper 1995</a>; <a href="./references#CD009687-bbs2-0016" title="GipL . Hydrocortisone 17‐butyrate 0.1% cream and fluocinolone acetonide 0.025% cream: a double‐blind comparison in patients suffering from psoriasis of the scalp. Current Therapeutic Research ‐ Clinical and Experimental1981;29(1 II):198‐201. [EMBASE: 1981110060] ">Gip 1981</a>). With regard to clearance, there was no significant difference between the treatment groups (RR 1.16; 95% CI 0.56 to 2.39). Heterogeneity between the trials was not important (I² = 35%). </p> <p> <ul id="CD009687-list-0036"> <li> <p>Number of participants achieving 'response' according to the IGA (<a href="./references#CD009687-fig-0035" title="">Analysis 6.2</a>) </p> </li> </ul> </p> <p>One study assessed treatment response in 123 participants that either received fluocinonide (high potency) or desoximetasone 0.05% (moderate potency) (<a href="./references#CD009687-bbs2-0057" title="WillisI , CornellRC , PenneysNS , ZaiasN . Multicenter study comparing 0.05% gel formulations of desoximetasone and fluocinonide in patients with scalp psoriasis. Clinical Therapeutics1986;8(3):275‐82. [MEDLINE: 3521856] ">Willis 1986</a>). There was no significant difference between the treatment groups (RR 0.94; 95% CI 0.61 to 1.44). </p> <p> <ul id="CD009687-list-0037"> <li> <p>Mean of the TSS (<a href="./references#CD009687-fig-0036" title="">Analysis 6.3</a>) </p> </li> </ul> </p> <p>One study, which compared the highly potent steroid mometasone furoate with moderately potent triamcinolone acetonide 0.1% in 202 participants, addressed reduction of disease severity by measuring the mean change of TSS from baseline (<a href="./references#CD009687-bbs2-0050" title="SwinehartJM , BarkoffJR , DvorkinD , FisherG , PeetsE . Mometasone furoate lotion once daily versus triamcinolone acetonide lotion twice daily in psoriasis. International Journal of Dermatology1989;28(10):680‐1. [MEDLINE: 2687182] ">Swinehart 1989</a>). The mean reduction for mometasone furoate and triamcinolone acetonide 0.1% was 79% and 70%, respectively. The measure of variance was not reported. </p> </section> </section> <section id="CD009687-sec-0132"> <h5 class="title">Secondary outcomes</h5> <section id="CD009687-sec-0133"> <h6 class="title">1) Number of participants with at least one adverse event</h6> <p>One study, which compared highly potent mometasone furoate with moderately potent triamcinolone acetonide 0.1%, reported this outcome for 202 participants (<a href="./references#CD009687-bbs2-0050" title="SwinehartJM , BarkoffJR , DvorkinD , FisherG , PeetsE . Mometasone furoate lotion once daily versus triamcinolone acetonide lotion twice daily in psoriasis. International Journal of Dermatology1989;28(10):680‐1. [MEDLINE: 2687182] ">Swinehart 1989</a>). There was no significant difference in the incidence of adverse events between participants treated with mometasone furoate and those receiving triamcinolone acetonide 0.01% (RR 1.12; 95% CI 0.39 to 3.22; <a href="./references#CD009687-fig-0037" title="">Analysis 6.4</a>). Another study (N = 40 participants) compared fluocinolone acetonide 0.025% with hydrocortisone 17‐butyrate 0.1% (<a href="./references#CD009687-bbs2-0016" title="GipL . Hydrocortisone 17‐butyrate 0.1% cream and fluocinolone acetonide 0.025% cream: a double‐blind comparison in patients suffering from psoriasis of the scalp. Current Therapeutic Research ‐ Clinical and Experimental1981;29(1 II):198‐201. [EMBASE: 1981110060] ">Gip 1981</a>). No adverse event occurred. </p> <p>Three studies reported the nature of adverse events that participants in both groups experienced (<a href="./references#CD009687-bbs2-0007" title="DeCuyperC , DeGreefH , De LaBrassinneM , DelesculeJ , DerumeuaxL , HeenenM , et al. A randomized single‐blind study to compare hydrocortisone 17‐butyrate 0.1% emulsion versus betamethasone 17,21‐dipropionate 0.05% lotion in the treatment of patients suffering from psoriasis of the scalp. Journal of the European Academy of Dermatology &amp; Venereology1995;5(Suppl 1):S104‐5. ">De Cuyper 1995</a>; <a href="./references#CD009687-bbs2-0050" title="SwinehartJM , BarkoffJR , DvorkinD , FisherG , PeetsE . Mometasone furoate lotion once daily versus triamcinolone acetonide lotion twice daily in psoriasis. International Journal of Dermatology1989;28(10):680‐1. [MEDLINE: 2687182] ">Swinehart 1989</a>; <a href="./references#CD009687-bbs2-0057" title="WillisI , CornellRC , PenneysNS , ZaiasN . Multicenter study comparing 0.05% gel formulations of desoximetasone and fluocinonide in patients with scalp psoriasis. Clinical Therapeutics1986;8(3):275‐82. [MEDLINE: 3521856] ">Willis 1986</a>). The most frequent were a local burning or stinging sensation, acne, folliculitis or pruritus. </p> </section> <section id="CD009687-sec-0134"> <h6 class="title">Additional studies</h6> <p>The cross‐over study of <a href="./references#CD009687-bbs2-0024" title="HousmanTS , McMichaelAJ , MellenBG , DerrowAE , McCartyMA , FeldmanSR . Use of 0.12% betamethasone valerate foam vs 0.01% fluocinolone acetonide topical oil to treat scalp psoriasis: quantitative assessment of patient preference and treatment efficacy. Cosmetic Dermatology2002;15(11):27‐30. [EMBASE: 2006007462] HousmanTS , McMichaelAJ , MellenBG , DerrowE , McCartyMA , FeldmanSR . Betamethasone valerate foam vs. fluocinolone acetonide topical oil in the treatment of scalp psoriasis: quantitative assessment of patients' preference and efficacy (Abstract 203). Journal of Investigative Dermatology2002;119(1):241. ">Housman 2002</a> (N = 25 participants) compared the efficacy and improvement in quality of life of betamethasone valerate 0.12% foam with fluocinolone acetonide 0.01% oil. Insufficient outcome data were provided and were therefore not eligible for analysis. However, the authors stated that the TSS between the groups was not significantly different before cross‐over was performed. </p> </section> </section> </section> <section id="CD009687-sec-0135"> <h4 class="title">7. Steroid versus steroid: both of high potency</h4> <section id="CD009687-sec-0136"> <h5 class="title">Primary outcomes</h5> <section id="CD009687-sec-0137"> <h6 class="title">1) Reduction in clinician‐assessed severity</h6> <p> <ul id="CD009687-list-0038"> <li> <p>Number of participants achieving 'clearance' according to the IGA (<a href="./references#CD009687-fig-0038" title="">Analysis 7.1</a>) </p> </li> </ul> </p> <p>One study that included 203 participants compared mometasone furoate with betamethasone valerate 0.1% (<a href="./references#CD009687-bbs2-0054" title="Van derPloegDE , CornellRC , BinderR , WeintraubJS , JarrattM , JonesML , et al. Clinical trial in scalp psoriasis mometasone furoate lotion 0.1% applied once daily vs betamethasone valerate lotion 0.1% applied twice daily. Acta Therapeutica1989;15(2):145‐52. ">Van der Ploeg 1989</a>). Significantly more participants that were treated with mometasone furoate showed clearing of psoriatic scalp lesions (RR 1.84; 95% CI 1.09 to 3.11; NNTB = 8; 95% CI 4 to 41). </p> <p> <ul id="CD009687-list-0039"> <li> <p>Number of participants achieving 'response' according to the IGA (<a href="./references#CD009687-fig-0039" title="">Analysis 7.2</a>) </p> </li> </ul> </p> <p>According to <a href="./references#CD009687-bbs2-0054" title="Van derPloegDE , CornellRC , BinderR , WeintraubJS , JarrattM , JonesML , et al. Clinical trial in scalp psoriasis mometasone furoate lotion 0.1% applied once daily vs betamethasone valerate lotion 0.1% applied twice daily. Acta Therapeutica1989;15(2):145‐52. ">Van der Ploeg 1989</a>, significantly more participants responded with mometasone furoate than with betamethasone valerate 0.1% (N = 203; RR 1.28; 95% CI 1.03 to 1.58; NNTB= 7; 95% CI 4 to 43). </p> <p> <ul id="CD009687-list-0040"> <li> <p>Mean score of the IGA</p> </li> </ul> </p> <p>One study that assessed 59 participants reported IGA as a continuous outcome (<a href="./references#CD009687-bbs2-0010" title="EllisCN , MenterMA . A randomized, blinded comparison of amcinonide lotion and fluocinonide solution in patients with psoriasis of the scalp. Current Therapeutic Research ‐ Clinical and Experimental1989;46(3):471‐7. [EMBASE: 1989232557] ">Ellis 1989</a>). The mean score according to a scale from 1 ('clear') to 4 ('fair improvement') for amcinonide 0.1% and fluocinonide was 2.25 and 2.2, respectively. Measure of variance was not reported. </p> <p> <ul id="CD009687-list-0041"> <li> <p>Mean of the TSS (<a href="./references#CD009687-fig-0040" title="">Analysis 7.3</a>) </p> </li> </ul> </p> <p>Two studies addressed reduction of disease severity by measuring the mean change of TSS from baseline. <a href="./references#CD009687-bbs2-0004" title="BrenemanDL , DavisMB , BergerV , ChaneyR . A double‐blind trial comparing the efficacy and safety of augmented betamethasone dipropionate lotion with fluocinonide solution in the treatment of severe scalp psoriasis. Journal of Dermatological Treatment1992;3(1):19‐21. [EMBASE: 1992153744] ">Breneman 1992</a>, which assessed 169 participants, found that TSS reduction between participants treated with fluocinonide was 84% and those treated with betamethasone dipropionate 85%. <a href="./references#CD009687-bbs2-0054" title="Van derPloegDE , CornellRC , BinderR , WeintraubJS , JarrattM , JonesML , et al. Clinical trial in scalp psoriasis mometasone furoate lotion 0.1% applied once daily vs betamethasone valerate lotion 0.1% applied twice daily. Acta Therapeutica1989;15(2):145‐52. ">Van der Ploeg 1989</a>, which included 203 participants, found a mean reduction of 85% and 70% for mometasone furoate and betamethasone dipropionate, respectively. Neither study reported any measure of variance. </p> </section> <section id="CD009687-sec-0138"> <h6 class="title">2) Number of participants withdrawing due to adverse events</h6> <p>Two studies reported this outcome. <a href="./references#CD009687-bbs2-0010" title="EllisCN , MenterMA . A randomized, blinded comparison of amcinonide lotion and fluocinonide solution in patients with psoriasis of the scalp. Current Therapeutic Research ‐ Clinical and Experimental1989;46(3):471‐7. [EMBASE: 1989232557] ">Ellis 1989</a> compared fluocinonide with amcinonide 0.1% and <a href="./references#CD009687-bbs2-0004" title="BrenemanDL , DavisMB , BergerV , ChaneyR . A double‐blind trial comparing the efficacy and safety of augmented betamethasone dipropionate lotion with fluocinonide solution in the treatment of severe scalp psoriasis. Journal of Dermatological Treatment1992;3(1):19‐21. [EMBASE: 1992153744] ">Breneman 1992</a> assessed fluocinonide and betamethasone dipropionate. According to both trials, there was no significant difference between the treatment groups: <a href="./references#CD009687-bbs2-0010" title="EllisCN , MenterMA . A randomized, blinded comparison of amcinonide lotion and fluocinonide solution in patients with psoriasis of the scalp. Current Therapeutic Research ‐ Clinical and Experimental1989;46(3):471‐7. [EMBASE: 1989232557] ">Ellis 1989</a> (N = 59 participants; RR 0.34; 95% CI 0.01 to 8.13), <a href="./references#CD009687-bbs2-0004" title="BrenemanDL , DavisMB , BergerV , ChaneyR . A double‐blind trial comparing the efficacy and safety of augmented betamethasone dipropionate lotion with fluocinonide solution in the treatment of severe scalp psoriasis. Journal of Dermatological Treatment1992;3(1):19‐21. [EMBASE: 1992153744] ">Breneman 1992</a> (N = 167 participants; RR 1.01; 95% CI 0.06 to 15.91) (<a href="./references#CD009687-fig-0041" title="">Analysis 7.4</a>). However, there were only few withdrawals in both studies: in the study by <a href="./references#CD009687-bbs2-0010" title="EllisCN , MenterMA . A randomized, blinded comparison of amcinonide lotion and fluocinonide solution in patients with psoriasis of the scalp. Current Therapeutic Research ‐ Clinical and Experimental1989;46(3):471‐7. [EMBASE: 1989232557] ">Ellis 1989</a>, one participant that applied fluocinonide withdrew because of eczematous dermatitis. In the other trial one participant in each group stopped the study medication (<a href="./references#CD009687-bbs2-0004" title="BrenemanDL , DavisMB , BergerV , ChaneyR . A double‐blind trial comparing the efficacy and safety of augmented betamethasone dipropionate lotion with fluocinonide solution in the treatment of severe scalp psoriasis. Journal of Dermatological Treatment1992;3(1):19‐21. [EMBASE: 1992153744] ">Breneman 1992</a>). The one that received betamethasone dipropionate withdrew due to mild cutaneous burning, dryness and tightness. The other that applied fluocinonide experienced severe pruritus and generalised urticaria. </p> </section> </section> <section id="CD009687-sec-0139"> <h5 class="title">Secondary outcomes</h5> <section id="CD009687-sec-0140"> <h6 class="title">1) Subjective reduction in severity of psoriasis</h6> <p> <ul id="CD009687-list-0042"> <li> <p>Mean score of the PGA.</p> </li> </ul> </p> <p>One study that included 59 participants addressed PGA as a continuous outcome (<a href="./references#CD009687-bbs2-0010" title="EllisCN , MenterMA . A randomized, blinded comparison of amcinonide lotion and fluocinonide solution in patients with psoriasis of the scalp. Current Therapeutic Research ‐ Clinical and Experimental1989;46(3):471‐7. [EMBASE: 1989232557] ">Ellis 1989</a>). Mean scores for amcinonide 0.1% and fluocinonide, according to a scale from 1 ('clear') to 4 ('fair improvement') were 2.6 and 2.25, respectively. The measure of variance was not reported in the studies. </p> </section> <section id="CD009687-sec-0141"> <h6 class="title">2) Number of participants with at least one adverse event</h6> <p><a href="./references#CD009687-bbs2-0010" title="EllisCN , MenterMA . A randomized, blinded comparison of amcinonide lotion and fluocinonide solution in patients with psoriasis of the scalp. Current Therapeutic Research ‐ Clinical and Experimental1989;46(3):471‐7. [EMBASE: 1989232557] ">Ellis 1989</a> (N = 59 participants) and <a href="./references#CD009687-bbs2-0004" title="BrenemanDL , DavisMB , BergerV , ChaneyR . A double‐blind trial comparing the efficacy and safety of augmented betamethasone dipropionate lotion with fluocinonide solution in the treatment of severe scalp psoriasis. Journal of Dermatological Treatment1992;3(1):19‐21. [EMBASE: 1992153744] ">Breneman 1992</a> (N = 167 participants) also addressed the secondary safety outcome. In both trials fluocinonide caused a higher rate of adverse events compared to amcinonide 0.1% or betamethasone dipropionate. However, both findings were not significant: <a href="./references#CD009687-bbs2-0010" title="EllisCN , MenterMA . A randomized, blinded comparison of amcinonide lotion and fluocinonide solution in patients with psoriasis of the scalp. Current Therapeutic Research ‐ Clinical and Experimental1989;46(3):471‐7. [EMBASE: 1989232557] ">Ellis 1989</a> (RR 0.09; 95% CI 0.01 to 1.63); <a href="./references#CD009687-bbs2-0004" title="BrenemanDL , DavisMB , BergerV , ChaneyR . A double‐blind trial comparing the efficacy and safety of augmented betamethasone dipropionate lotion with fluocinonide solution in the treatment of severe scalp psoriasis. Journal of Dermatological Treatment1992;3(1):19‐21. [EMBASE: 1992153744] ">Breneman 1992</a> (RR 0.38; 95% CI 0.10 to 1.38) (<a href="./references#CD009687-fig-0042" title="">Analysis 7.5</a>). </p> <p>All three studies that assessed steroids of high potency reported the nature of adverse events that occurred during the trial period (<a href="./references#CD009687-bbs2-0004" title="BrenemanDL , DavisMB , BergerV , ChaneyR . A double‐blind trial comparing the efficacy and safety of augmented betamethasone dipropionate lotion with fluocinonide solution in the treatment of severe scalp psoriasis. Journal of Dermatological Treatment1992;3(1):19‐21. [EMBASE: 1992153744] ">Breneman 1992</a>; <a href="./references#CD009687-bbs2-0010" title="EllisCN , MenterMA . A randomized, blinded comparison of amcinonide lotion and fluocinonide solution in patients with psoriasis of the scalp. Current Therapeutic Research ‐ Clinical and Experimental1989;46(3):471‐7. [EMBASE: 1989232557] ">Ellis 1989</a>; <a href="./references#CD009687-bbs2-0054" title="Van derPloegDE , CornellRC , BinderR , WeintraubJS , JarrattM , JonesML , et al. Clinical trial in scalp psoriasis mometasone furoate lotion 0.1% applied once daily vs betamethasone valerate lotion 0.1% applied twice daily. Acta Therapeutica1989;15(2):145‐52. ">Van der Ploeg 1989</a>). Common adverse events were a burning sensation, itching, acne and folliculitis at the site of application. </p> </section> </section> </section> <section id="CD009687-sec-0142"> <h4 class="title">8. Steroid versus vitamin D</h4> <section id="CD009687-sec-0143"> <h5 class="title">Primary outcomes</h5> <section id="CD009687-sec-0144"> <h6 class="title">1) Reduction in clinician‐assessed severity</h6> <p> <ul id="CD009687-list-0043"> <li> <p>Number of participants achieving 'clearance' according to the IGA (<a href="./references#CD009687-fig-0043" title="">Analysis 8.1</a>) </p> </li> </ul> </p> <p>Four studies, which compared a steroid with vitamin D, addressed this outcome for a total of 2180 participants (<a href="./references#CD009687-bbs2-0027" title="JemecGB , GanslandtC , OrtonneJP , PoulinY , BurdenAD , deUnamunoP , et al. A new scalp formulation of calcipotriene plus betamethasone compared with its active ingredients and the vehicle in the treatment of scalp psoriasis: a randomized, double‐blind, controlled trial. Journal of the American Academy of Dermatology2008;59(3):455‐63. [MEDLINE: 18694678] JemecGBE , BurdenD , PoulinY , OrtonneJP . A new scalp formulation of calcipotriene plus betamethasone in the treatment of scalp psoriasis compared to its active ingredients and the vehicle (Abstract P2733). Journal of the American Academy of Dermatology2007;56(2):AB182. ">Jemec 2008</a>; <a href="./references#CD009687-bbs2-0032" title="KlaberMR , HutchinsonPE , Pedvis‐LeftickA , KragballeK , ReunalaTL , van deKerkhofPC , et al. Comparative effects of calcipotriol solution (50 micrograms/ml) and betamethasone 17‐valerate solution (1 mg/ml) in the treatment of scalp psoriasis. British Journal of Dermatology1994;131(5):678‐83. [MEDLINE: 7999600] ">Klaber 1994</a>; <a href="./references#CD009687-bbs2-0053" title="van deKerkhofP , AnsteyA , BarnesL , BolducC . A new scalp formulation of calcipotriene plus betamethasone in the treatment of scalp psoriasis compared to its active ingredients in the same vehicle. Journal of the American Academy of Dermatology2007;56(2):AB182. van deKerkhofPC , HoffmannV , AnsteyA , BarnesL , BolducC , ReichK , et al. A new scalp formulation of calcipotriol plus betamethasone dipropionate compared with each of its active ingredients in the same vehicle for the treatment of scalp psoriasis: a randomized, double‐blind, controlled trial. British Journal of Dermatology2009;160(1):170‐6. [MEDLINE: 19067709] ">van de Kerkhof 2009</a>; <a href="./references#CD009687-bbs2-0059" title="YilmazH , AydinF , SenturkN , CanturkT , TuranliAY . A comparison between the effects of calcipotriol lotion, momethasone furoate lotion and their combinations for the treatment of scalp psoriasis [Kalsipotriol Losyon, Mometazon Furoat Losyonve Kombinasyonlarinin Saçli Deri Psoriazisi Tedavisindeki Etkinliginin Karsilastirilmasi]. Turkderm Deri Hastaliklari ve Frengi Arsivi2005;39(2):109‐14. [EMBASE: 2006204571] ">Yilmaz 2005</a>). Meta‐analysis showed that the steroid was significantly superior to vitamin D in clearing scalp psoriasis (RR 1.82; 95% CI 1.52 to 2.18; NNTB = 8; 95% CI 7 to 11). Heterogeneity was not important (I² = 0%). The quality of the evidence was moderate (<a href="./full#CD009687-tbl-0001">summary of findings Table for the main comparison</a>). </p> <p>Subgroup analysis with regard to the individual steroid agents emphasised the superiority of betamethasone valerate 1 mg/ml (RR 1.85; 95% CI 1.31 to 2.60; NNTB = 8; 95% CI 5 to 16; N = 474 participants; <a href="./references#CD009687-bbs2-0032" title="KlaberMR , HutchinsonPE , Pedvis‐LeftickA , KragballeK , ReunalaTL , van deKerkhofPC , et al. Comparative effects of calcipotriol solution (50 micrograms/ml) and betamethasone 17‐valerate solution (1 mg/ml) in the treatment of scalp psoriasis. British Journal of Dermatology1994;131(5):678‐83. [MEDLINE: 7999600] ">Klaber 1994</a>), and betamethasone dipropionate (RR 1.81; 95% CI 1.46 to 2.24; NNTB = 8; 95% CI 6 to 12; N = 1676 participants; <a href="./references#CD009687-bbs2-0027" title="JemecGB , GanslandtC , OrtonneJP , PoulinY , BurdenAD , deUnamunoP , et al. A new scalp formulation of calcipotriene plus betamethasone compared with its active ingredients and the vehicle in the treatment of scalp psoriasis: a randomized, double‐blind, controlled trial. Journal of the American Academy of Dermatology2008;59(3):455‐63. [MEDLINE: 18694678] JemecGBE , BurdenD , PoulinY , OrtonneJP . A new scalp formulation of calcipotriene plus betamethasone in the treatment of scalp psoriasis compared to its active ingredients and the vehicle (Abstract P2733). Journal of the American Academy of Dermatology2007;56(2):AB182. ">Jemec 2008</a>; <a href="./references#CD009687-bbs2-0053" title="van deKerkhofP , AnsteyA , BarnesL , BolducC . A new scalp formulation of calcipotriene plus betamethasone in the treatment of scalp psoriasis compared to its active ingredients in the same vehicle. Journal of the American Academy of Dermatology2007;56(2):AB182. van deKerkhofPC , HoffmannV , AnsteyA , BarnesL , BolducC , ReichK , et al. A new scalp formulation of calcipotriol plus betamethasone dipropionate compared with each of its active ingredients in the same vehicle for the treatment of scalp psoriasis: a randomized, double‐blind, controlled trial. British Journal of Dermatology2009;160(1):170‐6. [MEDLINE: 19067709] ">van de Kerkhof 2009</a>) over vitamin D, but not of mometasone furoate (RR 2.00; 95% CI 0.43 to 9.32; N = 30 participants; <a href="./references#CD009687-bbs2-0059" title="YilmazH , AydinF , SenturkN , CanturkT , TuranliAY . A comparison between the effects of calcipotriol lotion, momethasone furoate lotion and their combinations for the treatment of scalp psoriasis [Kalsipotriol Losyon, Mometazon Furoat Losyonve Kombinasyonlarinin Saçli Deri Psoriazisi Tedavisindeki Etkinliginin Karsilastirilmasi]. Turkderm Deri Hastaliklari ve Frengi Arsivi2005;39(2):109‐14. [EMBASE: 2006204571] ">Yilmaz 2005</a>). </p> <section id="CD009687-sec-0145"> <p><b>Sensitivity analysis</b></p> <p>Sensitivity analysis with regard to ITT population, which included three studies (<a href="./references#CD009687-bbs2-0027" title="JemecGB , GanslandtC , OrtonneJP , PoulinY , BurdenAD , deUnamunoP , et al. A new scalp formulation of calcipotriene plus betamethasone compared with its active ingredients and the vehicle in the treatment of scalp psoriasis: a randomized, double‐blind, controlled trial. Journal of the American Academy of Dermatology2008;59(3):455‐63. [MEDLINE: 18694678] JemecGBE , BurdenD , PoulinY , OrtonneJP . A new scalp formulation of calcipotriene plus betamethasone in the treatment of scalp psoriasis compared to its active ingredients and the vehicle (Abstract P2733). Journal of the American Academy of Dermatology2007;56(2):AB182. ">Jemec 2008</a>; <a href="./references#CD009687-bbs2-0053" title="van deKerkhofP , AnsteyA , BarnesL , BolducC . A new scalp formulation of calcipotriene plus betamethasone in the treatment of scalp psoriasis compared to its active ingredients in the same vehicle. Journal of the American Academy of Dermatology2007;56(2):AB182. van deKerkhofPC , HoffmannV , AnsteyA , BarnesL , BolducC , ReichK , et al. A new scalp formulation of calcipotriol plus betamethasone dipropionate compared with each of its active ingredients in the same vehicle for the treatment of scalp psoriasis: a randomized, double‐blind, controlled trial. British Journal of Dermatology2009;160(1):170‐6. [MEDLINE: 19067709] ">van de Kerkhof 2009</a>; <a href="./references#CD009687-bbs2-0059" title="YilmazH , AydinF , SenturkN , CanturkT , TuranliAY . A comparison between the effects of calcipotriol lotion, momethasone furoate lotion and their combinations for the treatment of scalp psoriasis [Kalsipotriol Losyon, Mometazon Furoat Losyonve Kombinasyonlarinin Saçli Deri Psoriazisi Tedavisindeki Etkinliginin Karsilastirilmasi]. Turkderm Deri Hastaliklari ve Frengi Arsivi2005;39(2):109‐14. [EMBASE: 2006204571] ">Yilmaz 2005</a>), supported the findings of the meta‐analysis (<a href="#CD009687-tbl-0005">Table 2</a>). </p> <p> <ul id="CD009687-list-0044"> <li> <p>Number of participants achieving 'response' according to the IGA (<a href="./references#CD009687-fig-0044" title="">Analysis 8.2</a>) </p> </li> </ul> </p> <p>Three studies that compared a steroid with vitamin D addressed this outcome for a total of 1827 participants. Meta‐analysis indicated that the steroid was superior to vitamin D (RR 2.09; 95% CI 1.80, 2.41; NNTB = 4; 95% CI 4 to 5). Heterogeneity among all three studies was not important (I² = 0%). The quality of the evidence was high (<a href="./full#CD009687-tbl-0001">summary of findings Table for the main comparison</a>). </p> <p>Subgroup analysis in respect of the individual steroid reflected this finding: clobetasol propionate (N = 151 participants; RR 1.79; 95% CI 1.17, 2.74; NNTB = 5; 95% CI 3 to 15; <a href="./references#CD009687-bbs2-0046" title="ReygagneP , MrowietzU , DecroixJ , deWaard‐van der SpekFB , AcebesLO , FigueiredoA , et al. Clobetasol propionate shampoo 0.05% and calcipotriol solution 0.005%: a randomized comparison of efficacy and safety in subjects with scalp psoriasis. Journal of Dermatological Treatment2005;16(1):31‐6. [MEDLINE: 15897165] ReygagneP , MrowietzU , DecroixJ , van derSpekW , Olmos AcebesL , et al. Four‐week efficacy and safety comparison of a new clobetasol shampoo and calcipotriol solution 0.005% in subjects with scalp psoriasis. Journal of the European Academy of Dermatology &amp; Venereology2002;16(Suppl 1):285. ">Reygagne 2005</a>), betamethasone dipropionate (N = 1676 participants; RR 2.13; 95% CI 1.82 to 2.50, NNTB = 4; 95% CI 4 to 5; <a href="./references#CD009687-bbs2-0027" title="JemecGB , GanslandtC , OrtonneJP , PoulinY , BurdenAD , deUnamunoP , et al. A new scalp formulation of calcipotriene plus betamethasone compared with its active ingredients and the vehicle in the treatment of scalp psoriasis: a randomized, double‐blind, controlled trial. Journal of the American Academy of Dermatology2008;59(3):455‐63. [MEDLINE: 18694678] JemecGBE , BurdenD , PoulinY , OrtonneJP . A new scalp formulation of calcipotriene plus betamethasone in the treatment of scalp psoriasis compared to its active ingredients and the vehicle (Abstract P2733). Journal of the American Academy of Dermatology2007;56(2):AB182. ">Jemec 2008</a>; <a href="./references#CD009687-bbs2-0053" title="van deKerkhofP , AnsteyA , BarnesL , BolducC . A new scalp formulation of calcipotriene plus betamethasone in the treatment of scalp psoriasis compared to its active ingredients in the same vehicle. Journal of the American Academy of Dermatology2007;56(2):AB182. van deKerkhofPC , HoffmannV , AnsteyA , BarnesL , BolducC , ReichK , et al. A new scalp formulation of calcipotriol plus betamethasone dipropionate compared with each of its active ingredients in the same vehicle for the treatment of scalp psoriasis: a randomized, double‐blind, controlled trial. British Journal of Dermatology2009;160(1):170‐6. [MEDLINE: 19067709] ">van de Kerkhof 2009</a>). </p> <p> <ul id="CD009687-list-0045"> <li> <p>Mean of the TSS (<a href="./references#CD009687-fig-0045" title="">Analysis 8.3</a>) </p> </li> </ul> </p> <p>Five studies that compared steroids with vitamin D addressed the reduction of disease severity by measuring the mean change of TSS from baseline (<a href="./references#CD009687-bbs2-0027" title="JemecGB , GanslandtC , OrtonneJP , PoulinY , BurdenAD , deUnamunoP , et al. A new scalp formulation of calcipotriene plus betamethasone compared with its active ingredients and the vehicle in the treatment of scalp psoriasis: a randomized, double‐blind, controlled trial. Journal of the American Academy of Dermatology2008;59(3):455‐63. [MEDLINE: 18694678] JemecGBE , BurdenD , PoulinY , OrtonneJP . A new scalp formulation of calcipotriene plus betamethasone in the treatment of scalp psoriasis compared to its active ingredients and the vehicle (Abstract P2733). Journal of the American Academy of Dermatology2007;56(2):AB182. ">Jemec 2008</a>; <a href="./references#CD009687-bbs2-0032" title="KlaberMR , HutchinsonPE , Pedvis‐LeftickA , KragballeK , ReunalaTL , van deKerkhofPC , et al. Comparative effects of calcipotriol solution (50 micrograms/ml) and betamethasone 17‐valerate solution (1 mg/ml) in the treatment of scalp psoriasis. British Journal of Dermatology1994;131(5):678‐83. [MEDLINE: 7999600] ">Klaber 1994</a>; <a href="./references#CD009687-bbs2-0046" title="ReygagneP , MrowietzU , DecroixJ , deWaard‐van der SpekFB , AcebesLO , FigueiredoA , et al. Clobetasol propionate shampoo 0.05% and calcipotriol solution 0.005%: a randomized comparison of efficacy and safety in subjects with scalp psoriasis. Journal of Dermatological Treatment2005;16(1):31‐6. [MEDLINE: 15897165] ReygagneP , MrowietzU , DecroixJ , van derSpekW , Olmos AcebesL , et al. Four‐week efficacy and safety comparison of a new clobetasol shampoo and calcipotriol solution 0.005% in subjects with scalp psoriasis. Journal of the European Academy of Dermatology &amp; Venereology2002;16(Suppl 1):285. ">Reygagne 2005</a>; <a href="./references#CD009687-bbs2-0053" title="van deKerkhofP , AnsteyA , BarnesL , BolducC . A new scalp formulation of calcipotriene plus betamethasone in the treatment of scalp psoriasis compared to its active ingredients in the same vehicle. Journal of the American Academy of Dermatology2007;56(2):AB182. van deKerkhofPC , HoffmannV , AnsteyA , BarnesL , BolducC , ReichK , et al. A new scalp formulation of calcipotriol plus betamethasone dipropionate compared with each of its active ingredients in the same vehicle for the treatment of scalp psoriasis: a randomized, double‐blind, controlled trial. British Journal of Dermatology2009;160(1):170‐6. [MEDLINE: 19067709] ">van de Kerkhof 2009</a>; <a href="./references#CD009687-bbs2-0059" title="YilmazH , AydinF , SenturkN , CanturkT , TuranliAY . A comparison between the effects of calcipotriol lotion, momethasone furoate lotion and their combinations for the treatment of scalp psoriasis [Kalsipotriol Losyon, Mometazon Furoat Losyonve Kombinasyonlarinin Saçli Deri Psoriazisi Tedavisindeki Etkinliginin Karsilastirilmasi]. Turkderm Deri Hastaliklari ve Frengi Arsivi2005;39(2):109‐14. [EMBASE: 2006204571] ">Yilmaz 2005</a>). All studies reported a greater reduction in disease severity in participants treated with steroids compared to those receiving vitamin D. The measure of variance was not reported. </p> </section> </section> <section id="CD009687-sec-0146"> <h6 class="title">2) Number of participants withdrawing due to adverse events</h6> <p>Six studies that compared a steroid with vitamin D addressed the incidence of withdrawals due to adverse events. Meta‐analysis of four studies (<a href="./references#CD009687-bbs2-0032" title="KlaberMR , HutchinsonPE , Pedvis‐LeftickA , KragballeK , ReunalaTL , van deKerkhofPC , et al. Comparative effects of calcipotriol solution (50 micrograms/ml) and betamethasone 17‐valerate solution (1 mg/ml) in the treatment of scalp psoriasis. British Journal of Dermatology1994;131(5):678‐83. [MEDLINE: 7999600] ">Klaber 1994</a>; <a href="./references#CD009687-bbs2-0027" title="JemecGB , GanslandtC , OrtonneJP , PoulinY , BurdenAD , deUnamunoP , et al. A new scalp formulation of calcipotriene plus betamethasone compared with its active ingredients and the vehicle in the treatment of scalp psoriasis: a randomized, double‐blind, controlled trial. Journal of the American Academy of Dermatology2008;59(3):455‐63. [MEDLINE: 18694678] JemecGBE , BurdenD , PoulinY , OrtonneJP . A new scalp formulation of calcipotriene plus betamethasone in the treatment of scalp psoriasis compared to its active ingredients and the vehicle (Abstract P2733). Journal of the American Academy of Dermatology2007;56(2):AB182. ">Jemec 2008</a>; <a href="./references#CD009687-bbs2-0053" title="van deKerkhofP , AnsteyA , BarnesL , BolducC . A new scalp formulation of calcipotriene plus betamethasone in the treatment of scalp psoriasis compared to its active ingredients in the same vehicle. Journal of the American Academy of Dermatology2007;56(2):AB182. van deKerkhofPC , HoffmannV , AnsteyA , BarnesL , BolducC , ReichK , et al. A new scalp formulation of calcipotriol plus betamethasone dipropionate compared with each of its active ingredients in the same vehicle for the treatment of scalp psoriasis: a randomized, double‐blind, controlled trial. British Journal of Dermatology2009;160(1):170‐6. [MEDLINE: 19067709] ">van de Kerkhof 2009</a>; <a href="./references#CD009687-bbs2-0046" title="ReygagneP , MrowietzU , DecroixJ , deWaard‐van der SpekFB , AcebesLO , FigueiredoA , et al. Clobetasol propionate shampoo 0.05% and calcipotriol solution 0.005%: a randomized comparison of efficacy and safety in subjects with scalp psoriasis. Journal of Dermatological Treatment2005;16(1):31‐6. [MEDLINE: 15897165] ReygagneP , MrowietzU , DecroixJ , van derSpekW , Olmos AcebesL , et al. Four‐week efficacy and safety comparison of a new clobetasol shampoo and calcipotriol solution 0.005% in subjects with scalp psoriasis. Journal of the European Academy of Dermatology &amp; Venereology2002;16(Suppl 1):285. ">Reygagne 2005</a>), which included a total of 2291 participants, indicated that participants in the steroid groups had a significantly lower risk of withdrawal due to adverse events compared to those in the vitamin D groups (RR 0.22; 95% CI 0.11 to 0.42; <a href="./references#CD009687-fig-0046" title="">Analysis 8.4</a>). There was no important heterogeneity among the studies (I² = 14%). There were no withdrawals due to adverse events in two studies (<a href="./references#CD009687-bbs2-0034" title="KöseO . Calcipotriol ointment vs clobetasol solution in scalp psoriasis. Journal of Dermatological Treatment1997;8(4):287. [EMBASE: 1998022654] ">Köse 1997</a>; <a href="./references#CD009687-bbs2-0059" title="YilmazH , AydinF , SenturkN , CanturkT , TuranliAY . A comparison between the effects of calcipotriol lotion, momethasone furoate lotion and their combinations for the treatment of scalp psoriasis [Kalsipotriol Losyon, Mometazon Furoat Losyonve Kombinasyonlarinin Saçli Deri Psoriazisi Tedavisindeki Etkinliginin Karsilastirilmasi]. Turkderm Deri Hastaliklari ve Frengi Arsivi2005;39(2):109‐14. [EMBASE: 2006204571] ">Yilmaz 2005</a>). In one trial (N = 43 participants) participants received either very potent clobetasol propionate in a hydrophilic leave‐on or vitamin D as an occlusive lipophilic dressing (<a href="./references#CD009687-bbs2-0034" title="KöseO . Calcipotriol ointment vs clobetasol solution in scalp psoriasis. Journal of Dermatological Treatment1997;8(4):287. [EMBASE: 1998022654] ">Köse 1997</a>). The other study (N = 30 participants) compared mometasone furoate with vitamin D, both agents within a hydrophilic leave‐on (<a href="./references#CD009687-bbs2-0059" title="YilmazH , AydinF , SenturkN , CanturkT , TuranliAY . A comparison between the effects of calcipotriol lotion, momethasone furoate lotion and their combinations for the treatment of scalp psoriasis [Kalsipotriol Losyon, Mometazon Furoat Losyonve Kombinasyonlarinin Saçli Deri Psoriazisi Tedavisindeki Etkinliginin Karsilastirilmasi]. Turkderm Deri Hastaliklari ve Frengi Arsivi2005;39(2):109‐14. [EMBASE: 2006204571] ">Yilmaz 2005</a>). The quality of the evidence was moderate (<a href="./full#CD009687-tbl-0001">summary of findings Table for the main comparison</a>). No study reported the sort of adverse event that caused discontinuation of the study treatment. </p> <p>Subgroup analysis with regard to the individual steroid agent reflected this finding for betamethasone valerate 1 mg/ml (N = 474 participants; RR 0.19; 95% CI 0.04 to 0.83; <a href="./references#CD009687-bbs2-0032" title="KlaberMR , HutchinsonPE , Pedvis‐LeftickA , KragballeK , ReunalaTL , van deKerkhofPC , et al. Comparative effects of calcipotriol solution (50 micrograms/ml) and betamethasone 17‐valerate solution (1 mg/ml) in the treatment of scalp psoriasis. British Journal of Dermatology1994;131(5):678‐83. [MEDLINE: 7999600] ">Klaber 1994</a>), and betamethasone dipropionate (N = 1666 participants; RR 0.25; 95% CI 0.08 to 0.74; <a href="./references#CD009687-bbs2-0027" title="JemecGB , GanslandtC , OrtonneJP , PoulinY , BurdenAD , deUnamunoP , et al. A new scalp formulation of calcipotriene plus betamethasone compared with its active ingredients and the vehicle in the treatment of scalp psoriasis: a randomized, double‐blind, controlled trial. Journal of the American Academy of Dermatology2008;59(3):455‐63. [MEDLINE: 18694678] JemecGBE , BurdenD , PoulinY , OrtonneJP . A new scalp formulation of calcipotriene plus betamethasone in the treatment of scalp psoriasis compared to its active ingredients and the vehicle (Abstract P2733). Journal of the American Academy of Dermatology2007;56(2):AB182. ">Jemec 2008</a>; <a href="./references#CD009687-bbs2-0053" title="van deKerkhofP , AnsteyA , BarnesL , BolducC . A new scalp formulation of calcipotriene plus betamethasone in the treatment of scalp psoriasis compared to its active ingredients in the same vehicle. Journal of the American Academy of Dermatology2007;56(2):AB182. van deKerkhofPC , HoffmannV , AnsteyA , BarnesL , BolducC , ReichK , et al. A new scalp formulation of calcipotriol plus betamethasone dipropionate compared with each of its active ingredients in the same vehicle for the treatment of scalp psoriasis: a randomized, double‐blind, controlled trial. British Journal of Dermatology2009;160(1):170‐6. [MEDLINE: 19067709] ">van de Kerkhof 2009</a>). For the latter subgroup, the heterogeneity was substantial (I² = 62%). Our investigation for clinical and methodological heterogeneity did not reveal any reasonable explanation: disease severity at baseline, mean age, female proportion and study duration were similar in both studies. The two trials also monitored similar adverse events. However, neither reported the sort of adverse effect that actually caused withdrawal. In one trial (<a href="./references#CD009687-bbs2-0046" title="ReygagneP , MrowietzU , DecroixJ , deWaard‐van der SpekFB , AcebesLO , FigueiredoA , et al. Clobetasol propionate shampoo 0.05% and calcipotriol solution 0.005%: a randomized comparison of efficacy and safety in subjects with scalp psoriasis. Journal of Dermatological Treatment2005;16(1):31‐6. [MEDLINE: 15897165] ReygagneP , MrowietzU , DecroixJ , van derSpekW , Olmos AcebesL , et al. Four‐week efficacy and safety comparison of a new clobetasol shampoo and calcipotriol solution 0.005% in subjects with scalp psoriasis. Journal of the European Academy of Dermatology &amp; Venereology2002;16(Suppl 1):285. ">Reygagne 2005</a>), which compared clobetasol propionate with vitamin D, the results indicated a tendency towards a higher incidence of withdrawals due to adverse events in the vitamin D group (RR 0.07; 95% CI 0.00 to 1.13). </p> <section id="CD009687-sec-0147"> <p><b>Sensitivity analysis</b></p> <p>Sensitivity analysis with regard to ITT population, which included three studies (<a href="./references#CD009687-bbs2-0027" title="JemecGB , GanslandtC , OrtonneJP , PoulinY , BurdenAD , deUnamunoP , et al. A new scalp formulation of calcipotriene plus betamethasone compared with its active ingredients and the vehicle in the treatment of scalp psoriasis: a randomized, double‐blind, controlled trial. Journal of the American Academy of Dermatology2008;59(3):455‐63. [MEDLINE: 18694678] JemecGBE , BurdenD , PoulinY , OrtonneJP . A new scalp formulation of calcipotriene plus betamethasone in the treatment of scalp psoriasis compared to its active ingredients and the vehicle (Abstract P2733). Journal of the American Academy of Dermatology2007;56(2):AB182. ">Jemec 2008</a>; <a href="./references#CD009687-bbs2-0046" title="ReygagneP , MrowietzU , DecroixJ , deWaard‐van der SpekFB , AcebesLO , FigueiredoA , et al. Clobetasol propionate shampoo 0.05% and calcipotriol solution 0.005%: a randomized comparison of efficacy and safety in subjects with scalp psoriasis. Journal of Dermatological Treatment2005;16(1):31‐6. [MEDLINE: 15897165] ReygagneP , MrowietzU , DecroixJ , van derSpekW , Olmos AcebesL , et al. Four‐week efficacy and safety comparison of a new clobetasol shampoo and calcipotriol solution 0.005% in subjects with scalp psoriasis. Journal of the European Academy of Dermatology &amp; Venereology2002;16(Suppl 1):285. ">Reygagne 2005</a>; <a href="./references#CD009687-bbs2-0053" title="van deKerkhofP , AnsteyA , BarnesL , BolducC . A new scalp formulation of calcipotriene plus betamethasone in the treatment of scalp psoriasis compared to its active ingredients in the same vehicle. Journal of the American Academy of Dermatology2007;56(2):AB182. van deKerkhofPC , HoffmannV , AnsteyA , BarnesL , BolducC , ReichK , et al. A new scalp formulation of calcipotriol plus betamethasone dipropionate compared with each of its active ingredients in the same vehicle for the treatment of scalp psoriasis: a randomized, double‐blind, controlled trial. British Journal of Dermatology2009;160(1):170‐6. [MEDLINE: 19067709] ">van de Kerkhof 2009</a>), supported the finding of the meta‐analysis (<a href="#CD009687-tbl-0005">Table 2</a>). </p> </section> </section> </section> <section id="CD009687-sec-0148"> <h5 class="title">Secondary outcomes</h5> <section id="CD009687-sec-0149"> <h6 class="title">1) Subjective reduction in severity of psoriasis</h6> <p> <ul id="CD009687-list-0046"> <li> <p>Number of participants achieving 'clearance' according to the PGA (<a href="./references#CD009687-fig-0047" title="">Analysis 8.5</a>) </p> </li> </ul> </p> <p>Two studies that compared a steroid with calcipotriol addressed this outcome for 504 participants (<a href="./references#CD009687-bbs2-0032" title="KlaberMR , HutchinsonPE , Pedvis‐LeftickA , KragballeK , ReunalaTL , van deKerkhofPC , et al. Comparative effects of calcipotriol solution (50 micrograms/ml) and betamethasone 17‐valerate solution (1 mg/ml) in the treatment of scalp psoriasis. British Journal of Dermatology1994;131(5):678‐83. [MEDLINE: 7999600] ">Klaber 1994</a>; <a href="./references#CD009687-bbs2-0059" title="YilmazH , AydinF , SenturkN , CanturkT , TuranliAY . A comparison between the effects of calcipotriol lotion, momethasone furoate lotion and their combinations for the treatment of scalp psoriasis [Kalsipotriol Losyon, Mometazon Furoat Losyonve Kombinasyonlarinin Saçli Deri Psoriazisi Tedavisindeki Etkinliginin Karsilastirilmasi]. Turkderm Deri Hastaliklari ve Frengi Arsivi2005;39(2):109‐14. [EMBASE: 2006204571] ">Yilmaz 2005</a>). Meta‐analysis of this patient‐assessed outcome indicated a significantly higher efficacy of steroids in clearing scalp psoriasis compared to calcipotriol (RR 2.22; 95% CI 1.47 to 3.35; NNTB = 8; 95% CI 5 to 15). Heterogeneity was not important (I² = 0%). </p> <section id="CD009687-sec-0150"> <p><b>Sensitivity analysis</b></p> <p>Sensitivity analysis with regard to ITT population, which included one study (<a href="./references#CD009687-bbs2-0059" title="YilmazH , AydinF , SenturkN , CanturkT , TuranliAY . A comparison between the effects of calcipotriol lotion, momethasone furoate lotion and their combinations for the treatment of scalp psoriasis [Kalsipotriol Losyon, Mometazon Furoat Losyonve Kombinasyonlarinin Saçli Deri Psoriazisi Tedavisindeki Etkinliginin Karsilastirilmasi]. Turkderm Deri Hastaliklari ve Frengi Arsivi2005;39(2):109‐14. [EMBASE: 2006204571] ">Yilmaz 2005</a>), supported the finding of the meta‐analysis (<a href="#CD009687-tbl-0005">Table 2</a>). </p> <p>Both individual steroids were superior to the vitamin D analogue: betamethasone valerate 1 mg/ml (<a href="./references#CD009687-bbs2-0032" title="KlaberMR , HutchinsonPE , Pedvis‐LeftickA , KragballeK , ReunalaTL , van deKerkhofPC , et al. Comparative effects of calcipotriol solution (50 micrograms/ml) and betamethasone 17‐valerate solution (1 mg/ml) in the treatment of scalp psoriasis. British Journal of Dermatology1994;131(5):678‐83. [MEDLINE: 7999600] ">Klaber 1994</a>) (N = 474 participants; RR 2.09; 95% CI 1.36 to 3.22; NNTB = 9; 95% CI 6 to 20) and mometasone furoate (<a href="./references#CD009687-bbs2-0059" title="YilmazH , AydinF , SenturkN , CanturkT , TuranliAY . A comparison between the effects of calcipotriol lotion, momethasone furoate lotion and their combinations for the treatment of scalp psoriasis [Kalsipotriol Losyon, Mometazon Furoat Losyonve Kombinasyonlarinin Saçli Deri Psoriazisi Tedavisindeki Etkinliginin Karsilastirilmasi]. Turkderm Deri Hastaliklari ve Frengi Arsivi2005;39(2):109‐14. [EMBASE: 2006204571] ">Yilmaz 2005</a>) (N = 30 participants; RR 4.00; 95% CI 1.01 to 15.81; NNTB = 3; 95% CI 2 to 11). </p> <p> <ul id="CD009687-list-0047"> <li> <p>Number of participants achieving 'response' according to the PGA (<a href="./references#CD009687-fig-0048" title="">Analysis 8.6</a>) </p> </li> </ul> </p> <p>Three studies that compared a steroid with vitamin D addressed this outcome for a total of 1827 participants. Meta‐analysis of this patient‐assessed outcome indicated a significantly higher efficacy of steroids compared to vitamin D (RR 1.48; 95% CI 1.28 to 1.72; NNTB = 5; 95% CI 5 to 7). There was moderate heterogeneity among the studies (I² = 39%). The quality of evidence was moderate (<a href="./full#CD009687-tbl-0001">summary of findings Table for the main comparison</a>). </p> <p>The superiority of clobetasol propionate was significant (N = 151 participants; RR 1.54; 95% CI 1.02 to 2.34; NNTB = 6; 95% CI 4 to 73; <a href="./references#CD009687-bbs2-0046" title="ReygagneP , MrowietzU , DecroixJ , deWaard‐van der SpekFB , AcebesLO , FigueiredoA , et al. Clobetasol propionate shampoo 0.05% and calcipotriol solution 0.005%: a randomized comparison of efficacy and safety in subjects with scalp psoriasis. Journal of Dermatological Treatment2005;16(1):31‐6. [MEDLINE: 15897165] ReygagneP , MrowietzU , DecroixJ , van derSpekW , Olmos AcebesL , et al. Four‐week efficacy and safety comparison of a new clobetasol shampoo and calcipotriol solution 0.005% in subjects with scalp psoriasis. Journal of the European Academy of Dermatology &amp; Venereology2002;16(Suppl 1):285. ">Reygagne 2005</a>). Two other studies that compared betamethasone dipropionate with vitamin D appeared to be substantially heterogenous (I² = 69%). Our investigation for clinical and methodological heterogeneity did not reveal any likely explanation: disease severity at baseline, mean age, female proportion and study duration were similar in both studies. However, in both the steroid was significantly more effective than vitamin D: <a href="./references#CD009687-bbs2-0053" title="van deKerkhofP , AnsteyA , BarnesL , BolducC . A new scalp formulation of calcipotriene plus betamethasone in the treatment of scalp psoriasis compared to its active ingredients in the same vehicle. Journal of the American Academy of Dermatology2007;56(2):AB182. van deKerkhofPC , HoffmannV , AnsteyA , BarnesL , BolducC , ReichK , et al. A new scalp formulation of calcipotriol plus betamethasone dipropionate compared with each of its active ingredients in the same vehicle for the treatment of scalp psoriasis: a randomized, double‐blind, controlled trial. British Journal of Dermatology2009;160(1):170‐6. [MEDLINE: 19067709] ">van de Kerkhof 2009</a> (RR 1.34; 95% CI 1.16 to 1.55; NNTB = 7; 95% CI 5 to 13); <a href="./references#CD009687-bbs2-0027" title="JemecGB , GanslandtC , OrtonneJP , PoulinY , BurdenAD , deUnamunoP , et al. A new scalp formulation of calcipotriene plus betamethasone compared with its active ingredients and the vehicle in the treatment of scalp psoriasis: a randomized, double‐blind, controlled trial. Journal of the American Academy of Dermatology2008;59(3):455‐63. [MEDLINE: 18694678] JemecGBE , BurdenD , PoulinY , OrtonneJP . A new scalp formulation of calcipotriene plus betamethasone in the treatment of scalp psoriasis compared to its active ingredients and the vehicle (Abstract P2733). Journal of the American Academy of Dermatology2007;56(2):AB182. ">Jemec 2008</a> (RR 1.64; 95% CI 1.39 to 1.93; NNTB = 5; 95% CI 4 to 6). </p> </section> </section> <section id="CD009687-sec-0151"> <h6 class="title">2) Number of participants with at least one adverse event</h6> <p>Five studies that compared a steroid with vitamin D addressed the risk of adverse events for a total of 2320 participants. Data indicated no difference in the risk of adverse events between the treatment groups. There was considerable heterogeneity among the studies (I² = 84.6%). See <a href="./references#CD009687-fig-0049" title="">Analysis 8.7</a>. </p> <p>Subgroup analysis showed that betamethasone valerate 1 mg/ml had a significantly lower risk of causing adverse events compared to calcipotriol (N = 474 participants; RR 0.37; 95% CI 0.25 to 0.53; <a href="./references#CD009687-bbs2-0032" title="KlaberMR , HutchinsonPE , Pedvis‐LeftickA , KragballeK , ReunalaTL , van deKerkhofPC , et al. Comparative effects of calcipotriol solution (50 micrograms/ml) and betamethasone 17‐valerate solution (1 mg/ml) in the treatment of scalp psoriasis. British Journal of Dermatology1994;131(5):678‐83. [MEDLINE: 7999600] ">Klaber 1994</a>). Highly potent betamethasone dipropionate was also shown to have a significantly lower incidence of adverse events than vitamin D (N = 1652 participants; RR 0.82; 95 CI 0.70 to 0.97; <a href="./references#CD009687-bbs2-0027" title="JemecGB , GanslandtC , OrtonneJP , PoulinY , BurdenAD , deUnamunoP , et al. A new scalp formulation of calcipotriene plus betamethasone compared with its active ingredients and the vehicle in the treatment of scalp psoriasis: a randomized, double‐blind, controlled trial. Journal of the American Academy of Dermatology2008;59(3):455‐63. [MEDLINE: 18694678] JemecGBE , BurdenD , PoulinY , OrtonneJP . A new scalp formulation of calcipotriene plus betamethasone in the treatment of scalp psoriasis compared to its active ingredients and the vehicle (Abstract P2733). Journal of the American Academy of Dermatology2007;56(2):AB182. ">Jemec 2008</a>; <a href="./references#CD009687-bbs2-0053" title="van deKerkhofP , AnsteyA , BarnesL , BolducC . A new scalp formulation of calcipotriene plus betamethasone in the treatment of scalp psoriasis compared to its active ingredients in the same vehicle. Journal of the American Academy of Dermatology2007;56(2):AB182. van deKerkhofPC , HoffmannV , AnsteyA , BarnesL , BolducC , ReichK , et al. A new scalp formulation of calcipotriol plus betamethasone dipropionate compared with each of its active ingredients in the same vehicle for the treatment of scalp psoriasis: a randomized, double‐blind, controlled trial. British Journal of Dermatology2009;160(1):170‐6. [MEDLINE: 19067709] ">van de Kerkhof 2009</a>). There was moderate heterogeneity in this subgroup (I² = 47%). <a href="./references#CD009687-bbs2-0034" title="KöseO . Calcipotriol ointment vs clobetasol solution in scalp psoriasis. Journal of Dermatological Treatment1997;8(4):287. [EMBASE: 1998022654] ">Köse 1997</a> did not find a significant difference in the risk of adverse events between participants treated with very high potency clobetasol propionate in a hydrophilic leave‐on compared to those receiving calcipotriol as an occlusive lipophilic dressing (N = 43 participants; RR 0.48; 95% CI 0.10 to 2.34). <a href="./references#CD009687-bbs2-0046" title="ReygagneP , MrowietzU , DecroixJ , deWaard‐van der SpekFB , AcebesLO , FigueiredoA , et al. Clobetasol propionate shampoo 0.05% and calcipotriol solution 0.005%: a randomized comparison of efficacy and safety in subjects with scalp psoriasis. Journal of Dermatological Treatment2005;16(1):31‐6. [MEDLINE: 15897165] ReygagneP , MrowietzU , DecroixJ , van derSpekW , Olmos AcebesL , et al. Four‐week efficacy and safety comparison of a new clobetasol shampoo and calcipotriol solution 0.005% in subjects with scalp psoriasis. Journal of the European Academy of Dermatology &amp; Venereology2002;16(Suppl 1):285. ">Reygagne 2005</a> reported a significant lower risk of adverse events in participants treated with the very high potency clobetasol propionate as a shampoo compared to those treated with calcipotriol in a lipophilic vehicle (N = 151 participants; RR 0.34; 95% CI 0.16 to 0.72). </p> <p>The most common adverse events that occurred with both therapies were local burning sensation and pruritus. Folliculitis and acne especially appeared in participants that applied steroids, whereas irritation and erythema were common local adverse events of vitamin D. </p> <p>The studies that performed ITT analysis were substantially heterogeneous (I² = 77%) (<a href="./references#CD009687-bbs2-0027" title="JemecGB , GanslandtC , OrtonneJP , PoulinY , BurdenAD , deUnamunoP , et al. A new scalp formulation of calcipotriene plus betamethasone compared with its active ingredients and the vehicle in the treatment of scalp psoriasis: a randomized, double‐blind, controlled trial. Journal of the American Academy of Dermatology2008;59(3):455‐63. [MEDLINE: 18694678] JemecGBE , BurdenD , PoulinY , OrtonneJP . A new scalp formulation of calcipotriene plus betamethasone in the treatment of scalp psoriasis compared to its active ingredients and the vehicle (Abstract P2733). Journal of the American Academy of Dermatology2007;56(2):AB182. ">Jemec 2008</a>; <a href="./references#CD009687-bbs2-0034" title="KöseO . Calcipotriol ointment vs clobetasol solution in scalp psoriasis. Journal of Dermatological Treatment1997;8(4):287. [EMBASE: 1998022654] ">Köse 1997</a>; <a href="./references#CD009687-bbs2-0046" title="ReygagneP , MrowietzU , DecroixJ , deWaard‐van der SpekFB , AcebesLO , FigueiredoA , et al. Clobetasol propionate shampoo 0.05% and calcipotriol solution 0.005%: a randomized comparison of efficacy and safety in subjects with scalp psoriasis. Journal of Dermatological Treatment2005;16(1):31‐6. [MEDLINE: 15897165] ReygagneP , MrowietzU , DecroixJ , van derSpekW , Olmos AcebesL , et al. Four‐week efficacy and safety comparison of a new clobetasol shampoo and calcipotriol solution 0.005% in subjects with scalp psoriasis. Journal of the European Academy of Dermatology &amp; Venereology2002;16(Suppl 1):285. ">Reygagne 2005</a>; <a href="./references#CD009687-bbs2-0053" title="van deKerkhofP , AnsteyA , BarnesL , BolducC . A new scalp formulation of calcipotriene plus betamethasone in the treatment of scalp psoriasis compared to its active ingredients in the same vehicle. Journal of the American Academy of Dermatology2007;56(2):AB182. van deKerkhofPC , HoffmannV , AnsteyA , BarnesL , BolducC , ReichK , et al. A new scalp formulation of calcipotriol plus betamethasone dipropionate compared with each of its active ingredients in the same vehicle for the treatment of scalp psoriasis: a randomized, double‐blind, controlled trial. British Journal of Dermatology2009;160(1):170‐6. [MEDLINE: 19067709] ">van de Kerkhof 2009</a>). It was therefore not feasible to undertake sensitivity analysis. </p> </section> <section id="CD009687-sec-0152"> <h6 class="title">Additional studies</h6> <p>The study <a href="./references#CD009687-bbs2-0008" title="DuwebGA , AbuzaribaO , RahimM , al‐TaweelM , AbdullaSA . Scalp psoriasis: topical calcipotriol 50 micrograms/g/ml solution vs. betamethasone valerate 1% lotion. International Journal of Clinical Pharmacology Research2000;20(3‐4):65‐8. [MEDLINE: 11314240] ">Duweb 2000</a> (N = 42 participants) compared betamethasone valerate 1% lotion and calcipotriol solution but was not eligible for analysis, because the outcome data within the publication were not consistent. </p> </section> </section> </section> <section id="CD009687-sec-0153"> <h4 class="title">9. Steroid plus salicylic acid versus steroid</h4> <p>One study with 59 participants (<a href="./references#CD009687-bbs2-0015" title="FredrikssonT . A clinical comparison of 3 corticosteroid alcoholic solutions in the treatment of psoriasis of the scalp. Pharmatherapeutica1976;1(4):252‐6. [EMBASE: 0977155168] ">Fredriksson 1976</a>), which compared a combination product of betamethasone dipropionate and salicylic acid (2.0%) with betamethasone dipropionate alone, addressed the following outcomes: </p> <section id="CD009687-sec-0154"> <h5 class="title">Primary outcomes</h5> <section id="CD009687-sec-0155"> <h6 class="title">1) Reduction in clinician‐assessed severity</h6> <p> <ul id="CD009687-list-0048"> <li> <p>Number of participants achieving 'clearance' according to the IGA (<a href="./references#CD009687-fig-0050" title="">Analysis 9.1</a>) </p> </li> </ul> </p> <p>This outcome with the two‐compound combination was not different to the corticosteroid as single preparation (N = 59 participants; RR 1.17; 95% CI 0.84 to 1.63). </p> <p> <ul id="CD009687-list-0049"> <li> <p>Number of participants achieving 'response' according to the IGA (<a href="./references#CD009687-fig-0051" title="">Analysis 9.2</a>) </p> </li> </ul> </p> <p>This outcome with the two‐compound combination was not different to the corticosteroid as single preparation (N = 59 participants; RR 1.08; 95% CI 0.91 to 1.29). </p> </section> <section id="CD009687-sec-0156"> <h6 class="title">2) Number of participants withdrawing due to adverse events</h6> <p>None of the 59 participants withdrew because of adverse effects.</p> </section> </section> <section id="CD009687-sec-0157"> <h5 class="title">Secondary outcomes</h5> <section id="CD009687-sec-0158"> <h6 class="title">1) Number of participants with at least one adverse event</h6> <p>None of the 59 participants experienced an adverse effect.</p> </section> </section> </section> <section id="CD009687-sec-0159"> <h4 class="title">10. Steroid plus vitamin D versus steroid</h4> <section id="CD009687-sec-0160"> <h5 class="title">Primary outcomes</h5> <section id="CD009687-sec-0161"> <h6 class="title">1) Reduction in clinician‐assessed severity</h6> <p> <ul id="CD009687-list-0050"> <li> <p>Number of participants achieving 'clearance' according to the IGA (<a href="./references#CD009687-fig-0052" title="">Analysis 10.1</a>) </p> </li> </ul> </p> <p>Four studies addressed this outcome for a total of 2474 participants (<a href="./references#CD009687-bbs2-0005" title="BuckleyC , HoffmannV . Calcipotriol plus betamethasone dipropionate gel is effective and safe in the treatment of scalp psoriasis (a phase II study). (Abstract P06.57). Journal of the European Academy of Dermatology &amp; Venereology2005;19(Suppl 2):175. BuckleyC , HoffmannV , ShapiroJ , SaariS , CambazardF , MilsgaardM . Calcipotriol plus betamethasone dipropionate scalp formulation is effective and well tolerated in the treatment of scalp psoriasis: a phase II study. Dermatology2008;217(2):107‐13. [MEDLINE: 18463448] ">Buckley 2008</a>; <a href="./references#CD009687-bbs2-0027" title="JemecGB , GanslandtC , OrtonneJP , PoulinY , BurdenAD , deUnamunoP , et al. A new scalp formulation of calcipotriene plus betamethasone compared with its active ingredients and the vehicle in the treatment of scalp psoriasis: a randomized, double‐blind, controlled trial. Journal of the American Academy of Dermatology2008;59(3):455‐63. [MEDLINE: 18694678] JemecGBE , BurdenD , PoulinY , OrtonneJP . A new scalp formulation of calcipotriene plus betamethasone in the treatment of scalp psoriasis compared to its active ingredients and the vehicle (Abstract P2733). Journal of the American Academy of Dermatology2007;56(2):AB182. ">Jemec 2008</a>; <a href="./references#CD009687-bbs2-0053" title="van deKerkhofP , AnsteyA , BarnesL , BolducC . A new scalp formulation of calcipotriene plus betamethasone in the treatment of scalp psoriasis compared to its active ingredients in the same vehicle. Journal of the American Academy of Dermatology2007;56(2):AB182. van deKerkhofPC , HoffmannV , AnsteyA , BarnesL , BolducC , ReichK , et al. A new scalp formulation of calcipotriol plus betamethasone dipropionate compared with each of its active ingredients in the same vehicle for the treatment of scalp psoriasis: a randomized, double‐blind, controlled trial. British Journal of Dermatology2009;160(1):170‐6. [MEDLINE: 19067709] ">van de Kerkhof 2009</a>; <a href="./references#CD009687-bbs2-0059" title="YilmazH , AydinF , SenturkN , CanturkT , TuranliAY . A comparison between the effects of calcipotriol lotion, momethasone furoate lotion and their combinations for the treatment of scalp psoriasis [Kalsipotriol Losyon, Mometazon Furoat Losyonve Kombinasyonlarinin Saçli Deri Psoriazisi Tedavisindeki Etkinliginin Karsilastirilmasi]. Turkderm Deri Hastaliklari ve Frengi Arsivi2005;39(2):109‐14. [EMBASE: 2006204571] ">Yilmaz 2005</a>). Meta‐analysis showed that the two‐compound combination is significantly more effective in clearing scalp psoriasis than the steroid alone. The superiority may not be clinically relevant (RR 1.22; 95% CI 1.08 to 1.36; NNTB = 17; 95% CI 11 to 41), which is reflected by a risk difference of 0.06 (95% CI 0.02 to 0.10). There was no important heterogeneity among the trials (I² = 0%). The quality of the evidence was moderate (<a href="./full#CD009687-tbl-0002">summary of findings Table 2</a>). </p> <p>Subgroup analysis, with respect to the individual steroid agent, showed a significantly higher efficacy of betamethasone dipropionate in combination with calcipotriol than alone (N = 2444 participants; RR 1.21; 95% CI 1.07 to 1.36; NNTB = 18; 95% CI 11 to 46; <a href="./references#CD009687-bbs2-0005" title="BuckleyC , HoffmannV . Calcipotriol plus betamethasone dipropionate gel is effective and safe in the treatment of scalp psoriasis (a phase II study). (Abstract P06.57). Journal of the European Academy of Dermatology &amp; Venereology2005;19(Suppl 2):175. BuckleyC , HoffmannV , ShapiroJ , SaariS , CambazardF , MilsgaardM . Calcipotriol plus betamethasone dipropionate scalp formulation is effective and well tolerated in the treatment of scalp psoriasis: a phase II study. Dermatology2008;217(2):107‐13. [MEDLINE: 18463448] ">Buckley 2008</a>; <a href="./references#CD009687-bbs2-0027" title="JemecGB , GanslandtC , OrtonneJP , PoulinY , BurdenAD , deUnamunoP , et al. A new scalp formulation of calcipotriene plus betamethasone compared with its active ingredients and the vehicle in the treatment of scalp psoriasis: a randomized, double‐blind, controlled trial. Journal of the American Academy of Dermatology2008;59(3):455‐63. [MEDLINE: 18694678] JemecGBE , BurdenD , PoulinY , OrtonneJP . A new scalp formulation of calcipotriene plus betamethasone in the treatment of scalp psoriasis compared to its active ingredients and the vehicle (Abstract P2733). Journal of the American Academy of Dermatology2007;56(2):AB182. ">Jemec 2008</a>; <a href="./references#CD009687-bbs2-0053" title="van deKerkhofP , AnsteyA , BarnesL , BolducC . A new scalp formulation of calcipotriene plus betamethasone in the treatment of scalp psoriasis compared to its active ingredients in the same vehicle. Journal of the American Academy of Dermatology2007;56(2):AB182. van deKerkhofPC , HoffmannV , AnsteyA , BarnesL , BolducC , ReichK , et al. A new scalp formulation of calcipotriol plus betamethasone dipropionate compared with each of its active ingredients in the same vehicle for the treatment of scalp psoriasis: a randomized, double‐blind, controlled trial. British Journal of Dermatology2009;160(1):170‐6. [MEDLINE: 19067709] ">van de Kerkhof 2009</a>). In this subgroup, heterogeneity was not important (I² = 0%). One study that assessed mometasone furoate showed no significant difference between treatment groups (N = 30 participants; RR 2.00; 95% CI 0.76 to 5.24) (<a href="./references#CD009687-bbs2-0059" title="YilmazH , AydinF , SenturkN , CanturkT , TuranliAY . A comparison between the effects of calcipotriol lotion, momethasone furoate lotion and their combinations for the treatment of scalp psoriasis [Kalsipotriol Losyon, Mometazon Furoat Losyonve Kombinasyonlarinin Saçli Deri Psoriazisi Tedavisindeki Etkinliginin Karsilastirilmasi]. Turkderm Deri Hastaliklari ve Frengi Arsivi2005;39(2):109‐14. [EMBASE: 2006204571] ">Yilmaz 2005</a>). </p> <p> <ul id="CD009687-list-0051"> <li> <p>Number of participants achieving 'response' according to the IGA (<a href="./references#CD009687-fig-0053" title="">Analysis 10.2</a>; <a href="#CD009687-fig-0003">Figure 3</a>) </p> </li> </ul> </p> <div class="figure" id="CD009687-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 10 Steroid plus vitamin D vs steroid, outcome: 10.2 IGA: response." data-id="CD009687-fig-0003" src="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/image_n/nCD009687-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 10 Steroid plus vitamin D vs steroid, outcome: 10.2 IGA: response. </p> </div> </div> </div> <p>Three studies, which compared the two‐compound combination of betamethasone dipropionate and vitamin D with betamethasone dipropionate alone, addressed this outcome for a total of 2444 participants (<a href="./references#CD009687-bbs2-0005" title="BuckleyC , HoffmannV . Calcipotriol plus betamethasone dipropionate gel is effective and safe in the treatment of scalp psoriasis (a phase II study). (Abstract P06.57). Journal of the European Academy of Dermatology &amp; Venereology2005;19(Suppl 2):175. BuckleyC , HoffmannV , ShapiroJ , SaariS , CambazardF , MilsgaardM . Calcipotriol plus betamethasone dipropionate scalp formulation is effective and well tolerated in the treatment of scalp psoriasis: a phase II study. Dermatology2008;217(2):107‐13. [MEDLINE: 18463448] ">Buckley 2008</a>; <a href="./references#CD009687-bbs2-0027" title="JemecGB , GanslandtC , OrtonneJP , PoulinY , BurdenAD , deUnamunoP , et al. A new scalp formulation of calcipotriene plus betamethasone compared with its active ingredients and the vehicle in the treatment of scalp psoriasis: a randomized, double‐blind, controlled trial. Journal of the American Academy of Dermatology2008;59(3):455‐63. [MEDLINE: 18694678] JemecGBE , BurdenD , PoulinY , OrtonneJP . A new scalp formulation of calcipotriene plus betamethasone in the treatment of scalp psoriasis compared to its active ingredients and the vehicle (Abstract P2733). Journal of the American Academy of Dermatology2007;56(2):AB182. ">Jemec 2008</a>; <a href="./references#CD009687-bbs2-0053" title="van deKerkhofP , AnsteyA , BarnesL , BolducC . A new scalp formulation of calcipotriene plus betamethasone in the treatment of scalp psoriasis compared to its active ingredients in the same vehicle. Journal of the American Academy of Dermatology2007;56(2):AB182. van deKerkhofPC , HoffmannV , AnsteyA , BarnesL , BolducC , ReichK , et al. A new scalp formulation of calcipotriol plus betamethasone dipropionate compared with each of its active ingredients in the same vehicle for the treatment of scalp psoriasis: a randomized, double‐blind, controlled trial. British Journal of Dermatology2009;160(1):170‐6. [MEDLINE: 19067709] ">van de Kerkhof 2009</a>). Meta‐analysis indicated that the two‐compound combination was significantly more effective than betamethasone dipropionate alone (RR 1.15; 95% CI 1.06 to 1.25; NNTB = 13; 95% CI 9 to 24). The superiority may not be clinically relevant, as reflected by a risk difference of 0.09 (95% CI 0.03 to 0.15). There was moderate heterogeneity between the studies (I² = 35%). The quality of the evidence was moderate (<a href="./full#CD009687-tbl-0002">summary of findings Table 2</a>). </p> <p> <ul id="CD009687-list-0052"> <li> <p>Mean of the TSS (<a href="./references#CD009687-fig-0054" title="">Analysis 10.3</a>) </p> </li> </ul> </p> <p>Four studies addressed the reduction of disease severity by measuring the mean change of the TSS from baseline (<a href="./references#CD009687-bbs2-0005" title="BuckleyC , HoffmannV . Calcipotriol plus betamethasone dipropionate gel is effective and safe in the treatment of scalp psoriasis (a phase II study). (Abstract P06.57). Journal of the European Academy of Dermatology &amp; Venereology2005;19(Suppl 2):175. BuckleyC , HoffmannV , ShapiroJ , SaariS , CambazardF , MilsgaardM . Calcipotriol plus betamethasone dipropionate scalp formulation is effective and well tolerated in the treatment of scalp psoriasis: a phase II study. Dermatology2008;217(2):107‐13. [MEDLINE: 18463448] ">Buckley 2008</a>; <a href="./references#CD009687-bbs2-0027" title="JemecGB , GanslandtC , OrtonneJP , PoulinY , BurdenAD , deUnamunoP , et al. A new scalp formulation of calcipotriene plus betamethasone compared with its active ingredients and the vehicle in the treatment of scalp psoriasis: a randomized, double‐blind, controlled trial. Journal of the American Academy of Dermatology2008;59(3):455‐63. [MEDLINE: 18694678] JemecGBE , BurdenD , PoulinY , OrtonneJP . A new scalp formulation of calcipotriene plus betamethasone in the treatment of scalp psoriasis compared to its active ingredients and the vehicle (Abstract P2733). Journal of the American Academy of Dermatology2007;56(2):AB182. ">Jemec 2008</a>; <a href="./references#CD009687-bbs2-0053" title="van deKerkhofP , AnsteyA , BarnesL , BolducC . A new scalp formulation of calcipotriene plus betamethasone in the treatment of scalp psoriasis compared to its active ingredients in the same vehicle. Journal of the American Academy of Dermatology2007;56(2):AB182. van deKerkhofPC , HoffmannV , AnsteyA , BarnesL , BolducC , ReichK , et al. A new scalp formulation of calcipotriol plus betamethasone dipropionate compared with each of its active ingredients in the same vehicle for the treatment of scalp psoriasis: a randomized, double‐blind, controlled trial. British Journal of Dermatology2009;160(1):170‐6. [MEDLINE: 19067709] ">van de Kerkhof 2009</a>; <a href="./references#CD009687-bbs2-0059" title="YilmazH , AydinF , SenturkN , CanturkT , TuranliAY . A comparison between the effects of calcipotriol lotion, momethasone furoate lotion and their combinations for the treatment of scalp psoriasis [Kalsipotriol Losyon, Mometazon Furoat Losyonve Kombinasyonlarinin Saçli Deri Psoriazisi Tedavisindeki Etkinliginin Karsilastirilmasi]. Turkderm Deri Hastaliklari ve Frengi Arsivi2005;39(2):109‐14. [EMBASE: 2006204571] ">Yilmaz 2005</a>). All two‐compound formulations showed a greater reduction of disease severity compared to the steroid alone. The measure of variance was not reported. </p> </section> <section id="CD009687-sec-0162"> <h6 class="title">2) Number of participants withdrawing due to adverse events</h6> <p>Four studies reported this outcome. Meta‐analysis of three trials (<a href="./references#CD009687-bbs2-0005" title="BuckleyC , HoffmannV . Calcipotriol plus betamethasone dipropionate gel is effective and safe in the treatment of scalp psoriasis (a phase II study). (Abstract P06.57). Journal of the European Academy of Dermatology &amp; Venereology2005;19(Suppl 2):175. BuckleyC , HoffmannV , ShapiroJ , SaariS , CambazardF , MilsgaardM . Calcipotriol plus betamethasone dipropionate scalp formulation is effective and well tolerated in the treatment of scalp psoriasis: a phase II study. Dermatology2008;217(2):107‐13. [MEDLINE: 18463448] ">Buckley 2008</a>; <a href="./references#CD009687-bbs2-0027" title="JemecGB , GanslandtC , OrtonneJP , PoulinY , BurdenAD , deUnamunoP , et al. A new scalp formulation of calcipotriene plus betamethasone compared with its active ingredients and the vehicle in the treatment of scalp psoriasis: a randomized, double‐blind, controlled trial. Journal of the American Academy of Dermatology2008;59(3):455‐63. [MEDLINE: 18694678] JemecGBE , BurdenD , PoulinY , OrtonneJP . A new scalp formulation of calcipotriene plus betamethasone in the treatment of scalp psoriasis compared to its active ingredients and the vehicle (Abstract P2733). Journal of the American Academy of Dermatology2007;56(2):AB182. ">Jemec 2008</a>; <a href="./references#CD009687-bbs2-0053" title="van deKerkhofP , AnsteyA , BarnesL , BolducC . A new scalp formulation of calcipotriene plus betamethasone in the treatment of scalp psoriasis compared to its active ingredients in the same vehicle. Journal of the American Academy of Dermatology2007;56(2):AB182. van deKerkhofPC , HoffmannV , AnsteyA , BarnesL , BolducC , ReichK , et al. A new scalp formulation of calcipotriol plus betamethasone dipropionate compared with each of its active ingredients in the same vehicle for the treatment of scalp psoriasis: a randomized, double‐blind, controlled trial. British Journal of Dermatology2009;160(1):170‐6. [MEDLINE: 19067709] ">van de Kerkhof 2009</a>), which included a total 2433 participants, indicated no significant differences between the treatment groups (RR 0.88; 95% CI 0.42 to 1.88; <a href="./references#CD009687-fig-0055" title="">Analysis 10.4</a>). The heterogeneity was not important among the studies (I² = 0%). None of the authors stated the type of adverse event that caused the withdrawal. The quality of the evidence was moderate (<a href="./full#CD009687-tbl-0002">summary of findings Table 2</a>). In the other study (N = 30 participants) that assessed mometasone furoate as corticosteroid, no withdrawals occurred (<a href="./references#CD009687-bbs2-0059" title="YilmazH , AydinF , SenturkN , CanturkT , TuranliAY . A comparison between the effects of calcipotriol lotion, momethasone furoate lotion and their combinations for the treatment of scalp psoriasis [Kalsipotriol Losyon, Mometazon Furoat Losyonve Kombinasyonlarinin Saçli Deri Psoriazisi Tedavisindeki Etkinliginin Karsilastirilmasi]. Turkderm Deri Hastaliklari ve Frengi Arsivi2005;39(2):109‐14. [EMBASE: 2006204571] ">Yilmaz 2005</a>). </p> </section> </section> <section id="CD009687-sec-0163"> <h5 class="title">Secondary outcomes</h5> <section id="CD009687-sec-0164"> <h6 class="title">1) Subjective reduction in severity of psoriasis</h6> <p> <ul id="CD009687-list-0053"> <li> <p>Number of participants achieving 'clearance' according to the PGA (<a href="./references#CD009687-fig-0056" title="">Analysis 10.5</a>) </p> </li> </ul> </p> <p>One study (N = 30 participants) addressed this outcome (<a href="./references#CD009687-bbs2-0059" title="YilmazH , AydinF , SenturkN , CanturkT , TuranliAY . A comparison between the effects of calcipotriol lotion, momethasone furoate lotion and their combinations for the treatment of scalp psoriasis [Kalsipotriol Losyon, Mometazon Furoat Losyonve Kombinasyonlarinin Saçli Deri Psoriazisi Tedavisindeki Etkinliginin Karsilastirilmasi]. Turkderm Deri Hastaliklari ve Frengi Arsivi2005;39(2):109‐14. [EMBASE: 2006204571] ">Yilmaz 2005</a>). Mometasone furoate tended to be more effective in combination with calcipotriol than as monotherapy. However, the superiority of the combination therapy was not significant (RR 1.50; 95% CI 0.88 to 2.57). </p> <p> <ul id="CD009687-list-0054"> <li> <p>Number of participants achieving 'response' according to the PGA (<a href="./references#CD009687-fig-0057" title="">Analysis 10.6</a>) </p> </li> </ul> </p> <p>Two studies addressed this outcome for a total of 2226 participants (<a href="./references#CD009687-bbs2-0027" title="JemecGB , GanslandtC , OrtonneJP , PoulinY , BurdenAD , deUnamunoP , et al. A new scalp formulation of calcipotriene plus betamethasone compared with its active ingredients and the vehicle in the treatment of scalp psoriasis: a randomized, double‐blind, controlled trial. Journal of the American Academy of Dermatology2008;59(3):455‐63. [MEDLINE: 18694678] JemecGBE , BurdenD , PoulinY , OrtonneJP . A new scalp formulation of calcipotriene plus betamethasone in the treatment of scalp psoriasis compared to its active ingredients and the vehicle (Abstract P2733). Journal of the American Academy of Dermatology2007;56(2):AB182. ">Jemec 2008</a>; <a href="./references#CD009687-bbs2-0053" title="van deKerkhofP , AnsteyA , BarnesL , BolducC . A new scalp formulation of calcipotriene plus betamethasone in the treatment of scalp psoriasis compared to its active ingredients in the same vehicle. Journal of the American Academy of Dermatology2007;56(2):AB182. van deKerkhofPC , HoffmannV , AnsteyA , BarnesL , BolducC , ReichK , et al. A new scalp formulation of calcipotriol plus betamethasone dipropionate compared with each of its active ingredients in the same vehicle for the treatment of scalp psoriasis: a randomized, double‐blind, controlled trial. British Journal of Dermatology2009;160(1):170‐6. [MEDLINE: 19067709] ">van de Kerkhof 2009</a>). Meta‐analysis indicated that betamethasone dipropionate in combination with vitamin D was significantly more effective than betamethasone dipropionate alone (RR 1.13; 95% CI 1.06 to 1.20; NNTB = 13; 95% CI 9 to 26), but the benefit may not be clinically relevant. Heterogeneity was not important (I² = 0%) and the quality of the evidence was high (<a href="./full#CD009687-tbl-0002">summary of findings Table 2</a>). </p> </section> <section id="CD009687-sec-0165"> <h6 class="title">2) Number of participants with at least one adverse event</h6> <p>Three studies addressed this outcome for 2414 participants (<a href="./references#CD009687-bbs2-0005" title="BuckleyC , HoffmannV . Calcipotriol plus betamethasone dipropionate gel is effective and safe in the treatment of scalp psoriasis (a phase II study). (Abstract P06.57). Journal of the European Academy of Dermatology &amp; Venereology2005;19(Suppl 2):175. BuckleyC , HoffmannV , ShapiroJ , SaariS , CambazardF , MilsgaardM . Calcipotriol plus betamethasone dipropionate scalp formulation is effective and well tolerated in the treatment of scalp psoriasis: a phase II study. Dermatology2008;217(2):107‐13. [MEDLINE: 18463448] ">Buckley 2008</a>; <a href="./references#CD009687-bbs2-0027" title="JemecGB , GanslandtC , OrtonneJP , PoulinY , BurdenAD , deUnamunoP , et al. A new scalp formulation of calcipotriene plus betamethasone compared with its active ingredients and the vehicle in the treatment of scalp psoriasis: a randomized, double‐blind, controlled trial. Journal of the American Academy of Dermatology2008;59(3):455‐63. [MEDLINE: 18694678] JemecGBE , BurdenD , PoulinY , OrtonneJP . A new scalp formulation of calcipotriene plus betamethasone in the treatment of scalp psoriasis compared to its active ingredients and the vehicle (Abstract P2733). Journal of the American Academy of Dermatology2007;56(2):AB182. ">Jemec 2008</a>; <a href="./references#CD009687-bbs2-0053" title="van deKerkhofP , AnsteyA , BarnesL , BolducC . A new scalp formulation of calcipotriene plus betamethasone in the treatment of scalp psoriasis compared to its active ingredients in the same vehicle. Journal of the American Academy of Dermatology2007;56(2):AB182. van deKerkhofPC , HoffmannV , AnsteyA , BarnesL , BolducC , ReichK , et al. A new scalp formulation of calcipotriol plus betamethasone dipropionate compared with each of its active ingredients in the same vehicle for the treatment of scalp psoriasis: a randomized, double‐blind, controlled trial. British Journal of Dermatology2009;160(1):170‐6. [MEDLINE: 19067709] ">van de Kerkhof 2009</a>). Meta‐analysis showed no significant differences in the risk of adverse events between participants treated with combination therapy and those treated with betamethasone dipropionate monotherapy (RR 0.97; 95% CI 0.87 to 1.07). There was no important heterogeneity among the three trials (I² = 0%). Common adverse events were pruritus, burning sensation, skin pain, folliculitis and alopecia. (See <a href="./references#CD009687-fig-0058" title="">Analysis 10.7</a>; <a href="#CD009687-fig-0004">Figure 4</a>). </p> <div class="figure" id="CD009687-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 10 Steroid plus vitamin D vs steroid, outcome: 10.7 Number of participants with at least one AE." data-id="CD009687-fig-0004" src="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/image_n/nCD009687-AFig-FIG04.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 10 Steroid plus vitamin D vs steroid, outcome: 10.7 Number of participants with at least one AE. </p> </div> </div> </div> </section> </section> </section> <section id="CD009687-sec-0166"> <h4 class="title">11. Steroid plus vitamin D versus vitamin D</h4> <p>Six studies compared the combination of a steroid and vitamin D with vitamin D monotherapy. Four assessed betamethasone dipropionate as the corticosteroid within the combination therapy (<a href="./references#CD009687-bbs2-0027" title="JemecGB , GanslandtC , OrtonneJP , PoulinY , BurdenAD , deUnamunoP , et al. A new scalp formulation of calcipotriene plus betamethasone compared with its active ingredients and the vehicle in the treatment of scalp psoriasis: a randomized, double‐blind, controlled trial. Journal of the American Academy of Dermatology2008;59(3):455‐63. [MEDLINE: 18694678] JemecGBE , BurdenD , PoulinY , OrtonneJP . A new scalp formulation of calcipotriene plus betamethasone in the treatment of scalp psoriasis compared to its active ingredients and the vehicle (Abstract P2733). Journal of the American Academy of Dermatology2007;56(2):AB182. ">Jemec 2008</a>; <a href="./references#CD009687-bbs2-0035" title="KragballeK , GanslandtC , OrtonneJP . A calcipotriol plus betamethasone dipropionate scalp formulation significantly reduces itching in scalp psoriasis. Abstract P3343. American Academy of Dermatology 67th Annual Meeting March 6‐10, 2009. Journal of the American Academy of Dermatology2009;60(3 Suppl 1):AB172. KragballeK , HoffmannV , OrtonneJP , TanJ , NordinP , SegaertS . Efficacy and safety of calcipotriol plus betamethasone dipropionate scalp formulation compared with calcipotriol scalp solution in the treatment of scalp psoriasis: a randomized controlled trial. British Journal of Dermatology2009;161(1):159‐66. [MEDLINE: 19416259] NCT00243464 . A calcipotriol plus betamethasone diproprionate scalp formulation significantly reduces itching in scalp. www.clinicaltrials.gov/show/NCT00243464?term=NCT00243464 (accessed 5 November 2014). OrtonneJP , GanslandtC , TanJ , NordinP , KragballeK , SegaertS . Quality of life in patients with scalp psoriasis treated with calcipotriol/betamethasone dipropionate scalp formulation: a randomized controlled trial. Journal of the European Academy of Dermatology &amp; Venereology2009;23(8):919‐26. [MEDLINE: 19453810] ">Kragballe 2009</a>; <a href="./references#CD009687-bbs2-0038" title="CambazardF . Xamiol, a new treatment in scalp psoriasis: short‐ and long‐term results [Un nouveau traitement dans le psoriasis du cuir chevelu : Xamiol®: Résultats à court terme et à long terme]. Annales de Dermatologie et de Vénéréologie2009;136(Suppl 3):546‐50. [EMBASE: 2009406816] LugerTA , CambazardF , LarsenFG , BourcierM , GuptaG , ClonierF , et al. A study of the safety and efficacy of calcipotriol and betamethasone dipropionate scalp formulation in the long‐term management of scalp psoriasis. Dermatology2008;217(4):321‐8. [MEDLINE: 18787325] ">Luger 2008</a>; <a href="./references#CD009687-bbs2-0041" title="NCT01195831 . Efficacy and safety of Xamiol® gel compared to calcipotriol scalp solution in patients with scalp psoriasis. clinicaltrials.gov/show/NCT01195831 (accessed 5 November 2014). ">NCT01195831</a>; <a href="./references#CD009687-bbs2-0053" title="van deKerkhofP , AnsteyA , BarnesL , BolducC . A new scalp formulation of calcipotriene plus betamethasone in the treatment of scalp psoriasis compared to its active ingredients in the same vehicle. Journal of the American Academy of Dermatology2007;56(2):AB182. van deKerkhofPC , HoffmannV , AnsteyA , BarnesL , BolducC , ReichK , et al. A new scalp formulation of calcipotriol plus betamethasone dipropionate compared with each of its active ingredients in the same vehicle for the treatment of scalp psoriasis: a randomized, double‐blind, controlled trial. British Journal of Dermatology2009;160(1):170‐6. [MEDLINE: 19067709] ">van de Kerkhof 2009</a>), and one used mometasone furoate (<a href="./references#CD009687-bbs2-0059" title="YilmazH , AydinF , SenturkN , CanturkT , TuranliAY . A comparison between the effects of calcipotriol lotion, momethasone furoate lotion and their combinations for the treatment of scalp psoriasis [Kalsipotriol Losyon, Mometazon Furoat Losyonve Kombinasyonlarinin Saçli Deri Psoriazisi Tedavisindeki Etkinliginin Karsilastirilmasi]. Turkderm Deri Hastaliklari ve Frengi Arsivi2005;39(2):109‐14. [EMBASE: 2006204571] ">Yilmaz 2005</a>). </p> <section id="CD009687-sec-0167"> <h5 class="title">Primary outcomes</h5> <section id="CD009687-sec-0168"> <h6 class="title">1) Reduction in clinician‐assessed severity</h6> <p> <ul id="CD009687-list-0055"> <li> <p>Number of participants achieving 'clearance' according to the IGA (<a href="./references#CD009687-fig-0059" title="">Analysis 11.1</a>) </p> </li> </ul> </p> <p>Four studies addressed this outcome for a total of 2008 participants (<a href="./references#CD009687-bbs2-0027" title="JemecGB , GanslandtC , OrtonneJP , PoulinY , BurdenAD , deUnamunoP , et al. A new scalp formulation of calcipotriene plus betamethasone compared with its active ingredients and the vehicle in the treatment of scalp psoriasis: a randomized, double‐blind, controlled trial. Journal of the American Academy of Dermatology2008;59(3):455‐63. [MEDLINE: 18694678] JemecGBE , BurdenD , PoulinY , OrtonneJP . A new scalp formulation of calcipotriene plus betamethasone in the treatment of scalp psoriasis compared to its active ingredients and the vehicle (Abstract P2733). Journal of the American Academy of Dermatology2007;56(2):AB182. ">Jemec 2008</a>; <a href="./references#CD009687-bbs2-0035" title="KragballeK , GanslandtC , OrtonneJP . A calcipotriol plus betamethasone dipropionate scalp formulation significantly reduces itching in scalp psoriasis. Abstract P3343. American Academy of Dermatology 67th Annual Meeting March 6‐10, 2009. Journal of the American Academy of Dermatology2009;60(3 Suppl 1):AB172. KragballeK , HoffmannV , OrtonneJP , TanJ , NordinP , SegaertS . Efficacy and safety of calcipotriol plus betamethasone dipropionate scalp formulation compared with calcipotriol scalp solution in the treatment of scalp psoriasis: a randomized controlled trial. British Journal of Dermatology2009;161(1):159‐66. [MEDLINE: 19416259] NCT00243464 . A calcipotriol plus betamethasone diproprionate scalp formulation significantly reduces itching in scalp. www.clinicaltrials.gov/show/NCT00243464?term=NCT00243464 (accessed 5 November 2014). OrtonneJP , GanslandtC , TanJ , NordinP , KragballeK , SegaertS . Quality of life in patients with scalp psoriasis treated with calcipotriol/betamethasone dipropionate scalp formulation: a randomized controlled trial. Journal of the European Academy of Dermatology &amp; Venereology2009;23(8):919‐26. [MEDLINE: 19453810] ">Kragballe 2009</a>; <a href="./references#CD009687-bbs2-0053" title="van deKerkhofP , AnsteyA , BarnesL , BolducC . A new scalp formulation of calcipotriene plus betamethasone in the treatment of scalp psoriasis compared to its active ingredients in the same vehicle. Journal of the American Academy of Dermatology2007;56(2):AB182. van deKerkhofPC , HoffmannV , AnsteyA , BarnesL , BolducC , ReichK , et al. A new scalp formulation of calcipotriol plus betamethasone dipropionate compared with each of its active ingredients in the same vehicle for the treatment of scalp psoriasis: a randomized, double‐blind, controlled trial. British Journal of Dermatology2009;160(1):170‐6. [MEDLINE: 19067709] ">van de Kerkhof 2009</a>; <a href="./references#CD009687-bbs2-0059" title="YilmazH , AydinF , SenturkN , CanturkT , TuranliAY . A comparison between the effects of calcipotriol lotion, momethasone furoate lotion and their combinations for the treatment of scalp psoriasis [Kalsipotriol Losyon, Mometazon Furoat Losyonve Kombinasyonlarinin Saçli Deri Psoriazisi Tedavisindeki Etkinliginin Karsilastirilmasi]. Turkderm Deri Hastaliklari ve Frengi Arsivi2005;39(2):109‐14. [EMBASE: 2006204571] ">Yilmaz 2005</a>). Meta‐analysis showed that the combination therapy was significantly superior to vitamin D monotherapy in clearing scalp psoriasis (RR 2.28; 95% CI 1.87 to 2.78; NNTB = 6; 95% CI 5 to 7). The quality of the evidence was high (<a href="./full#CD009687-tbl-0003">summary of findings Table 3</a>). Heterogeneity was not important (I² = 0%). Subgroup analysis in respect of the type of steroid showed a significantly higher efficacy of both two‐compound combinations compared to vitamin D: betamethasone dipropionate plus vitamin D (N = 1978 participants; RR 2.25; 95% CI 1.83 to 2.77; I² = 4%; NNTB = 5; 95% CI 5 to 7; three studies: <a href="./references#CD009687-bbs2-0027" title="JemecGB , GanslandtC , OrtonneJP , PoulinY , BurdenAD , deUnamunoP , et al. A new scalp formulation of calcipotriene plus betamethasone compared with its active ingredients and the vehicle in the treatment of scalp psoriasis: a randomized, double‐blind, controlled trial. Journal of the American Academy of Dermatology2008;59(3):455‐63. [MEDLINE: 18694678] JemecGBE , BurdenD , PoulinY , OrtonneJP . A new scalp formulation of calcipotriene plus betamethasone in the treatment of scalp psoriasis compared to its active ingredients and the vehicle (Abstract P2733). Journal of the American Academy of Dermatology2007;56(2):AB182. ">Jemec 2008</a>; <a href="./references#CD009687-bbs2-0035" title="KragballeK , GanslandtC , OrtonneJP . A calcipotriol plus betamethasone dipropionate scalp formulation significantly reduces itching in scalp psoriasis. Abstract P3343. American Academy of Dermatology 67th Annual Meeting March 6‐10, 2009. Journal of the American Academy of Dermatology2009;60(3 Suppl 1):AB172. KragballeK , HoffmannV , OrtonneJP , TanJ , NordinP , SegaertS . Efficacy and safety of calcipotriol plus betamethasone dipropionate scalp formulation compared with calcipotriol scalp solution in the treatment of scalp psoriasis: a randomized controlled trial. British Journal of Dermatology2009;161(1):159‐66. [MEDLINE: 19416259] NCT00243464 . A calcipotriol plus betamethasone diproprionate scalp formulation significantly reduces itching in scalp. www.clinicaltrials.gov/show/NCT00243464?term=NCT00243464 (accessed 5 November 2014). OrtonneJP , GanslandtC , TanJ , NordinP , KragballeK , SegaertS . Quality of life in patients with scalp psoriasis treated with calcipotriol/betamethasone dipropionate scalp formulation: a randomized controlled trial. Journal of the European Academy of Dermatology &amp; Venereology2009;23(8):919‐26. [MEDLINE: 19453810] ">Kragballe 2009</a>; <a href="./references#CD009687-bbs2-0053" title="van deKerkhofP , AnsteyA , BarnesL , BolducC . A new scalp formulation of calcipotriene plus betamethasone in the treatment of scalp psoriasis compared to its active ingredients in the same vehicle. Journal of the American Academy of Dermatology2007;56(2):AB182. van deKerkhofPC , HoffmannV , AnsteyA , BarnesL , BolducC , ReichK , et al. A new scalp formulation of calcipotriol plus betamethasone dipropionate compared with each of its active ingredients in the same vehicle for the treatment of scalp psoriasis: a randomized, double‐blind, controlled trial. British Journal of Dermatology2009;160(1):170‐6. [MEDLINE: 19067709] ">van de Kerkhof 2009</a>); mometasone furoate plus calcipotriol (N = 30 participants; RR 4.00; 95% CI 1.01 to 15.81; NNTB = 3; 95% CI 2 to 11; one study: <a href="./references#CD009687-bbs2-0059" title="YilmazH , AydinF , SenturkN , CanturkT , TuranliAY . A comparison between the effects of calcipotriol lotion, momethasone furoate lotion and their combinations for the treatment of scalp psoriasis [Kalsipotriol Losyon, Mometazon Furoat Losyonve Kombinasyonlarinin Saçli Deri Psoriazisi Tedavisindeki Etkinliginin Karsilastirilmasi]. Turkderm Deri Hastaliklari ve Frengi Arsivi2005;39(2):109‐14. [EMBASE: 2006204571] ">Yilmaz 2005</a>). </p> <section id="CD009687-sec-0169"> <p><b>Sensitivity analysis</b></p> <p>Sensitivity analyses with regard to adequate allocation concealment, which included one study (<a href="./references#CD009687-bbs2-0035" title="KragballeK , GanslandtC , OrtonneJP . A calcipotriol plus betamethasone dipropionate scalp formulation significantly reduces itching in scalp psoriasis. Abstract P3343. American Academy of Dermatology 67th Annual Meeting March 6‐10, 2009. Journal of the American Academy of Dermatology2009;60(3 Suppl 1):AB172. KragballeK , HoffmannV , OrtonneJP , TanJ , NordinP , SegaertS . Efficacy and safety of calcipotriol plus betamethasone dipropionate scalp formulation compared with calcipotriol scalp solution in the treatment of scalp psoriasis: a randomized controlled trial. British Journal of Dermatology2009;161(1):159‐66. [MEDLINE: 19416259] NCT00243464 . A calcipotriol plus betamethasone diproprionate scalp formulation significantly reduces itching in scalp. www.clinicaltrials.gov/show/NCT00243464?term=NCT00243464 (accessed 5 November 2014). OrtonneJP , GanslandtC , TanJ , NordinP , KragballeK , SegaertS . Quality of life in patients with scalp psoriasis treated with calcipotriol/betamethasone dipropionate scalp formulation: a randomized controlled trial. Journal of the European Academy of Dermatology &amp; Venereology2009;23(8):919‐26. [MEDLINE: 19453810] ">Kragballe 2009</a>), supported the findings of the meta‐analysis of the four studies (<a href="#CD009687-tbl-0005">Table 2</a>). </p> <p> <ul id="CD009687-list-0056"> <li> <p>Number of participants achieving 'response' according to the IGA (<a href="./references#CD009687-fig-0060" title="">Analysis 11.2</a>; <a href="#CD009687-fig-0005">Figure 5</a>) </p> </li> </ul> </p> <div class="figure" id="CD009687-fig-0005"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 5</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 11 Steroid plus vitamin D vs vitamin D, outcome: 11.2 IGA: response." data-id="CD009687-fig-0005" src="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/image_n/nCD009687-AFig-FIG05.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 11 Steroid plus vitamin D vs vitamin D, outcome: 11.2 IGA: response. </p> </div> </div> </div> <p>Four studies reported this outcome for a total of 2222 participants (<a href="./references#CD009687-bbs2-0027" title="JemecGB , GanslandtC , OrtonneJP , PoulinY , BurdenAD , deUnamunoP , et al. A new scalp formulation of calcipotriene plus betamethasone compared with its active ingredients and the vehicle in the treatment of scalp psoriasis: a randomized, double‐blind, controlled trial. Journal of the American Academy of Dermatology2008;59(3):455‐63. [MEDLINE: 18694678] JemecGBE , BurdenD , PoulinY , OrtonneJP . A new scalp formulation of calcipotriene plus betamethasone in the treatment of scalp psoriasis compared to its active ingredients and the vehicle (Abstract P2733). Journal of the American Academy of Dermatology2007;56(2):AB182. ">Jemec 2008</a>; <a href="./references#CD009687-bbs2-0035" title="KragballeK , GanslandtC , OrtonneJP . A calcipotriol plus betamethasone dipropionate scalp formulation significantly reduces itching in scalp psoriasis. Abstract P3343. American Academy of Dermatology 67th Annual Meeting March 6‐10, 2009. Journal of the American Academy of Dermatology2009;60(3 Suppl 1):AB172. KragballeK , HoffmannV , OrtonneJP , TanJ , NordinP , SegaertS . Efficacy and safety of calcipotriol plus betamethasone dipropionate scalp formulation compared with calcipotriol scalp solution in the treatment of scalp psoriasis: a randomized controlled trial. British Journal of Dermatology2009;161(1):159‐66. [MEDLINE: 19416259] NCT00243464 . A calcipotriol plus betamethasone diproprionate scalp formulation significantly reduces itching in scalp. www.clinicaltrials.gov/show/NCT00243464?term=NCT00243464 (accessed 5 November 2014). OrtonneJP , GanslandtC , TanJ , NordinP , KragballeK , SegaertS . Quality of life in patients with scalp psoriasis treated with calcipotriol/betamethasone dipropionate scalp formulation: a randomized controlled trial. Journal of the European Academy of Dermatology &amp; Venereology2009;23(8):919‐26. [MEDLINE: 19453810] ">Kragballe 2009</a>; <a href="./references#CD009687-bbs2-0041" title="NCT01195831 . Efficacy and safety of Xamiol® gel compared to calcipotriol scalp solution in patients with scalp psoriasis. clinicaltrials.gov/show/NCT01195831 (accessed 5 November 2014). ">NCT01195831</a>; <a href="./references#CD009687-bbs2-0053" title="van deKerkhofP , AnsteyA , BarnesL , BolducC . A new scalp formulation of calcipotriene plus betamethasone in the treatment of scalp psoriasis compared to its active ingredients in the same vehicle. Journal of the American Academy of Dermatology2007;56(2):AB182. van deKerkhofPC , HoffmannV , AnsteyA , BarnesL , BolducC , ReichK , et al. A new scalp formulation of calcipotriol plus betamethasone dipropionate compared with each of its active ingredients in the same vehicle for the treatment of scalp psoriasis: a randomized, double‐blind, controlled trial. British Journal of Dermatology2009;160(1):170‐6. [MEDLINE: 19067709] ">van de Kerkhof 2009</a>). There was considerable heterogeneity between the studies (I² = 81%). However, all trials found that the two‐compound combination was significantly more effective than vitamin D monotherapy (RR 2.31; 95% CI 1.75 to 3.04; NNTB = 3; 95% CI 3 to 4). Thus, heterogeneity may not be clinically important. Several aspects may have contributed to the high level of heterogeneity. We extracted the data from one study, <a href="./references#CD009687-bbs2-0041" title="NCT01195831 . Efficacy and safety of Xamiol® gel compared to calcipotriol scalp solution in patients with scalp psoriasis. clinicaltrials.gov/show/NCT01195831 (accessed 5 November 2014). ">NCT01195831</a>, from the trial register, where not all relevant data (e.g. baseline disease severity) were sufficiently reported. The participants' mean age was more than 10 years younger, and the percentage of female participants was smaller compared to the other three trials (<a href="./references#CD009687-bbs2-0027" title="JemecGB , GanslandtC , OrtonneJP , PoulinY , BurdenAD , deUnamunoP , et al. A new scalp formulation of calcipotriene plus betamethasone compared with its active ingredients and the vehicle in the treatment of scalp psoriasis: a randomized, double‐blind, controlled trial. Journal of the American Academy of Dermatology2008;59(3):455‐63. [MEDLINE: 18694678] JemecGBE , BurdenD , PoulinY , OrtonneJP . A new scalp formulation of calcipotriene plus betamethasone in the treatment of scalp psoriasis compared to its active ingredients and the vehicle (Abstract P2733). Journal of the American Academy of Dermatology2007;56(2):AB182. ">Jemec 2008</a>; <a href="./references#CD009687-bbs2-0035" title="KragballeK , GanslandtC , OrtonneJP . A calcipotriol plus betamethasone dipropionate scalp formulation significantly reduces itching in scalp psoriasis. Abstract P3343. American Academy of Dermatology 67th Annual Meeting March 6‐10, 2009. Journal of the American Academy of Dermatology2009;60(3 Suppl 1):AB172. KragballeK , HoffmannV , OrtonneJP , TanJ , NordinP , SegaertS . Efficacy and safety of calcipotriol plus betamethasone dipropionate scalp formulation compared with calcipotriol scalp solution in the treatment of scalp psoriasis: a randomized controlled trial. British Journal of Dermatology2009;161(1):159‐66. [MEDLINE: 19416259] NCT00243464 . A calcipotriol plus betamethasone diproprionate scalp formulation significantly reduces itching in scalp. www.clinicaltrials.gov/show/NCT00243464?term=NCT00243464 (accessed 5 November 2014). OrtonneJP , GanslandtC , TanJ , NordinP , KragballeK , SegaertS . Quality of life in patients with scalp psoriasis treated with calcipotriol/betamethasone dipropionate scalp formulation: a randomized controlled trial. Journal of the European Academy of Dermatology &amp; Venereology2009;23(8):919‐26. [MEDLINE: 19453810] ">Kragballe 2009</a>; <a href="./references#CD009687-bbs2-0053" title="van deKerkhofP , AnsteyA , BarnesL , BolducC . A new scalp formulation of calcipotriene plus betamethasone in the treatment of scalp psoriasis compared to its active ingredients in the same vehicle. Journal of the American Academy of Dermatology2007;56(2):AB182. van deKerkhofPC , HoffmannV , AnsteyA , BarnesL , BolducC , ReichK , et al. A new scalp formulation of calcipotriol plus betamethasone dipropionate compared with each of its active ingredients in the same vehicle for the treatment of scalp psoriasis: a randomized, double‐blind, controlled trial. British Journal of Dermatology2009;160(1):170‐6. [MEDLINE: 19067709] ">van de Kerkhof 2009</a>). The latter three were similar with regard to severity at baseline, mean age, percentage of female participants and study duration. Two studies only masked the investigator, and the application frequency varied between the treatment groups (once versus twice daily) (<a href="./references#CD009687-bbs2-0035" title="KragballeK , GanslandtC , OrtonneJP . A calcipotriol plus betamethasone dipropionate scalp formulation significantly reduces itching in scalp psoriasis. Abstract P3343. American Academy of Dermatology 67th Annual Meeting March 6‐10, 2009. Journal of the American Academy of Dermatology2009;60(3 Suppl 1):AB172. KragballeK , HoffmannV , OrtonneJP , TanJ , NordinP , SegaertS . Efficacy and safety of calcipotriol plus betamethasone dipropionate scalp formulation compared with calcipotriol scalp solution in the treatment of scalp psoriasis: a randomized controlled trial. British Journal of Dermatology2009;161(1):159‐66. [MEDLINE: 19416259] NCT00243464 . A calcipotriol plus betamethasone diproprionate scalp formulation significantly reduces itching in scalp. www.clinicaltrials.gov/show/NCT00243464?term=NCT00243464 (accessed 5 November 2014). OrtonneJP , GanslandtC , TanJ , NordinP , KragballeK , SegaertS . Quality of life in patients with scalp psoriasis treated with calcipotriol/betamethasone dipropionate scalp formulation: a randomized controlled trial. Journal of the European Academy of Dermatology &amp; Venereology2009;23(8):919‐26. [MEDLINE: 19453810] ">Kragballe 2009</a>; <a href="./references#CD009687-bbs2-0041" title="NCT01195831 . Efficacy and safety of Xamiol® gel compared to calcipotriol scalp solution in patients with scalp psoriasis. clinicaltrials.gov/show/NCT01195831 (accessed 5 November 2014). ">NCT01195831</a>). The other two trials had a double‐blind design and participants applied the study medication once daily (<a href="./references#CD009687-bbs2-0027" title="JemecGB , GanslandtC , OrtonneJP , PoulinY , BurdenAD , deUnamunoP , et al. A new scalp formulation of calcipotriene plus betamethasone compared with its active ingredients and the vehicle in the treatment of scalp psoriasis: a randomized, double‐blind, controlled trial. Journal of the American Academy of Dermatology2008;59(3):455‐63. [MEDLINE: 18694678] JemecGBE , BurdenD , PoulinY , OrtonneJP . A new scalp formulation of calcipotriene plus betamethasone in the treatment of scalp psoriasis compared to its active ingredients and the vehicle (Abstract P2733). Journal of the American Academy of Dermatology2007;56(2):AB182. ">Jemec 2008</a>; <a href="./references#CD009687-bbs2-0053" title="van deKerkhofP , AnsteyA , BarnesL , BolducC . A new scalp formulation of calcipotriene plus betamethasone in the treatment of scalp psoriasis compared to its active ingredients in the same vehicle. Journal of the American Academy of Dermatology2007;56(2):AB182. van deKerkhofPC , HoffmannV , AnsteyA , BarnesL , BolducC , ReichK , et al. A new scalp formulation of calcipotriol plus betamethasone dipropionate compared with each of its active ingredients in the same vehicle for the treatment of scalp psoriasis: a randomized, double‐blind, controlled trial. British Journal of Dermatology2009;160(1):170‐6. [MEDLINE: 19067709] ">van de Kerkhof 2009</a>). The quality of the evidence was moderate (<a href="./full#CD009687-tbl-0003">summary of findings Table 3</a>). </p> <p>We created two subgroups that differed in terms of female proportion and mean age of the participants. One subgroup included the trial register study, the other contained the three published trials. The trial register study, which assessed a younger study population and had a lower female proportion, showed a tendency towards a smaller benefit of the two‐compound combination over vitamin D. However, effect estimates of both subgroups emphasised the higher efficacy of the two‐compound combination product. </p> </section> <section id="CD009687-sec-0170"> <p><b>Sensitivity analysis</b></p> <p>Sensitivity analyses with regard to adequate allocation concealment, which included one study (<a href="./references#CD009687-bbs2-0035" title="KragballeK , GanslandtC , OrtonneJP . A calcipotriol plus betamethasone dipropionate scalp formulation significantly reduces itching in scalp psoriasis. Abstract P3343. American Academy of Dermatology 67th Annual Meeting March 6‐10, 2009. Journal of the American Academy of Dermatology2009;60(3 Suppl 1):AB172. KragballeK , HoffmannV , OrtonneJP , TanJ , NordinP , SegaertS . Efficacy and safety of calcipotriol plus betamethasone dipropionate scalp formulation compared with calcipotriol scalp solution in the treatment of scalp psoriasis: a randomized controlled trial. British Journal of Dermatology2009;161(1):159‐66. [MEDLINE: 19416259] NCT00243464 . A calcipotriol plus betamethasone diproprionate scalp formulation significantly reduces itching in scalp. www.clinicaltrials.gov/show/NCT00243464?term=NCT00243464 (accessed 5 November 2014). OrtonneJP , GanslandtC , TanJ , NordinP , KragballeK , SegaertS . Quality of life in patients with scalp psoriasis treated with calcipotriol/betamethasone dipropionate scalp formulation: a randomized controlled trial. Journal of the European Academy of Dermatology &amp; Venereology2009;23(8):919‐26. [MEDLINE: 19453810] ">Kragballe 2009</a>), supported the findings of the meta‐analysis of the four studies (<a href="#CD009687-tbl-0005">Table 2</a>). </p> <p> <ul id="CD009687-list-0057"> <li> <p>Mean of the TSS (<a href="./references#CD009687-fig-0061" title="">Analysis 11.3</a>) </p> </li> </ul> </p> <p>Four studies addressed the reduction of disease severity by measuring the mean change of TSS from baseline (<a href="./references#CD009687-bbs2-0027" title="JemecGB , GanslandtC , OrtonneJP , PoulinY , BurdenAD , deUnamunoP , et al. A new scalp formulation of calcipotriene plus betamethasone compared with its active ingredients and the vehicle in the treatment of scalp psoriasis: a randomized, double‐blind, controlled trial. Journal of the American Academy of Dermatology2008;59(3):455‐63. [MEDLINE: 18694678] JemecGBE , BurdenD , PoulinY , OrtonneJP . A new scalp formulation of calcipotriene plus betamethasone in the treatment of scalp psoriasis compared to its active ingredients and the vehicle (Abstract P2733). Journal of the American Academy of Dermatology2007;56(2):AB182. ">Jemec 2008</a>; <a href="./references#CD009687-bbs2-0035" title="KragballeK , GanslandtC , OrtonneJP . A calcipotriol plus betamethasone dipropionate scalp formulation significantly reduces itching in scalp psoriasis. Abstract P3343. American Academy of Dermatology 67th Annual Meeting March 6‐10, 2009. Journal of the American Academy of Dermatology2009;60(3 Suppl 1):AB172. KragballeK , HoffmannV , OrtonneJP , TanJ , NordinP , SegaertS . Efficacy and safety of calcipotriol plus betamethasone dipropionate scalp formulation compared with calcipotriol scalp solution in the treatment of scalp psoriasis: a randomized controlled trial. British Journal of Dermatology2009;161(1):159‐66. [MEDLINE: 19416259] NCT00243464 . A calcipotriol plus betamethasone diproprionate scalp formulation significantly reduces itching in scalp. www.clinicaltrials.gov/show/NCT00243464?term=NCT00243464 (accessed 5 November 2014). OrtonneJP , GanslandtC , TanJ , NordinP , KragballeK , SegaertS . Quality of life in patients with scalp psoriasis treated with calcipotriol/betamethasone dipropionate scalp formulation: a randomized controlled trial. Journal of the European Academy of Dermatology &amp; Venereology2009;23(8):919‐26. [MEDLINE: 19453810] ">Kragballe 2009</a>; <a href="./references#CD009687-bbs2-0053" title="van deKerkhofP , AnsteyA , BarnesL , BolducC . A new scalp formulation of calcipotriene plus betamethasone in the treatment of scalp psoriasis compared to its active ingredients in the same vehicle. Journal of the American Academy of Dermatology2007;56(2):AB182. van deKerkhofPC , HoffmannV , AnsteyA , BarnesL , BolducC , ReichK , et al. A new scalp formulation of calcipotriol plus betamethasone dipropionate compared with each of its active ingredients in the same vehicle for the treatment of scalp psoriasis: a randomized, double‐blind, controlled trial. British Journal of Dermatology2009;160(1):170‐6. [MEDLINE: 19067709] ">van de Kerkhof 2009</a>; <a href="./references#CD009687-bbs2-0059" title="YilmazH , AydinF , SenturkN , CanturkT , TuranliAY . A comparison between the effects of calcipotriol lotion, momethasone furoate lotion and their combinations for the treatment of scalp psoriasis [Kalsipotriol Losyon, Mometazon Furoat Losyonve Kombinasyonlarinin Saçli Deri Psoriazisi Tedavisindeki Etkinliginin Karsilastirilmasi]. Turkderm Deri Hastaliklari ve Frengi Arsivi2005;39(2):109‐14. [EMBASE: 2006204571] ">Yilmaz 2005</a>). All studies reported a greater reduction of TSS in participants treated with the two‐compound combination. The measure of variance was not reported. </p> </section> </section> <section id="CD009687-sec-0171"> <h6 class="title">2) Improvement in quality of life</h6> <p><a href="./references#CD009687-bbs2-0156" title="OrtonneJ , ChimentiS , LugerT , PuigL , ReidF , TruebRM . Scalp psoriasis: European consensus on grading and treatment algorithm. Journal of the European Academy of Dermatology &amp; Venereology2009;23(12):1435‐44. [MEDLINE: 19614856] ">Ortonne 2009</a> reported quality of life measures for the study population (N = 312 participants) of <a href="./references#CD009687-bbs2-0035" title="KragballeK , GanslandtC , OrtonneJP . A calcipotriol plus betamethasone dipropionate scalp formulation significantly reduces itching in scalp psoriasis. Abstract P3343. American Academy of Dermatology 67th Annual Meeting March 6‐10, 2009. Journal of the American Academy of Dermatology2009;60(3 Suppl 1):AB172. KragballeK , HoffmannV , OrtonneJP , TanJ , NordinP , SegaertS . Efficacy and safety of calcipotriol plus betamethasone dipropionate scalp formulation compared with calcipotriol scalp solution in the treatment of scalp psoriasis: a randomized controlled trial. British Journal of Dermatology2009;161(1):159‐66. [MEDLINE: 19416259] NCT00243464 . A calcipotriol plus betamethasone diproprionate scalp formulation significantly reduces itching in scalp. www.clinicaltrials.gov/show/NCT00243464?term=NCT00243464 (accessed 5 November 2014). OrtonneJP , GanslandtC , TanJ , NordinP , KragballeK , SegaertS . Quality of life in patients with scalp psoriasis treated with calcipotriol/betamethasone dipropionate scalp formulation: a randomized controlled trial. Journal of the European Academy of Dermatology &amp; Venereology2009;23(8):919‐26. [MEDLINE: 19453810] ">Kragballe 2009</a>. The investigators used two different tools: the SF‐36v2 and the scalp‐specific Skindex‐16. For the latter, the authors reported a greater improvement from baseline in the two‐compound group compared to the calcipotriol group (mean score at week 4: 28.1 (two‐compound) and 13.1 (calcipotriol)). The combination therapy also revealed a greater mean change compared to baseline, according to the SF‐36v2: the physical component summary was +0.8 (two‐compound) versus ‐0.8 (calcipotriol) and the mental component summary was +1.6 (two‐compound) versus +0.6 (calcipotriol). The measures of variance were not reported. </p> </section> <section id="CD009687-sec-0172"> <h6 class="title">3) Number of participants withdrawing due to adverse events</h6> <p> <ul id="CD009687-list-0058"> <li> <p>Short‐term (<a href="./references#CD009687-fig-0062" title="">Analysis 11.4</a>) </p> </li> </ul> </p> <p>Four studies reported this outcome for short‐term therapy (<a href="./references#CD009687-bbs2-0027" title="JemecGB , GanslandtC , OrtonneJP , PoulinY , BurdenAD , deUnamunoP , et al. A new scalp formulation of calcipotriene plus betamethasone compared with its active ingredients and the vehicle in the treatment of scalp psoriasis: a randomized, double‐blind, controlled trial. Journal of the American Academy of Dermatology2008;59(3):455‐63. [MEDLINE: 18694678] JemecGBE , BurdenD , PoulinY , OrtonneJP . A new scalp formulation of calcipotriene plus betamethasone in the treatment of scalp psoriasis compared to its active ingredients and the vehicle (Abstract P2733). Journal of the American Academy of Dermatology2007;56(2):AB182. ">Jemec 2008</a>; <a href="./references#CD009687-bbs2-0035" title="KragballeK , GanslandtC , OrtonneJP . A calcipotriol plus betamethasone dipropionate scalp formulation significantly reduces itching in scalp psoriasis. Abstract P3343. American Academy of Dermatology 67th Annual Meeting March 6‐10, 2009. Journal of the American Academy of Dermatology2009;60(3 Suppl 1):AB172. KragballeK , HoffmannV , OrtonneJP , TanJ , NordinP , SegaertS . Efficacy and safety of calcipotriol plus betamethasone dipropionate scalp formulation compared with calcipotriol scalp solution in the treatment of scalp psoriasis: a randomized controlled trial. British Journal of Dermatology2009;161(1):159‐66. [MEDLINE: 19416259] NCT00243464 . A calcipotriol plus betamethasone diproprionate scalp formulation significantly reduces itching in scalp. www.clinicaltrials.gov/show/NCT00243464?term=NCT00243464 (accessed 5 November 2014). OrtonneJP , GanslandtC , TanJ , NordinP , KragballeK , SegaertS . Quality of life in patients with scalp psoriasis treated with calcipotriol/betamethasone dipropionate scalp formulation: a randomized controlled trial. Journal of the European Academy of Dermatology &amp; Venereology2009;23(8):919‐26. [MEDLINE: 19453810] ">Kragballe 2009</a>; <a href="./references#CD009687-bbs2-0041" title="NCT01195831 . Efficacy and safety of Xamiol® gel compared to calcipotriol scalp solution in patients with scalp psoriasis. clinicaltrials.gov/show/NCT01195831 (accessed 5 November 2014). ">NCT01195831</a>; <a href="./references#CD009687-bbs2-0053" title="van deKerkhofP , AnsteyA , BarnesL , BolducC . A new scalp formulation of calcipotriene plus betamethasone in the treatment of scalp psoriasis compared to its active ingredients in the same vehicle. Journal of the American Academy of Dermatology2007;56(2):AB182. van deKerkhofPC , HoffmannV , AnsteyA , BarnesL , BolducC , ReichK , et al. A new scalp formulation of calcipotriol plus betamethasone dipropionate compared with each of its active ingredients in the same vehicle for the treatment of scalp psoriasis: a randomized, double‐blind, controlled trial. British Journal of Dermatology2009;160(1):170‐6. [MEDLINE: 19067709] ">van de Kerkhof 2009</a>). None of the study authors stated which specific adverse events caused withdrawal from the study. There was substantial heterogeneity among the four trials (I² = 85.2%). This may be due to the findings of <a href="./references#CD009687-bbs2-0041" title="NCT01195831 . Efficacy and safety of Xamiol® gel compared to calcipotriol scalp solution in patients with scalp psoriasis. clinicaltrials.gov/show/NCT01195831 (accessed 5 November 2014). ">NCT01195831</a>, which did not show a significant difference in tolerability between the treatments (RR 2.07; 95% CI 0.39 to 11.07). Not all data from this trial were available, since we extracted the data from a trial register. Therefore, the baseline severity of the included participants remained unclear. Additionally, the study population differed from the other three trials in terms of mean age and percentage of female participants. We therefore performed a subgroup analysis that included only the three studies <a href="./references#CD009687-bbs2-0027" title="JemecGB , GanslandtC , OrtonneJP , PoulinY , BurdenAD , deUnamunoP , et al. A new scalp formulation of calcipotriene plus betamethasone compared with its active ingredients and the vehicle in the treatment of scalp psoriasis: a randomized, double‐blind, controlled trial. Journal of the American Academy of Dermatology2008;59(3):455‐63. [MEDLINE: 18694678] JemecGBE , BurdenD , PoulinY , OrtonneJP . A new scalp formulation of calcipotriene plus betamethasone in the treatment of scalp psoriasis compared to its active ingredients and the vehicle (Abstract P2733). Journal of the American Academy of Dermatology2007;56(2):AB182. ">Jemec 2008</a>, <a href="./references#CD009687-bbs2-0035" title="KragballeK , GanslandtC , OrtonneJP . A calcipotriol plus betamethasone dipropionate scalp formulation significantly reduces itching in scalp psoriasis. Abstract P3343. American Academy of Dermatology 67th Annual Meeting March 6‐10, 2009. Journal of the American Academy of Dermatology2009;60(3 Suppl 1):AB172. KragballeK , HoffmannV , OrtonneJP , TanJ , NordinP , SegaertS . Efficacy and safety of calcipotriol plus betamethasone dipropionate scalp formulation compared with calcipotriol scalp solution in the treatment of scalp psoriasis: a randomized controlled trial. British Journal of Dermatology2009;161(1):159‐66. [MEDLINE: 19416259] NCT00243464 . A calcipotriol plus betamethasone diproprionate scalp formulation significantly reduces itching in scalp. www.clinicaltrials.gov/show/NCT00243464?term=NCT00243464 (accessed 5 November 2014). OrtonneJP , GanslandtC , TanJ , NordinP , KragballeK , SegaertS . Quality of life in patients with scalp psoriasis treated with calcipotriol/betamethasone dipropionate scalp formulation: a randomized controlled trial. Journal of the European Academy of Dermatology &amp; Venereology2009;23(8):919‐26. [MEDLINE: 19453810] ">Kragballe 2009</a> and <a href="./references#CD009687-bbs2-0053" title="van deKerkhofP , AnsteyA , BarnesL , BolducC . A new scalp formulation of calcipotriene plus betamethasone in the treatment of scalp psoriasis compared to its active ingredients in the same vehicle. Journal of the American Academy of Dermatology2007;56(2):AB182. van deKerkhofPC , HoffmannV , AnsteyA , BarnesL , BolducC , ReichK , et al. A new scalp formulation of calcipotriol plus betamethasone dipropionate compared with each of its active ingredients in the same vehicle for the treatment of scalp psoriasis: a randomized, double‐blind, controlled trial. British Journal of Dermatology2009;160(1):170‐6. [MEDLINE: 19067709] ">van de Kerkhof 2009</a>. According to this subgroup, the two‐compound combination led to significantly fewer withdrawals due to adverse events (RR 0.19; 95% CI 0.11 to 0.36). Heterogeneity of the three studies with 1970 participants was not important (I² = 0%) and the quality of the evidence was high (<a href="./full#CD009687-tbl-0003">summary of findings Table 3</a>). </p> <p>In another study (N = 30 participants) no withdrawals due to adverse events occurred (<a href="./references#CD009687-bbs2-0059" title="YilmazH , AydinF , SenturkN , CanturkT , TuranliAY . A comparison between the effects of calcipotriol lotion, momethasone furoate lotion and their combinations for the treatment of scalp psoriasis [Kalsipotriol Losyon, Mometazon Furoat Losyonve Kombinasyonlarinin Saçli Deri Psoriazisi Tedavisindeki Etkinliginin Karsilastirilmasi]. Turkderm Deri Hastaliklari ve Frengi Arsivi2005;39(2):109‐14. [EMBASE: 2006204571] ">Yilmaz 2005</a>). </p> <section id="CD009687-sec-0173"> <p><b>Sensitivity analysis</b></p> <p>Sensitivity analyses with regard to adequate allocation concealment, which included one study (<a href="./references#CD009687-bbs2-0035" title="KragballeK , GanslandtC , OrtonneJP . A calcipotriol plus betamethasone dipropionate scalp formulation significantly reduces itching in scalp psoriasis. Abstract P3343. American Academy of Dermatology 67th Annual Meeting March 6‐10, 2009. Journal of the American Academy of Dermatology2009;60(3 Suppl 1):AB172. KragballeK , HoffmannV , OrtonneJP , TanJ , NordinP , SegaertS . Efficacy and safety of calcipotriol plus betamethasone dipropionate scalp formulation compared with calcipotriol scalp solution in the treatment of scalp psoriasis: a randomized controlled trial. British Journal of Dermatology2009;161(1):159‐66. [MEDLINE: 19416259] NCT00243464 . A calcipotriol plus betamethasone diproprionate scalp formulation significantly reduces itching in scalp. www.clinicaltrials.gov/show/NCT00243464?term=NCT00243464 (accessed 5 November 2014). OrtonneJP , GanslandtC , TanJ , NordinP , KragballeK , SegaertS . Quality of life in patients with scalp psoriasis treated with calcipotriol/betamethasone dipropionate scalp formulation: a randomized controlled trial. Journal of the European Academy of Dermatology &amp; Venereology2009;23(8):919‐26. [MEDLINE: 19453810] ">Kragballe 2009</a>), supported the findings of the meta‐analysis of the three studies (<a href="#CD009687-tbl-0005">Table 2</a>). </p> <p> <ul id="CD009687-list-0059"> <li> <p>Long‐term (<a href="./references#CD009687-fig-0063" title="">Analysis 11.5</a>) </p> </li> </ul> </p> <p>One study addressed this outcome for the long‐term therapy for a total of 869 participants (<a href="./references#CD009687-bbs2-0038" title="CambazardF . Xamiol, a new treatment in scalp psoriasis: short‐ and long‐term results [Un nouveau traitement dans le psoriasis du cuir chevelu : Xamiol®: Résultats à court terme et à long terme]. Annales de Dermatologie et de Vénéréologie2009;136(Suppl 3):546‐50. [EMBASE: 2009406816] LugerTA , CambazardF , LarsenFG , BourcierM , GuptaG , ClonierF , et al. A study of the safety and efficacy of calcipotriol and betamethasone dipropionate scalp formulation in the long‐term management of scalp psoriasis. Dermatology2008;217(4):321‐8. [MEDLINE: 18787325] ">Luger 2008</a>). After 12 months, significantly fewer participants treated with the combination therapy withdrew due to unacceptable adverse events (RR 0.21; 95% CI 0.10 to 0.42). </p> </section> </section> </section> <section id="CD009687-sec-0174"> <h5 class="title">Secondary outcomes</h5> <section id="CD009687-sec-0175"> <h6 class="title">1) Subjective reduction in severity of psoriasis</h6> <p> <ul id="CD009687-list-0060"> <li> <p>Number of participants achieving 'clearance' according to the PGA (<a href="./references#CD009687-fig-0064" title="">Analysis 11.6</a>) </p> </li> </ul> </p> <p>One study addressed this outcome (<a href="./references#CD009687-bbs2-0059" title="YilmazH , AydinF , SenturkN , CanturkT , TuranliAY . A comparison between the effects of calcipotriol lotion, momethasone furoate lotion and their combinations for the treatment of scalp psoriasis [Kalsipotriol Losyon, Mometazon Furoat Losyonve Kombinasyonlarinin Saçli Deri Psoriazisi Tedavisindeki Etkinliginin Karsilastirilmasi]. Turkderm Deri Hastaliklari ve Frengi Arsivi2005;39(2):109‐14. [EMBASE: 2006204571] ">Yilmaz 2005</a>). Mometasone furoate in combination with calcipotriol was significantly more effective in clearing scalp psoriasis than calcipotriol alone (N = 30 participants; RR 6.00; 95% CI 1.61 to 22.34; NNTB = 2; 95% CI 2 to 3). </p> <p> <ul id="CD009687-list-0061"> <li> <p>Number of participants achieving 'response' according to the PGA (<a href="./references#CD009687-fig-0065" title="">Analysis 11.7</a>) </p> </li> </ul> </p> <p>Four studies addressed this outcome for a total of 2222 participants (<a href="./references#CD009687-bbs2-0027" title="JemecGB , GanslandtC , OrtonneJP , PoulinY , BurdenAD , deUnamunoP , et al. A new scalp formulation of calcipotriene plus betamethasone compared with its active ingredients and the vehicle in the treatment of scalp psoriasis: a randomized, double‐blind, controlled trial. Journal of the American Academy of Dermatology2008;59(3):455‐63. [MEDLINE: 18694678] JemecGBE , BurdenD , PoulinY , OrtonneJP . A new scalp formulation of calcipotriene plus betamethasone in the treatment of scalp psoriasis compared to its active ingredients and the vehicle (Abstract P2733). Journal of the American Academy of Dermatology2007;56(2):AB182. ">Jemec 2008</a>; <a href="./references#CD009687-bbs2-0035" title="KragballeK , GanslandtC , OrtonneJP . A calcipotriol plus betamethasone dipropionate scalp formulation significantly reduces itching in scalp psoriasis. Abstract P3343. American Academy of Dermatology 67th Annual Meeting March 6‐10, 2009. Journal of the American Academy of Dermatology2009;60(3 Suppl 1):AB172. KragballeK , HoffmannV , OrtonneJP , TanJ , NordinP , SegaertS . Efficacy and safety of calcipotriol plus betamethasone dipropionate scalp formulation compared with calcipotriol scalp solution in the treatment of scalp psoriasis: a randomized controlled trial. British Journal of Dermatology2009;161(1):159‐66. [MEDLINE: 19416259] NCT00243464 . A calcipotriol plus betamethasone diproprionate scalp formulation significantly reduces itching in scalp. www.clinicaltrials.gov/show/NCT00243464?term=NCT00243464 (accessed 5 November 2014). OrtonneJP , GanslandtC , TanJ , NordinP , KragballeK , SegaertS . Quality of life in patients with scalp psoriasis treated with calcipotriol/betamethasone dipropionate scalp formulation: a randomized controlled trial. Journal of the European Academy of Dermatology &amp; Venereology2009;23(8):919‐26. [MEDLINE: 19453810] ">Kragballe 2009</a>; <a href="./references#CD009687-bbs2-0041" title="NCT01195831 . Efficacy and safety of Xamiol® gel compared to calcipotriol scalp solution in patients with scalp psoriasis. clinicaltrials.gov/show/NCT01195831 (accessed 5 November 2014). ">NCT01195831</a>; <a href="./references#CD009687-bbs2-0053" title="van deKerkhofP , AnsteyA , BarnesL , BolducC . A new scalp formulation of calcipotriene plus betamethasone in the treatment of scalp psoriasis compared to its active ingredients in the same vehicle. Journal of the American Academy of Dermatology2007;56(2):AB182. van deKerkhofPC , HoffmannV , AnsteyA , BarnesL , BolducC , ReichK , et al. A new scalp formulation of calcipotriol plus betamethasone dipropionate compared with each of its active ingredients in the same vehicle for the treatment of scalp psoriasis: a randomized, double‐blind, controlled trial. British Journal of Dermatology2009;160(1):170‐6. [MEDLINE: 19067709] ">van de Kerkhof 2009</a>). According to the participants, the two‐compound combination was significantly more effective than vitamin D alone (RR 1.76; 95% CI 1.46 to 2.12; NNTB = 4; 95% CI 3 to 6). The quality of the evidence was moderate (<a href="./full#CD009687-tbl-0003">summary of findings Table 3</a>). Heterogeneity among the trials was substantial (I² = 77%), but the direction of effect was consistent throughout the studies. Thus, the high level of heterogeneity may be clinically unimportant. However, there may be different aspects explaining the high degree of heterogeneity. We retrieved data (e.g. baseline severity) from the trial <a href="./references#CD009687-bbs2-0041" title="NCT01195831 . Efficacy and safety of Xamiol® gel compared to calcipotriol scalp solution in patients with scalp psoriasis. clinicaltrials.gov/show/NCT01195831 (accessed 5 November 2014). ">NCT01195831</a> from the trial register, where information was sparse. In addition, the participants' mean age was more than 10 years younger, and the percentage of female participants was smaller, compared to the other three trials. The latter were similar with regard to severity at baseline, mean age, percentage of female participants and study duration. Two studies only masked the investigator and the application frequency varied between the treatment groups (once versus twice daily) (<a href="./references#CD009687-bbs2-0035" title="KragballeK , GanslandtC , OrtonneJP . A calcipotriol plus betamethasone dipropionate scalp formulation significantly reduces itching in scalp psoriasis. Abstract P3343. American Academy of Dermatology 67th Annual Meeting March 6‐10, 2009. Journal of the American Academy of Dermatology2009;60(3 Suppl 1):AB172. KragballeK , HoffmannV , OrtonneJP , TanJ , NordinP , SegaertS . Efficacy and safety of calcipotriol plus betamethasone dipropionate scalp formulation compared with calcipotriol scalp solution in the treatment of scalp psoriasis: a randomized controlled trial. British Journal of Dermatology2009;161(1):159‐66. [MEDLINE: 19416259] NCT00243464 . A calcipotriol plus betamethasone diproprionate scalp formulation significantly reduces itching in scalp. www.clinicaltrials.gov/show/NCT00243464?term=NCT00243464 (accessed 5 November 2014). OrtonneJP , GanslandtC , TanJ , NordinP , KragballeK , SegaertS . Quality of life in patients with scalp psoriasis treated with calcipotriol/betamethasone dipropionate scalp formulation: a randomized controlled trial. Journal of the European Academy of Dermatology &amp; Venereology2009;23(8):919‐26. [MEDLINE: 19453810] ">Kragballe 2009</a>; <a href="./references#CD009687-bbs2-0041" title="NCT01195831 . Efficacy and safety of Xamiol® gel compared to calcipotriol scalp solution in patients with scalp psoriasis. clinicaltrials.gov/show/NCT01195831 (accessed 5 November 2014). ">NCT01195831</a>). The other two trials had a double‐blind design and the treatment groups received the topical therapy once a day (<a href="./references#CD009687-bbs2-0027" title="JemecGB , GanslandtC , OrtonneJP , PoulinY , BurdenAD , deUnamunoP , et al. A new scalp formulation of calcipotriene plus betamethasone compared with its active ingredients and the vehicle in the treatment of scalp psoriasis: a randomized, double‐blind, controlled trial. Journal of the American Academy of Dermatology2008;59(3):455‐63. [MEDLINE: 18694678] JemecGBE , BurdenD , PoulinY , OrtonneJP . A new scalp formulation of calcipotriene plus betamethasone in the treatment of scalp psoriasis compared to its active ingredients and the vehicle (Abstract P2733). Journal of the American Academy of Dermatology2007;56(2):AB182. ">Jemec 2008</a>; <a href="./references#CD009687-bbs2-0053" title="van deKerkhofP , AnsteyA , BarnesL , BolducC . A new scalp formulation of calcipotriene plus betamethasone in the treatment of scalp psoriasis compared to its active ingredients in the same vehicle. Journal of the American Academy of Dermatology2007;56(2):AB182. van deKerkhofPC , HoffmannV , AnsteyA , BarnesL , BolducC , ReichK , et al. A new scalp formulation of calcipotriol plus betamethasone dipropionate compared with each of its active ingredients in the same vehicle for the treatment of scalp psoriasis: a randomized, double‐blind, controlled trial. British Journal of Dermatology2009;160(1):170‐6. [MEDLINE: 19067709] ">van de Kerkhof 2009</a>). </p> <p>We created two subgroups that differed in terms of female proportion and mean age of the participants. One subgroup included the trial register study, the other contained the three published trials. The effect estimates of both subgroups emphasised the higher efficacy of the two‐compound combination product compared to vitamin D alone. </p> </section> <section id="CD009687-sec-0176"> <h6 class="title">2) Number of participants with at least one adverse event</h6> <p> <ul id="CD009687-list-0062"> <li> <p>Short‐term (<a href="./references#CD009687-fig-0066" title="">Analysis 11.8</a>; <a href="#CD009687-fig-0006">Figure 6</a>) </p> </li> </ul> </p> <div class="figure" id="CD009687-fig-0006"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 6</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 11 Steroid plus vitamin D vs vitamin D, outcome: 11.8 Number of participants with at least one AE (short term)." data-id="CD009687-fig-0006" src="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/image_n/nCD009687-AFig-FIG06.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 11 Steroid plus vitamin D vs vitamin D, outcome: 11.8 Number of participants with at least one AE (short term). </p> </div> </div> </div> <p>Four studies reported this outcome for a total of 2193 participants. Heterogeneity was substantial among the four studies (I² = 64%). However, all studies showed that significantly fewer adverse events occurred with the two‐compound preparation (RR 0.70; 95% CI 0.58 to 0.85). Heterogeneity may therefore be clinically unimportant. The trial register study <a href="./references#CD009687-bbs2-0041" title="NCT01195831 . Efficacy and safety of Xamiol® gel compared to calcipotriol scalp solution in patients with scalp psoriasis. clinicaltrials.gov/show/NCT01195831 (accessed 5 November 2014). ">NCT01195831</a> was different to the other three trials in terms of mean age and percentage of female participants, and did not report baseline severity. We therefore created two subgroups with respect to mean age. One included the trial register study (<a href="./references#CD009687-bbs2-0041" title="NCT01195831 . Efficacy and safety of Xamiol® gel compared to calcipotriol scalp solution in patients with scalp psoriasis. clinicaltrials.gov/show/NCT01195831 (accessed 5 November 2014). ">NCT01195831</a>; RR 0.44; 95% CI 0.25 to 0.76), the other the three published trials (<a href="./references#CD009687-bbs2-0027" title="JemecGB , GanslandtC , OrtonneJP , PoulinY , BurdenAD , deUnamunoP , et al. A new scalp formulation of calcipotriene plus betamethasone compared with its active ingredients and the vehicle in the treatment of scalp psoriasis: a randomized, double‐blind, controlled trial. Journal of the American Academy of Dermatology2008;59(3):455‐63. [MEDLINE: 18694678] JemecGBE , BurdenD , PoulinY , OrtonneJP . A new scalp formulation of calcipotriene plus betamethasone in the treatment of scalp psoriasis compared to its active ingredients and the vehicle (Abstract P2733). Journal of the American Academy of Dermatology2007;56(2):AB182. ">Jemec 2008</a>; <a href="./references#CD009687-bbs2-0035" title="KragballeK , GanslandtC , OrtonneJP . A calcipotriol plus betamethasone dipropionate scalp formulation significantly reduces itching in scalp psoriasis. Abstract P3343. American Academy of Dermatology 67th Annual Meeting March 6‐10, 2009. Journal of the American Academy of Dermatology2009;60(3 Suppl 1):AB172. KragballeK , HoffmannV , OrtonneJP , TanJ , NordinP , SegaertS . Efficacy and safety of calcipotriol plus betamethasone dipropionate scalp formulation compared with calcipotriol scalp solution in the treatment of scalp psoriasis: a randomized controlled trial. British Journal of Dermatology2009;161(1):159‐66. [MEDLINE: 19416259] NCT00243464 . A calcipotriol plus betamethasone diproprionate scalp formulation significantly reduces itching in scalp. www.clinicaltrials.gov/show/NCT00243464?term=NCT00243464 (accessed 5 November 2014). OrtonneJP , GanslandtC , TanJ , NordinP , KragballeK , SegaertS . Quality of life in patients with scalp psoriasis treated with calcipotriol/betamethasone dipropionate scalp formulation: a randomized controlled trial. Journal of the European Academy of Dermatology &amp; Venereology2009;23(8):919‐26. [MEDLINE: 19453810] ">Kragballe 2009</a>; <a href="./references#CD009687-bbs2-0053" title="van deKerkhofP , AnsteyA , BarnesL , BolducC . A new scalp formulation of calcipotriene plus betamethasone in the treatment of scalp psoriasis compared to its active ingredients in the same vehicle. Journal of the American Academy of Dermatology2007;56(2):AB182. van deKerkhofPC , HoffmannV , AnsteyA , BarnesL , BolducC , ReichK , et al. A new scalp formulation of calcipotriol plus betamethasone dipropionate compared with each of its active ingredients in the same vehicle for the treatment of scalp psoriasis: a randomized, double‐blind, controlled trial. British Journal of Dermatology2009;160(1):170‐6. [MEDLINE: 19067709] ">van de Kerkhof 2009</a>). Within the latter, studies were moderately heterogenous (I² = 56%; RR 0.74; 95% CI 0.63 to 0.88). The effect estimates of both subgroups emphasised the lower risk of adverse events in the two‐compound preparation. Common adverse events in both treatment groups were a burning sensation, pruritus, irritation, folliculitis and pain at the site of application. </p> <section id="CD009687-sec-0177"> <p><b>Sensitivity analysis</b></p> <p>Sensitivity analyses with regard to adequate allocation concealment, which included one study (<a href="./references#CD009687-bbs2-0035" title="KragballeK , GanslandtC , OrtonneJP . A calcipotriol plus betamethasone dipropionate scalp formulation significantly reduces itching in scalp psoriasis. Abstract P3343. American Academy of Dermatology 67th Annual Meeting March 6‐10, 2009. Journal of the American Academy of Dermatology2009;60(3 Suppl 1):AB172. KragballeK , HoffmannV , OrtonneJP , TanJ , NordinP , SegaertS . Efficacy and safety of calcipotriol plus betamethasone dipropionate scalp formulation compared with calcipotriol scalp solution in the treatment of scalp psoriasis: a randomized controlled trial. British Journal of Dermatology2009;161(1):159‐66. [MEDLINE: 19416259] NCT00243464 . A calcipotriol plus betamethasone diproprionate scalp formulation significantly reduces itching in scalp. www.clinicaltrials.gov/show/NCT00243464?term=NCT00243464 (accessed 5 November 2014). OrtonneJP , GanslandtC , TanJ , NordinP , KragballeK , SegaertS . Quality of life in patients with scalp psoriasis treated with calcipotriol/betamethasone dipropionate scalp formulation: a randomized controlled trial. Journal of the European Academy of Dermatology &amp; Venereology2009;23(8):919‐26. [MEDLINE: 19453810] ">Kragballe 2009</a>), supported the findings of the meta‐analysis of the four studies (<a href="#CD009687-tbl-0005">Table 2</a>). </p> <p> <ul id="CD009687-list-0063"> <li> <p>Long‐term (<a href="./references#CD009687-fig-0067" title="">Analysis 11.9</a>) </p> </li> </ul> </p> <p>One study reported this outcome for long‐term therapy (<a href="./references#CD009687-bbs2-0038" title="CambazardF . Xamiol, a new treatment in scalp psoriasis: short‐ and long‐term results [Un nouveau traitement dans le psoriasis du cuir chevelu : Xamiol®: Résultats à court terme et à long terme]. Annales de Dermatologie et de Vénéréologie2009;136(Suppl 3):546‐50. [EMBASE: 2009406816] LugerTA , CambazardF , LarsenFG , BourcierM , GuptaG , ClonierF , et al. A study of the safety and efficacy of calcipotriol and betamethasone dipropionate scalp formulation in the long‐term management of scalp psoriasis. Dermatology2008;217(4):321‐8. [MEDLINE: 18787325] ">Luger 2008</a>). After 12 months, significantly fewer participants in the two‐compound group experienced adverse events (N = 850 participants; RR 0.58; 95% CI 0.45 to 0.75). The main adverse events were pruritus, burning sensation, irritation, erythema and folliculitis. The authors emphasised that no participant reported skin atrophy. Yet, it was unclear if skin atrophy was actively measured. </p> </section> </section> </section> </section> <section id="CD009687-sec-0178"> <h4 class="title">12. Tar and dithranol</h4> <section id="CD009687-sec-0179"> <h5 class="title">Primary outcomes</h5> </section> <section id="CD009687-sec-0180"> <h5 class="title">1) Reduction in clinician‐assessed severity</h5> <p> <ul id="CD009687-list-0064"> <li> <p>Number of participants achieving 'clearance' according to the IGA (<a href="./references#CD009687-fig-0068" title="">Analysis 12.1</a>) </p> </li> </ul> </p> <p>Three trials that assessed therapies including tar or dithranol addressed this outcome. The study <a href="./references#CD009687-bbs2-0052" title="Van deKerkhofPC , GreenC , HambergKJ , HutchinsonPE , JensenJK , KidsonP , et al. Safety and efficacy of combined high‐dose treatment with calcipotriol ointment and solution in patients with psoriasis. Dermatology2002;204(3):214‐21. [MEDLINE: 12037450] ">van de Kerkhof 2002</a> found no significant difference between calcipotriol and a tar/dithranol regimen (N = 88 participants; RR 5.71; 95% CI 0.28 to 115.70). Participants that used the tar/dithranol regimen could either apply the agents separately or in combination. The concentration of the dithranol and tar preparations ranged from 0.125% to 8% and 1% to 25%, respectively. <a href="./references#CD009687-bbs2-0020" title="HeYL , GuoZP . Clinical efficacy of 0.1% tacrolimus ointment on plaque psoriasis of scalp and face. Journal of Clinical Dermatology2008;37(4):254‐5. [EMBASE: 2008250949] ">He 2008</a> showed that significantly more participants achieved clearance of their scalp psoriasis with tacrolimus compared to those treated with pine tar (N = 40 participants; RR 2.75; 95% CI 1.05 to 7.20; NNTB = 3; 95% CI 2 to 15). According to <a href="./references#CD009687-bbs2-0058" title="WrightS , MannRJ . Comparison of a cream containing 0.1% dithranol in a 17% urea base (Psoradrate(TM)) with coal tar pomade in the treatment of scalp psoriasis. Clinical &amp; Experimental Dermatology1985;10(4):375‐8. [MEDLINE: 3899424] ">Wright 1985</a>, there was no difference in clearing scalp psoriasis between dithranol/urea or coal tar/salicylic acid (2%), both as lipophilic leave‐on combination products (N = 38 participants; RR 1.11; 95% CI 0.90 to 1.38). </p> <p> <ul id="CD009687-list-0065"> <li> <p>Number of participants achieving 'response' according to the IGA (<a href="./references#CD009687-fig-0069" title="">Analysis 12.2</a>) </p> </li> </ul> </p> <p>Two tar‐controlled trials addressed this outcome. One found calcipotriol to be significantly more effective than a dithranol/tar preparation (N = 88 participants; RR 2.58; 95% CI 1.51 to 4.41; NNTB = 3; 95% CI 2 to 5) (<a href="./references#CD009687-bbs2-0052" title="Van deKerkhofPC , GreenC , HambergKJ , HutchinsonPE , JensenJK , KidsonP , et al. Safety and efficacy of combined high‐dose treatment with calcipotriol ointment and solution in patients with psoriasis. Dermatology2002;204(3):214‐21. [MEDLINE: 12037450] ">van de Kerkhof 2002</a>). </p> <p>We obtained information on the second study, <a href="./references#CD009687-bbs2-0002" title="BarrettC , LowsonD , BladesKJ . Limited benefit of combined use of tar‐based shampoo with 50 mug/ml calcipotriol solution in scalp psoriasis. Journal of Dermatological Treatment2005;16(3):175. [EMBASE: 2005434030] ">Barrett 2005</a>, from a correspondence letter. It assessed the once daily use of a combination regimen of calcipotriol as solution together with a tar‐based shampoo or a placebo shampoo. The number of participants was unknown. The authors reported that 55.9% of the participants who received the tar‐based shampoo and calcipotriol solution, and 51.7% of the group that used placebo shampoo and calcipotriol solution responded within eight weeks of treatment. The difference was not significant, but the letter did not provide more statistical information (e.g. P value or measure of variance). </p> <p> <ul id="CD009687-list-0066"> <li> <p>Mean score of the IGA</p> </li> </ul> </p> <p>One study that was only available as an abstract compared a shampoo containing urea, salicylic acid, glycolic acid, ichthyol pale and polidocanol to a coal tar shampoo (<a href="./references#CD009687-bbs2-0044" title="ReganaMS , MiradaA , TrullásC , DilméE . Increased efficacy and acceptability of a nonecoal tar shampoo for scalp psoriasis: Better efficacy and acceptability. 67th Annual Meeting of the American Academy of Dermatology, AAD San Francisco, CA United States. Conference Start: 20090306 Conference End: 20090310. Journal of the American Academy of Dermatology2009;60(3 Suppl 1):AB179. [EMBASE: 70142428] ">Regaña 2009</a>). The investigators found that 27 participants treated with the multi‐compound shampoo responded better than 10 other participants that applied a coal tar shampoo: mean 2.46 versus 1.80 (on a scale from 0 = poor to 3 = excellent efficacy). The measure of variance was not reported. Another study (N = 162 participants) compared participants treated with clobetasol propionate shampoo with those receiving a tar blend 1% shampoo (<a href="./references#CD009687-bbs2-0018" title="GriffithsC , BarkerJ , FinlayA , MizziF , ArsonnaudS . A new formulation of clobetasol proprionate is more effective and safer than 1% tar shampoo in scalp. Annales de Dermatologie et de Vénéréologie2002;129:1S740. GriffithsC , BarkerJ , FinlayA , MizziF , ArsonnaudS . A new formulation of clobetasol proprionate is safe and more effective than 1% tar shampoo in scalp psoriasis. Journal of the European Academy of Dermatology &amp; Venereology2002;16(Suppl 1):277. GriffithsCE , FinlayAY , FlemingCJ , BarkerJN , MizziF , ArsonnaudS . A randomized, investigator‐masked clinical evaluation of the efficacy and safety of clobetasol propionate 0.05% shampoo and tar blend 1% shampoo in the treatment of moderate to severe scalp psoriasis. Journal of Dermatological Treatment2006;17(2):90‐5. [MEDLINE: 16766333] ">Griffiths 2006</a>). On a scale from 0 = none to 5 = very severe scalp psoriasis, the clobetasol propionate group achieved a reduction from 3.4 to 1.9 (‐44%) whereas the tar blend group decreased from 3.5 to a mean of 3.0 (‐14%). The measure of variance was not reported. </p> <p>According to <a href="./references#CD009687-bbs2-0040" title="MonkBE , MasonRBS , MunroCS , DarleyCR . An open and single‐blind comparative assessment of unguentum cocois compound in the treatment of psoriasis of the scalp. Journal of Dermatological Treatment1995;6(3):159‐61. [EMBASE: 1995319726] ">Monk 1995</a>, which included 34 participants, the IGA of participants treated with "ung cocois co" improved by 73% compared with 42% improvement in participants treated with coal tar. The study authors did not report any measure of variance. </p> <p> <ul id="CD009687-list-0067"> <li> <p>Mean of the TSS (<a href="./references#CD009687-fig-0070" title="">Analysis 12.3</a>) </p> </li> </ul> </p> <p>Seven studies addressed the reduction of disease severity by measuring the mean change of TSS from baseline for a vast variety of treatments compared to tar preparations (<a href="./references#CD009687-bbs2-0018" title="GriffithsC , BarkerJ , FinlayA , MizziF , ArsonnaudS . A new formulation of clobetasol proprionate is more effective and safer than 1% tar shampoo in scalp. Annales de Dermatologie et de Vénéréologie2002;129:1S740. GriffithsC , BarkerJ , FinlayA , MizziF , ArsonnaudS . A new formulation of clobetasol proprionate is safe and more effective than 1% tar shampoo in scalp psoriasis. Journal of the European Academy of Dermatology &amp; Venereology2002;16(Suppl 1):277. GriffithsCE , FinlayAY , FlemingCJ , BarkerJN , MizziF , ArsonnaudS . A randomized, investigator‐masked clinical evaluation of the efficacy and safety of clobetasol propionate 0.05% shampoo and tar blend 1% shampoo in the treatment of moderate to severe scalp psoriasis. Journal of Dermatological Treatment2006;17(2):90‐5. [MEDLINE: 16766333] ">Griffiths 2006</a>; <a href="./references#CD009687-bbs2-0020" title="HeYL , GuoZP . Clinical efficacy of 0.1% tacrolimus ointment on plaque psoriasis of scalp and face. Journal of Clinical Dermatology2008;37(4):254‐5. [EMBASE: 2008250949] ">He 2008</a>; <a href="./references#CD009687-bbs2-0033" title="KlaberMR , McKinnonC . Calcipotriol (Dovonex©) scalp solution in the treatment of scalp psoriasis: comparative efficacy with 1% coal tar/1% coconut oil/0.5% salicylic acid (Capasal©) shampoo, and long‐term experience. Journal of Dermatological Treatment2000;11(1):21‐8. [EMBASE: 2000114933] ">Klaber 2000</a>; <a href="./references#CD009687-bbs2-0040" title="MonkBE , MasonRBS , MunroCS , DarleyCR . An open and single‐blind comparative assessment of unguentum cocois compound in the treatment of psoriasis of the scalp. Journal of Dermatological Treatment1995;6(3):159‐61. [EMBASE: 1995319726] ">Monk 1995</a>; <a href="./references#CD009687-bbs2-0052" title="Van deKerkhofPC , GreenC , HambergKJ , HutchinsonPE , JensenJK , KidsonP , et al. Safety and efficacy of combined high‐dose treatment with calcipotriol ointment and solution in patients with psoriasis. Dermatology2002;204(3):214‐21. [MEDLINE: 12037450] ">van de Kerkhof 2002</a>; <a href="./references#CD009687-bbs2-0055" title="WallARJ , BibbyAJ . Combined use of calcipotriol solution (50 ug/ml) and Polytar Liquid in scalp psoriasis (Abstract P‐689). Journal of the European Academy of Dermatology &amp; Venereology1999;12(Suppl 2):S337. ">Wall 1999</a>; <a href="./references#CD009687-bbs2-0058" title="WrightS , MannRJ . Comparison of a cream containing 0.1% dithranol in a 17% urea base (Psoradrate(TM)) with coal tar pomade in the treatment of scalp psoriasis. Clinical &amp; Experimental Dermatology1985;10(4):375‐8. [MEDLINE: 3899424] ">Wright 1985</a>). Tar, as a single preparation or in combination therapy, was less effective compared to each individual experimental treatment. Only coal tar in combination with calcipotriol showed a greater reduction (48%) than calcipotriol alone (41%) (<a href="./references#CD009687-bbs2-0055" title="WallARJ , BibbyAJ . Combined use of calcipotriol solution (50 ug/ml) and Polytar Liquid in scalp psoriasis (Abstract P‐689). Journal of the European Academy of Dermatology &amp; Venereology1999;12(Suppl 2):S337. ">Wall 1999</a>). In this study, all participants applied calcipotriol twice daily within a hydrophilic leave‐on and coal tar shampoo or a non‐medicated shampoo twice a week, depending on the study group to which they had been randomised. The measure of variance was not reported. </p> <p>We obtained data from another study by correspondence (<a href="./references#CD009687-bbs2-0002" title="BarrettC , LowsonD , BladesKJ . Limited benefit of combined use of tar‐based shampoo with 50 mug/ml calcipotriol solution in scalp psoriasis. Journal of Dermatological Treatment2005;16(3):175. [EMBASE: 2005434030] ">Barrett 2005</a>). It assessed the once‐daily use of a combination regimen of calcipotriol as solution together with either a tar‐based shampoo or a placebo shampoo. The number of participants was unknown. The authors reported that participants who received the tar‐based shampoo with calcipotriol solution had a significantly greater reduction in the mean TSS than those who used placebo shampoo with calcipotriol solution (P value = 0.04). The letter did not report TSS data in more detail. </p> </section> <section id="CD009687-sec-0181"> <h5 class="title">2) Quality of life</h5> <p>Data from <a href="./references#CD009687-bbs2-0002" title="BarrettC , LowsonD , BladesKJ . Limited benefit of combined use of tar‐based shampoo with 50 mug/ml calcipotriol solution in scalp psoriasis. Journal of Dermatological Treatment2005;16(3):175. [EMBASE: 2005434030] ">Barrett 2005</a>, which were obtained by letter, assessed the once‐daily use of a combination regimen of calcipotriol as solution together with either a tar‐based shampoo or a placebo shampoo. The number of participants was unknown. Quality of life improved in both treatment groups according to the Dermatology Life Quality Index (DLQI), but there was no significant difference between regimens. However, the correspondence did not report DLQI data in more detail. </p> </section> <section id="CD009687-sec-0182"> <h5 class="title">3) Number of participants withdrawing due to adverse events</h5> <p>Four tar‐controlled trials addressed this outcome (see <a href="./references#CD009687-fig-0071" title="">Analysis 12.4</a>). One that included 446 participants found a significantly lower risk of withdrawal in participants treated with a shampoo containing tar/coconut oil/salicylic acid (0.5%) compared to those treated with calcipotriol solution (RR 2.05; 95% CI 1.17 to 3.60) (<a href="./references#CD009687-bbs2-0033" title="KlaberMR , McKinnonC . Calcipotriol (Dovonex©) scalp solution in the treatment of scalp psoriasis: comparative efficacy with 1% coal tar/1% coconut oil/0.5% salicylic acid (Capasal©) shampoo, and long‐term experience. Journal of Dermatological Treatment2000;11(1):21‐8. [EMBASE: 2000114933] ">Klaber 2000</a>). Another study that included 88 participants found no significant difference in withdrawal rates between participants treated with calcipotriol and those treated with a tar/dithranol regimen (RR 1.15; 95% CI 0.07 to 17.75) (<a href="./references#CD009687-bbs2-0052" title="Van deKerkhofPC , GreenC , HambergKJ , HutchinsonPE , JensenJK , KidsonP , et al. Safety and efficacy of combined high‐dose treatment with calcipotriol ointment and solution in patients with psoriasis. Dermatology2002;204(3):214‐21. [MEDLINE: 12037450] ">van de Kerkhof 2002</a>). Also no significant difference was found in participants treated with clobetasol propionate and those who received a tar blend preparation (N = 162 participants; RR 1.03; 95% CI 0.04 to 24.87; <a href="./references#CD009687-bbs2-0018" title="GriffithsC , BarkerJ , FinlayA , MizziF , ArsonnaudS . A new formulation of clobetasol proprionate is more effective and safer than 1% tar shampoo in scalp. Annales de Dermatologie et de Vénéréologie2002;129:1S740. GriffithsC , BarkerJ , FinlayA , MizziF , ArsonnaudS . A new formulation of clobetasol proprionate is safe and more effective than 1% tar shampoo in scalp psoriasis. Journal of the European Academy of Dermatology &amp; Venereology2002;16(Suppl 1):277. GriffithsCE , FinlayAY , FlemingCJ , BarkerJN , MizziF , ArsonnaudS . A randomized, investigator‐masked clinical evaluation of the efficacy and safety of clobetasol propionate 0.05% shampoo and tar blend 1% shampoo in the treatment of moderate to severe scalp psoriasis. Journal of Dermatological Treatment2006;17(2):90‐5. [MEDLINE: 16766333] ">Griffiths 2006</a>), as well as in those who applied cocois or coal tar (N = 34 participants; RR 4.47; 95% CI 0.23 to 86.77; <a href="./references#CD009687-bbs2-0040" title="MonkBE , MasonRBS , MunroCS , DarleyCR . An open and single‐blind comparative assessment of unguentum cocois compound in the treatment of psoriasis of the scalp. Journal of Dermatological Treatment1995;6(3):159‐61. [EMBASE: 1995319726] ">Monk 1995</a>). In the latter study, two participants that applied cocois withdrew from the trial: one because of skin tightness, the other because of folliculitis. The other studies did not report which adverse event had led to withdrawal. </p> </section> <section id="CD009687-sec-0183"> <h5 class="title">Secondary outcomes</h5> <section id="CD009687-sec-0184"> <h6 class="title">1) Subjective reduction in severity of psoriasis</h6> <p> <ul id="CD009687-list-0068"> <li> <p>Number of participants achieving 'clearance' according to the PGA (<a href="./references#CD009687-fig-0072" title="">Analysis 12.5</a>) </p> </li> </ul> </p> <p>One tar‐controlled trial that included 88 participants addressed PGA clearance rates (<a href="./references#CD009687-bbs2-0052" title="Van deKerkhofPC , GreenC , HambergKJ , HutchinsonPE , JensenJK , KidsonP , et al. Safety and efficacy of combined high‐dose treatment with calcipotriol ointment and solution in patients with psoriasis. Dermatology2002;204(3):214‐21. [MEDLINE: 12037450] ">van de Kerkhof 2002</a>). There was no significant difference in the clearance between calcipotriol and a tar/dithranol combination regimen, according to participants' assessment (RR 3.43; 95% CI 0.14 to 81.93). </p> <p> <ul id="CD009687-list-0069"> <li> <p>Number of participants achieving 'response' according to the PGA (<a href="./references#CD009687-fig-0073" title="">Analysis 12.6</a>) </p> </li> </ul> </p> <p>One tar‐controlled trial (N = 88 participants) addressed PGA response rates (<a href="./references#CD009687-bbs2-0052" title="Van deKerkhofPC , GreenC , HambergKJ , HutchinsonPE , JensenJK , KidsonP , et al. Safety and efficacy of combined high‐dose treatment with calcipotriol ointment and solution in patients with psoriasis. Dermatology2002;204(3):214‐21. [MEDLINE: 12037450] ">van de Kerkhof 2002</a>). There was a significantly higher efficacy seen in calcipotriol compared to a tar/dithranol combination regimen, according to the participants' assessment (RR 1.72; 95% CI 1.07 to 2.76; NNTB = 5; 95% CI 3 to 24). </p> <p>We obtained information from another study in a letter (<a href="./references#CD009687-bbs2-0002" title="BarrettC , LowsonD , BladesKJ . Limited benefit of combined use of tar‐based shampoo with 50 mug/ml calcipotriol solution in scalp psoriasis. Journal of Dermatological Treatment2005;16(3):175. [EMBASE: 2005434030] ">Barrett 2005</a>). It assessed the once‐daily use of a combination regimen containing calcipotriol as solution together with either a tar‐based shampoo or a placebo shampoo. The number of participants was unknown. There was no significant difference between the treatment groups according to the patient‐assessed overall response. The letter did not contain more detailed information. </p> <p> <ul id="CD009687-list-0070"> <li> <p>Mean score of the PGA</p> </li> </ul> </p> <p>Three tar‐controlled studies addressed PGA as a continuous outcome without providing any measure of variance. <a href="./references#CD009687-bbs2-0018" title="GriffithsC , BarkerJ , FinlayA , MizziF , ArsonnaudS . A new formulation of clobetasol proprionate is more effective and safer than 1% tar shampoo in scalp. Annales de Dermatologie et de Vénéréologie2002;129:1S740. GriffithsC , BarkerJ , FinlayA , MizziF , ArsonnaudS . A new formulation of clobetasol proprionate is safe and more effective than 1% tar shampoo in scalp psoriasis. Journal of the European Academy of Dermatology &amp; Venereology2002;16(Suppl 1):277. GriffithsCE , FinlayAY , FlemingCJ , BarkerJN , MizziF , ArsonnaudS . A randomized, investigator‐masked clinical evaluation of the efficacy and safety of clobetasol propionate 0.05% shampoo and tar blend 1% shampoo in the treatment of moderate to severe scalp psoriasis. Journal of Dermatological Treatment2006;17(2):90‐5. [MEDLINE: 16766333] ">Griffiths 2006</a> reported mean scores at the end of treatment for participants receiving clobetasol propionate and those treated with tar blend (N = 162 participants). On a scale from 0 = no change to 5 = clear, the mean score of the clobetasol propionate group was 2.6 and the mean score of participants treated with tar blend was 0.9. In the study <a href="./references#CD009687-bbs2-0040" title="MonkBE , MasonRBS , MunroCS , DarleyCR . An open and single‐blind comparative assessment of unguentum cocois compound in the treatment of psoriasis of the scalp. Journal of Dermatological Treatment1995;6(3):159‐61. [EMBASE: 1995319726] ">Monk 1995</a>, which included 34 participants, PGA showed a mean improvement of 73% in participants treated with ung cocois co compared with 33% improvement in participants treated with coal tar. Another study compared a shampoo containing urea, salicylic acid, glycolic acid, ichthyol pale and polidocanol to a coal tar shampoo (<a href="./references#CD009687-bbs2-0044" title="ReganaMS , MiradaA , TrullásC , DilméE . Increased efficacy and acceptability of a nonecoal tar shampoo for scalp psoriasis: Better efficacy and acceptability. 67th Annual Meeting of the American Academy of Dermatology, AAD San Francisco, CA United States. Conference Start: 20090306 Conference End: 20090310. Journal of the American Academy of Dermatology2009;60(3 Suppl 1):AB179. [EMBASE: 70142428] ">Regaña 2009</a>). The investigators found that 27 participants treated with the multi‐compound shampoo responded better than 10 other participants who were applying a coal tar shampoo: mean 2.63 versus 1.70 (on a scale from 0 = poor to 3 = excellent efficacy). </p> </section> <section id="CD009687-sec-0185"> <h6 class="title">2) Number of participants with at least one adverse event</h6> <p>Please see <a href="./references#CD009687-fig-0074" title="">Analysis 12.7</a> </p> <section id="CD009687-sec-0186"> <p><b>Calcipotriol versus tar/dithranol combination regimen (hydro/lipophilic leave‐on combination)</b></p> <p>One study found no significant difference in the incidence of adverse events between the treatments (N = 87 participants; RR 1.54; 95% CI 0.95 to 2.51) (<a href="./references#CD009687-bbs2-0052" title="Van deKerkhofPC , GreenC , HambergKJ , HutchinsonPE , JensenJK , KidsonP , et al. Safety and efficacy of combined high‐dose treatment with calcipotriol ointment and solution in patients with psoriasis. Dermatology2002;204(3):214‐21. [MEDLINE: 12037450] ">van de Kerkhof 2002</a>). Both treatment groups experienced disorders of the skin and appendages, the central and peripheric nervous system and the respiratory system, among others. </p> </section> <section id="CD009687-sec-0187"> <p><b>Calcipotriol in a hydrophilic leave‐on versus coal tar/coconut oil/salicylic acid (0.5%) in a rinse‐off preparation</b></p> <p>One study that included 445 participants found a significantly higher risk of adverse events for participants treated with calcipotriol solution compared to those treated with a shampoo containing tar/coconut oil/salicylic acid (0.5%) (RR 1.66; 95% CI 1.35 to 2.05) (<a href="./references#CD009687-bbs2-0033" title="KlaberMR , McKinnonC . Calcipotriol (Dovonex©) scalp solution in the treatment of scalp psoriasis: comparative efficacy with 1% coal tar/1% coconut oil/0.5% salicylic acid (Capasal©) shampoo, and long‐term experience. Journal of Dermatological Treatment2000;11(1):21‐8. [EMBASE: 2000114933] ">Klaber 2000</a>). Participants mainly experienced lesional and peri‐lesional irritation. </p> <p>In the study by <a href="./references#CD009687-bbs2-0018" title="GriffithsC , BarkerJ , FinlayA , MizziF , ArsonnaudS . A new formulation of clobetasol proprionate is more effective and safer than 1% tar shampoo in scalp. Annales de Dermatologie et de Vénéréologie2002;129:1S740. GriffithsC , BarkerJ , FinlayA , MizziF , ArsonnaudS . A new formulation of clobetasol proprionate is safe and more effective than 1% tar shampoo in scalp psoriasis. Journal of the European Academy of Dermatology &amp; Venereology2002;16(Suppl 1):277. GriffithsCE , FinlayAY , FlemingCJ , BarkerJN , MizziF , ArsonnaudS . A randomized, investigator‐masked clinical evaluation of the efficacy and safety of clobetasol propionate 0.05% shampoo and tar blend 1% shampoo in the treatment of moderate to severe scalp psoriasis. Journal of Dermatological Treatment2006;17(2):90‐5. [MEDLINE: 16766333] ">Griffiths 2006</a>, which included 162 participants, 11 participants in the clobetasol propionate group experienced burning, pruritus, tingling or unacceptable worsening of psoriasis, and one participant in the tar blend group reported mild tightness and burning on the scalp but the difference was not significant (RR 3.73; 95% CI 0.50 to 27.99). </p> </section> <section id="CD009687-sec-0188"> <p><b>Tacrolimus versus pine tar (lipophilic leave‐ons)</b></p> <p>One study found no significant difference in the risk of adverse events between the treatments (N = 40 participants; RR 0.33; 95% CI 0.04 to 2.94) (<a href="./references#CD009687-bbs2-0020" title="HeYL , GuoZP . Clinical efficacy of 0.1% tacrolimus ointment on plaque psoriasis of scalp and face. Journal of Clinical Dermatology2008;37(4):254‐5. [EMBASE: 2008250949] ">He 2008</a>). </p> </section> <section id="CD009687-sec-0189"> <p><b>Dithranol/urea combination versus coal tar plus salicylic acid (2%) combination (lipophilic leave‐ons)</b></p> <p>One study found a significantly higher risk of adverse events for participants treated with a dithranol/urea combination compared to those treated with a coal tar/salicylic acid (2%) combination therapy (N = 38 participants; RR 16.67; 95% CI 2.44 to 113.85) (<a href="./references#CD009687-bbs2-0058" title="WrightS , MannRJ . Comparison of a cream containing 0.1% dithranol in a 17% urea base (Psoradrate(TM)) with coal tar pomade in the treatment of scalp psoriasis. Clinical &amp; Experimental Dermatology1985;10(4):375‐8. [MEDLINE: 3899424] ">Wright 1985</a>). Stinging and burning occurred with both treatments. However, only dithranol caused skin staining. </p> </section> <section id="CD009687-sec-0190"> <p><b>Cocois versus coal tar (lipophilic leave‐on versus rinse‐off)</b></p> <p>One study that included 34 participants found no significant difference in the risk of adverse events between the treatments (RR 1.78; 95% CI 0.18 to 17.80) (<a href="./references#CD009687-bbs2-0040" title="MonkBE , MasonRBS , MunroCS , DarleyCR . An open and single‐blind comparative assessment of unguentum cocois compound in the treatment of psoriasis of the scalp. Journal of Dermatological Treatment1995;6(3):159‐61. [EMBASE: 1995319726] ">Monk 1995</a>). The participants experienced tightness of the skin, folliculitis or irritation. </p> <p><i>Calcipotriol/tar versus calcipotriol/placebo (hydrophilic leave‐on/shampoo versus hydrophilic leave‐on/shampoo)</i> </p> <p>We obtained information from another study by letter (<a href="./references#CD009687-bbs2-0002" title="BarrettC , LowsonD , BladesKJ . Limited benefit of combined use of tar‐based shampoo with 50 mug/ml calcipotriol solution in scalp psoriasis. Journal of Dermatological Treatment2005;16(3):175. [EMBASE: 2005434030] ">Barrett 2005</a>). The authors assessed the once‐daily use of a combination regimen containing calcipotriol in solution together with either tar‐based shampoo or placebo shampoo. The number of participants was unknown. The authors stated that adverse events were similar and acceptable among the treatment groups, but did not provide more detailed information. </p> </section> </section> </section> </section> <section id="CD009687-sec-0191"> <h4 class="title">13. Steroid: vehicle comparisons</h4> <section id="CD009687-sec-0192"> <h5 class="title">Primary outcomes</h5> <section id="CD009687-sec-0193"> <h6 class="title">1) Reduction in clinician‐assessed severity</h6> <p> <ul id="CD009687-list-0071"> <li> <p>Number of participants achieving 'clearance' according to the IGA (<a href="./references#CD009687-fig-0075" title="">Analysis 13.1</a>) </p> </li> </ul> </p> <p><i>Rinse‐off versus rinse‐off</i> </p> <p>In the study <a href="./references#CD009687-bbs2-0028" title="JosseM , MengeaudV , KhemisA . Efficacy of a new keratolytic shampoo containing glycolic acid and ictyol for the treatment of scalp psoriasis: results of a comparative study (Abstract P1604). Journal of the American Academy of Dermatology2006;54(3 Suppl):AB128. JosseM , MengeaudV , KhemisA , OrtonneJP . Efficacy of a new keratolytic shampoo containing glycolic acid and ictyol for the treatment of scalp psoriasis ‐ results of a comparative study (Abstract P16.34). Journal of the European Academy of Dermatology &amp; Venereology2005;19(Suppl 2):391. ">Josse 2005</a>, the experimental group applied betamethasone dipropionate lotion plus RV3423A shampoo alternated with extra gentle shampoo every day. The control group received the combination of betamethasone dipropionate lotion plus extra gentle shampoo alone. There was no significant difference between the treatment regimens in clearing scalp psoriasis (N = 79 participants; RR 1.63; 95% CI 0.65 to 4.04). </p> <p> <ul id="CD009687-list-0072"> <li> <p>Number of participants achieving 'response' according to the IGA (<a href="./references#CD009687-fig-0076" title="">Analysis 13.2</a>) </p> </li> </ul> </p> <section id="CD009687-sec-0194"> <p><b>Foam versus lotion</b></p> <p>The study <a href="./references#CD009687-bbs2-0013" title="FranzTJ , ParsellDA , HalualaniRM , HanniganJF , KalbachJP , HarkonenWS . Betamethasone valerate foam 0.12%: a novel vehicle with enhanced delivery and efficacy. International Journal of Dermatology1999;38(8):628‐32. [MEDLINE: 10487457] ">Franz 1999</a> found betamethasone valerate 0.1% to be significantly more effective within a foam preparation than within a lotion (N = 115 participants; RR 1.55; 95% CI 1.12 to 2.13; NNTB = 4; 95% CI 3 to 13). </p> </section> <section id="CD009687-sec-0195"> <p><b>Foam versus solution</b></p> <p>The study <a href="./references#CD009687-bbs2-0014" title="FranzTJ , ParsellDA , MyersJA , HanniganJF . Clobetasol propionate foam 0.05%: a novel vehicle with enhanced delivery. International Journal of Dermatology2000;39(7):535‐8. [MEDLINE: 10940121] ">Franz 2000</a> found the efficacy of clobetasol propionate to be no different whether in a foam preparation or a solution (N = 125 participants; RR 1.17; 95% CI 0.92 to 1.48). </p> <p> <ul id="CD009687-list-0073"> <li> <p>Mean of the TSS (<a href="./references#CD009687-fig-0077" title="">Analysis 13.3</a>) </p> </li> </ul> </p> <p>Six studies addressed the reduction of disease severity by measuring the mean change of TSS from baseline. Clobetasol propionate as a hydrophilic leave‐on vehicle led to a greater decrease in TSS than as a rinse‐off shampoo (<a href="./references#CD009687-bbs2-0001" title="AndresP , PoncetM , FarzanehS , SotoP . Short‐term safety assessment of clobetasol propionate 0.05% shampoo: hypothalamic‐pituitary‐adrenal axis suppression, atrophogenicity, and ocular safety in subjects with scalp psoriasis. Journal of Drugs in Dermatology2006;5(4):328‐32. [MEDLINE: 16673799] ">Andres 2006</a>; <a href="./references#CD009687-bbs2-0045" title="ReygagneP , DiaconuJ , PrèsH , ErnstTM , MeyerKG . Efficacy and safety comparison of clobetasol proprionate shampoo, gel and vehicle in scalp psoriasis. Journal of the European Academy of Dermatology &amp; Venereology2002;16(Suppl 1):283. ">Reygagne 2002</a>). Foam was superior to a lotion or a solution, whether with clobetasol propionate or betamethasone valerate 0.1% as active agent (<a href="./references#CD009687-bbs2-0013" title="FranzTJ , ParsellDA , HalualaniRM , HanniganJF , KalbachJP , HarkonenWS . Betamethasone valerate foam 0.12%: a novel vehicle with enhanced delivery and efficacy. International Journal of Dermatology1999;38(8):628‐32. [MEDLINE: 10487457] ">Franz 1999</a>; <a href="./references#CD009687-bbs2-0014" title="FranzTJ , ParsellDA , MyersJA , HanniganJF . Clobetasol propionate foam 0.05%: a novel vehicle with enhanced delivery. International Journal of Dermatology2000;39(7):535‐8. [MEDLINE: 10940121] ">Franz 2000</a>). Betamethasone dipropionate with RV3423A shampoo and extra gentle shampoo in daily alternation led to a 10% higher reduction in TSS than with extra gentle shampoo alone (<a href="./references#CD009687-bbs2-0028" title="JosseM , MengeaudV , KhemisA . Efficacy of a new keratolytic shampoo containing glycolic acid and ictyol for the treatment of scalp psoriasis: results of a comparative study (Abstract P1604). Journal of the American Academy of Dermatology2006;54(3 Suppl):AB128. JosseM , MengeaudV , KhemisA , OrtonneJP . Efficacy of a new keratolytic shampoo containing glycolic acid and ictyol for the treatment of scalp psoriasis ‐ results of a comparative study (Abstract P16.34). Journal of the European Academy of Dermatology &amp; Venereology2005;19(Suppl 2):391. ">Josse 2005</a>). The measurement of variance was not reported in any study. </p> <p>One study that assessed 70 participants compared mometasone furoate within an emulsion (LAS41002) with the same steroid within a solution (<a href="./references#CD009687-bbs2-0056" title="WilhemKP , OckerG , TebbsV , GuilabertA . A new mometasone formulation (LAS 41002 emulsion with 36% water content) is effective, well tolerated and cosmetically acceptable in the treatment of scalp psoriasis. Abstract ‐ 22nd Congress of the European Academy of Dermatology and Venereology, 2‐6 October 2013, Istanbul. Journal of the European Academy of Dermatology &amp; Venereology. 2013. ">Wilhelm 2013</a>). The study could not be sufficiently analysed, because it was only available as an abstract and a power‐point presentation. For instance, the number of participants per treatment group remained unclear. The authors stated that there was no significant difference between regimens (mean ratio 0.97; 95% CI 0.85 to 1.10). </p> </section> </section> <section id="CD009687-sec-0196"> <h6 class="title">2) Quality of life</h6> <section id="CD009687-sec-0197"> <p><b>Foam versus solution</b></p> <p><a href="./references#CD009687-bbs2-0003" title="BergstromKG , ArambulaK , KimballAB . Medication formulation affects quality of life: a randomized single‐blind study of clobetasol propionate foam 0.05% compared with a combined program of clobetasol cream 0.05% and solution 0.05% for the treatment of psoriasis. Cutis2003;72(5):407‐11. [MEDLINE: 14655784] ">Bergstrom 2003</a> compared the treatment efficacy and improvement in quality of life of 32 participants receiving either clobetasol propionate within foam or within a combination regimen of cream and solution. The findings could not be sufficiently analysed, because the sample size of each treatment group was not provided. The quality of life was measured by two scores, the EQ‐5D and the DLQI. In the former score, clobetasol propionate in a foam preparation showed a stronger improvement in quality of life than when applied within a solution. However, the improvement according to the DLQI was not significantly different between the vehicles. </p> </section> </section> <section id="CD009687-sec-0198"> <h6 class="title">3) Number of participants withdrawing due to adverse events</h6> <section id="CD009687-sec-0199"> <p><b>Foam versus lotion</b></p> <p>In the study <a href="./references#CD009687-bbs2-0013" title="FranzTJ , ParsellDA , HalualaniRM , HanniganJF , KalbachJP , HarkonenWS . Betamethasone valerate foam 0.12%: a novel vehicle with enhanced delivery and efficacy. International Journal of Dermatology1999;38(8):628‐32. [MEDLINE: 10487457] ">Franz 1999</a>, which assessed 115 participants, none of the participants, whether treated with betamethasone valerate 0.1% within a foam preparation or a lotion, withdrew due to adverse events. </p> </section> </section> </section> <section id="CD009687-sec-0200"> <h5 class="title">Secondary outcomes</h5> <section id="CD009687-sec-0201"> <h6 class="title">1) Subjective reduction in severity of psoriasis</h6> <p> <ul id="CD009687-list-0074"> <li> <p>Number of participants achieving 'response' according to the PGA (<a href="./references#CD009687-fig-0078" title="">Analysis 13.4</a>) </p> </li> </ul> </p> <section id="CD009687-sec-0202"> <p><b>Foam versus lotion</b></p> <p>According to <a href="./references#CD009687-bbs2-0013" title="FranzTJ , ParsellDA , HalualaniRM , HanniganJF , KalbachJP , HarkonenWS . Betamethasone valerate foam 0.12%: a novel vehicle with enhanced delivery and efficacy. International Journal of Dermatology1999;38(8):628‐32. [MEDLINE: 10487457] ">Franz 1999</a>, betamethasone valerate 0.1% was significantly more effective as a foam preparation than as a lotion, according to the participants' assessment (N = 115 participants; RR 1.66; 95% CI 1.22 to 2.26; NNTB = 4; 95% CI 3 to 8). </p> </section> <section id="CD009687-sec-0203"> <p><b>Foam versus solution</b></p> <p><a href="./references#CD009687-bbs2-0014" title="FranzTJ , ParsellDA , MyersJA , HanniganJF . Clobetasol propionate foam 0.05%: a novel vehicle with enhanced delivery. International Journal of Dermatology2000;39(7):535‐8. [MEDLINE: 10940121] ">Franz 2000</a> found the efficacy of clobetasol propionate to be no different whether in a foam preparation or a solution, according to the participants' assessment (N = 125 participants; RR 1.16; 95% CI 0.88 to 1.53). </p> </section> </section> <section id="CD009687-sec-0204"> <h6 class="title">2) Number of participants with at least one adverse event</h6> <section id="CD009687-sec-0205"> <p><b>Rinse‐off versus hydrophilic leave‐on</b></p> <p>According to the study <a href="./references#CD009687-bbs2-0045" title="ReygagneP , DiaconuJ , PrèsH , ErnstTM , MeyerKG . Efficacy and safety comparison of clobetasol proprionate shampoo, gel and vehicle in scalp psoriasis. Journal of the European Academy of Dermatology &amp; Venereology2002;16(Suppl 1):283. ">Reygagne 2002</a>, the risk of adverse events did not significantly differ between participants treated with clobetasol propionate as a rinse‐off vehicle and a hydrophilic leave‐on (N = 124 participants; RR 1.94; 95% CI 95% CI 0.18 to 20.81). Most participants reported mild stinging or burning and one person who used clobetasol propionate shampoo experienced moderate folliculitis. See <a href="./references#CD009687-fig-0079" title="">Analysis 13.5</a>. </p> <p>One study (N = 172 participants) compared two vehicles, foam and solution, that contained betamethasone valerate 0.1% as active agent (<a href="./references#CD009687-bbs2-0013" title="FranzTJ , ParsellDA , HalualaniRM , HanniganJF , KalbachJP , HarkonenWS . Betamethasone valerate foam 0.12%: a novel vehicle with enhanced delivery and efficacy. International Journal of Dermatology1999;38(8):628‐32. [MEDLINE: 10487457] ">Franz 1999</a>). Adverse events included a stinging and burning sensation, as well as pruritus on the scalp. Another study (N = 32 participants) stated that clobetasol propionate foam caused a minimal burning sensation after application, compared to clobetasol propionate solution (<a href="./references#CD009687-bbs2-0003" title="BergstromKG , ArambulaK , KimballAB . Medication formulation affects quality of life: a randomized single‐blind study of clobetasol propionate foam 0.05% compared with a combined program of clobetasol cream 0.05% and solution 0.05% for the treatment of psoriasis. Cutis2003;72(5):407‐11. [MEDLINE: 14655784] ">Bergstrom 2003</a>). However, the authors of both studies did not report the number of participants from each group that experienced at least one adverse event. </p> </section> <section id="CD009687-sec-0206"> <p><b>Emulsion versus solution</b></p> <p>One study that assessed 70 participants compared mometasone furoate within an emulsion (LAS41002) with mometasone furoate within a solution (<a href="https://email.charite.de/owa/UrlBlockedError.aspx" target="_blank">Wilhem 2013</a>). The study could not be sufficiently analysed, because it was only available as an abstract and power‐point presentation. The authors stated that in both groups together a total of three serious and eight non‐serious adverse events occurred. They were classified as unlikely to be related to the study drug. </p> </section> </section> </section> </section> <section id="CD009687-sec-0207"> <h4 class="title">14. Other steroid and salicylic acid containing comparisons</h4> <section id="CD009687-sec-0208"> <h5 class="title">Primary outcomes</h5> <section id="CD009687-sec-0209"> <h6 class="title">1) Reduction in clinician‐assessed severity</h6> <p> <ul id="CD009687-list-0075"> <li> <p>Number of participants achieving 'clearance' according to the IGA (<a href="./references#CD009687-fig-0080" title="">Analysis 14.1</a>) </p> </li> </ul> </p> <section id="CD009687-sec-0210"> <p><b>Betamethasone dipropionate plus salicylic acid (2%) versus triamcinolone acetonide 0.2% plus salicylic acid (2%) (hydrophilic leave‐ons)</b></p> <p>One study found salicylic acid (2%) in a combination with betamethasone dipropionate to be significantly more effective than in a combination with triamcinolone acetonide 0.2% in clearing scalp psoriasis (N = 61 participants; RR 2.64; 95% CI 1.47 to 4.74; NNTB = 3; 95% CI 2 to 4) (<a href="./references#CD009687-bbs2-0015" title="FredrikssonT . A clinical comparison of 3 corticosteroid alcoholic solutions in the treatment of psoriasis of the scalp. Pharmatherapeutica1976;1(4):252‐6. [EMBASE: 0977155168] ">Fredriksson 1976</a>). </p> </section> <section id="CD009687-sec-0211"> <p><b>Betamethasone dipropionate plus salicylic acid versus betamethasone valerate 0.1% (hydrophilic leave‐ons)</b></p> <p>Two studies reported this outcome for a total of 115 participants treated either with betamethasone dipropionate in a combination with salicylic acid (2%) or with betamethasone valerate 0.1% as a single preparation (<a href="./references#CD009687-bbs2-0006" title="CurleyRK , VickersCF , NorrisT , GloverDR . A comparative study of betamethasone dipropionate with salicylic acid and betamethasone valerate for the treatment of steroid‐responsive dermatoses of the scalp. Journal of Dermatological Treatment1990;1(4):203‐6. [EMBASE: 1990343409] ">Curley 1990</a>; <a href="./references#CD009687-bbs2-0021" title="HillstromL , PetterssonL . Studies with betamethasone dipropionate lotion with salicylic acid (Diprosalic) in psoriasis and seborrhoic eczema of the scalp. Current Therapeutic Research ‐ Clinical and Experimental1978;24(1):46‐50. [EMBASE: 0979244015] ">Hillstrom 1978</a>). Meta‐analysis indicated no significant difference between the treatment groups (RR 1.40; 95% CI 0.59 to 3.32). Heterogeneity among the studies was not important (I² = 28%). </p> </section> <section id="CD009687-sec-0212"> <p><b>Betamethasone dipropionate plus salicylic acid versus clobetasol propionate (hydrophilic leave‐ons)</b></p> <p>One study compared the combination of betamethasone dipropionate and salicylic acid (2%) with clobetasol propionate monotherapy (<a href="./references#CD009687-bbs2-0022" title="HillstromL , PetterssonL , SvenssonL . Comparison of betamethasone dipropionate lotion with salicylic acid (Diprosalic(TM)) and clobetasol propionate lotion (Dermovate(TM)) in the treatment of psoriasis of the scalp. Journal of International Medical Research1982;10(6):419‐22. [MEDLINE: 7152080] ">Hillstrom 1982</a>). Even though there was no statistically significant difference, the two‐compound combination tended to lead more often to clearing of psoriatic scalp lesions than clobetasol propionate (N = 50 participants; RR 1.40; 95% CI 0.97 to 2.01). </p> </section> <section id="CD009687-sec-0213"> <p><b>Betamethasone dipropionate versus triamcinolone acetonide 0.2% plus salicylic acid (2%) (hydrophilic leave‐ons)</b></p> <p>Betamethasone dipropionate as monotherapy was significantly more effective than the two‐compound combination in clearing psoriatic scalp lesions (N = 60 participants; RR 2.26; 955 CI 1.23 to 4.16; NNTB = 3; 95% CI 2 to 8; <a href="./references#CD009687-bbs2-0015" title="FredrikssonT . A clinical comparison of 3 corticosteroid alcoholic solutions in the treatment of psoriasis of the scalp. Pharmatherapeutica1976;1(4):252‐6. [EMBASE: 0977155168] ">Fredriksson 1976</a>). </p> <p> <ul id="CD009687-list-0076"> <li> <p>Number of participants achieving 'response' according to the IGA (<a href="./references#CD009687-fig-0081" title="">Analysis 14.2</a>) </p> </li> </ul> </p> </section> <section id="CD009687-sec-0214"> <p><b>Betamethasone dipropionate plus salicylic acid (2%) versus triamcinolone acetonide 0.2% plus salicylic acid (hydrophilic leave‐ons)</b></p> <p>The two‐compound product including betamethasone dipropionate was significantly more effective (RR 1.61; 95% CI 1.17 to 2.20; N = 61 participants; NNTB = 3; 95% CI 2 to 7; <a href="./references#CD009687-bbs2-0015" title="FredrikssonT . A clinical comparison of 3 corticosteroid alcoholic solutions in the treatment of psoriasis of the scalp. Pharmatherapeutica1976;1(4):252‐6. [EMBASE: 0977155168] ">Fredriksson 1976</a>). </p> </section> <section id="CD009687-sec-0215"> <p><b>Betamethasone dipropionate versus triamcinolone acetonide 0.2% plus salicylic acid (2%) (hydrophilic leave‐ons)</b></p> <p>The two‐compound combination was shown to be significantly less effective than betamethasone dipropionate as monotherapy (N = 60 participants; RR 1.48; 95% CI 1.06 to 2.07; NNTB = 4; 95% CI 3 to 15; <a href="./references#CD009687-bbs2-0015" title="FredrikssonT . A clinical comparison of 3 corticosteroid alcoholic solutions in the treatment of psoriasis of the scalp. Pharmatherapeutica1976;1(4):252‐6. [EMBASE: 0977155168] ">Fredriksson 1976</a>). </p> <p> <ul id="CD009687-list-0077"> <li> <p>Mean of the TSS</p> </li> </ul> </p> <p>One study, which compared the combination of desoximetasone 0.25% and salicylic acid (1%) with betamethasone valerate 0.1%, addressed the reduction of disease severity by measuring the mean change of TSS from baseline (<a href="./references#CD009687-bbs2-0023" title="HillstromL . Comparison of topical treatment with desoxymethasone solution 0.25% with salicylic acid 1% and betamethasone valerate solution 0.1% in patients with psoriasis of the scalp. Journal of International Medical Research1984;12(3):170‐3. [MEDLINE: 6734919] ">Hillstrom 1984</a>). The two‐compound combination showed a higher reduction of disease severity (78%) compared to betamethasone valerate 0.1% (56%). The measurement of variance was not reported. </p> </section> </section> <section id="CD009687-sec-0216"> <h6 class="title">2) Number of participants withdrawing due to adverse events</h6> <section id="CD009687-sec-0217"> <p><b>Betamethasone dipropionate plus salicylic acid versus clobetasol propionate (hydrophilic leave‐ons)</b></p> <p>There was no significant difference in the risk of withdrawal due to adverse events between the treatment groups (N = 50 participants; RR 0.33; 95% CI 0.01 to 7.81; <a href="./references#CD009687-bbs2-0022" title="HillstromL , PetterssonL , SvenssonL . Comparison of betamethasone dipropionate lotion with salicylic acid (Diprosalic(TM)) and clobetasol propionate lotion (Dermovate(TM)) in the treatment of psoriasis of the scalp. Journal of International Medical Research1982;10(6):419‐22. [MEDLINE: 7152080] ">Hillstrom 1982</a>). The authors did not state the sort of adverse event that caused discontinuation of the therapy. See <a href="./references#CD009687-fig-0082" title="">Analysis 14.3</a>. </p> </section> <section id="CD009687-sec-0218"> <p><b>Betamethasone dipropionate plus salicylic acid versus triamcinolone acetonide 0.2% plus salicylic acid (hydrophilic leave‐ons)</b></p> <p>No participant withdrew because of adverse events (<a href="./references#CD009687-bbs2-0015" title="FredrikssonT . A clinical comparison of 3 corticosteroid alcoholic solutions in the treatment of psoriasis of the scalp. Pharmatherapeutica1976;1(4):252‐6. [EMBASE: 0977155168] ">Fredriksson 1976</a>). </p> </section> <section id="CD009687-sec-0219"> <p><b>Betamethasone dipropionate versus triamcinolone acetonide 0.2% plus salicylic acid (hydrophilic leave‐ons)</b></p> <p>No participant withdrew because of adverse events (<a href="./references#CD009687-bbs2-0015" title="FredrikssonT . A clinical comparison of 3 corticosteroid alcoholic solutions in the treatment of psoriasis of the scalp. Pharmatherapeutica1976;1(4):252‐6. [EMBASE: 0977155168] ">Fredriksson 1976</a>). </p> </section> </section> </section> <section id="CD009687-sec-0220"> <h5 class="title">Secondary outcomes</h5> <section id="CD009687-sec-0221"> <h6 class="title">1) Number of participants with at least one adverse event</h6> <section id="CD009687-sec-0222"> <p><b>Steroid plus salicylic acid versus a different steroid alone</b></p> <p>Four studies that compared a steroid and salicylic acid (2%) combination with a steroid alone addressed this outcome for a total of 258 participants. </p> <p>One study provided data for two different two‐compound combinations compared with a steroid (<a href="./references#CD009687-bbs2-0015" title="FredrikssonT . A clinical comparison of 3 corticosteroid alcoholic solutions in the treatment of psoriasis of the scalp. Pharmatherapeutica1976;1(4):252‐6. [EMBASE: 0977155168] ">Fredriksson 1976</a>). The steroids assessed in each individual comparison varied from study to study. In two trials in which adverse events occurred, there was no significant difference whether participants were treated with the two‐compound combination or with a steroid alone: <a href="./references#CD009687-bbs2-0021" title="HillstromL , PetterssonL . Studies with betamethasone dipropionate lotion with salicylic acid (Diprosalic) in psoriasis and seborrhoic eczema of the scalp. Current Therapeutic Research ‐ Clinical and Experimental1978;24(1):46‐50. [EMBASE: 0979244015] ">Hillstrom 1978</a> (RR 0.50; 95% CI 0.05 to 5.29); <a href="./references#CD009687-bbs2-0022" title="HillstromL , PetterssonL , SvenssonL . Comparison of betamethasone dipropionate lotion with salicylic acid (Diprosalic(TM)) and clobetasol propionate lotion (Dermovate(TM)) in the treatment of psoriasis of the scalp. Journal of International Medical Research1982;10(6):419‐22. [MEDLINE: 7152080] ">Hillstrom 1982</a> (RR 0.50; 95% CI 0.05 to 5.17). Common adverse events were pruritus, burning and itching. See <a href="./references#CD009687-fig-0083" title="">Analysis 14.4</a>. </p> <p>In the other two comparisons, no adverse events occurred (<a href="./references#CD009687-bbs2-0015" title="FredrikssonT . A clinical comparison of 3 corticosteroid alcoholic solutions in the treatment of psoriasis of the scalp. Pharmatherapeutica1976;1(4):252‐6. [EMBASE: 0977155168] ">Fredriksson 1976</a>; <a href="./references#CD009687-bbs2-0023" title="HillstromL . Comparison of topical treatment with desoxymethasone solution 0.25% with salicylic acid 1% and betamethasone valerate solution 0.1% in patients with psoriasis of the scalp. Journal of International Medical Research1984;12(3):170‐3. [MEDLINE: 6734919] ">Hillstrom 1984</a>). </p> </section> </section> </section> </section> <section id="CD009687-sec-0223"> <h4 class="title">15. Antifungals versus vehicle</h4> <p>One study that included 40 participants compared ciclopirox olamine with its vehicle (<a href="./references#CD009687-bbs2-0048" title="ShuttleworthD , GallowayDB , BoormanGC , DonaldAE . A double‐blind, placebo‐controlled study of the clinical efficacy of ciclopirox olamine (1.5%) shampoo for the control of scalp psoriasis. Journal of Dermatological Treatment1998;9(3):163‐7. [EMBASE: 1998346163] ">Shuttleworth 1998</a>). </p> <section id="CD009687-sec-0224"> <h5 class="title">Primary outcomes</h5> <section id="CD009687-sec-0225"> <h6 class="title">1) Reduction in clinician‐assessed severity</h6> <p> <ul id="CD009687-list-0078"> <li> <p>Mean score of the IGA (<a href="./references#CD009687-fig-0084" title="">Analysis 15.1</a>) </p> </li> </ul> </p> <p>There was no significant difference between ciclopirox olamine and its vehicle for this outcome (MD ‐0.19; 95% CI ‐2.00 to 1.62). </p> </section> <section id="CD009687-sec-0226"> <h6 class="title">2) Number of participants withdrawing due to adverse events</h6> <p>There was no significant difference between ciclopirox olamine and the vehicle for this outcome (RR 0.08; 95% CI 0.00 to 1.55). Both participants that discontinued treatment had received the vehicle and experienced severe pruritus and increased scaling. See <a href="./references#CD009687-fig-0085" title="">Analysis 15.2</a>. </p> </section> </section> <section id="CD009687-sec-0227"> <h5 class="title">Secondary outcomes</h5> <section id="CD009687-sec-0228"> <h6 class="title">1) Subjective reduction in severity of psoriasis</h6> <p> <ul id="CD009687-list-0079"> <li> <p>Mean score of the PGA (<a href="./references#CD009687-fig-0086" title="">Analysis 15.3</a>) </p> </li> </ul> </p> <p>There was no significant difference between ciclopirox olamine and the vehicle for this participant‐assessed outcome (MD 0.11; 95% CI ‐0.52 to 0.74). </p> </section> <section id="CD009687-sec-0229"> <h6 class="title">2) Number of participants with at least one adverse event</h6> <p>There was no significant difference between ciclopirox olamine and the vehicle for this outcome (RR 1.33; 95% CI 0.32 to 5.44). The authors believed that most adverse events were not treatment‐related. However, one participant that applied ciclopirox suffered from psoriasis spreading to his forehead and cheeks, while another that received the vehicle reported severe pruritus. See <a href="./references#CD009687-fig-0087" title="">Analysis 15.4</a>. </p> </section> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD009687-sec-0230" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD009687-sec-0230">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD009687-sec-0294">Español</a> </li> </nav> </div> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD009687-sec-0230"></div> <section id="CD009687-sec-0231"> <h3 class="title" id="CD009687-sec-0231">Summary of main results</h3> <p>This review summarises the evidence of the efficacy and safety of topical treatments for scalp psoriasis. We grouped all 59 included studies into 15 main comparisons of which four were vehicle‐controlled. The other 11 head‐to‐head comparisons investigated either single preparations (e.g. steroid versus vitamin D) or analysed combination therapies (e.g. calcipotriol versus coal tar or coconut oil or salicylic acid). In particular, we also included comparisons that included corticosteroids of similar or different potency. Furthermore, we included one study that evaluated once versus twice‐daily use of corticosteroids and studies that assessed corticosteroids in different vehicles. Thirty studies (51%) were either conducted or sponsored by the manufacturer of the study medication. However, not all studies stated their source of financial support. </p> <section id="CD009687-sec-0232"> <h4 class="title">Efficacy</h4> <p>The evaluation of efficacy is based on outcomes that compared the number of participants where psoriatic scalp lesions responded or cleared due to the individual therapy. Efficacy was assessed either by the investigator or the participant and sometimes by both. However, investigators and participants rated the efficacy of the individual treatments similarly. </p> <section id="CD009687-sec-0233"> <h5 class="title">Vehicle‐controlled comparisons</h5> <p>Based on the results of the studies, corticosteroids, vitamin D and their combination product were all more effective than their vehicle in clearing and reducing scalp psoriasis. In a small trial, ciclopirox olamine was not different to the vehicle in reducing scalp psoriasis. </p> </section> <section id="CD009687-sec-0234"> <h5 class="title">Head‐to‐head comparisons</h5> <p>Corticosteroids of high and very high potency were more effective than vitamin D in clearing and reducing scalp psoriasis (<a href="./full#CD009687-tbl-0001">summary of findings Table for the main comparison</a>). The combination of a corticosteroid with vitamin D was significantly more effective than corticosteroids as monotherapy, but the additional benefit might not be clinically relevant (<a href="./full#CD009687-tbl-0002">summary of findings Table 2</a>). This is based on a total risk difference of 0.06 (95% confidence interval (CI) 0.02 to 0.10; 'Number of participants achieving clearance by IGA'). Indirect comparison of both treatments also indicated that topical corticosteroids were more successful in the number of participants achieving 'clearance' when compared to the vehicle than the two‐compound combination compared to the vehicle (risk ratio (RR) 14.58; 95% CI 7.28 to 29.17 versus RR 11.31; 95% CI 4.28 to 29.93). The two‐compound combination was superior to vitamin D alone (<a href="./full#CD009687-tbl-0003">summary of findings Table 3</a>). We graded the quality of evidence for the direct comparisons as moderate to high, depending on the efficacy outcome. </p> <p>In a single study, there was no difference in participants achieving 'clearance' between the high potency steroid betamethasone dipropionate and the very highly potent clobetasol propionate. A within‐patient study had a similar finding. Within the class of steroids of high potency, mometasone furoate was more effective than betamethasone valerate 0.1%. The twice‐daily use of betamethasone valerate 0.12% was better than once‐daily by the mean Investigator Global Assessment (IGA) but not the mean Participant Global Assessment (PGA) score, however this was not a clinically important benefit. All corticosteroid head‐to‐head comparisons were based on the results of single studies and should be interpreted with caution. Moreover, there were poor data on vehicle comparisons. Based on single studies, foam was shown to be superior to lotion, but not to solution. </p> <p>The addition of salicylic acid to betamethasone dipropionate did not show significant benefit compared to betamethasone valerate alone or clobetasol propionate alone. This finding should be interpreted carefully, since the role of salicylic acid in reducing the scaling may not be sufficiently captured by the IGA. </p> <p>In one study, whether betamethasone dipropionate was combined with salicylic acid or not participants achieved 'clearance' better than with triamcinolone acetonide when that was combined with salicylic acid. </p> <p>Among tar‐controlled comparisons, more participants achieved a 'response' as determined by the IGA with calcipotriol than with a tar/dithranol regimen and tacrolimus showed better clearance than pine tar. These results were based on poor data and are therefore linked to substantial uncertainty. There are further treatments, such as clobetasol propionate, calcipotriol, cocois or a dithranol/urea combination that may be superior to tar as a single agent or in combination therapy. However, due to poor reporting of measures of variance, it was not possible to determine any statistically significant superiority of treatment efficacy. </p> </section> </section> <section id="CD009687-sec-0235"> <h4 class="title">Safety</h4> <p>We reported all safety evaluations with regard to the number of participants with at least one adverse event and the withdrawal rate due to adverse events. It should be considered that the particular risk of specific adverse events (e.g. skin irritation, skin atrophy) for individual treatments was not evaluated in this review. Most adverse events were limited to the site of application. Systemic adverse events were significantly rare and most likely not drug‐related, as judged by the authors of the studies. </p> <section id="CD009687-sec-0236"> <h5 class="title">Vehicle‐controlled comparisons</h5> <p>Corticosteroids, vitamin D and their combination product did not differ from the vehicle in the risk of adverse events, such as burning sensation, skin irritation or folliculitis. Study authors poorly reported the nature of adverse events that caused withdrawal. However, it appeared that most participants stopped treatment because of unacceptable local adverse events, such as a burning sensation. The risk of withdrawal due to adverse events did not differ between corticosteroids, vitamin D or their combination product and the vehicle. In fact, one study even detected that betamethasone dipropionate was associated with a lower risk of adverse events leading to withdrawal compared to the vehicle (<a href="./references#CD009687-bbs2-0027" title="JemecGB , GanslandtC , OrtonneJP , PoulinY , BurdenAD , deUnamunoP , et al. A new scalp formulation of calcipotriene plus betamethasone compared with its active ingredients and the vehicle in the treatment of scalp psoriasis: a randomized, double‐blind, controlled trial. Journal of the American Academy of Dermatology2008;59(3):455‐63. [MEDLINE: 18694678] JemecGBE , BurdenD , PoulinY , OrtonneJP . A new scalp formulation of calcipotriene plus betamethasone in the treatment of scalp psoriasis compared to its active ingredients and the vehicle (Abstract P2733). Journal of the American Academy of Dermatology2007;56(2):AB182. ">Jemec 2008</a>). This was shown for both betamethasone dipropionate as a single preparation and in combination with vitamin D. The authors distinguished between withdrawals due to unacceptable adverse events and those due to unacceptable treatment efficacy. However, this finding may be explained by the assumption that participants, who applied the vehicle, withdrew because of dissatisfaction with a lack of relief from distressing symptoms (e.g. pruritus or pain). The distressing symptoms may have been misinterpreted as adverse events. In reality they might have been due to the scalp psoriasis itself and were not adequately relieved by the vehicle. </p> </section> <section id="CD009687-sec-0237"> <h5 class="title">Head‐to‐head comparisons</h5> <p>There was moderate quality evidence that corticosteroids led to fewer withdrawals due to adverse events than vitamin D (<a href="./full#CD009687-tbl-0001">summary of findings Table for the main comparison</a>). The number of participants with adverse events was also lower for steroids compared to vitamin D. Moderate quality evidence also indicated that the two‐compound combination did not differ from corticosteroid monotherapy in the number of withdrawals due to adverse events (<a href="./full#CD009687-tbl-0002">summary of findings Table 2</a>); nor was there a difference in the number of participants with adverse events. High quality evidence indicated that significantly fewer withdrawals due to adverse events were caused by the two‐compound combination compared to vitamin D alone (<a href="./full#CD009687-tbl-0003">summary of findings Table 3</a>). Compared to vitamin D the two‐compound combination also caused fewer local adverse events such as skin irritation, for short‐ and long‐term therapy. The better safety profile of the two‐compound combination compared to vitamin D was also seen in one trial that assessed long‐term treatment (<a href="./references#CD009687-bbs2-0038" title="CambazardF . Xamiol, a new treatment in scalp psoriasis: short‐ and long‐term results [Un nouveau traitement dans le psoriasis du cuir chevelu : Xamiol®: Résultats à court terme et à long terme]. Annales de Dermatologie et de Vénéréologie2009;136(Suppl 3):546‐50. [EMBASE: 2009406816] LugerTA , CambazardF , LarsenFG , BourcierM , GuptaG , ClonierF , et al. A study of the safety and efficacy of calcipotriol and betamethasone dipropionate scalp formulation in the long‐term management of scalp psoriasis. Dermatology2008;217(4):321‐8. [MEDLINE: 18787325] ">Luger 2008</a>). </p> <p>Betamethasone valerate 0.1% and dipropionate were better tolerated than calcipotriol in the same vehicle. In contrast, calcipotriol as a hydrophilic leave‐on showed a lower risk of causing adverse events than clobetasol propionate as shampoo. However, clobetasol propionate in a hydrophilic vehicle did not differ in the risk of unpleasant side effects compared to calcipotriol when used in an occlusive dressing. The latter two findings were based on poor data and should be interpreted with caution. </p> <p>Due to poor data we could not make a clear statement about whether there was a difference between individual steroids or if specific vehicles influenced their risk of causing adverse events. Steroid‐induced skin atrophy or telangiectasia were remarkably rare. Yet, it is unclear if these particular adverse events did not actually occur or if they were simply not monitored by most studies. Comparisons between individual corticosteroids of moderate, high and very high potency revealed that they did not differ significantly in their low risk of causing adverse events, such as a burning sensation, folliculitis or pruritus on the scalp. However, one of two studies that compared clobetasol propionate (very high potency) with betamethasone dipropionate (high potency), detected remarkably more adverse events in both treatment groups (<a href="./references#CD009687-bbs2-0029" title="KatzHI , LindholmJS , WeissJS , ShavinJS , MormanM , BressinckR , et al. Efficacy and safety of twice‐daily augmented betamethasone dipropionate lotion versus clobetasol propionate solution in patients with moderate‐to‐severe scalp psoriasis. Clinical Therapeutics1995;17(3):390‐401. [MEDLINE: 7585843] ">Katz 1995</a>). This study may have recorded different sorts of adverse events and in a more rigorous manner. According to one study, individual vehicle formulations did not have an impact on the safety properties of clobetasol propionate (<a href="./references#CD009687-bbs2-0045" title="ReygagneP , DiaconuJ , PrèsH , ErnstTM , MeyerKG . Efficacy and safety comparison of clobetasol proprionate shampoo, gel and vehicle in scalp psoriasis. Journal of the European Academy of Dermatology &amp; Venereology2002;16(Suppl 1):283. ">Reygagne 2002</a>). </p> <p>It was not possible to assess the safety features of salicylic acid in combination with corticosteroids, since none of the included studies addressed data that matched the safety outcomes of this review. Tar in combination with salicylic acid, however, caused significantly fewer adverse events (e.g. burning sensation) and withdrawal rates due to adverse events, than calcipotriol monotherapy. It was also shown to be safer than a urea/dithranol regimen, which frequently caused skin staining. However, all other tar preparations did not have different safety profiles to cocois, tacrolimus, calcipotriol or clobetasol propionate. </p> </section> </section> <section id="CD009687-sec-0238"> <h4 class="title">Quality of life</h4> <p>There was a considerable lack of trials that investigated the quality of life. However, there were two recent trials that addressed this outcome. One found that participants that applied clobetasol propionate experienced a better improvement in quality of life than those treated with the vehicle (<a href="./references#CD009687-bbs2-0049" title="Cook‐BoldenFE , GoffeBS , HudsonCP , SofenHL . Efficacy and safety results from a randomized, double‐blind, vehicle‐controlled study of clobetasol propionate spray for the treatment of moderate to severe plaque psoriasis of the scalp (Poster P3368) 68th Annual Meeting of the American Academy of Dermatology, AAD Miami, FL United States. Journal of the American Academy of Dermatology2010;62(3 Suppl 1):AB140. [EMBASE: 70142994] Cook‐BoldenFE , GoffeBS , HudsonCP , SofenHL . Patient satisfaction with clobetasol propionate spray, 0.05% for the management of moderate to severe plaque psoriasis of the scalp. 70th Annual Meeting of the American Academy of Dermatology San Diego, CA United States. Conference Start: 20120316 Conference End: 20120320. Journal of the American Academy of Dermatology2012;66(4 Suppl 1):AB197. [EMBASE: 70704639] Cook‐BoldenFE , GoffeBS , SofenHL , ColonLE , GottschalkRW . Successful treatment of moderate to severe plaque psoriasis of the scalp with clobetasol propionate spray, 0.05% (Abstract P3347). 69th Annual Meeting of the American Academy of Dermatology New Orleans, LA United States. Conference Start: 20110204 Conference End: 20110208. Journal of the American Academy of Dermatology2011;64(2 Suppl 1):AB157. [EMBASE: 70331905] Cook‐BoldenFE , GoffeBS , SofenHL , HudsonCP , ColonLE , GottschalkRW , et al. Patient satisfaction with clobetasol proprionate spray, 0.05% for the treatment of moderate to severe plaque psoriasis of the scalp. 36th Annual Hawaii Dermatology Seminar of the Skin Disease Education Foundation Waikoloa, HI United States. Conference Start: 20120219 Conference End: 20120224. Seminars in Cutaneous Medicine &amp; Surgery2012;31(1):A9‐A10. [EMBASE: 70706927] SofenH , HudsonCP , Cook‐BoldenFE , PrestonN , ColonLE , CaveneySW , et al. Clobetasol propionate 0.05% spray for the management of moderate‐to‐severe plaque psoriasis of the scalp: results from a randomized controlled trial. Journal of Drugs in Dermatology2011;10(8):885‐92. [MEDLINE: 21818510] ">Sofen 2011</a>). The other trial revealed that the combination of betamethasone dipropionate and vitamin D was associated with a greater improvement in quality of life compared to calcipotriol monotherapy (<a href="./references#CD009687-bbs2-0035" title="KragballeK , GanslandtC , OrtonneJP . A calcipotriol plus betamethasone dipropionate scalp formulation significantly reduces itching in scalp psoriasis. Abstract P3343. American Academy of Dermatology 67th Annual Meeting March 6‐10, 2009. Journal of the American Academy of Dermatology2009;60(3 Suppl 1):AB172. KragballeK , HoffmannV , OrtonneJP , TanJ , NordinP , SegaertS . Efficacy and safety of calcipotriol plus betamethasone dipropionate scalp formulation compared with calcipotriol scalp solution in the treatment of scalp psoriasis: a randomized controlled trial. British Journal of Dermatology2009;161(1):159‐66. [MEDLINE: 19416259] NCT00243464 . A calcipotriol plus betamethasone diproprionate scalp formulation significantly reduces itching in scalp. www.clinicaltrials.gov/show/NCT00243464?term=NCT00243464 (accessed 5 November 2014). OrtonneJP , GanslandtC , TanJ , NordinP , KragballeK , SegaertS . Quality of life in patients with scalp psoriasis treated with calcipotriol/betamethasone dipropionate scalp formulation: a randomized controlled trial. Journal of the European Academy of Dermatology &amp; Venereology2009;23(8):919‐26. [MEDLINE: 19453810] ">Kragballe 2009</a>). Both findings seem reliable, however we did not assess the quality of evidence, because the comparison of clobetasol propionate versus vehicle was not of major interest and the <a href="./references#CD009687-bbs2-0035" title="KragballeK , GanslandtC , OrtonneJP . A calcipotriol plus betamethasone dipropionate scalp formulation significantly reduces itching in scalp psoriasis. Abstract P3343. American Academy of Dermatology 67th Annual Meeting March 6‐10, 2009. Journal of the American Academy of Dermatology2009;60(3 Suppl 1):AB172. KragballeK , HoffmannV , OrtonneJP , TanJ , NordinP , SegaertS . Efficacy and safety of calcipotriol plus betamethasone dipropionate scalp formulation compared with calcipotriol scalp solution in the treatment of scalp psoriasis: a randomized controlled trial. British Journal of Dermatology2009;161(1):159‐66. [MEDLINE: 19416259] NCT00243464 . A calcipotriol plus betamethasone diproprionate scalp formulation significantly reduces itching in scalp. www.clinicaltrials.gov/show/NCT00243464?term=NCT00243464 (accessed 5 November 2014). OrtonneJP , GanslandtC , TanJ , NordinP , KragballeK , SegaertS . Quality of life in patients with scalp psoriasis treated with calcipotriol/betamethasone dipropionate scalp formulation: a randomized controlled trial. Journal of the European Academy of Dermatology &amp; Venereology2009;23(8):919‐26. [MEDLINE: 19453810] ">Kragballe 2009</a> study (see <a href="./references#CD009687-bbs2-0156" title="OrtonneJ , ChimentiS , LugerT , PuigL , ReidF , TruebRM . Scalp psoriasis: European consensus on grading and treatment algorithm. Journal of the European Academy of Dermatology &amp; Venereology2009;23(12):1435‐44. [MEDLINE: 19614856] ">Ortonne 2009</a>) did not provide enough data to calculate an estimate of effect. We could not analyse the results of two other trials in an appropriate manner (<a href="./references#CD009687-bbs2-0002" title="BarrettC , LowsonD , BladesKJ . Limited benefit of combined use of tar‐based shampoo with 50 mug/ml calcipotriol solution in scalp psoriasis. Journal of Dermatological Treatment2005;16(3):175. [EMBASE: 2005434030] ">Barrett 2005</a>; <a href="./references#CD009687-bbs2-0003" title="BergstromKG , ArambulaK , KimballAB . Medication formulation affects quality of life: a randomized single‐blind study of clobetasol propionate foam 0.05% compared with a combined program of clobetasol cream 0.05% and solution 0.05% for the treatment of psoriasis. Cutis2003;72(5):407‐11. [MEDLINE: 14655784] ">Bergstrom 2003</a>), because they did not report relevant data either; one concluded that clobetasol propionate within foam improved the quality of life better than clobetasol propionate as a combination programme of cream and solution. The other found no difference in quality of life for the vitamin D solution, whether combined with a tar‐based shampoo or vehicle shampoo. These findings should be interpreted with caution. </p> </section> </section> <section id="CD009687-sec-0239"> <h3 class="title" id="CD009687-sec-0239">Overall completeness and applicability of evidence</h3> <p>We aimed to include all topical treatment and found a wide variety of different interventions.</p> <p>We identified multicentre trials that included large study populations for the interventions that are most established such as topical corticosteroids, vitamin D and their combination therapy. The evidence of the efficacy and safety of these therapies supports the current European, American and Asian consensus recommendations (<a href="./references#CD009687-bbs2-0115" title="ChanCS , VanVoorheesAS , LebwohlMG , KormanNJ , YoungM , BeboBFJr , et al. Treatment of severe scalp psoriasis: from the Medical Board of the National Psoriasis Foundation. Journal of the American Academy of Dermatology2009;60(6):962‐71. [MEDLINE: 19375191] ">Chan 2009</a>; <a href="./references#CD009687-bbs2-0131" title="FrezML , AsawanondaP , GunasekaraC , KohC , LooS , OonHH , et al. Recommendations for a patient‐centred approach to the assessment and treatment of scalp psoriasis: a consensus statement from the Asia Scalp Psoriasis Study Group. Journal of Dermatological Treatment2014; Vol. 25, issue 1:38‐45. ">Frez 2014</a>; <a href="./references#CD009687-bbs2-0156" title="OrtonneJ , ChimentiS , LugerT , PuigL , ReidF , TruebRM . Scalp psoriasis: European consensus on grading and treatment algorithm. Journal of the European Academy of Dermatology &amp; Venereology2009;23(12):1435‐44. [MEDLINE: 19614856] ">Ortonne 2009</a>). </p> <p>A great part of the included interventions were evaluated in single studies, such as tar‐controlled interventions, vehicle comparisons, steroids of varying application frequency and salicylic acid in combination with corticosteroids. For these comparisons, the assessment of consistency of results across the studies was limited or not feasible. This may be a considerable threat to external validity. </p> <p>One reason why there were poor data on 'older' treatments, such as tar preparations, may be that randomised controlled trials were not yet established at that time as the gold standard. Studies that assessed those treatments may simply not be of an adequate design to meet our inclusion criteria. Moreover, the objective of recent studies might have been focused on the comparison of those interventions that have already been shown to be effective and safe. </p> <p>Only one trial with a duration of 12 months was feasible for long‐term safety analysis (<a href="./references#CD009687-bbs2-0038" title="CambazardF . Xamiol, a new treatment in scalp psoriasis: short‐ and long‐term results [Un nouveau traitement dans le psoriasis du cuir chevelu : Xamiol®: Résultats à court terme et à long terme]. Annales de Dermatologie et de Vénéréologie2009;136(Suppl 3):546‐50. [EMBASE: 2009406816] LugerTA , CambazardF , LarsenFG , BourcierM , GuptaG , ClonierF , et al. A study of the safety and efficacy of calcipotriol and betamethasone dipropionate scalp formulation in the long‐term management of scalp psoriasis. Dermatology2008;217(4):321‐8. [MEDLINE: 18787325] ">Luger 2008</a>). All other included trials were carried out for less than six months. Therefore efficacy and safety analyses are mainly restricted to short‐term treatments. </p> <p>None of the identified studies provided data on the time to relapse as it was defined in the protocol for this review. We therefore did not analyse this outcome. </p> <p>Only four studies reported the outcome 'quality of life' but it was not in a form in which we were able to evaluate the quality of evidence. </p> </section> <section id="CD009687-sec-0240"> <h3 class="title" id="CD009687-sec-0240">Quality of the evidence</h3> <section id="CD009687-sec-0241"> <h4 class="title">Limitations in study design and implementation</h4> <p>Our 'Risk of bias' assessment showed that limitations in study design and implementation varied considerably among the included studies (<a href="#CD009687-sec-0082">Risk of bias in included studies</a>). Only 11 studies clearly addressed the randomisation method and only four study authors stated how they concealed the allocation, which represents a potential risk of selection bias. More than half of the studies had a double‐blind design. Of the 14 single‐blind studies, only the investigator was blinded in 12 as the study medications varied in application frequency or were applied in different vehicles, however in two studies it was not clear who was blinded. Given that most of the 10 non‐blinded trials assessed interventions of minor clinical interest, the risk of performance and detection bias for comparisons of major interest may not be unduly affected. We rated one‐third of the trials to be at high or unclear risk of attrition bias. </p> </section> <section id="CD009687-sec-0242"> <h4 class="title">Indirectness of the evidence</h4> <p>The studies included in this review assessed representative populations, though only a few studies included children (less than 18 years). However, psoriasis in children is a rather rare condition. In this review, we included vehicle‐ and active‐controlled trials, which allowed a clear judgement on comparative efficacy for most interventions. </p> </section> <section id="CD009687-sec-0243"> <h4 class="title">Inconsistency of the results</h4> <p>In only three instances we downgraded the quality of the evidence because of heterogeneity among the trial results. However, in one case heterogeneity was only moderate and thus we did not seek to identify a plausible explanation. Study results from the four trials that assessed 'IGA response' for the comparison 'Steroid plus vitamin D versus vitamin D' were substantially heterogenous (<a href="./references#CD009687-bbs2-0027" title="JemecGB , GanslandtC , OrtonneJP , PoulinY , BurdenAD , deUnamunoP , et al. A new scalp formulation of calcipotriene plus betamethasone compared with its active ingredients and the vehicle in the treatment of scalp psoriasis: a randomized, double‐blind, controlled trial. Journal of the American Academy of Dermatology2008;59(3):455‐63. [MEDLINE: 18694678] JemecGBE , BurdenD , PoulinY , OrtonneJP . A new scalp formulation of calcipotriene plus betamethasone in the treatment of scalp psoriasis compared to its active ingredients and the vehicle (Abstract P2733). Journal of the American Academy of Dermatology2007;56(2):AB182. ">Jemec 2008</a>; <a href="./references#CD009687-bbs2-0035" title="KragballeK , GanslandtC , OrtonneJP . A calcipotriol plus betamethasone dipropionate scalp formulation significantly reduces itching in scalp psoriasis. Abstract P3343. American Academy of Dermatology 67th Annual Meeting March 6‐10, 2009. Journal of the American Academy of Dermatology2009;60(3 Suppl 1):AB172. KragballeK , HoffmannV , OrtonneJP , TanJ , NordinP , SegaertS . Efficacy and safety of calcipotriol plus betamethasone dipropionate scalp formulation compared with calcipotriol scalp solution in the treatment of scalp psoriasis: a randomized controlled trial. British Journal of Dermatology2009;161(1):159‐66. [MEDLINE: 19416259] NCT00243464 . A calcipotriol plus betamethasone diproprionate scalp formulation significantly reduces itching in scalp. www.clinicaltrials.gov/show/NCT00243464?term=NCT00243464 (accessed 5 November 2014). OrtonneJP , GanslandtC , TanJ , NordinP , KragballeK , SegaertS . Quality of life in patients with scalp psoriasis treated with calcipotriol/betamethasone dipropionate scalp formulation: a randomized controlled trial. Journal of the European Academy of Dermatology &amp; Venereology2009;23(8):919‐26. [MEDLINE: 19453810] ">Kragballe 2009</a>; <a href="./references#CD009687-bbs2-0041" title="NCT01195831 . Efficacy and safety of Xamiol® gel compared to calcipotriol scalp solution in patients with scalp psoriasis. clinicaltrials.gov/show/NCT01195831 (accessed 5 November 2014). ">NCT01195831</a>; <a href="./references#CD009687-bbs2-0053" title="van deKerkhofP , AnsteyA , BarnesL , BolducC . A new scalp formulation of calcipotriene plus betamethasone in the treatment of scalp psoriasis compared to its active ingredients in the same vehicle. Journal of the American Academy of Dermatology2007;56(2):AB182. van deKerkhofPC , HoffmannV , AnsteyA , BarnesL , BolducC , ReichK , et al. A new scalp formulation of calcipotriol plus betamethasone dipropionate compared with each of its active ingredients in the same vehicle for the treatment of scalp psoriasis: a randomized, double‐blind, controlled trial. British Journal of Dermatology2009;160(1):170‐6. [MEDLINE: 19067709] ">van de Kerkhof 2009</a>). The study populations differed in mean age and percentage of female participants. Two of the studies only masked the outcome assessor (<a href="./references#CD009687-bbs2-0027" title="JemecGB , GanslandtC , OrtonneJP , PoulinY , BurdenAD , deUnamunoP , et al. A new scalp formulation of calcipotriene plus betamethasone compared with its active ingredients and the vehicle in the treatment of scalp psoriasis: a randomized, double‐blind, controlled trial. Journal of the American Academy of Dermatology2008;59(3):455‐63. [MEDLINE: 18694678] JemecGBE , BurdenD , PoulinY , OrtonneJP . A new scalp formulation of calcipotriene plus betamethasone in the treatment of scalp psoriasis compared to its active ingredients and the vehicle (Abstract P2733). Journal of the American Academy of Dermatology2007;56(2):AB182. ">Jemec 2008</a>; <a href="./references#CD009687-bbs2-0035" title="KragballeK , GanslandtC , OrtonneJP . A calcipotriol plus betamethasone dipropionate scalp formulation significantly reduces itching in scalp psoriasis. Abstract P3343. American Academy of Dermatology 67th Annual Meeting March 6‐10, 2009. Journal of the American Academy of Dermatology2009;60(3 Suppl 1):AB172. KragballeK , HoffmannV , OrtonneJP , TanJ , NordinP , SegaertS . Efficacy and safety of calcipotriol plus betamethasone dipropionate scalp formulation compared with calcipotriol scalp solution in the treatment of scalp psoriasis: a randomized controlled trial. British Journal of Dermatology2009;161(1):159‐66. [MEDLINE: 19416259] NCT00243464 . A calcipotriol plus betamethasone diproprionate scalp formulation significantly reduces itching in scalp. www.clinicaltrials.gov/show/NCT00243464?term=NCT00243464 (accessed 5 November 2014). OrtonneJP , GanslandtC , TanJ , NordinP , KragballeK , SegaertS . Quality of life in patients with scalp psoriasis treated with calcipotriol/betamethasone dipropionate scalp formulation: a randomized controlled trial. Journal of the European Academy of Dermatology &amp; Venereology2009;23(8):919‐26. [MEDLINE: 19453810] ">Kragballe 2009</a>), and only two had a double‐blind design (<a href="./references#CD009687-bbs2-0027" title="JemecGB , GanslandtC , OrtonneJP , PoulinY , BurdenAD , deUnamunoP , et al. A new scalp formulation of calcipotriene plus betamethasone compared with its active ingredients and the vehicle in the treatment of scalp psoriasis: a randomized, double‐blind, controlled trial. Journal of the American Academy of Dermatology2008;59(3):455‐63. [MEDLINE: 18694678] JemecGBE , BurdenD , PoulinY , OrtonneJP . A new scalp formulation of calcipotriene plus betamethasone in the treatment of scalp psoriasis compared to its active ingredients and the vehicle (Abstract P2733). Journal of the American Academy of Dermatology2007;56(2):AB182. ">Jemec 2008</a>; <a href="./references#CD009687-bbs2-0053" title="van deKerkhofP , AnsteyA , BarnesL , BolducC . A new scalp formulation of calcipotriene plus betamethasone in the treatment of scalp psoriasis compared to its active ingredients in the same vehicle. Journal of the American Academy of Dermatology2007;56(2):AB182. van deKerkhofPC , HoffmannV , AnsteyA , BarnesL , BolducC , ReichK , et al. A new scalp formulation of calcipotriol plus betamethasone dipropionate compared with each of its active ingredients in the same vehicle for the treatment of scalp psoriasis: a randomized, double‐blind, controlled trial. British Journal of Dermatology2009;160(1):170‐6. [MEDLINE: 19067709] ">van de Kerkhof 2009</a>). However, we had serious doubts that these aspects alone were responsible for the variability of results. </p> </section> <section id="CD009687-sec-0244"> <h4 class="title">Imprecision of the results</h4> <p>We lowered the quality of evidence in only two instances because of serious imprecision. In both cases the confidence interval crossed the minimal important difference (MID) thresholds. </p> </section> <section id="CD009687-sec-0245"> <h4 class="title">Publication bias</h4> <p>The assessment of publication bias was not feasible, as none of the comparisons included more than 10 studies. For this reason we did not create any funnel plots, since this would not give any meaningful information. </p> </section> <section id="CD009687-sec-0246"> <h4 class="title">Sensitivity analysis</h4> <p>In one case, sensitivity analysis with respect to allocation concealment did not confirm that steroids caused fewer withdrawals due to adverse events than the vehicle. However, the value of this finding may be questionable for several reasons: only one trial was eligible for sensitivity analysis, because it reported an adequate concealment of allocation (<a href="./references#CD009687-bbs2-0049" title="Cook‐BoldenFE , GoffeBS , HudsonCP , SofenHL . Efficacy and safety results from a randomized, double‐blind, vehicle‐controlled study of clobetasol propionate spray for the treatment of moderate to severe plaque psoriasis of the scalp (Poster P3368) 68th Annual Meeting of the American Academy of Dermatology, AAD Miami, FL United States. Journal of the American Academy of Dermatology2010;62(3 Suppl 1):AB140. [EMBASE: 70142994] Cook‐BoldenFE , GoffeBS , HudsonCP , SofenHL . Patient satisfaction with clobetasol propionate spray, 0.05% for the management of moderate to severe plaque psoriasis of the scalp. 70th Annual Meeting of the American Academy of Dermatology San Diego, CA United States. Conference Start: 20120316 Conference End: 20120320. Journal of the American Academy of Dermatology2012;66(4 Suppl 1):AB197. [EMBASE: 70704639] Cook‐BoldenFE , GoffeBS , SofenHL , ColonLE , GottschalkRW . Successful treatment of moderate to severe plaque psoriasis of the scalp with clobetasol propionate spray, 0.05% (Abstract P3347). 69th Annual Meeting of the American Academy of Dermatology New Orleans, LA United States. Conference Start: 20110204 Conference End: 20110208. Journal of the American Academy of Dermatology2011;64(2 Suppl 1):AB157. [EMBASE: 70331905] Cook‐BoldenFE , GoffeBS , SofenHL , HudsonCP , ColonLE , GottschalkRW , et al. Patient satisfaction with clobetasol proprionate spray, 0.05% for the treatment of moderate to severe plaque psoriasis of the scalp. 36th Annual Hawaii Dermatology Seminar of the Skin Disease Education Foundation Waikoloa, HI United States. Conference Start: 20120219 Conference End: 20120224. Seminars in Cutaneous Medicine &amp; Surgery2012;31(1):A9‐A10. [EMBASE: 70706927] SofenH , HudsonCP , Cook‐BoldenFE , PrestonN , ColonLE , CaveneySW , et al. Clobetasol propionate 0.05% spray for the management of moderate‐to‐severe plaque psoriasis of the scalp: results from a randomized controlled trial. Journal of Drugs in Dermatology2011;10(8):885‐92. [MEDLINE: 21818510] ">Sofen 2011</a>); the fact that the other studies did not report any allocation concealment does not imply that they did not perform it. Moreover, sensitivity analysis with regard to the intention‐to‐treat (ITT) population supported the finding that steroids cause fewer withdrawals due to adverse events than the vehicle. It is unlikely that adequate allocation concealment in this one study would have had sufficient impact on this outcome. The contradictory finding may be explained by the small sample (N = 81) in the study by <a href="./references#CD009687-bbs2-0049" title="Cook‐BoldenFE , GoffeBS , HudsonCP , SofenHL . Efficacy and safety results from a randomized, double‐blind, vehicle‐controlled study of clobetasol propionate spray for the treatment of moderate to severe plaque psoriasis of the scalp (Poster P3368) 68th Annual Meeting of the American Academy of Dermatology, AAD Miami, FL United States. Journal of the American Academy of Dermatology2010;62(3 Suppl 1):AB140. [EMBASE: 70142994] Cook‐BoldenFE , GoffeBS , HudsonCP , SofenHL . Patient satisfaction with clobetasol propionate spray, 0.05% for the management of moderate to severe plaque psoriasis of the scalp. 70th Annual Meeting of the American Academy of Dermatology San Diego, CA United States. Conference Start: 20120316 Conference End: 20120320. Journal of the American Academy of Dermatology2012;66(4 Suppl 1):AB197. [EMBASE: 70704639] Cook‐BoldenFE , GoffeBS , SofenHL , ColonLE , GottschalkRW . Successful treatment of moderate to severe plaque psoriasis of the scalp with clobetasol propionate spray, 0.05% (Abstract P3347). 69th Annual Meeting of the American Academy of Dermatology New Orleans, LA United States. Conference Start: 20110204 Conference End: 20110208. Journal of the American Academy of Dermatology2011;64(2 Suppl 1):AB157. [EMBASE: 70331905] Cook‐BoldenFE , GoffeBS , SofenHL , HudsonCP , ColonLE , GottschalkRW , et al. Patient satisfaction with clobetasol proprionate spray, 0.05% for the treatment of moderate to severe plaque psoriasis of the scalp. 36th Annual Hawaii Dermatology Seminar of the Skin Disease Education Foundation Waikoloa, HI United States. Conference Start: 20120219 Conference End: 20120224. Seminars in Cutaneous Medicine &amp; Surgery2012;31(1):A9‐A10. [EMBASE: 70706927] SofenH , HudsonCP , Cook‐BoldenFE , PrestonN , ColonLE , CaveneySW , et al. Clobetasol propionate 0.05% spray for the management of moderate‐to‐severe plaque psoriasis of the scalp: results from a randomized controlled trial. Journal of Drugs in Dermatology2011;10(8):885‐92. [MEDLINE: 21818510] ">Sofen 2011</a>, although the other study that used clobetasol, <a href="./references#CD009687-bbs2-0042" title="OlsenEA , CramDL , EllisCN , HickmanJG , JacobsonC , JenkinsEE , et al. A double‐blind, vehicle‐controlled study of clobetasol propionate 0.05% (Temovate) scalp application in the treatment of moderate to severe scalp psoriasis. Journal of the American Academy of Dermatology1991;24(3):443‐7. [MEDLINE: 2061442] ">Olsen 1991</a>, had a similar finding to <a href="./references#CD009687-bbs2-0049" title="Cook‐BoldenFE , GoffeBS , HudsonCP , SofenHL . Efficacy and safety results from a randomized, double‐blind, vehicle‐controlled study of clobetasol propionate spray for the treatment of moderate to severe plaque psoriasis of the scalp (Poster P3368) 68th Annual Meeting of the American Academy of Dermatology, AAD Miami, FL United States. Journal of the American Academy of Dermatology2010;62(3 Suppl 1):AB140. [EMBASE: 70142994] Cook‐BoldenFE , GoffeBS , HudsonCP , SofenHL . Patient satisfaction with clobetasol propionate spray, 0.05% for the management of moderate to severe plaque psoriasis of the scalp. 70th Annual Meeting of the American Academy of Dermatology San Diego, CA United States. Conference Start: 20120316 Conference End: 20120320. Journal of the American Academy of Dermatology2012;66(4 Suppl 1):AB197. [EMBASE: 70704639] Cook‐BoldenFE , GoffeBS , SofenHL , ColonLE , GottschalkRW . Successful treatment of moderate to severe plaque psoriasis of the scalp with clobetasol propionate spray, 0.05% (Abstract P3347). 69th Annual Meeting of the American Academy of Dermatology New Orleans, LA United States. Conference Start: 20110204 Conference End: 20110208. Journal of the American Academy of Dermatology2011;64(2 Suppl 1):AB157. [EMBASE: 70331905] Cook‐BoldenFE , GoffeBS , SofenHL , HudsonCP , ColonLE , GottschalkRW , et al. Patient satisfaction with clobetasol proprionate spray, 0.05% for the treatment of moderate to severe plaque psoriasis of the scalp. 36th Annual Hawaii Dermatology Seminar of the Skin Disease Education Foundation Waikoloa, HI United States. Conference Start: 20120219 Conference End: 20120224. Seminars in Cutaneous Medicine &amp; Surgery2012;31(1):A9‐A10. [EMBASE: 70706927] SofenH , HudsonCP , Cook‐BoldenFE , PrestonN , ColonLE , CaveneySW , et al. Clobetasol propionate 0.05% spray for the management of moderate‐to‐severe plaque psoriasis of the scalp: results from a randomized controlled trial. Journal of Drugs in Dermatology2011;10(8):885‐92. [MEDLINE: 21818510] ">Sofen 2011</a>. </p> </section> </section> <section id="CD009687-sec-0247"> <h3 class="title" id="CD009687-sec-0247">Potential biases in the review process</h3> <p>We aimed to minimise potential biases during our search for relevant trials and data extraction. Therefore, two authors independently screened abstracts, evaluated full texts for eligibility, extracted data and screened for ongoing trials. Both authors also searched conferences for relevant poster abstracts and checked the reference lists of included studies for further potentially relevant randomised controlled trials (RCTs). Those studies where we were unable to obtain the full text or where our requests to the study authors or sponsors for unpublished data were unsuccessful are listed in '<a href="./references#CD009687-sec-0268" title="">Characteristics of studies awaiting classification</a>'. The fact that 14 studies have not yet been incorporated may be a source of potential bias. </p> <p>Since almost none of the publications clearly stated measures of variance, most available continuous outcomes, particularly total severity scores (TSS), were inaccurate and therefore not feasible for meta‐analysis. Even though we calculated the mean percentage TSS change from baseline, an interpretation of these findings remains strongly limited. Furthermore, most TSS data were calculated from graphs, which additionally implies a certain degree of inaccuracy. </p> </section> <section id="CD009687-sec-0248"> <h3 class="title" id="CD009687-sec-0248">Agreements and disagreements with other studies or reviews</h3> <p>As part of a Cochrane review on topical treatments for chronic plaque psoriasis, <a href="./references#CD009687-bbs2-0152" title="MasonAR , MasonJM , CorkMJ , HancockH , DooleyG . Topical treatments for chronic plaque psoriasis of the scalp: a systematic review. British Journal of Dermatology2013;169(3):519‐27. [MEDLINE: 23796133] ">Mason 2013</a> investigated treatments for scalp psoriasis with the focus on vehicle‐controlled trials and active comparisons with vitamin D preparations. With regard to these treatments, our results concerning efficacy and safety correspond closely. Contrary to <a href="./references#CD009687-bbs2-0152" title="MasonAR , MasonJM , CorkMJ , HancockH , DooleyG . Topical treatments for chronic plaque psoriasis of the scalp: a systematic review. British Journal of Dermatology2013;169(3):519‐27. [MEDLINE: 23796133] ">Mason 2013</a>, we did not make restrictions with regard to other topical treatments. Our findings concerning topical corticosteroids, vitamin D analogues, tar preparations and application frequency are in accordance with the results of another systematic review (<a href="./references#CD009687-bbs2-0168" title="SamarasekeraEJ , SawyerL , WonderlingD , TuckerR , SmithCH . Topical therapies for the treatment of plaque psoriasis: systematic review and network meta‐analyses. British Journal of Dermatology2013;168(5):954‐67. [MEDLINE: 23413913] ">Samarasekera 2013</a>). However, these authors did not find the marginal benefit of the combination product of a potent corticosteroid with calcipotriol compared to corticosteroid as monotherapy. This may be for two reasons: in their meta‐analysis of IGA response, the authors did not include the trial <a href="./references#CD009687-bbs2-0005" title="BuckleyC , HoffmannV . Calcipotriol plus betamethasone dipropionate gel is effective and safe in the treatment of scalp psoriasis (a phase II study). (Abstract P06.57). Journal of the European Academy of Dermatology &amp; Venereology2005;19(Suppl 2):175. BuckleyC , HoffmannV , ShapiroJ , SaariS , CambazardF , MilsgaardM . Calcipotriol plus betamethasone dipropionate scalp formulation is effective and well tolerated in the treatment of scalp psoriasis: a phase II study. Dermatology2008;217(2):107‐13. [MEDLINE: 18463448] ">Buckley 2008</a>, which found a small benefit of the two‐compound combination with respect to IGA and PGA; and <a href="./references#CD009687-bbs2-0168" title="SamarasekeraEJ , SawyerL , WonderlingD , TuckerR , SmithCH . Topical therapies for the treatment of plaque psoriasis: systematic review and network meta‐analyses. British Journal of Dermatology2013;168(5):954‐67. [MEDLINE: 23413913] ">Samarasekera 2013</a> did not meta‐analyse data from the participants' assessment of treatment efficacy. Both aspects would have emphasised the small but statistically significant benefit of the combination product. </p> <p><a href="./references#CD009687-bbs2-0170" title="ShokeenJ , O'NeillJL , TaheriA , FeldmanSR . Are topical keratolytic agents needed in the treatment of scalp psoriasis?. Dermatology Online Journal2014;20(3):‐. [MEDLINE: 24656276] ">Shokeen 2014</a> reviewed the efficacy of topical keratolytic agents and their adjunctive benefit in combination with topical corticosteroids. In concordance with our findings, the authors reported that steroids were highly effective in clearing scalp psoriasis. However, in contrast to our results, <a href="./references#CD009687-bbs2-0170" title="ShokeenJ , O'NeillJL , TaheriA , FeldmanSR . Are topical keratolytic agents needed in the treatment of scalp psoriasis?. Dermatology Online Journal2014;20(3):‐. [MEDLINE: 24656276] ">Shokeen 2014</a> concluded that salicylic acid in a single combination product with a corticosteroid may be of additional benefit. This conclusion was based on the results of studies of which some were neither randomised nor controlled. Only one RCT was identified by the authors that evaluated the same corticosteroid as part of the combination product (experimental group) and as monotherapy (control group) (<a href="./references#CD009687-bbs2-0064" title="ElieR , DurocherLP , KavalecEC . Effect of salicylic acid on the activity of betamethasone‐17,21‐dipropionate in the treatment of erythematous squamous dermatoses. Journal of International Medical Research1983;11(2):108‐12. [MEDLINE: 6852357] ">Elie 1983</a>). However, this RCT included participants with different erythematous squamous dermatoses and did not provide results for participants with scalp psoriasis separately. For this reason, we excluded this trial. The only RCT that we could identify that assessed the role of salicylic acid combined with corticosteroids did not indicate a significant additional benefit of the keratolytic agent (<a href="./references#CD009687-bbs2-0015" title="FredrikssonT . A clinical comparison of 3 corticosteroid alcoholic solutions in the treatment of psoriasis of the scalp. Pharmatherapeutica1976;1(4):252‐6. [EMBASE: 0977155168] ">Fredriksson 1976</a>). However, the keratolytic effect of salicylic acid may not have been sufficiently assessed by our pre‐specified outcomes. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD009687-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/urn:x-wiley:14651858:media:CD009687:CD009687-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/image_t/tCD009687-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD009687-fig-0001" src="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/image_n/nCD009687-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/full#CD009687-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/image_n/nCD009687-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009687-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/urn:x-wiley:14651858:media:CD009687:CD009687-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/image_t/tCD009687-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study.Legend: &quot;?&quot; = unclear risk of bias; &quot;+&quot; = low risk of bias; &quot;‐&quot; = high risk of bias" data-id="CD009687-fig-0002" src="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/image_n/nCD009687-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study. </p> <p>Legend: "?" = unclear risk of bias; "+" = low risk of bias; "‐" = high risk of bias</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/full#CD009687-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/image_n/nCD009687-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009687-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/urn:x-wiley:14651858:media:CD009687:CD009687-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/image_t/tCD009687-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 10 Steroid plus vitamin D vs steroid, outcome: 10.2 IGA: response." data-id="CD009687-fig-0003" src="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/image_n/nCD009687-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Forest plot of comparison: 10 Steroid plus vitamin D vs steroid, outcome: 10.2 IGA: response. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/full#CD009687-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/image_n/nCD009687-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009687-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/urn:x-wiley:14651858:media:CD009687:CD009687-AFig-FIG04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/image_t/tCD009687-AFig-FIG04.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 10 Steroid plus vitamin D vs steroid, outcome: 10.7 Number of participants with at least one AE." data-id="CD009687-fig-0004" src="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/image_n/nCD009687-AFig-FIG04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Forest plot of comparison: 10 Steroid plus vitamin D vs steroid, outcome: 10.7 Number of participants with at least one AE. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/full#CD009687-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/image_n/nCD009687-AFig-FIG04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009687-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/urn:x-wiley:14651858:media:CD009687:CD009687-AFig-FIG05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/image_t/tCD009687-AFig-FIG05.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 11 Steroid plus vitamin D vs vitamin D, outcome: 11.2 IGA: response." data-id="CD009687-fig-0005" src="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/image_n/nCD009687-AFig-FIG05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 5</div> <div class="figure-caption"> <p>Forest plot of comparison: 11 Steroid plus vitamin D vs vitamin D, outcome: 11.2 IGA: response. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/full#CD009687-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/image_n/nCD009687-AFig-FIG05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009687-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/urn:x-wiley:14651858:media:CD009687:CD009687-AFig-FIG06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/image_t/tCD009687-AFig-FIG06.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 11 Steroid plus vitamin D vs vitamin D, outcome: 11.8 Number of participants with at least one AE (short term)." data-id="CD009687-fig-0006" src="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/image_n/nCD009687-AFig-FIG06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 6</div> <div class="figure-caption"> <p>Forest plot of comparison: 11 Steroid plus vitamin D vs vitamin D, outcome: 11.8 Number of participants with at least one AE (short term). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/full#CD009687-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/image_n/nCD009687-AFig-FIG06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009687-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/urn:x-wiley:14651858:media:CD009687:CD009687-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/image_t/tCD009687-CMP-001-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Steroid: once versus twice daily, Outcome 1 Mean score of the IGA." data-id="CD009687-fig-0007" src="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/image_n/nCD009687-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Steroid: once versus twice daily, Outcome 1 Mean score of the IGA.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/references#CD009687-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/image_n/nCD009687-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009687-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/urn:x-wiley:14651858:media:CD009687:CD009687-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/image_t/tCD009687-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Steroid: once versus twice daily, Outcome 2 Mean score of the PGA." data-id="CD009687-fig-0008" src="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/image_n/nCD009687-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Steroid: once versus twice daily, Outcome 2 Mean score of the PGA.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/references#CD009687-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/image_n/nCD009687-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009687-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/urn:x-wiley:14651858:media:CD009687:CD009687-CMP-002-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/image_t/tCD009687-CMP-002-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Steroid versus the vehicle, Outcome 1 Number of participants achieving 'clearance' by IGA." data-id="CD009687-fig-0009" src="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/image_n/nCD009687-CMP-002-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 Steroid versus the vehicle, Outcome 1 Number of participants achieving 'clearance' by IGA. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/references#CD009687-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/image_n/nCD009687-CMP-002-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009687-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/urn:x-wiley:14651858:media:CD009687:CD009687-CMP-002-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/image_t/tCD009687-CMP-002-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Steroid versus the vehicle, Outcome 2 Number of participants achieving 'response' by IGA." data-id="CD009687-fig-0010" src="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/image_n/nCD009687-CMP-002-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2 Steroid versus the vehicle, Outcome 2 Number of participants achieving 'response' by IGA. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/references#CD009687-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/image_n/nCD009687-CMP-002-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009687-fig-0011"> <p> <div class="table" id="CD009687-tblf-0001"> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Comparison: Steroid vs vehicle</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Steroid</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Placebo</b> </p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Franz 1999</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Betamethasone valerate (hydrophilic leave‐on) vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐57%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐24%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Franz 2000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clobetasol propionate (hydrophilic leave‐on) vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐72%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐37%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Jarratt 2004</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clobetasol propionate (rinse‐off) vs placebo vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐49%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐18%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Jemec 2008</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Betamethasone dipropionate (hydrophilic leave‐on) vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐64%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐36%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Olsen 1991</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clobetasol propionate (hydrophilic leave‐on) vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐72%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐30%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pauporte 2004</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Fluocinolone acetonide (hydrophilic leave‐on) vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐59%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐32%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sofen 2011</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clobetasol propionate (hydrophilic leave‐on) vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐79%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐25%</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2 Steroid versus the vehicle, Outcome 3 Mean of the TSS.</p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/references#CD009687-fig-0011">Navigate to figure in review</a></div> </div> <div class="figure" id="CD009687-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/urn:x-wiley:14651858:media:CD009687:CD009687-CMP-002-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/image_t/tCD009687-CMP-002-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Steroid versus the vehicle, Outcome 4 Improvement in quality of life." data-id="CD009687-fig-0012" src="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/image_n/nCD009687-CMP-002-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2 Steroid versus the vehicle, Outcome 4 Improvement in quality of life.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/references#CD009687-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/image_n/nCD009687-CMP-002-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009687-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/urn:x-wiley:14651858:media:CD009687:CD009687-CMP-002-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/image_t/tCD009687-CMP-002-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Steroid versus the vehicle, Outcome 5 Number of participants withdrawing due to adverse events." data-id="CD009687-fig-0013" src="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/image_n/nCD009687-CMP-002-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.5</div> <div class="figure-caption"> <p>Comparison 2 Steroid versus the vehicle, Outcome 5 Number of participants withdrawing due to adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/references#CD009687-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/image_n/nCD009687-CMP-002-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009687-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/urn:x-wiley:14651858:media:CD009687:CD009687-CMP-002-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/image_t/tCD009687-CMP-002-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Steroid versus the vehicle, Outcome 6 Number of participants achieving 'response' by PGA." data-id="CD009687-fig-0014" src="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/image_n/nCD009687-CMP-002-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.6</div> <div class="figure-caption"> <p>Comparison 2 Steroid versus the vehicle, Outcome 6 Number of participants achieving 'response' by PGA. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/references#CD009687-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/image_n/nCD009687-CMP-002-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009687-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/urn:x-wiley:14651858:media:CD009687:CD009687-CMP-002-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/image_t/tCD009687-CMP-002-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Steroid versus the vehicle, Outcome 7 Mean score of the PGA." data-id="CD009687-fig-0015" src="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/image_n/nCD009687-CMP-002-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.7</div> <div class="figure-caption"> <p>Comparison 2 Steroid versus the vehicle, Outcome 7 Mean score of the PGA.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/references#CD009687-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/image_n/nCD009687-CMP-002-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009687-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/urn:x-wiley:14651858:media:CD009687:CD009687-CMP-002-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/image_t/tCD009687-CMP-002-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Steroid versus the vehicle, Outcome 8 Number of participants with at least one adverse event." data-id="CD009687-fig-0016" src="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/image_n/nCD009687-CMP-002-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.8</div> <div class="figure-caption"> <p>Comparison 2 Steroid versus the vehicle, Outcome 8 Number of participants with at least one adverse event. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/references#CD009687-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/image_n/nCD009687-CMP-002-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009687-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/urn:x-wiley:14651858:media:CD009687:CD009687-CMP-003-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/image_t/tCD009687-CMP-003-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Vitamin D versus the vehicle, Outcome 1 Number of participants achieving 'clearance' by IGA." data-id="CD009687-fig-0017" src="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/image_n/nCD009687-CMP-003-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3 Vitamin D versus the vehicle, Outcome 1 Number of participants achieving 'clearance' by IGA. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/references#CD009687-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/image_n/nCD009687-CMP-003-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009687-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/urn:x-wiley:14651858:media:CD009687:CD009687-CMP-003-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/image_t/tCD009687-CMP-003-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Vitamin D versus the vehicle, Outcome 2 Number of participants achieving 'response' by IGA." data-id="CD009687-fig-0018" src="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/image_n/nCD009687-CMP-003-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3 Vitamin D versus the vehicle, Outcome 2 Number of participants achieving 'response' by IGA. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/references#CD009687-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/image_n/nCD009687-CMP-003-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009687-fig-0019"> <p> <div class="table" id="CD009687-tblf-0002"> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Vitamin D vs vehicle</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Vitamin D</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Vehicle</b> </p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Green 1994</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Calcipotriol vs vehicle</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐52%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐24%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Jemec 2008</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Calcipotriene vs vehicle</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐54%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐36%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ruzicka 2004</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Tacalcitol vs vehicle</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐53%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐30%</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3 Vitamin D versus the vehicle, Outcome 3 Mean of the TSS.</p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/references#CD009687-fig-0019">Navigate to figure in review</a></div> </div> <div class="figure" id="CD009687-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/urn:x-wiley:14651858:media:CD009687:CD009687-CMP-003-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/image_t/tCD009687-CMP-003-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Vitamin D versus the vehicle, Outcome 4 Number of participants withdrawing due to adverse events." data-id="CD009687-fig-0020" src="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/image_n/nCD009687-CMP-003-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.4</div> <div class="figure-caption"> <p>Comparison 3 Vitamin D versus the vehicle, Outcome 4 Number of participants withdrawing due to adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/references#CD009687-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/image_n/nCD009687-CMP-003-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009687-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/urn:x-wiley:14651858:media:CD009687:CD009687-CMP-003-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/image_t/tCD009687-CMP-003-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Vitamin D versus the vehicle, Outcome 5 Number of participants achieving 'clearance' by PGA." data-id="CD009687-fig-0021" src="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/image_n/nCD009687-CMP-003-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.5</div> <div class="figure-caption"> <p>Comparison 3 Vitamin D versus the vehicle, Outcome 5 Number of participants achieving 'clearance' by PGA. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/references#CD009687-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/image_n/nCD009687-CMP-003-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009687-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/urn:x-wiley:14651858:media:CD009687:CD009687-CMP-003-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/image_t/tCD009687-CMP-003-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Vitamin D versus the vehicle, Outcome 6 Number of participants achieving 'response' by PGA." data-id="CD009687-fig-0022" src="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/image_n/nCD009687-CMP-003-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.6</div> <div class="figure-caption"> <p>Comparison 3 Vitamin D versus the vehicle, Outcome 6 Number of participants achieving 'response' by PGA. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/references#CD009687-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/image_n/nCD009687-CMP-003-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009687-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/urn:x-wiley:14651858:media:CD009687:CD009687-CMP-003-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/image_t/tCD009687-CMP-003-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Vitamin D versus the vehicle, Outcome 7 Number of participants with at least one adverse event." data-id="CD009687-fig-0023" src="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/image_n/nCD009687-CMP-003-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.7</div> <div class="figure-caption"> <p>Comparison 3 Vitamin D versus the vehicle, Outcome 7 Number of participants with at least one adverse event. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/references#CD009687-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/image_n/nCD009687-CMP-003-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009687-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/urn:x-wiley:14651858:media:CD009687:CD009687-CMP-004-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/image_t/tCD009687-CMP-004-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Steroid plus vitamin D versus the vehicle, Outcome 1 Number of participants achieving 'clearance' by IGA." data-id="CD009687-fig-0024" src="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/image_n/nCD009687-CMP-004-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4 Steroid plus vitamin D versus the vehicle, Outcome 1 Number of participants achieving 'clearance' by IGA. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/references#CD009687-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/image_n/nCD009687-CMP-004-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009687-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/urn:x-wiley:14651858:media:CD009687:CD009687-CMP-004-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/image_t/tCD009687-CMP-004-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Steroid plus vitamin D versus the vehicle, Outcome 2 Number of participants achieving 'response' by IGA." data-id="CD009687-fig-0025" src="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/image_n/nCD009687-CMP-004-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.2</div> <div class="figure-caption"> <p>Comparison 4 Steroid plus vitamin D versus the vehicle, Outcome 2 Number of participants achieving 'response' by IGA. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/references#CD009687-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/image_n/nCD009687-CMP-004-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009687-fig-0026"> <p> <div class="table" id="CD009687-tblf-0003"> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Betamethasone dipropionate/calcipotriene combination</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Placebo (vehicle)</b> </p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Jemec 2008</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐70%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐36%</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.3</div> <div class="figure-caption"> <p>Comparison 4 Steroid plus vitamin D versus the vehicle, Outcome 3 Mean of the TSS.</p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/references#CD009687-fig-0026">Navigate to figure in review</a></div> </div> <div class="figure" id="CD009687-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/urn:x-wiley:14651858:media:CD009687:CD009687-CMP-004-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/image_t/tCD009687-CMP-004-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Steroid plus vitamin D versus the vehicle, Outcome 4 Number of participants withdrawing due to adverse events." data-id="CD009687-fig-0027" src="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/image_n/nCD009687-CMP-004-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.4</div> <div class="figure-caption"> <p>Comparison 4 Steroid plus vitamin D versus the vehicle, Outcome 4 Number of participants withdrawing due to adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/references#CD009687-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/image_n/nCD009687-CMP-004-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009687-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/urn:x-wiley:14651858:media:CD009687:CD009687-CMP-004-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/image_t/tCD009687-CMP-004-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Steroid plus vitamin D versus the vehicle, Outcome 5 Number of participants achieving 'response' by PGA." data-id="CD009687-fig-0028" src="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/image_n/nCD009687-CMP-004-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.5</div> <div class="figure-caption"> <p>Comparison 4 Steroid plus vitamin D versus the vehicle, Outcome 5 Number of participants achieving 'response' by PGA. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/references#CD009687-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/image_n/nCD009687-CMP-004-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009687-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/urn:x-wiley:14651858:media:CD009687:CD009687-CMP-004-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/image_t/tCD009687-CMP-004-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Steroid plus vitamin D versus the vehicle, Outcome 6 Number of participants with at least one adverse event." data-id="CD009687-fig-0029" src="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/image_n/nCD009687-CMP-004-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.6</div> <div class="figure-caption"> <p>Comparison 4 Steroid plus vitamin D versus the vehicle, Outcome 6 Number of participants with at least one adverse event. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/references#CD009687-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/image_n/nCD009687-CMP-004-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009687-fig-0030"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/urn:x-wiley:14651858:media:CD009687:CD009687-CMP-005-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/image_t/tCD009687-CMP-005-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Steroid versus steroid: very high versus high potency, Outcome 1 Number of participants achieving 'clearance' by IGA." data-id="CD009687-fig-0030" src="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/image_n/nCD009687-CMP-005-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.1</div> <div class="figure-caption"> <p>Comparison 5 Steroid versus steroid: very high versus high potency, Outcome 1 Number of participants achieving 'clearance' by IGA. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/references#CD009687-fig-0030">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/image_n/nCD009687-CMP-005-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009687-fig-0031"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/urn:x-wiley:14651858:media:CD009687:CD009687-CMP-005-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/image_t/tCD009687-CMP-005-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Steroid versus steroid: very high versus high potency, Outcome 2 Number of participants achieving 'response' by IGA." data-id="CD009687-fig-0031" src="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/image_n/nCD009687-CMP-005-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.2</div> <div class="figure-caption"> <p>Comparison 5 Steroid versus steroid: very high versus high potency, Outcome 2 Number of participants achieving 'response' by IGA. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/references#CD009687-fig-0031">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/image_n/nCD009687-CMP-005-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009687-fig-0032"> <p> <div class="table" id="CD009687-tblf-0004"> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Clobetasol propionate</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Betamethasone dipropionate</b> </p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Katz 1995</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐75%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐83%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Lassus 1976</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐81%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐58%</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.3</div> <div class="figure-caption"> <p>Comparison 5 Steroid versus steroid: very high versus high potency, Outcome 3 Mean of the TSS. </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/references#CD009687-fig-0032">Navigate to figure in review</a></div> </div> <div class="figure" id="CD009687-fig-0033"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/urn:x-wiley:14651858:media:CD009687:CD009687-CMP-005-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/image_t/tCD009687-CMP-005-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Steroid versus steroid: very high versus high potency, Outcome 4 Number of participants with at least one adverse event." data-id="CD009687-fig-0033" src="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/image_n/nCD009687-CMP-005-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.4</div> <div class="figure-caption"> <p>Comparison 5 Steroid versus steroid: very high versus high potency, Outcome 4 Number of participants with at least one adverse event. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/references#CD009687-fig-0033">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/image_n/nCD009687-CMP-005-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009687-fig-0034"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/urn:x-wiley:14651858:media:CD009687:CD009687-CMP-006-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/image_t/tCD009687-CMP-006-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Steroid versus steroid: high versus moderate potency, Outcome 1 Number of participants achieving 'clearance' by IGA." data-id="CD009687-fig-0034" src="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/image_n/nCD009687-CMP-006-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.1</div> <div class="figure-caption"> <p>Comparison 6 Steroid versus steroid: high versus moderate potency, Outcome 1 Number of participants achieving 'clearance' by IGA. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/references#CD009687-fig-0034">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/image_n/nCD009687-CMP-006-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009687-fig-0035"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/urn:x-wiley:14651858:media:CD009687:CD009687-CMP-006-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/image_t/tCD009687-CMP-006-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Steroid versus steroid: high versus moderate potency, Outcome 2 Number of participants achieving 'response' by IGA." data-id="CD009687-fig-0035" src="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/image_n/nCD009687-CMP-006-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.2</div> <div class="figure-caption"> <p>Comparison 6 Steroid versus steroid: high versus moderate potency, Outcome 2 Number of participants achieving 'response' by IGA. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/references#CD009687-fig-0035">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/image_n/nCD009687-CMP-006-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009687-fig-0036"> <p> <div class="table" id="CD009687-tblf-0005"> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Mometasone furoate</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Triamcinolone acetonide</b> </p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Swinehart 1989</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐79%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐70%</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.3</div> <div class="figure-caption"> <p>Comparison 6 Steroid versus steroid: high versus moderate potency, Outcome 3 Mean of the TSS. </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/references#CD009687-fig-0036">Navigate to figure in review</a></div> </div> <div class="figure" id="CD009687-fig-0037"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/urn:x-wiley:14651858:media:CD009687:CD009687-CMP-006-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/image_t/tCD009687-CMP-006-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Steroid versus steroid: high versus moderate potency, Outcome 4 Number of participants with at least one adverse event." data-id="CD009687-fig-0037" src="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/image_n/nCD009687-CMP-006-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.4</div> <div class="figure-caption"> <p>Comparison 6 Steroid versus steroid: high versus moderate potency, Outcome 4 Number of participants with at least one adverse event. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/references#CD009687-fig-0037">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/image_n/nCD009687-CMP-006-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009687-fig-0038"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/urn:x-wiley:14651858:media:CD009687:CD009687-CMP-007-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/image_t/tCD009687-CMP-007-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Steroids versus steroid: both of high potency, Outcome 1 Number of participants achieving 'clearance' by IGA." data-id="CD009687-fig-0038" src="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/image_n/nCD009687-CMP-007-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.1</div> <div class="figure-caption"> <p>Comparison 7 Steroids versus steroid: both of high potency, Outcome 1 Number of participants achieving 'clearance' by IGA. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/references#CD009687-fig-0038">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/image_n/nCD009687-CMP-007-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009687-fig-0039"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/urn:x-wiley:14651858:media:CD009687:CD009687-CMP-007-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/image_t/tCD009687-CMP-007-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Steroids versus steroid: both of high potency, Outcome 2 Number of participants achieving 'response' by IGA." data-id="CD009687-fig-0039" src="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/image_n/nCD009687-CMP-007-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.2</div> <div class="figure-caption"> <p>Comparison 7 Steroids versus steroid: both of high potency, Outcome 2 Number of participants achieving 'response' by IGA. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/references#CD009687-fig-0039">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/image_n/nCD009687-CMP-007-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009687-fig-0040"> <p> <div class="table" id="CD009687-tblf-0006"> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Steroid vs steroid of high potency</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Steroid (1)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Steroid (2)</b> </p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Breneman 1992</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Fluocinonide (1) vs BTM dipropionate (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐84%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐85%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Van der Ploeg 1989</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mometasone furoate (1) vs BTM valerate (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐85%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐70%</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.3</div> <div class="figure-caption"> <p>Comparison 7 Steroids versus steroid: both of high potency, Outcome 3 Mean of the TSS. </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/references#CD009687-fig-0040">Navigate to figure in review</a></div> </div> <div class="figure" id="CD009687-fig-0041"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/urn:x-wiley:14651858:media:CD009687:CD009687-CMP-007-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/image_t/tCD009687-CMP-007-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Steroids versus steroid: both of high potency, Outcome 4 Number of participants withdrawing due to adverse events." data-id="CD009687-fig-0041" src="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/image_n/nCD009687-CMP-007-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.4</div> <div class="figure-caption"> <p>Comparison 7 Steroids versus steroid: both of high potency, Outcome 4 Number of participants withdrawing due to adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/references#CD009687-fig-0041">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/image_n/nCD009687-CMP-007-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009687-fig-0042"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/urn:x-wiley:14651858:media:CD009687:CD009687-CMP-007-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/image_t/tCD009687-CMP-007-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Steroids versus steroid: both of high potency, Outcome 5 Number of participants with at least one adverse event." data-id="CD009687-fig-0042" src="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/image_n/nCD009687-CMP-007-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.5</div> <div class="figure-caption"> <p>Comparison 7 Steroids versus steroid: both of high potency, Outcome 5 Number of participants with at least one adverse event. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/references#CD009687-fig-0042">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/image_n/nCD009687-CMP-007-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009687-fig-0043"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/urn:x-wiley:14651858:media:CD009687:CD009687-CMP-008-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/image_t/tCD009687-CMP-008-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Steroid versus vitamin D, Outcome 1 Number of participants achieving 'clearance' by IGA." data-id="CD009687-fig-0043" src="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/image_n/nCD009687-CMP-008-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.1</div> <div class="figure-caption"> <p>Comparison 8 Steroid versus vitamin D, Outcome 1 Number of participants achieving 'clearance' by IGA. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/references#CD009687-fig-0043">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/image_n/nCD009687-CMP-008-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009687-fig-0044"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/urn:x-wiley:14651858:media:CD009687:CD009687-CMP-008-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/image_t/tCD009687-CMP-008-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Steroid versus vitamin D, Outcome 2 Number of participants achieving 'response' by IGA." data-id="CD009687-fig-0044" src="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/image_n/nCD009687-CMP-008-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.2</div> <div class="figure-caption"> <p>Comparison 8 Steroid versus vitamin D, Outcome 2 Number of participants achieving 'response' by IGA. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/references#CD009687-fig-0044">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/image_n/nCD009687-CMP-008-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009687-fig-0045"> <p> <div class="table" id="CD009687-tblf-0007"> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Corticosteroid vs</b> </p> <p><b>vitamin D</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Corticosteroid</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Calcipotriol</b> </p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Jemec 2008</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Betamethasone dipropionate vs calcipotriene</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐62%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐44%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Klaber 1994</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Betamethasone valerate vs calcipotriol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐62%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐48%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Reygagne 2005</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clobetasol vs calcipotriol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐64%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐52%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>van de Kerkhof 2009</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Betamethasone dipropionate vs calcipotriol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐57%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐43%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yilmaz 2005</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mometasone vs calcipotriol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐52%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐49%</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.3</div> <div class="figure-caption"> <p>Comparison 8 Steroid versus vitamin D, Outcome 3 Mean of the TSS.</p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/references#CD009687-fig-0045">Navigate to figure in review</a></div> </div> <div class="figure" id="CD009687-fig-0046"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/urn:x-wiley:14651858:media:CD009687:CD009687-CMP-008-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/image_t/tCD009687-CMP-008-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Steroid versus vitamin D, Outcome 4 Number of participants withdrawing due to adverse events." data-id="CD009687-fig-0046" src="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/image_n/nCD009687-CMP-008-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.4</div> <div class="figure-caption"> <p>Comparison 8 Steroid versus vitamin D, Outcome 4 Number of participants withdrawing due to adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/references#CD009687-fig-0046">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/image_n/nCD009687-CMP-008-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009687-fig-0047"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/urn:x-wiley:14651858:media:CD009687:CD009687-CMP-008-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/image_t/tCD009687-CMP-008-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Steroid versus vitamin D, Outcome 5 Number of participants achieving 'clearance' by PGA." data-id="CD009687-fig-0047" src="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/image_n/nCD009687-CMP-008-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.5</div> <div class="figure-caption"> <p>Comparison 8 Steroid versus vitamin D, Outcome 5 Number of participants achieving 'clearance' by PGA. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/references#CD009687-fig-0047">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/image_n/nCD009687-CMP-008-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009687-fig-0048"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/urn:x-wiley:14651858:media:CD009687:CD009687-CMP-008-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/image_t/tCD009687-CMP-008-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Steroid versus vitamin D, Outcome 6 Number of participants achieving 'response' by PGA." data-id="CD009687-fig-0048" src="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/image_n/nCD009687-CMP-008-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.6</div> <div class="figure-caption"> <p>Comparison 8 Steroid versus vitamin D, Outcome 6 Number of participants achieving 'response' by PGA. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/references#CD009687-fig-0048">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/image_n/nCD009687-CMP-008-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009687-fig-0049"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/urn:x-wiley:14651858:media:CD009687:CD009687-CMP-008-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/image_t/tCD009687-CMP-008-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Steroid versus vitamin D, Outcome 7 Number of participants with at least one adverse event." data-id="CD009687-fig-0049" src="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/image_n/nCD009687-CMP-008-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.7</div> <div class="figure-caption"> <p>Comparison 8 Steroid versus vitamin D, Outcome 7 Number of participants with at least one adverse event. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/references#CD009687-fig-0049">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/image_n/nCD009687-CMP-008-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009687-fig-0050"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/urn:x-wiley:14651858:media:CD009687:CD009687-CMP-009-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/image_t/tCD009687-CMP-009-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 9 Steroid plus salicylic acid versus steroid, Outcome 1 Number of participants achieving 'clearance' by IGA." data-id="CD009687-fig-0050" src="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/image_n/nCD009687-CMP-009-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.1</div> <div class="figure-caption"> <p>Comparison 9 Steroid plus salicylic acid versus steroid, Outcome 1 Number of participants achieving 'clearance' by IGA. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/references#CD009687-fig-0050">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/image_n/nCD009687-CMP-009-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009687-fig-0051"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/urn:x-wiley:14651858:media:CD009687:CD009687-CMP-009-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/image_t/tCD009687-CMP-009-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 9 Steroid plus salicylic acid versus steroid, Outcome 2 Number of participants achieving 'response' by IGA." data-id="CD009687-fig-0051" src="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/image_n/nCD009687-CMP-009-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.2</div> <div class="figure-caption"> <p>Comparison 9 Steroid plus salicylic acid versus steroid, Outcome 2 Number of participants achieving 'response' by IGA. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/references#CD009687-fig-0051">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/image_n/nCD009687-CMP-009-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009687-fig-0052"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/urn:x-wiley:14651858:media:CD009687:CD009687-CMP-010-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/image_t/tCD009687-CMP-010-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 10 Steroid plus vitamin D versus steroid, Outcome 1 Number of participants achieving 'clearance' by IGA." data-id="CD009687-fig-0052" src="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/image_n/nCD009687-CMP-010-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.1</div> <div class="figure-caption"> <p>Comparison 10 Steroid plus vitamin D versus steroid, Outcome 1 Number of participants achieving 'clearance' by IGA. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/references#CD009687-fig-0052">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/image_n/nCD009687-CMP-010-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009687-fig-0053"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/urn:x-wiley:14651858:media:CD009687:CD009687-CMP-010-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/image_t/tCD009687-CMP-010-02.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 10 Steroid plus vitamin D versus steroid, Outcome 2 Number of participants achieving 'response' by IGA." data-id="CD009687-fig-0053" src="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/image_n/nCD009687-CMP-010-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.2</div> <div class="figure-caption"> <p>Comparison 10 Steroid plus vitamin D versus steroid, Outcome 2 Number of participants achieving 'response' by IGA. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/references#CD009687-fig-0053">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/image_n/nCD009687-CMP-010-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009687-fig-0054"> <p> <div class="table" id="CD009687-tblf-0008"> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Steroid/</b> </p> <p><b>vitamin D</b> </p> <p><b>combination vs steroid</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Steroid/calcipotriol</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Steroid</b> </p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Buckley 2008</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Betamethasone dipropionate/calcipotriol vs betamethasone dipropionate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐69%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐62%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Jemec 2008</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Betamethasone dipropionate/calcipotriene vs betamethasone dipropionate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐70%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐64%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>van de Kerkhof 2009</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Betamethasone dipropionate/calcipotriol vs betamethasone dipropionate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐62%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐57%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yilmaz 2005</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mometasone/calcipotriol vs mometasone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐81%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐52%</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.3</div> <div class="figure-caption"> <p>Comparison 10 Steroid plus vitamin D versus steroid, Outcome 3 Mean of the TSS.</p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/references#CD009687-fig-0054">Navigate to figure in review</a></div> </div> <div class="figure" id="CD009687-fig-0055"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/urn:x-wiley:14651858:media:CD009687:CD009687-CMP-010-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/image_t/tCD009687-CMP-010-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 10 Steroid plus vitamin D versus steroid, Outcome 4 Number of participants withdrawing due to adverse events." data-id="CD009687-fig-0055" src="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/image_n/nCD009687-CMP-010-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.4</div> <div class="figure-caption"> <p>Comparison 10 Steroid plus vitamin D versus steroid, Outcome 4 Number of participants withdrawing due to adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/references#CD009687-fig-0055">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/image_n/nCD009687-CMP-010-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009687-fig-0056"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/urn:x-wiley:14651858:media:CD009687:CD009687-CMP-010-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/image_t/tCD009687-CMP-010-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 10 Steroid plus vitamin D versus steroid, Outcome 5 Number of participants achieving 'clearance' by PGA." data-id="CD009687-fig-0056" src="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/image_n/nCD009687-CMP-010-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.5</div> <div class="figure-caption"> <p>Comparison 10 Steroid plus vitamin D versus steroid, Outcome 5 Number of participants achieving 'clearance' by PGA. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/references#CD009687-fig-0056">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/image_n/nCD009687-CMP-010-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009687-fig-0057"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/urn:x-wiley:14651858:media:CD009687:CD009687-CMP-010-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/image_t/tCD009687-CMP-010-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 10 Steroid plus vitamin D versus steroid, Outcome 6 Number of participants achieving 'response' by PGA." data-id="CD009687-fig-0057" src="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/image_n/nCD009687-CMP-010-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.6</div> <div class="figure-caption"> <p>Comparison 10 Steroid plus vitamin D versus steroid, Outcome 6 Number of participants achieving 'response' by PGA. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/references#CD009687-fig-0057">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/image_n/nCD009687-CMP-010-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009687-fig-0058"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/urn:x-wiley:14651858:media:CD009687:CD009687-CMP-010-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/image_t/tCD009687-CMP-010-07.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 10 Steroid plus vitamin D versus steroid, Outcome 7 Number of participants with at least one adverse event." data-id="CD009687-fig-0058" src="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/image_n/nCD009687-CMP-010-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.7</div> <div class="figure-caption"> <p>Comparison 10 Steroid plus vitamin D versus steroid, Outcome 7 Number of participants with at least one adverse event. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/references#CD009687-fig-0058">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/image_n/nCD009687-CMP-010-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009687-fig-0059"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/urn:x-wiley:14651858:media:CD009687:CD009687-CMP-011-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/image_t/tCD009687-CMP-011-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 11 Steroid plus vitamin D versus vitamin D, Outcome 1 Number of participants achieving 'clearance' by IGA." data-id="CD009687-fig-0059" src="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/image_n/nCD009687-CMP-011-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.1</div> <div class="figure-caption"> <p>Comparison 11 Steroid plus vitamin D versus vitamin D, Outcome 1 Number of participants achieving 'clearance' by IGA. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/references#CD009687-fig-0059">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/image_n/nCD009687-CMP-011-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009687-fig-0060"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/urn:x-wiley:14651858:media:CD009687:CD009687-CMP-011-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/image_t/tCD009687-CMP-011-02.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 11 Steroid plus vitamin D versus vitamin D, Outcome 2 Number of participants achieving 'response' by IGA." data-id="CD009687-fig-0060" src="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/image_n/nCD009687-CMP-011-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.2</div> <div class="figure-caption"> <p>Comparison 11 Steroid plus vitamin D versus vitamin D, Outcome 2 Number of participants achieving 'response' by IGA. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/references#CD009687-fig-0060">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/image_n/nCD009687-CMP-011-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009687-fig-0061"> <p> <div class="table" id="CD009687-tblf-0009"> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Steroid/vitamin D combination vs vitamin D</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Steroid/calcipotriol</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Calcipotriol</b> </p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Jemec 2008</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Betamethasone dipropionate/calcipotriol vs calcipotriol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐70%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐54%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Kragballe 2009</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Betamethasone dipropionate/calcipotriol vs calcipotriol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐64%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐38%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>van de Kerkhof 2009</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Betamethasone dipropionate/calcipotriol vs calcipotriol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐62%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐43%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yilmaz 2005</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mometasone/calcipotriol vs calcipotriol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐81%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐49%</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.3</div> <div class="figure-caption"> <p>Comparison 11 Steroid plus vitamin D versus vitamin D, Outcome 3 Mean of the TSS.</p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/references#CD009687-fig-0061">Navigate to figure in review</a></div> </div> <div class="figure" id="CD009687-fig-0062"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/urn:x-wiley:14651858:media:CD009687:CD009687-CMP-011-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/image_t/tCD009687-CMP-011-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 11 Steroid plus vitamin D versus vitamin D, Outcome 4 Number of participants withdrawing due to adverse events (short‐term)." data-id="CD009687-fig-0062" src="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/image_n/nCD009687-CMP-011-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.4</div> <div class="figure-caption"> <p>Comparison 11 Steroid plus vitamin D versus vitamin D, Outcome 4 Number of participants withdrawing due to adverse events (short‐term). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/references#CD009687-fig-0062">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/image_n/nCD009687-CMP-011-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009687-fig-0063"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/urn:x-wiley:14651858:media:CD009687:CD009687-CMP-011-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/image_t/tCD009687-CMP-011-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 11 Steroid plus vitamin D versus vitamin D, Outcome 5 Number of participants withdrawing due to adverse events (long‐term)." data-id="CD009687-fig-0063" src="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/image_n/nCD009687-CMP-011-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.5</div> <div class="figure-caption"> <p>Comparison 11 Steroid plus vitamin D versus vitamin D, Outcome 5 Number of participants withdrawing due to adverse events (long‐term). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/references#CD009687-fig-0063">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/image_n/nCD009687-CMP-011-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009687-fig-0064"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/urn:x-wiley:14651858:media:CD009687:CD009687-CMP-011-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/image_t/tCD009687-CMP-011-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 11 Steroid plus vitamin D versus vitamin D, Outcome 6 Number of participants achieving 'clearance' by PGA." data-id="CD009687-fig-0064" src="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/image_n/nCD009687-CMP-011-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.6</div> <div class="figure-caption"> <p>Comparison 11 Steroid plus vitamin D versus vitamin D, Outcome 6 Number of participants achieving 'clearance' by PGA. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/references#CD009687-fig-0064">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/image_n/nCD009687-CMP-011-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009687-fig-0065"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/urn:x-wiley:14651858:media:CD009687:CD009687-CMP-011-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/image_t/tCD009687-CMP-011-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 11 Steroid plus vitamin D versus vitamin D, Outcome 7 Number of participants achieving 'response' by PGA." data-id="CD009687-fig-0065" src="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/image_n/nCD009687-CMP-011-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.7</div> <div class="figure-caption"> <p>Comparison 11 Steroid plus vitamin D versus vitamin D, Outcome 7 Number of participants achieving 'response' by PGA. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/references#CD009687-fig-0065">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/image_n/nCD009687-CMP-011-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009687-fig-0066"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/urn:x-wiley:14651858:media:CD009687:CD009687-CMP-011-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/image_t/tCD009687-CMP-011-08.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 11 Steroid plus vitamin D versus vitamin D, Outcome 8 Number of participants with at least one adverse event (short‐term)." data-id="CD009687-fig-0066" src="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/image_n/nCD009687-CMP-011-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.8</div> <div class="figure-caption"> <p>Comparison 11 Steroid plus vitamin D versus vitamin D, Outcome 8 Number of participants with at least one adverse event (short‐term). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/references#CD009687-fig-0066">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/image_n/nCD009687-CMP-011-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009687-fig-0067"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/urn:x-wiley:14651858:media:CD009687:CD009687-CMP-011-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/image_t/tCD009687-CMP-011-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 11 Steroid plus vitamin D versus vitamin D, Outcome 9 Number of participants with at least one adverse event (long‐term)." data-id="CD009687-fig-0067" src="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/image_n/nCD009687-CMP-011-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.9</div> <div class="figure-caption"> <p>Comparison 11 Steroid plus vitamin D versus vitamin D, Outcome 9 Number of participants with at least one adverse event (long‐term). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/references#CD009687-fig-0067">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/image_n/nCD009687-CMP-011-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009687-fig-0068"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/urn:x-wiley:14651858:media:CD009687:CD009687-CMP-012-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/image_t/tCD009687-CMP-012-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 12 Tar and dithranol, Outcome 1 Number of participants achieving 'clearance' by IGA." data-id="CD009687-fig-0068" src="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/image_n/nCD009687-CMP-012-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 12.1</div> <div class="figure-caption"> <p>Comparison 12 Tar and dithranol, Outcome 1 Number of participants achieving 'clearance' by IGA. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/references#CD009687-fig-0068">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/image_n/nCD009687-CMP-012-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009687-fig-0069"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/urn:x-wiley:14651858:media:CD009687:CD009687-CMP-012-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/image_t/tCD009687-CMP-012-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 12 Tar and dithranol, Outcome 2 Number of participants achieving 'response' by IGA." data-id="CD009687-fig-0069" src="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/image_n/nCD009687-CMP-012-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 12.2</div> <div class="figure-caption"> <p>Comparison 12 Tar and dithranol, Outcome 2 Number of participants achieving 'response' by IGA. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/references#CD009687-fig-0069">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/image_n/nCD009687-CMP-012-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009687-fig-0070"> <p> <div class="table" id="CD009687-tblf-0010"> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Comparison</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Other therapy</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Tar containing product</b> </p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Griffiths 2006</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clobetasol propionate vs tar blend</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐48%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐16%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>He 2008</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Tacrolimus vs pine tar</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐80%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐55%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Klaber 2000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Calcipotriol vs coal tar/coconut oil/salicylic acid combination</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐28%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐23%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Monk 1995</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cocois vs coal tar</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐67%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐14%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>van de Kerkhof 2002</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Calcipotriol vs tar/dithranol‐combination</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐51%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐17%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Wall 1999</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Calcipotriol vs calcipotriol/coal tar combination</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐41%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐48%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Wright 1985</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Dithranol/urea vs coal tar</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐51%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐47%</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 12.3</div> <div class="figure-caption"> <p>Comparison 12 Tar and dithranol, Outcome 3 Mean of the TSS.</p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/references#CD009687-fig-0070">Navigate to figure in review</a></div> </div> <div class="figure" id="CD009687-fig-0071"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/urn:x-wiley:14651858:media:CD009687:CD009687-CMP-012-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/image_t/tCD009687-CMP-012-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 12 Tar and dithranol, Outcome 4 Number of participants withdrawing due to adverse events." data-id="CD009687-fig-0071" src="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/image_n/nCD009687-CMP-012-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 12.4</div> <div class="figure-caption"> <p>Comparison 12 Tar and dithranol, Outcome 4 Number of participants withdrawing due to adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/references#CD009687-fig-0071">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/image_n/nCD009687-CMP-012-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009687-fig-0072"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/urn:x-wiley:14651858:media:CD009687:CD009687-CMP-012-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/image_t/tCD009687-CMP-012-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 12 Tar and dithranol, Outcome 5 Number of participants achieving 'clearance' by PGA." data-id="CD009687-fig-0072" src="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/image_n/nCD009687-CMP-012-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 12.5</div> <div class="figure-caption"> <p>Comparison 12 Tar and dithranol, Outcome 5 Number of participants achieving 'clearance' by PGA. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/references#CD009687-fig-0072">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/image_n/nCD009687-CMP-012-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009687-fig-0073"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/urn:x-wiley:14651858:media:CD009687:CD009687-CMP-012-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/image_t/tCD009687-CMP-012-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 12 Tar and dithranol, Outcome 6 Number of participants achieving 'response' by PGA." data-id="CD009687-fig-0073" src="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/image_n/nCD009687-CMP-012-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 12.6</div> <div class="figure-caption"> <p>Comparison 12 Tar and dithranol, Outcome 6 Number of participants achieving 'response' by PGA. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/references#CD009687-fig-0073">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/image_n/nCD009687-CMP-012-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009687-fig-0074"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/urn:x-wiley:14651858:media:CD009687:CD009687-CMP-012-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/image_t/tCD009687-CMP-012-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 12 Tar and dithranol, Outcome 7 Number of participants with at least one adverse event." data-id="CD009687-fig-0074" src="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/image_n/nCD009687-CMP-012-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 12.7</div> <div class="figure-caption"> <p>Comparison 12 Tar and dithranol, Outcome 7 Number of participants with at least one adverse event. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/references#CD009687-fig-0074">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/image_n/nCD009687-CMP-012-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009687-fig-0075"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/urn:x-wiley:14651858:media:CD009687:CD009687-CMP-013-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/image_t/tCD009687-CMP-013-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 13 Steroid: vehicle comparisons, Outcome 1 Number of participants achieving 'clearance' by IGA." data-id="CD009687-fig-0075" src="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/image_n/nCD009687-CMP-013-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 13.1</div> <div class="figure-caption"> <p>Comparison 13 Steroid: vehicle comparisons, Outcome 1 Number of participants achieving 'clearance' by IGA. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/references#CD009687-fig-0075">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/image_n/nCD009687-CMP-013-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009687-fig-0076"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/urn:x-wiley:14651858:media:CD009687:CD009687-CMP-013-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/image_t/tCD009687-CMP-013-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 13 Steroid: vehicle comparisons, Outcome 2 Number of participants achieving 'response' by IGA." data-id="CD009687-fig-0076" src="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/image_n/nCD009687-CMP-013-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 13.2</div> <div class="figure-caption"> <p>Comparison 13 Steroid: vehicle comparisons, Outcome 2 Number of participants achieving 'response' by IGA. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/references#CD009687-fig-0076">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/image_n/nCD009687-CMP-013-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009687-fig-0077"> <p> <div class="table" id="CD009687-tblf-0011"> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Comparison: vehicle (1) vs (2)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Vehicle 1</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Vehicle 2</b> </p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Andres 2006</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clobetasol propionate: rinse‐off (1) vs hydrophilic leave‐on (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐70%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐75%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Franz 1999</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Betamethasone valerate: foam (1) vs lotion (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐65%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐49%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Franz 2000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clobetasol propionate: foam (1) vs solution (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐75%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐68%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Josse 2005</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Betamethasone dipropionate: RV3423A/extra gentle shampoo (1) vs extra gentle shampoo (2) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐63%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐53%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Reygagne 2002</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clobetasol propionate: rinse‐off (1) vs hydrophilic leave‐on (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐67%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐80%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Wilhelm 2013</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mometasone: emulsion (LAS41002) (1) vs solution (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐81.82%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐84.55%</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 13.3</div> <div class="figure-caption"> <p>Comparison 13 Steroid: vehicle comparisons, Outcome 3 Mean of the TSS.</p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/references#CD009687-fig-0077">Navigate to figure in review</a></div> </div> <div class="figure" id="CD009687-fig-0078"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/urn:x-wiley:14651858:media:CD009687:CD009687-CMP-013-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/image_t/tCD009687-CMP-013-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 13 Steroid: vehicle comparisons, Outcome 4 Number of participants achieving 'response' by PGA." data-id="CD009687-fig-0078" src="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/image_n/nCD009687-CMP-013-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 13.4</div> <div class="figure-caption"> <p>Comparison 13 Steroid: vehicle comparisons, Outcome 4 Number of participants achieving 'response' by PGA. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/references#CD009687-fig-0078">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/image_n/nCD009687-CMP-013-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009687-fig-0079"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/urn:x-wiley:14651858:media:CD009687:CD009687-CMP-013-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/image_t/tCD009687-CMP-013-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 13 Steroid: vehicle comparisons, Outcome 5 Number of participants with at least one adverse event." data-id="CD009687-fig-0079" src="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/image_n/nCD009687-CMP-013-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 13.5</div> <div class="figure-caption"> <p>Comparison 13 Steroid: vehicle comparisons, Outcome 5 Number of participants with at least one adverse event. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/references#CD009687-fig-0079">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/image_n/nCD009687-CMP-013-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009687-fig-0080"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/urn:x-wiley:14651858:media:CD009687:CD009687-CMP-014-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/image_t/tCD009687-CMP-014-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 14 Other steroid plus salicylic acid comparisons, Outcome 1 Number of participants achieving 'clearance' by IGA." data-id="CD009687-fig-0080" src="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/image_n/nCD009687-CMP-014-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 14.1</div> <div class="figure-caption"> <p>Comparison 14 Other steroid plus salicylic acid comparisons, Outcome 1 Number of participants achieving 'clearance' by IGA. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/references#CD009687-fig-0080">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/image_n/nCD009687-CMP-014-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009687-fig-0081"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/urn:x-wiley:14651858:media:CD009687:CD009687-CMP-014-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/image_t/tCD009687-CMP-014-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 14 Other steroid plus salicylic acid comparisons, Outcome 2 Number of participants achieving 'response' by IGA." data-id="CD009687-fig-0081" src="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/image_n/nCD009687-CMP-014-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 14.2</div> <div class="figure-caption"> <p>Comparison 14 Other steroid plus salicylic acid comparisons, Outcome 2 Number of participants achieving 'response' by IGA. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/references#CD009687-fig-0081">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/image_n/nCD009687-CMP-014-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009687-fig-0082"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/urn:x-wiley:14651858:media:CD009687:CD009687-CMP-014-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/image_t/tCD009687-CMP-014-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 14 Other steroid plus salicylic acid comparisons, Outcome 3 Number of participants withdrawing due to adverse events." data-id="CD009687-fig-0082" src="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/image_n/nCD009687-CMP-014-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 14.3</div> <div class="figure-caption"> <p>Comparison 14 Other steroid plus salicylic acid comparisons, Outcome 3 Number of participants withdrawing due to adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/references#CD009687-fig-0082">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/image_n/nCD009687-CMP-014-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009687-fig-0083"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/urn:x-wiley:14651858:media:CD009687:CD009687-CMP-014-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/image_t/tCD009687-CMP-014-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 14 Other steroid plus salicylic acid comparisons, Outcome 4 Number of participants with at least one adverse event." data-id="CD009687-fig-0083" src="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/image_n/nCD009687-CMP-014-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 14.4</div> <div class="figure-caption"> <p>Comparison 14 Other steroid plus salicylic acid comparisons, Outcome 4 Number of participants with at least one adverse event. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/references#CD009687-fig-0083">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/image_n/nCD009687-CMP-014-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009687-fig-0084"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/urn:x-wiley:14651858:media:CD009687:CD009687-CMP-015-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/image_t/tCD009687-CMP-015-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 15 Antifungals versus vehicle, Outcome 1 Mean score of the IGA." data-id="CD009687-fig-0084" src="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/image_n/nCD009687-CMP-015-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 15.1</div> <div class="figure-caption"> <p>Comparison 15 Antifungals versus vehicle, Outcome 1 Mean score of the IGA.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/references#CD009687-fig-0084">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/image_n/nCD009687-CMP-015-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009687-fig-0085"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/urn:x-wiley:14651858:media:CD009687:CD009687-CMP-015-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/image_t/tCD009687-CMP-015-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 15 Antifungals versus vehicle, Outcome 2 Number of participants withdrawing due to adverse events." data-id="CD009687-fig-0085" src="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/image_n/nCD009687-CMP-015-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 15.2</div> <div class="figure-caption"> <p>Comparison 15 Antifungals versus vehicle, Outcome 2 Number of participants withdrawing due to adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/references#CD009687-fig-0085">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/image_n/nCD009687-CMP-015-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009687-fig-0086"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/urn:x-wiley:14651858:media:CD009687:CD009687-CMP-015-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/image_t/tCD009687-CMP-015-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 15 Antifungals versus vehicle, Outcome 3 Mean score of the PGA." data-id="CD009687-fig-0086" src="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/image_n/nCD009687-CMP-015-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 15.3</div> <div class="figure-caption"> <p>Comparison 15 Antifungals versus vehicle, Outcome 3 Mean score of the PGA.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/references#CD009687-fig-0086">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/image_n/nCD009687-CMP-015-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009687-fig-0087"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/urn:x-wiley:14651858:media:CD009687:CD009687-CMP-015-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/image_t/tCD009687-CMP-015-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 15 Antifungals versus vehicle, Outcome 4 Number of participants with at least one adverse event." data-id="CD009687-fig-0087" src="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/image_n/nCD009687-CMP-015-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 15.4</div> <div class="figure-caption"> <p>Comparison 15 Antifungals versus vehicle, Outcome 4 Number of participants with at least one adverse event. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/references#CD009687-fig-0087">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/media/CDSR/CD009687/image_n/nCD009687-CMP-015-04.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD009687-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Steroid compared to vitamin D for scalp psoriasis</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Steroid compared to vitamin D for scalp psoriasis</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> scalp psoriasis<br/> <b>Intervention:</b> steroid <br/> <b>Comparison:</b> vitamin D </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with vitamin D</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with steroid</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Number of participants achieving 'clearance' by IGA</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.82<br/> (1.52 to 2.18) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2180<br/> (4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>159 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>289 per 1000<br/> (241 to 346) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Number of participants achieving 'response' by IGA</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 2.09<br/> (1.80 to 2.41) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1827<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/> HIGH </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>251 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>525 per 1000<br/> (452 to 605) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Quality of life</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>(0 studies)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>No study addressed this outcome.</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000<br/> (0 to 0) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Number of participants withdrawing due to adverse events (AE)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.22<br/> (0.11 to 0.42) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2291<br/> (4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>No study reported the sort of AE that caused withdrawal. In 2 small studies with high risk of bias (<a href="./references#CD009687-bbs2-0034" title="KöseO . Calcipotriol ointment vs clobetasol solution in scalp psoriasis. Journal of Dermatological Treatment1997;8(4):287. [EMBASE: 1998022654] ">Köse 1997</a>, N = 43 participants; <a href="./references#CD009687-bbs2-0059" title="YilmazH , AydinF , SenturkN , CanturkT , TuranliAY . A comparison between the effects of calcipotriol lotion, momethasone furoate lotion and their combinations for the treatment of scalp psoriasis [Kalsipotriol Losyon, Mometazon Furoat Losyonve Kombinasyonlarinin Saçli Deri Psoriazisi Tedavisindeki Etkinliginin Karsilastirilmasi]. Turkderm Deri Hastaliklari ve Frengi Arsivi2005;39(2):109‐14. [EMBASE: 2006204571] ">Yilmaz 2005</a>, N = 30 participants) no withdrawals occurred. </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>53 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>12 per 1000<br/> (6 to 22) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Number of participants achieving 'response' by PGA</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.48<br/> (1.28 to 1.72) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1827<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>403 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>596 per 1000<br/> (516 to 693) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>AE:</b> adverse event; <b>CI:</b> confidence interval; <b>IGA:</b> investigator's global assessment; <b>OR:</b> odds ratio; <b>PGA:</b> patient global assessment; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Downgraded by one level for risk of bias: three out of four studies with unclear blinding of outcome assessment (<a href="./references#CD009687-bbs2-0032" title="KlaberMR , HutchinsonPE , Pedvis‐LeftickA , KragballeK , ReunalaTL , van deKerkhofPC , et al. Comparative effects of calcipotriol solution (50 micrograms/ml) and betamethasone 17‐valerate solution (1 mg/ml) in the treatment of scalp psoriasis. British Journal of Dermatology1994;131(5):678‐83. [MEDLINE: 7999600] ">Klaber 1994</a>; <a href="./references#CD009687-bbs2-0053" title="van deKerkhofP , AnsteyA , BarnesL , BolducC . A new scalp formulation of calcipotriene plus betamethasone in the treatment of scalp psoriasis compared to its active ingredients in the same vehicle. Journal of the American Academy of Dermatology2007;56(2):AB182. van deKerkhofPC , HoffmannV , AnsteyA , BarnesL , BolducC , ReichK , et al. A new scalp formulation of calcipotriol plus betamethasone dipropionate compared with each of its active ingredients in the same vehicle for the treatment of scalp psoriasis: a randomized, double‐blind, controlled trial. British Journal of Dermatology2009;160(1):170‐6. [MEDLINE: 19067709] ">van de Kerkhof 2009</a>; <a href="./references#CD009687-bbs2-0059" title="YilmazH , AydinF , SenturkN , CanturkT , TuranliAY . A comparison between the effects of calcipotriol lotion, momethasone furoate lotion and their combinations for the treatment of scalp psoriasis [Kalsipotriol Losyon, Mometazon Furoat Losyonve Kombinasyonlarinin Saçli Deri Psoriazisi Tedavisindeki Etkinliginin Karsilastirilmasi]. Turkderm Deri Hastaliklari ve Frengi Arsivi2005;39(2):109‐14. [EMBASE: 2006204571] ">Yilmaz 2005</a>); all studies with unclear allocation concealment. </p> <p><sup>2</sup> Downgraded by one level for risk of bias: two out of four studies with unclear blinding of outcome assessment (<a href="./references#CD009687-bbs2-0032" title="KlaberMR , HutchinsonPE , Pedvis‐LeftickA , KragballeK , ReunalaTL , van deKerkhofPC , et al. Comparative effects of calcipotriol solution (50 micrograms/ml) and betamethasone 17‐valerate solution (1 mg/ml) in the treatment of scalp psoriasis. British Journal of Dermatology1994;131(5):678‐83. [MEDLINE: 7999600] ">Klaber 1994</a>; <a href="./references#CD009687-bbs2-0053" title="van deKerkhofP , AnsteyA , BarnesL , BolducC . A new scalp formulation of calcipotriene plus betamethasone in the treatment of scalp psoriasis compared to its active ingredients in the same vehicle. Journal of the American Academy of Dermatology2007;56(2):AB182. van deKerkhofPC , HoffmannV , AnsteyA , BarnesL , BolducC , ReichK , et al. A new scalp formulation of calcipotriol plus betamethasone dipropionate compared with each of its active ingredients in the same vehicle for the treatment of scalp psoriasis: a randomized, double‐blind, controlled trial. British Journal of Dermatology2009;160(1):170‐6. [MEDLINE: 19067709] ">van de Kerkhof 2009</a>); all studies with unclear allocation concealment. </p> <p><sup>3</sup> Downgraded by one level for risk of bias: all three studies with unclear allocation concealment; one study with unclear risk of bias in selective reporting (<a href="./references#CD009687-bbs2-0046" title="ReygagneP , MrowietzU , DecroixJ , deWaard‐van der SpekFB , AcebesLO , FigueiredoA , et al. Clobetasol propionate shampoo 0.05% and calcipotriol solution 0.005%: a randomized comparison of efficacy and safety in subjects with scalp psoriasis. Journal of Dermatological Treatment2005;16(1):31‐6. [MEDLINE: 15897165] ReygagneP , MrowietzU , DecroixJ , van derSpekW , Olmos AcebesL , et al. Four‐week efficacy and safety comparison of a new clobetasol shampoo and calcipotriol solution 0.005% in subjects with scalp psoriasis. Journal of the European Academy of Dermatology &amp; Venereology2002;16(Suppl 1):285. ">Reygagne 2005</a>); one study with unclear blinding of outcome assessment (<a href="./references#CD009687-bbs2-0053" title="van deKerkhofP , AnsteyA , BarnesL , BolducC . A new scalp formulation of calcipotriene plus betamethasone in the treatment of scalp psoriasis compared to its active ingredients in the same vehicle. Journal of the American Academy of Dermatology2007;56(2):AB182. van deKerkhofPC , HoffmannV , AnsteyA , BarnesL , BolducC , ReichK , et al. A new scalp formulation of calcipotriol plus betamethasone dipropionate compared with each of its active ingredients in the same vehicle for the treatment of scalp psoriasis: a randomized, double‐blind, controlled trial. British Journal of Dermatology2009;160(1):170‐6. [MEDLINE: 19067709] ">van de Kerkhof 2009</a>). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Steroid compared to vitamin D for scalp psoriasis</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/full#CD009687-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD009687-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Steroid plus vitamin D compared to steroid for scalp psoriasis</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Steroid plus vitamin D compared to steroid for scalp psoriasis</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> scalp psoriasis <br/> <b>Intervention:</b> steroid plus vitamin D<br/> <b>Comparison:</b> steroid </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with steroid</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with steroid plus vitamin D</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Number of participants achieving 'clearance' by IGA</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.22<br/> (1.08 to 1.36) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2474<br/> (4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>287 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>350 per 1000<br/> (310 to 391) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Number of participants achieving 'response' by IGA</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.15<br/> (1.06 to 1.25) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2444<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>546 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>628 per 1000<br/> (579 to 683) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Quality of life</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>(0 studies)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>No study addressed this outcome</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000<br/> (0 to 0) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Number of participants withdrawing due to adverse events (AE)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.88<br/> (0.42 to 1.88) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2433<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>No study reported the sort of AE that caused withdrawal. In one small study with high risk of bias (<a href="./references#CD009687-bbs2-0059" title="YilmazH , AydinF , SenturkN , CanturkT , TuranliAY . A comparison between the effects of calcipotriol lotion, momethasone furoate lotion and their combinations for the treatment of scalp psoriasis [Kalsipotriol Losyon, Mometazon Furoat Losyonve Kombinasyonlarinin Saçli Deri Psoriazisi Tedavisindeki Etkinliginin Karsilastirilmasi]. Turkderm Deri Hastaliklari ve Frengi Arsivi2005;39(2):109‐14. [EMBASE: 2006204571] ">Yilmaz 2005</a>, N = 30 participants) no withdrawals occurred. </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>12 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>11 per 1000<br/> (5 to 23) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Number of participants achieving 'response' by PGA</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.13<br/> (1.06 to 1.20) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2226<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/> HIGH </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>613 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>692 per 1000<br/> (649 to 735) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>AE:</b> adverse event; <b>CI:</b> confidence interval; <b>IGA:</b> investigator's global assessment; <b>OR:</b> odds ratio; <b>PGA:</b> patient global assessment; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Downgraded by one level for imprecision because CI crosses line of minimal important difference (MID) threshold: statistically significant difference of uncertain clinical importance. </p> <p><sup>2</sup> Downgraded by one level for inconsistency due to moderate heterogeneity (I² = 35%). </p> <p><sup>3</sup> Downgraded by one level for imprecision because CI crosses line of MID threshold: uncertain whether there is any difference. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Steroid plus vitamin D compared to steroid for scalp psoriasis</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/full#CD009687-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD009687-tbl-0003"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Steroid plus vitamin D compared to vitamin D for scalp psoriasis</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Steroid plus vitamin D compared to vitamin D for scalp psoriasis</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> scalp psoriasis <br/> <b>Intervention:</b> steroid plus vitamin D<br/> <b>Comparison:</b> vitamin D </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with vitamin D</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with steroid plus vitamin D</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Number of participants achieving 'clearance' by IGA</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 2.28<br/> (1.87 to 2.78) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2008<br/> (4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/> HIGH </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>145 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>330 per 1000<br/> (270 to 402) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Number of participants achieving 'response' by IGA</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 2.31<br/> (1.75 to 3.04) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2222<br/> (4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>280 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>646 per 1000<br/> (489 to 850) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Quality of life</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>(0 studies)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Only one study (<a href="./references#CD009687-bbs2-0156" title="OrtonneJ , ChimentiS , LugerT , PuigL , ReidF , TruebRM . Scalp psoriasis: European consensus on grading and treatment algorithm. Journal of the European Academy of Dermatology &amp; Venereology2009;23(12):1435‐44. [MEDLINE: 19614856] ">Ortonne 2009</a>) addressed this outcome, but did not provide sufficient information to allow assessment of the quality of evidence. </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000<br/> (0 to 0) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Number of participants withdrawing due to adverse events</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.19<br/> (0.11 to 0.36) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1970<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/> HIGH </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>No study reported the sort of AE that caused withdrawal. In one small study with high risk of bias (<a href="./references#CD009687-bbs2-0059" title="YilmazH , AydinF , SenturkN , CanturkT , TuranliAY . A comparison between the effects of calcipotriol lotion, momethasone furoate lotion and their combinations for the treatment of scalp psoriasis [Kalsipotriol Losyon, Mometazon Furoat Losyonve Kombinasyonlarinin Saçli Deri Psoriazisi Tedavisindeki Etkinliginin Karsilastirilmasi]. Turkderm Deri Hastaliklari ve Frengi Arsivi2005;39(2):109‐14. [EMBASE: 2006204571] ">Yilmaz 2005</a>, N = 30 participants) no withdrawals occurred. </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>56 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>11 per 1000<br/> (6 to 20) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Number of participants achieving 'response' by PGA</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.76<br/> (1.46 to 2.12) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2222<br/> (4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>427 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>751 per 1000<br/> (623 to 905) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>AE:</b> adverse event; <b>CI:</b> confidence interval; <b>IGA:</b> investigator's global assessment; <b>OR:</b> odds ratio; <b>PGA:</b> patient global assessment; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Downgraded by one level for inconsistency due to substantial heterogeneity (I² = 81%), may be due to different application frequency in studies (once versus twice daily). </p> <p><sup>2</sup> Downgraded by one level for inconsistency due to substantial heterogeneity (I² = 77%), may be due to different application frequency in studies (once versus twice daily). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Steroid plus vitamin D compared to vitamin D for scalp psoriasis</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/full#CD009687-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD009687-tbl-0004"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Glossary of technical and medical terms</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Medical terms</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Explanation</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Apoptosis</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The process of programmed cell death, which is the natural developmental and maintenance process of the normal removal of cells </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Immuno‐suppressive</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Specific property of certain medications (e.g. corticosteroids) that diminish the response or activation of the immune system </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hyperproliferation</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>An abnormality associated with a high rate of growth of cells by rapid division</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Differentiation</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The process by which a less specialised cell becomes a more specialised cell type</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Erythematous</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>An abnormal redness of the skin caused by various agents, such as sunlight or drugs etc, which irritate and congest the blood capillaries </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Plaque psoriasis</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Patches with the well‐defined characteristic of red, raised skin. They can appear on any skin surface, although the knees, elbows, scalp, trunk and nails are the most common locations. </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Keratolytic agents</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A chemical or physical agent that causes peeling by the softening and shedding of the horny outer layer of the skin </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hypervascularisation</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A local increase in the formation of blood vessels leading to a higher blood supply of the tissue mainly as a response to the action of the vascular endothelial growth factor (VEGF) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pro‐inflammatory</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Provoking inflammation</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Anti‐inflammatory</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Inhibiting or reducing inflammation</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Keratinocytes</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Skin cells forming the superficial layer of the skin (epidermis)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Epigenetics</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The interactions of specific proteins with the genome that influence the expression of certain genes without changing the genetic sequence </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PUVA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A photochemotherapy of certain dermatological conditions with psoralen and ultra violet A light (UVA). Usually, psoralen is applied topically on the affected area to increase the sensibility to the UVA light. </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rosacea</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A chronic skin disease affecting mainly the cheeks, nose, forehead, scalp and ears. On the involved ruddy skin thin superficial blood vessels (teleangiectasia), papules and pustules may appear. In a certain type of rosacea, some facial areas (e.g. nose) enlarge and become bulbous (e.g. rhinophyma). </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cytoplasm</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The watery fluid (cytosol) inside the cell in which the organelles and the skeleton of the cell are embedded </p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Glossary of technical and medical terms</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/full#CD009687-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD009687-tbl-0005"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Sensitivity analyses: summary table</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Comparison</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Outcome</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Sensitivity analysis: ITT population¹</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Sensitivity analysis: allocation concealment²</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Meta‐analysis³</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Steroid versus the vehicle</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IGA: clearance</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 11.67; 95% CI 4.88 to 27.90</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 20.49; 95% CI 2.89 to 145.19</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 14.58; 95% CI 7.28 to 29.17</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IGA: response</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 7.67; 95% CI 4.24 to 13.89</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 6.11; 95% CI 2.98 to 12.52</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 5.24; 95% CI 3.83 to 7.17</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Withdrawal due to AE</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.22; 95% CI 0.08 to 0.61</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.33; 95% CI 0.01 to 7.76</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.27; 95% CI 0.11 to 0.67</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of participants with at least 1 AE</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.87; 95% CI 0.70 to 1.09</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.56; 95% CI 0.56 to 4.37</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.87; 95% CI 0.70 to 1.08</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Steroid versus vitamin D</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IGA: clearance</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.81; 95% CI 1.47 to 2.24</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not applicable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.82; 95% CI 1.52 to 2.18</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Withdrawal due to AE</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.22; 95% CI 0.08 to 0.57</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not applicable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.22; 95% CI 0.11 to 0.42</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PGA: clearance</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 4.00; 95% CI 1.01 to 15.81</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not applicable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 2.22; 95% CI 1.47 to 3.35</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Steroid plus vitamin D versus vitamin D</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IGA: clearance</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not applicable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 3.55; 95% CI 1.84 to 6.85</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 2.28; 95% CI 1.87 to 2.78</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IGA: response</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not applicable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 3.04; 95% CI 1.99 to 4.66</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 2.31; 95% CI 1.75 to 3.04</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Withdrawal due to AE (short‐term)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not applicable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.11; 95% CI 0.02 to 0.51</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.19; 95% CI 0.11 to 0.36</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of participants with at least 1 AE (short‐term)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not applicable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.61; 95% CI 0.47 to 0.78</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.70; 95% CI 0.58 to 0.85</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="5"> <div class="table-footnote"> <p>Bold text indicates a meaningful difference between effect estimates.</p> <p><sup>1</sup>Total effect estimate of all studies that provided sufficient information to ensure that ITT analysis was performed. </p> <p><sup>2</sup>Total effect estimate of all studies that provided sufficient information to ensure that allocation concealment was adequately performed. </p> <p><sup>3</sup>Total effect estimate of meta‐analysis that included all relevant studies, regardless if ITT analysis or allocation concealment was performed or not. </p> <p>AE: adverse event<br/> CI: confidence interval<br/> IGA: investigator's global assessment<br/> ITT: intention‐to‐treat<br/> PGA: patient global assessment<br/> RR: risk ratio </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Sensitivity analyses: summary table</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/full#CD009687-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD009687-tbl-0006"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Steroid: once versus twice daily</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Mean score of the IGA <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Betamethasone valerate 0.12% (hydrophilic leave‐on)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Mean score of the PGA <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Betamethasone valerate 0.12% (hydrophilic leave‐on)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Steroid: once versus twice daily</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/references#CD009687-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD009687-tbl-0007"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Steroid versus the vehicle</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Number of participants achieving 'clearance' by IGA <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1315</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>14.58 [7.28, 29.17]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Amcinonide 0.1% (hydrophilic leave‐on)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>165</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>16.80 [2.29, 123.30]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Betamethasone dipropionate (hydrophilic leave‐on)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>692</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>10.15 [3.83, 26.88]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 Clobetasol propionate (hydrophilic leave‐on)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>458</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>22.83 [7.31, 71.30]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Number of participants achieving 'response' by IGA <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2114</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.24 [3.83, 7.17]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Betamethasone dipropionate (hydrophilic leave‐on)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>911</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.06 [2.85, 5.79]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Amcinonide 0.1% (hydrophilic leave‐on)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>165</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.19 [2.60, 10.36]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3 Betamethasone valerate 0.1% (hydrophilic leave‐on)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>250</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.96 [1.81, 4.85]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.4 Clobetasol propionate (hydrophilic leave‐on)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>646</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>7.93 [5.46, 11.51]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.5 Clobetasol propionate (rinse‐off)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>142</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>15.83 [2.23, 112.33]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Mean of the TSS <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Improvement in quality of life <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Scalpdex</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Number of participants withdrawing due to adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1315</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.27 [0.11, 0.67]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Betamethasone dipropionate (hydrophilic leave‐on)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>692</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.21 [0.07, 0.61]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 Amcinonide 0.1% (hydrophilic leave‐on)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>165</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.06, 15.53]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.3 Clobetasol propionate (hydrophilic leave‐on)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>458</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.03, 3.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Number of participants achieving 'response' by PGA <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 Betamethasone dipropionate (hydrophilic leave‐on)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>692</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.04 [2.17, 4.26]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 Betamethasone valerate 0.1% (hydrophilic leave‐on)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>172</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.52 [1.97, 6.29]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.3 Clobetasol propionate (hydrophilic leave‐on)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>565</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>6.92 [4.42, 10.83]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.4 Clobetasol propionate (rinse‐off)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>142</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>14.35 [2.02, 102.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Mean score of the PGA <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 Amcinonide 0.1% (hydrophilic leave‐on)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Number of participants with at least one adverse event <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1307</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [0.70, 1.08]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1 Betamethasone valerate 0.1% (hydrophilic leave‐on)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>78</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.25 [0.01, 5.86]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.2 Amcinonide 0.1% (hydrophilic leave‐on)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>157</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.39 [0.32, 5.99]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.3 Betamethasone dipropionate (hydrophilic leave‐on)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>683</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [0.69, 1.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.4 Fluocinolone acetonide 0.01% (lipophilic leave‐on)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>84</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.0 [0.13, 71.61]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.5 Clobetasol propionate (hydrophilic leave‐on)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>81</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.56 [0.56, 4.37]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.6 Clobetasol propionate (rinse‐off)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>224</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.59 [0.29, 1.18]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Steroid versus the vehicle</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/references#CD009687-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD009687-tbl-0008"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Vitamin D versus the vehicle</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Number of participants achieving 'clearance' by IGA <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Vitamin D (hydrophilic leave‐on)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>457</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.88 [1.49, 10.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Number of participants achieving 'response' by IGA <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Calcipotriene (hydrophilic leave‐on)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>771</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.11 [1.20, 3.69]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Mean of the TSS <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Number of participants withdrawing due to adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Vitamin D (hydrophilic leave‐on)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>820</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.43 [0.72, 2.83]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Number of participants achieving 'clearance' by PGA <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Calcipotriol (hydrophilic leave‐on)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Number of participants achieving 'response' by PGA <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 Calcipotriene (hydrophilic leave‐on)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Number of participants with at least one adverse event <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 Vitamin D (hydrophilic leave‐on)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>813</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.12 [0.92, 1.36]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Vitamin D versus the vehicle</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/references#CD009687-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD009687-tbl-0009"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Steroid plus vitamin D versus the vehicle</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Number of participants achieving 'clearance' by IGA <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Betamethasone dipropionate plus calcipotriene (hydrophilic leave‐on)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Number of participants achieving 'response' by IGA <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Betamethasone dipropionate plus calcipotriene (hydrophilic leave‐on)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Mean of the TSS <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Number of participants withdrawing due to adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Betamethasone dipropionate plus calcipotriene (hydrophilic leave‐on)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>843</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.48 [0.08, 2.83]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Number of participants achieving 'response' by PGA <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Betamethasone dipropionate plus calcipotriene (hydrophilic leave‐on)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Number of participants with at least one adverse event <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 Betamethasone dipropionate plus calcipotriene (hydrophilic leave‐on)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>831</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.86 [0.68, 1.09]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Steroid plus vitamin D versus the vehicle</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/references#CD009687-tbl-0009">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD009687-tbl-0010"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Steroid versus steroid: very high versus high potency</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Number of participants achieving 'clearance' by IGA <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Clobetasol propionate vs betamethasone dipropionate (hydrophilic leave‐ons)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Number of participants achieving 'response' by IGA <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Clobetasol propionate vs betamethasone dipropionate (hydrophilic leave‐ons)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Mean of the TSS <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Number of participants with at least one adverse event <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Clobetasol propionate vs betamethasone dipropionate (hydrophilic leave‐ons)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>236</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.32, 2.48]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Steroid versus steroid: very high versus high potency</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/references#CD009687-tbl-0010">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD009687-tbl-0011"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Steroid versus steroid: high versus moderate potency</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Number of participants achieving 'clearance' by IGA <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>190</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.16 [0.56, 2.39]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Betamethasone dipropionate vs hydrocortisone 17‐butyrate 0.1% (hydrophilic leave‐on)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>150</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.76 [0.30, 1.93]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Fluocinolone acetonide 0.025% vs hydrocortisone 17‐butyrate 0.1% (lipophilic leave‐on)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.57 [0.77, 3.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Number of participants achieving 'response' by IGA <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Fluocinonide 0.05% vs desoximetasone 0.05% (hydrophilic leave‐ons)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Mean of the TSS <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Number of participants with at least one adverse event <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Mometasone furoate vs triamcinolone acetonide 0.1% (hydrophilic leave‐on)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Steroid versus steroid: high versus moderate potency</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/references#CD009687-tbl-0011">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD009687-tbl-0012"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">Steroids versus steroid: both of high potency</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Number of participants achieving 'clearance' by IGA <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Mometasone furoate vs betamethasone valerate 0.1% (hydrophilic leave‐ons)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Number of participants achieving 'response' by IGA <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Mometasone furoate vs betamethasone valerate 0.1% (hydrophilic leave‐ons)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Mean of the TSS <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Number of participants withdrawing due to adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Amcinonide 0.1% vs fluocinonide (hydrophilic leave‐ons)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 Betamethasone vs fluocinonide (hydrophilic leave‐ons)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Number of participants with at least one adverse event <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Amcinonide 0.1% vs fluocinonide (hydrophilic leave‐ons)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 Betamethasone dipropionate vs fluocinonide (hydrophilic leave‐ons)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">Steroids versus steroid: both of high potency</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/references#CD009687-tbl-0012">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD009687-tbl-0013"> <div class="table-heading"><span class="table-label">Comparison 8.</span> <span class="table-title">Steroid versus vitamin D</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Number of participants achieving 'clearance' by IGA <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2180</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.82 [1.52, 2.18]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Betamethasone valerate 1 mg/ml vs calcipotriol (hydrophilic leave‐ons)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>474</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.85 [1.31, 2.60]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Betamethasone dipropionate vs vitamin D (hydrophilic leave‐ons)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1676</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.81 [1.46, 2.24]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 Mometasone furoate vs calcipotriol (hydrophilic leave‐ons)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.0 [0.43, 9.32]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Number of participants achieving 'response' by IGA <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1827</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.09 [1.80, 2.41]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Clobetasol propionate vs calcipotriol (rinse‐off vs hydrophilic leave‐on)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>151</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.79 [1.17, 2.74]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Betamethasone dipropionate vs vitamin D (hydrophilic leave‐ons)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1676</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.13 [1.82, 2.50]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Mean of the TSS <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Number of participants withdrawing due to adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2291</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.22 [0.11, 0.42]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Betamethasone valerate 1 mg/ml vs calcipotriol (hydrophilic leave‐ons)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>474</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.19 [0.04, 0.83]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 Betamethasone dipropionate vs vitamin D (hydrophilic leave‐ons)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1666</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.25 [0.08, 0.74]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3 Clobetasol propionate vs calcipotriol (rinse‐off vs hydrophilic leave‐on)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>151</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.07 [0.00, 1.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Number of participants achieving 'clearance' by PGA <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>504</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.22 [1.47, 3.35]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Betamethasone valerate 1 mg/ml vs calcipotriol (hydrophilic leave‐ons)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>474</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.09 [1.36, 3.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 Mometasone furoate vs calcipotriol (hydrophilic leave‐ons)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.0 [1.01, 15.81]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Number of participants achieving 'response' by PGA <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1827</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.48 [1.28, 1.72]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 Clobetasol propionate vs calcipotriol (rinse‐off vs hydrophilic leave‐on)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>151</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.54 [1.02, 2.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 Betamethasone dipropionate vs vitamin D (hydrophilic leave‐ons)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1676</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.48 [1.21, 1.80]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Number of participants with at least one adverse event <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 Betamethasone valerate 1 mg/ml vs calcipotriol (hydrophilic leave‐ons)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>474</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.37 [0.25, 0.53]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2 Betamethasone dipropionate vs vitamin D (hydrophilic leave‐ons)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1652</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.82 [0.70, 0.97]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.3 Clobetasol propionate vs calcipotriol (hydrophilic leave‐on vs occlusive lipophilic leave‐on) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.48 [0.10, 2.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.4 Clobetasol propionate vs calcipotriol (rinse‐off vs hydrophilic leave‐on)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>151</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.34 [0.16, 0.72]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 8.</span> <span class="table-title">Steroid versus vitamin D</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/references#CD009687-tbl-0013">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD009687-tbl-0014"> <div class="table-heading"><span class="table-label">Comparison 9.</span> <span class="table-title">Steroid plus salicylic acid versus steroid</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Number of participants achieving 'clearance' by IGA <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Betamethasone dipropionate plus SA vs betamethasone dipropionate (hydrophilic leave‐on) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Number of participants achieving 'response' by IGA <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Betamethasone dipropionate plus SA vs betamethasone dipropionate (hydrophilic leave‐ons) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 9.</span> <span class="table-title">Steroid plus salicylic acid versus steroid</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/references#CD009687-tbl-0014">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD009687-tbl-0015"> <div class="table-heading"><span class="table-label">Comparison 10.</span> <span class="table-title">Steroid plus vitamin D versus steroid</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Number of participants achieving 'clearance' by IGA <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2474</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.22 [1.08, 1.36]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Betamethasone dipropionate plus vitamin D vs betamethasone dipropionate (hydrophilic leave‐ons) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2444</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.21 [1.07, 1.36]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Mometasone furoate plus calcipotriol vs mometasone furoate (hydrophilic leave‐ons)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.0 [0.76, 5.24]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Number of participants achieving 'response' by IGA <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Betamethasone dipropionate plus vitamin D vs betamethasone dipropionate (hydrophilic leave‐ons) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2444</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.15 [1.06, 1.25]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Mean of the TSS <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Number of participants withdrawing due to adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Betamethasone dipropionate plus vitamin D vs betamethasone dipropionate (hydrophilic leave‐ons) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2433</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [0.42, 1.88]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Number of participants achieving 'clearance' by PGA <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Mometasone furoate plus calcipotriol vs mometasone furoate (hydrophilic leave‐ons)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Number of participants achieving 'response' by PGA <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 Betamethasone dipropionate plus vitamin D vs betamethasone dipropionate (hydrophilic leave‐ons) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2226</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.13 [1.06, 1.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Number of participants with at least one adverse event <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 Betamethasone dipropionate plus vitamin D vs betamethasone dipropionate (hydrophilic leave‐ons) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2414</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.87, 1.07]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 10.</span> <span class="table-title">Steroid plus vitamin D versus steroid</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/references#CD009687-tbl-0015">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD009687-tbl-0016"> <div class="table-heading"><span class="table-label">Comparison 11.</span> <span class="table-title">Steroid plus vitamin D versus vitamin D</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Number of participants achieving 'clearance' by IGA <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2008</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.28 [1.87, 2.78]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Betamethasone dipropionate plus vitamin D vs vitamin D (hydrophilic leave‐ons)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1978</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.25 [1.83, 2.77]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Mometasone furoate plus calcipotriol vs calcipotriol (hydrophilic leave‐ons)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.0 [1.01, 15.81]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Number of participants achieving 'response' by IGA <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2222</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.31 [1.75, 3.04]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Betamethasone dipropionate plus vitamin D vs vitamin D (hydrophilic leave‐on)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1978</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.56 [2.03, 3.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Betamethasone dipropionate plus calcipotriol vs calcipotriol (hydrophilic leave‐on) ‐ trial register study </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>244</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.72 [1.43, 2.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Mean of the TSS <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Number of participants withdrawing due to adverse events (short‐term) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Betamethasone dipropionate plus vitamin D vs vitamin Dg (hydrophilic leave‐on)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1970</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.19 [0.11, 0.36]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 Betamethasone dipropionate plus calcipotriol vs calcipotriol (hydrophilic leave‐on) ‐ trial register study </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>244</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.07 [0.39, 11.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Number of participants withdrawing due to adverse events (long‐term) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Betamethasone dipropionate plus calcipotriol vs calcipotriol (hydrophilic leave‐on)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Number of participants achieving 'clearance' by PGA <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 Mometasone furoate plus calcipotriol vs calcipotriol (hydrophilic leave‐ons)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Number of participants achieving 'response' by PGA <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2222</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.76 [1.46, 2.12]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 Betamethasone dipropionate plus vitamin D vs vitamin D (hydrophilic leave‐on)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1978</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.89 [1.47, 2.42]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2 Betamethasone dipropionate plus calcipotriol vs calcipotriol (hydrophilic leave‐on)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>244</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.50 [1.29, 1.75]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Number of participants with at least one adverse event (short‐term) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2193</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.70 [0.58, 0.85]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1 Betamethasone dipropionate plus vitamin D vs vitamin D (hydrophilic leave‐on)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1951</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.74 [0.63, 0.88]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.2 Betamethasone dipropionate plus calcipotriol vs calcipotriol (hydrophilic leave‐on) ‐ trial register study </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>242</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.44 [0.25, 0.76]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Number of participants with at least one adverse event (long‐term) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1 Betamethasone dipropionate plus calcipotriol vs calcipotriol (hydrophilic leave‐on)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 11.</span> <span class="table-title">Steroid plus vitamin D versus vitamin D</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/references#CD009687-tbl-0016">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD009687-tbl-0017"> <div class="table-heading"><span class="table-label">Comparison 12.</span> <span class="table-title">Tar and dithranol</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Number of participants achieving 'clearance' by IGA <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Calcipotriol vs tar/dithranol combination (hydro/lipophilic leave‐on combination)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Tacrolimus vs pine tar (lipophilic leave‐ons)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 Dithranol/urea combination vs coal tar plus salicylic acid combination (lipophilic leave‐ons) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Number of participants achieving 'response' by IGA <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Calcipotriol vs tar/dithranol combination (hydro/lipophilic leave‐on combination)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Mean of the TSS <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Number of participants withdrawing due to adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Calcipotriol vs tar/dithranol combination (hydro/lipophilic leave‐on combination)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 Calcipotriol vs coal tar/coconut oil/salicylic acid (hydrophilic leave‐on vs rinse‐off)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3 Clobetasol propionate vs tar blend (rinse‐offs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.4 Cocois vs coal tar (lipophilic leave‐on vs rinse‐off)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Number of participants achieving 'clearance' by PGA <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Calcipotriol vs tar/dithranol combination (hydro/lipophilic leave‐on combination)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Number of participants achieving 'response' by PGA <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 Calcipotriol vs tar/dithranol combination (hydro/lipophilic leave‐on combination)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Number of participants with at least one adverse event <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 Calcipotriol vs tar/dithranol combination (hydro/lipophilic leave‐on combination)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2 Calcipotriol vs coal tar/coconut oil/salicylic acid (hydrophilic leave‐on vs rinse‐off)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.3 Clobetasol propionate vs tar blend (rinse‐offs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.4 Tacrolimus vs pine tar (lipophilic leave‐ons)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.5 Dithranol/urea combination vs coal tar plus salicylic acid combination (lipophilic leave‐ons) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.6 Cocois vs coal tar (lipophilic leave‐on vs rinse‐off)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 12.</span> <span class="table-title">Tar and dithranol</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/references#CD009687-tbl-0017">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD009687-tbl-0018"> <div class="table-heading"><span class="table-label">Comparison 13.</span> <span class="table-title">Steroid: vehicle comparisons</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Number of participants achieving 'clearance' by IGA <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Betameth diprop (BP) + RV3423A shampoo/shampoo vs BP + shampoo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Number of participants achieving 'response' by IGA <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Betamethasone valerate 0.1%: foam vs lotion</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Clobetasol propionate: foam vs solution</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Mean of the TSS <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Number of participants achieving 'response' by PGA <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Betamethasone valerate 0.1%: foam vs lotion</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 Clobetasol propionate: foam vs solution</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Number of participants with at least one adverse event <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Clobetasol: shampoo vs hydrophilic leave‐on</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 13.</span> <span class="table-title">Steroid: vehicle comparisons</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/references#CD009687-tbl-0018">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD009687-tbl-0019"> <div class="table-heading"><span class="table-label">Comparison 14.</span> <span class="table-title">Other steroid plus salicylic acid comparisons</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Number of participants achieving 'clearance' by IGA <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Betamethasone dipropionate (BDP) plus SA vs triamcinolone acetonide 0.2% plus SA (hydrophilic leave‐ons) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>61</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.64 [1.47, 4.74]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Betamethasone dipropionate (BDP) plus SA vs betamethasone valerate 0.1% (hydrophilic leave‐ons) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>116</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.40 [0.59, 3.32]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 Betamethasone dipropionate (BDP) plus SA vs clobetasol propionate (hydrophilic leave‐ons) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.4 [0.97, 2.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4 Betamethasone dipropionate (BDP) vs triamcinolone acetonide 0.2% plus SA (hydrophilic leave‐on) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.26 [1.23, 4.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Number of participants achieving 'response' by IGA <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Betameth diprop plus SA vs triamcin acet 0.2% plus SA (hydrophilic leave‐ons)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Betameth diprop vs triamcin acet 0.2% plus SA (hydrophilic leave‐ons)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Number of participants withdrawing due to adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Betamethasone dipropionate plus SA vs clobetasol propionate (hydrophilic leave‐ons)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Number of participants with at least one adverse event <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Betamethasone dipropionate plus SA vs betamethasone valerate 0.1% (hydrophilic leave‐ons) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 Betamethasone dipropionate plus SA vs clobetasol propionate (hydrophilic leave‐ons)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 14.</span> <span class="table-title">Other steroid plus salicylic acid comparisons</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/references#CD009687-tbl-0019">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD009687-tbl-0020"> <div class="table-heading"><span class="table-label">Comparison 15.</span> <span class="table-title">Antifungals versus vehicle</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Mean score of the IGA <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Number of participants withdrawing due to adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Ciclopirox olamine (hydrophilic leave‐on)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Mean score of the PGA <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Number of participants with at least one adverse event <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Ciclopirox olamine (hydrophilic leave‐on) vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 15.</span> <span class="table-title">Antifungals versus vehicle</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009687.pub2/references#CD009687-tbl-0020">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD009687.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="de#CD009687-note-0001">Deutsch</a> </li> <li class="section-language"> <a class="" href="es#CD009687-note-0005">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD009687-note-0014">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD009687-note-0004">Français</a> </li> <li class="section-language"> <a class="" href="hr#CD009687-note-0003">Hrvatski</a> </li> <li class="section-language"> <a class="" href="ru#CD009687-note-0002">Русский</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734739000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734739000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773542000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773471000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009687\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009687\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009687\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD009687\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009687\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009687\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009687\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009687\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009687\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD009687\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009687\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009687\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009687\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD009687\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009687\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009687\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009687\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD009687\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=EBp84H4P&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD009687.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD009687.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD009687.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD009687.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD009687.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740728748689"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD009687.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740728748692"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD009687.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918ecc03ed0cf56f',t:'MTc0MDcyODc0OS4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 